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Abstract
The work described in this thesis had the main aim of understanding protein solution
rheology. This was from a biopharmaceutical perspective, with account of the biophysical
properties of proteins and in particular their level of aggregation. Molecular interactions
influencing the rheology of a range of protein solutions were studied. Proteins were se-
lected to relate directly to the diversity of protein types used in biopharmaceuticals. In
addition, the roles of a surfactant formulation additive and synthetic amphiphilic poly-
mers in the flow behaviour of protein solutions were studied.
The effect of protein concentration on solution viscosity in a commercially available
biopharmaceutical formulation of a recombinant albumin (rAlbumin) was studied. The
effect of the level of protein aggregation, variation in protein concentration and its im-
pact on solution viscosity was revealed. Theoretical models predicting the increase of
viscosity with concentration were applied to these data. A recent model that accounts
for multiple protein species in solution, predicted the experimental data best. The rAl-
bumin study, although a relatively simple system, represented a ’real-life’ formulation
with results highlighting the need to account for heterogeneity in the level of aggrega-
tion when addressing the increase of viscosity observed at high concentration of protein
solutions.
β-lactoglobulin (β-LG) excipient-free solutions were characterised by bulk and inter-
facial shear rheology. Solutions at various concentrations, characterised using conven-
iii
tional rheology instrumentation, evidenced an apparent yield stress behaviour at a low
shear rate range (0.01 - 10 s−1), whilst showing constant viscosities throughout higher
shear rates. Comparing interfacial shear rheology, air-water interface-free bulk rheology
measurements, and tensiometry results, it was demonstrated that the complexity of this
protein’s solution rheology was due to the formation of a protein viscoelastic film at
the air-water interface, as present in conventional rheometry. This is in agreement with
literature. Further studies considered the effect of insoluble β-LG aggregates on the
solutions’ rheology, linking with their characterisation in size and quantification. The
presence of insoluble proteinaceous particles was suggested to have an impact on the
solution’s flow behaviour, particularly at the lower shear rates.
Excipient-free monoclonal antibody (mAb) solutions were studied with the aim of
generating protein aggregates (soluble and insoluble) to explore their impact on solu-
tion rheology. mAb samples were subjected to thermal stress and were characterised
for their purity, aggregate content and size. The change in species content did not alter
the original protein’s yield-stress behaviour at low shear rates. An increase in aggregate
content was related to the increase of viscosities observed at high shear rates. Estab-
lishing a relationship between species content (in volume fraction) and viscosities, as for
the rAlbumin study, was not possible due to this mAbs specific aggregation behaviour.
However, from the β-LG and mAb case studies, our results highlight the importance of
detailed characterisation of protein solutions with orthogonal biophysical techniques so
as to better understand protein solution rheology.
An additional study looking at the effect of polysorbate-80 upon protein rheology was
made. In agreement with literature, this commonly used excipient in biopharmaceuticals
was demonstrated to affect the rheological measurements of globular protein solutions.
Amphiphilic brush-like poly(ethylene glycol) methacrylate polymers were also synthes-
ised and tested as novel additives with β-LG and mAb solutions, for their potential effects
iv
on protein solution rheology, similar to those observed with polysorbate-80. Preliminary
results showed that the effects of these polymers are likely related to competition for the
air-water interface, between these and the proteins involved. This competition leads to
changes in the yield-like behaviour at low shear rates.
v
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For the past two decades, advances in recombinant DNA technology have allowed a
progressive change in therapeutics from small molecule therapies to biological macro-
molecular formulations, including medicines where the active ingredients are peptides,
proteins and nucleic acids. The target specificity of protein drugs, reaching the potential
for low side effects in comparison to small molecule drugs, along with advances in protein
production at large scales with lower costs, lead to a significant role of protein therapies
in the pharmaceutical industry [1, 2].
Currently there are various protein formulation strategies, spanning from the tradi-
tional parental administration route of a protein solution with stabilizing additives, to
new strategies that explore new administration routes (e.g. non-invasive mucosal route)
or others which are more adequate to the macromolecule’s specific properties or phar-
maceutical needs (e.g. sustained protein formulations) [3].
In protein therapeutics, monoclonal antibodies (mAb) have been essential in medi-
cine targeting many diseases such as rheumatoid arthritis, inflammation, cancer and
infectious diseases [1]. Monoclonal antibodies constituted 20 % of biopharmaceutical
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products in 2008, where projections were that this value would increase in coming
years [1, 2]. With advances in biotechnology, in particular of methods to clone mur-
ine and human antibody sequences, the generation of monoclonal antibodies has moved
from fully murine to fully humanised constructs. Also contributing to the success of
monoclonal antibody therapeutics are the technological developments related to mAb
expression and purification [4]. However, to formulate such complex molecules in stable
formulations, it is necessary to understand the protein’s physicochemical properties and
thermodynamic stability [1, 2].
The administration route normally chosen for protein formulations has largely been
intravenous, since it is a faster and easier way to formulate; allowing better bioavailab-
ility than most other routes and good control in administration [5]. The subcutaneous
route presents a good alternative for products that require a higher frequency of ad-
ministration. This route also has the advantage of allowing a better quality of life for
the patient, providing the potential of using devices such as auto-injectors or pre-filled
syringes permitting home use [6]. However, therapeutic proteins such as monoclonal
antibodies often need to be delivered in high concentration for increased bioavailability
even if administered frequently, due to its low potency. At high concentrations, e.g. 100
mg per dose or higher, special care is required in formulating these medicines so that
a convenient use of an aqueous low volume (1 - 1.5 mL) solution can be administered
through the subcutaneous route [7, 8].
Many challenges arise when formulating a suitable aqueous highly concentrated pro-
tein formulation. Not only there are difficulties in stability, but there can be challenges
in manufacturing processes and delivery [5]. Considering stability challenges, these are
present in general protein formulations and are divided between chemical and physical
instabilities [1]. Aggregation and denaturation are the major pathways to physical in-
stabilities in protein formulation. In medicines where protein is in high concentration,
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the presence of water is reduced and chemical instabilities that are hydrolytically driven
are less expected to induce degradation. However, aggregation is highly dependent on
concentration, and therefore is the primary expected pathway to instability of high con-
centration protein formulations [1, 5]. With reduced volume and the increased possibil-
ity of occurring aggregation, high viscosity is frequently observed in these formulations.
Highly viscous solutions can impair the manufacturing process, and are impractical for
patient use because using a larger needle gauge can lead to pain at administration as
well as more force required to inject [2, 9].
Characterising and studying the properties of a high concentration protein formula-
tion often involves dilution for sample analysis since commonly used techniques require
this (e.g. such as dynamic light scattering, size-exclusion chromatography, analytical
ultracentrifugation) [10]. By diluting the sample, one may possibly create artifacts (e.g.
dissociating soluble aggregates), thus disallowing a proper investigation of high concen-
tration formulation [11]. Due to such analysis challenges, the effect of high concentra-
tions within protein formulations is still poorly understood at a molecular level, and in
particular how molecular interactions within these formulations can lead to aggregation
and high viscosity [6,9]. In addition, understanding the effect of excipients on such pro-
cesses/properties is crucial, so that we are able to understand and manage the challenges.
1.2 Main Aims
The work described in this thesis had the main aim of understanding protein solution
rheology from a biopharmaceutical perspective, with account of the biophysical prop-
erties of proteins and in particular their level of aggregation. Therefore, one of this
thesis aims was focused on understanding the molecular basis of rheological properties
of high protein concentration solutions using a commercially available biopharmaceut-
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ical formulation as a model. The other aim of this thesis was to understand how the
level of aggregation of protein solutions and their underpinning molecular interactions
can influence their rheological measurements. Finally, another aim of this thesis was to
explore the impact of surface active organic molecules on protein solution rheology.
1.3 Protein formulations - monoclonal antibody formula-
tions
As mentioned earlier, monoclonal antibody formulations constitute an important section
within protein formulations. However, it is assumed that achieving commercially viable
antibody products is not straight-forward [1]. Consequently, this has translated into a
thriving development of technology involved in formulating such therapeutic biomacro-
molecules.
The following sections describe briefly the antibody structure and function, their
common instabilities, and a general background on formulation development and char-
acterisation, focusing on high antibody concentration formulations and its relationship
with viscosity, fitting the remit of this thesis.
1.3.1 Antibody structure and function
Antibodies, immunoglobulins, are a family of multidomain glycoproteins in a Y-shape
or can be a combination of such molecules. These soluble proteins are present in the
serum, tissue fluids or on the cell membranes. Their purpose is to help eliminate their
specific antigens or microorganisms bearing these antigens [12]. The structure of an
immunoglobulin is divided into two regions: the variable (V) region, which is on the top
part of the Y-shape; and the constant (C) region, which is the stem of the Y. Immuno-
globulins comprise five classes - IgA, IgD, IgE, IgM and IgG. This division is based on
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the C region, denominated as α, δ, ǫ, µ, and γ, respectively.
IgGs are the most abundant immunoglobulin, accounting for 70-75% of total serum
immunoglobulin pool, occurring as monomers. Also, IgGs are widely used for thera-
peutic purposes as a therapeutic agent (monoclonal IgGs) [1,12]. The primary structure
of IgGs is defined by a four-chain structure with two identical heavy chains - H, 50 kDa -
and two identical light chains (L, 25 kDa) (Figure 1.1). The typical molecular weight of
IgG is between 146-170 kDa [1, 12]. IgGs are divided into subclasses: IgG1, IgG2, IgG3
and IgG4, which is in order of typical quantity present in human plasma. This division
is due to different heavy chains, named γ1, γ2, γ3, and γ4, respectively. The difference
among the isotypes (subclasses) are the interchain disulfide bonds (number and location)
and the length of the hinge region [1, 12]. Regarding the light chains, which can be of
two types: lambda (λ) and kappa (κ). Either light chain type may combine with any
of the heavy chain types, but within any individual immunoglobulin molecule both light
and heavy chains are of the same type [12].
(a) (b)
Figure 1.1: Molecular architecture of an IgG: a) ribbon model (adapted from [4]); b) schematic
model (adapted from [13]).
The variable regions of both light and heavy chains consist approximately of 110
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amino acids, forming the antigen-binding regions (Fab fragment). The remaining se-
quence of amino acids are part of the constant region, forming the Fc region (fragment
crystallisable) [1]. The constant domains of the heavy chains are generally designated
as CH1, CH2, CH3 and CH4. The V regions are divided into hypervariable sequences -
HV1, HV2 and HV3 - on both heavy and light chains. The HV sequences are referred to
as complementarity determining regions - CDR1, CDR2 and CDR3, which form three
loops at the edge of the β barrel. The three CDRs from the light chain are called L1, L2
and L3, in order of appearance in the sequence. Correspondingly, the three CDRs from
the heavy chain are called H1, H2 and H3. Other sequences are the framework regions
- FR1, FR2, FR3 and FR4. These form β-sheets and determine the fold that help the
CDRs to be close to each other, maintaining the folded structure [1, 12, 14].
The secondary structure of IgGs comprises the polypeptide chains assembled in anti-
parallel β-sheets which represent roughly 70% of total structure. Two domains form
the light chains while four domains form the heavy chains, each of these domains are
approximately 110 amino acid long (∼12 kDa in size). All of these domains form a β
barrel, called the immunoglobulin fold [12]. This structure is stabilised by a disulfide
bond and hydrophobic interactions. Each of these domains interact amongst themselves,
are linked by the hinge region and form three spherical shapes of similar size. These
spheres give the Y-shape configuration to the antibody. Its less globular shape is sta-
bilised by interactions via disulfide bonds and strong non-covalent between the heavy
chains and each of the heavy/light chain pairs [1, 12].
In general, IgGs have four interchain disulfide bonds: two connecting the two heavy
chains at the hinge region; and two connecting the two light chains to the heavy chains.
Four intrachain disulfide bonds are also present within each domain of the heavy and
light chains which help stabilise the domains. The intrachain dissulfide bonds between
the VH and VL are required for functional antigen binding [1].
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As mentioned above, IgGs have two functional areas - the V and C regions. The
CDR regions with the framework regions are specifically the antigen-binding sites at
the end of the Fab arms, shown to have a unique surface topography that seems to be
complementary to structures on the antigen [4,12]. Regarding the constant region of an-
tibodies, these have three main effector functions: (1) initiating antibody-dependent cell
cytotoxicities (ADCC), being recognised by receptors on immune cells; (2) by binding to
complement; and (3) being transported throughout the organism to many places, such as
tears and milk [1]. The IgG subclasses interact with cellular Fc receptors (FcγRI, FcγRII
and FcγRIII) expressed on various cell types (e.g. monocytes, neutrophils, eosinophils,
lymphocytes). These receptors are characterised by a glycoprotein α chain that binds
to the antibody and has extracellular domains homologous with the IgG domains, i.e.
they belong to the immunoglobulin super family. These receptors may be upregulated
or induced by environmental factors (e.g. cytokines) [12].
An oligosaccharide chain is found in IgGs, typically N-linked to the conserved as-
paragine Asn 297 residue present between the CH2 domains. This oligosaccharide is
normally fucosylated in antibodies produced in CHO or myeloma cell lines and may
differ in other cell lines [1]. There are many factors that determine the nature of the
glycan micro-heterogeneity on IgGs, including cell line, the bioreactor conditions and
downstream processing. It has been shown that the sugar composition also influences
functionality. For example, other oligosaccharides can be found in IgGs due to process,
and the presence of oligosaccharides in other regions rather than in CH2 domain, can
influence the antibody’s activity. It is essential that correct glycosylation of the antibody
occurs, since it is critical for the binding and activation of Fc receptor. Also, it has been
shown that glycosylation can affect antibody conformation, since it can form multiple
non-covalent interactions with the polypeptide [1, 12].
All purified monoclonal antibodies (mAbs) are heterogeneous in structure due to
7
differences in glycosylation patterns, instability throughout production and terminal
processing. Examples of this are occurring deamidation forms in both heavy and light
chains or, more rarely, formation of abnormal heavy chains with less amino acid residues
than normal heavy chain. [1] Undesirable post-translational chemical modifications, such
as asparagine deamidation, or degradation products are also sources of molecular vari-
ability in antibody engineering. However, these problems can be solved by prediction of
problematic residues and omitting these from the sequence of the coding gene [4].
1.3.2 Instability in protein formulations
Like other proteins, antibodies are subject to a number of degradation pathways. These
pathways are divided into chemical and physical instabilities.
1.3.2.1 Chemical Instability
Numerous chemical degradation pathways have been reported. Proteins may lose biolo-
gical activity depending on the site where the chemical changes occurred [1]. The major
chemical degradation pathways occurring in an antibdoy are dissulfide formation/ ex-
change, cross-linking, deamidation, isomerisation, oxidation and fragmentation.
Disulfide Formation or Exchange
In native proteins / peptides, cystein is rarely in the reduced form, being present
typically linked with another cysteine residue as a cystine disulfide (R-S-S-R). In the
presence of other thiols (H-S-R’), a disulfide can interchange to give a mixed disulfide
(H-S-S-R’) [15]. This type of chemical instability a common pathway for cross-linking,
influencing increased protein aggregation [11]. A participating thiolate ion can come
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from a free cysteine in a reduced peptide or protein, or it can come from species added
or occurring during numerous processing steps, such as lyophilisation [1, 15]. This type
of degradation reaction is base catalysed, which means that peptides or proteins cystine-
rich should not be stored in alkaline pH buffers [1, 15].
Non-reducible Cross-Linking
Non-reducible cross-linking between proteins has also been observed as a possible
degradation pathway. Nonreducible cross-linking can lead to high molecular weight ag-
gregates that cross-link due to other chemical pathways than disulfide formation, such as
oxidative steps. It can occur during storage in either liquid or solid protein products [1].
Deamidation
Deamidation has been extensively reported in literature [1, 16–19]. It is the most
common chemical degradation pathway that occurs in proteins which is a nonenzymatic
covalent modification. Deamidation can occur in both liquid and solid state and during
storage [1]. In proteins corresponds to conversion of asparagine aminoacid residue (Asn)
to aspartate or iso-aspartate, by loss of an amide functional group, release of ammonia
and transformation to acidic groups. The pathway goes through the intermediate of
succinimide at Asn and Gln (glutamine), occurring more readily in the former [1, 20].
This reaction occurs in water-accessible regions of proteins at basic or neutral condi-
tions. The key step is the formation of a deprotonated amide nitrogen which attacks a
side-chain carbonyl, resulting in a tetrahedral intermediate and formation of the succin-
imide ring. The ring is then subject to hydrolysis, resulting in either aspartic acid or
the iso-aspartic acid [20]. Although depending on the protein, deamidation can result
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in thermal instability or further chemical susceptibility, influencing in many cases the
protein’s secondary structure by affecting its folding pattern [20,21].
Many factors, such as sequence, steric effect and pH can affect the deamidation rate
via succinimidation in proteins. Buffers, ionic strength, solvents and polymers and sug-
ars have been studied to allow stabilisation of proteins and peptides in order to minimise
deamidation [20].
Isomerisation
Isomerisation in proteins commonly occurs with formation of iso-aspartic acid, which
results from direct isomerisation of aspartic acid (Asp) and from hydrolysis of succinim-
ide intermediate. This intermediate’s production can be pH dependent occurring either
due to asparagine deamidation or aspartate dehydration. It has been shown that pH
and steric effects can influence the rate of this degradation [22,23]. In general, modific-
ations of amino acid side chains by both deamidation and isomerisation may lead to a
different conformation of the protein which can potentially lead to aggregation or self-
association [11].
Oxidation
Amino acid residues in proteins that can be oxidisable are methionine (Met), tyr-
osine (Tyr), tryptophan (Trp), histidine (His), cysteine (Cys), phenylalanine (Phe) and
proline (Pro). Although not as prevalent as deamidation or isomerisation, oxidation
can easily occur during storage of antibodies. A variety of oxidation initiators have
been reported, such as photochemical, metal ion catalysed, high energy γ-radiation and
sonication by generation of reactive oxygen species [1, 20]. This degradation pathway
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can lead to a change in biological activity of the therapeutic protein if a critical residue
for that particular activity is oxidised, or by leading to conformational change due to
oxidation [20].
Fragmentation
This kind of chemical degradation may occur in antibodies during production pro-
cesses: acidic and basic treatments, thermal stress, freeze-thaw and storage [1,24]. Frag-
ments can be masses of antibodies without a light-chain or a Fab arm, or separation
of heavy-chain and light-chain. The hinge region is very susceptible to enzymatic and
nonenzymatic cleavage, leading to fragmentation of the antibody. As examples of en-
zymatic fragmentation, papain and pepsin are the most common enzymes to generate
antibody fragments, cleaving the antibody in the hinge region or in its proximity (CH2
domain) [24]. Hydrolysis is the mechanism that can explain nonenzymatic fragmenta-
tion in the hinge region, being pH and temperature two accelerating conditions for this
degradation pathway [24]. Other less common species, resulting in both peptide and/or
disulfide bond cleavage can occur as fragments [1].
Other chemical degradation pathways
Additional degradation pathways include the formation of acidic and basic species
and terminal clipping.
Acidic and basic species formation is influenced by deamidation, making the form-
ation of acidic or basic species of an antibody an easy indication of deamidation. pH-
dependency is most likely to be the source of this chemical instability. Another pathway
that can lead to acidic or basic forms of antibodies is the Maillard reaction, where re-
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ducing sugars can react with amino acid residues leading to glycosylation [20, 25]. This
reaction results in more acidic antibody species (negatively charged). The formation of
basic species can also result from succinimide formation or removal of sialic acids [1].
Terminal clipping can occur during antibody production and processing, possibly
due to the action of basic carboxypeptidases during product processing [1, 15, 26].
1.3.2.2 Physical Instabilities
Two major physical instabilities are protein denaturation and aggregation [1, 27].
Denaturation
When proteins cannot remain stable indefinitely in the folded native state, they un-
dergo processes of denaturation, i.e. changes of its conformation, thus changing from
its native state (unfolding) [27]. A protein unfolding process can include an interme-
diate step, usually unstable, between the completely folded and the unfolded protein
monomer [27,28]. At an extreme state, these unfolded monomers can eventually lead to
protein aggregation (see below for more detailed explanation). However, not only the
unfolding state can be reversible but this process can involve partially the native state,
i.e. unfolding can be localised within the protein monomer [28].
There are many conditions that can lead to antibody denaturation, including tem-
perature change, and processing steps.
In terms of protein unfolding due to temperature, it occurs only when above a certain
temperature, denoted as ’melting temperature’, where the higher this temperature is,
the more thermally-resistant the protein is. Proteins can exhibit more than one melting
temperature, depending on the experimental and analytical settings used [27]. In the
case of monoclonal antibody formulations, it is often to evaluate conformational stabil-
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ity in the presence of various formulation (solution) conditions via determination of the
protein’s melting temperature [7].
As mentioned above, proteins can suffer denaturation (and eventually aggregation)
during production, transportation, storage and delivery steps, during which shaking
and stirring may occur. It has been recently demonstrated that denaturation due to
shear/ shaking is more likely to occur when air-liquid or solid-liquid interfaces are
present [29–32]. As an example, a study evidenced that directly inserting a needle
through an air-liquid interface of a protein solution yielded to observation of protein
aggregates that are suggested to only occur at the interface [33].
Indeed, protein adsorption to surfaces is a well documented circumstance that can
lead to protein unfolding [34–37]. This can occur since proteins present surface activity,
where in the case of fluid interfaces, this translates in a decrease of interfacial surface
tension [35]. It is the molecular structure of proteins the main factor which controls
adsorption to interfaces, with its charge distribution and hydrophobicity determinant
to this phenomenon, depending on the interface, e.g. if it is highly charged or highly
hydrophobic [34]. In its native folded state, a protein monomer tends to have its amino
acids with h hydrophobic residues buried in its core, hidden from contact with solvent to
allow the protein to remain molecularly soluble. However, proteins can still have some
amino acids with hydrophobic side chains in towards the surface of the molecule, which
can readily absorb at the interface. After adsorption, the protein can suffer conforma-
tional rearrangements that lead to partial or further unfolding [28, 34]. Once unfolding
occurs, inter-protein associations can occur and lead to aggregation [38].
Aggregation
Aggregation in antibody formulation is the most common manifestation of physical
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instability. Protein aggregates can be present and produced in liquid and solid formula-
tions depending on various conditions. Protein aggregation can be due to protein-protein
interactions, depending on the diffusion rate and geometric constraints of the interac-
tion sites. Factors such as concentration, pH, ionic strength, viscosity, and temperature
can influence the aggregation rate. Other factors such as shearing/shaking, long-term
storage or freeze-thawing may also affect antibody aggregation [1].
For therapeutic antibodies, a consequence of aggregation is that aggregates can
lead to reduced activity and increased immunogenicity potential due to conformational
changes and/or higher recognition by the immune system [10]. Therefore, it is import-
ant to control the aggregate level in antibody formulations assuring that therapeutic
protein formulations remain at their highest purity levels possible complying with U.S.
and European Pharmacopoeias [39].
Protein aggregation is comprised of multiple pathways. Figure 1.2 shows a scheme
that demonstrates the various steps involved, focusing on bulk solution conditions. In
the figure, starting with a folded protein (F) in its native state, it can form strongly
associated multimers between two or more folded monomers (Ny) [40]. Another type
of folded self-association is when self-association oligomers (F2, F3) form from folded
monomers. These monomers are formed via colloidal forces, i.e. ”weak” inter-particle
interactions. Due to the nature of these interactions, formation and dissociation of these
protein oligomers can be described as an equilibrium [41].
The other steps represented in this figure refer to aggregation starting from a non-
native (partially unfolded) protein monomer (R). In this case, R is representative of a
’reactive’ monomer that will form oligomers of irreversible nature (Ax), at the condi-
tions the aggregation occurred (e.g. due to thermal stress) [28]. The ’reactive’ partially















Figure 1.2: Scheme illustrating multiple stages and pathways to protein aggregation (adapted
from [28]).
be of reversible nature. It is from these pronuclei that a further step leads to irreversible
aggregates (Ax). These can be termed nucleus, and can include several monomer chains
(x), constituting dimers (x = 2), oligomers (x = 3 - 10) or multimers [28, 42]. The
mechanisms described here are related to non-native aggregation occurring in bulk solu-
tions, however the presence of interfaces (e.g. air-liquid, or solid-liquid) can integrate
this scheme as precursor of those species [28]. Finally, Figure 1.2 refers to behaviour
that aggregates can follow: 1) remaining soluble in solution while not suffering sub-
stantial addition of ’reactive’ monomers; 2) remaining soluble but continue to increase
the monomer chains associated, creating higher molecular weight species (in relation to
the monomer’s molecular weight); 3) are soluble but can self-assemble to create protein
precipitates (visible particles) or even lead to a change in phase (e.g. gel) [43].
As discussed earlier, in bulk solution, thermal stress can induce chemical degrada-
tions to proteins, also leading to non-native forms [11, 38]. A chemical modification of
native form of the protein can lead to aggregation, since it often induces change to non-
native form. [11, 38]. Another possible mechanism can imply the generation of critical
nucleation due to a possible formulation contaminant. In this case, continuous addition
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of native protein to the nucleus will eventually lead to visible particulates or even pre-
cipitation [38]. Freeze-thawing is an example where such aggregation mechanism could
occur, not only due to ice-solution interface present, but also due to pH changes when
crystallisation of buffer occurs as well as saturation of protein and solutes when cryo-
concentration occurs [11].
1.4 Types of formulations
According to Wang (1999), protein stability can be defined by the result of balancing
between the stabilising forces, provided by protein-protein interactions, and destabilizing
forces, mainly due to the protein’s tendency to unfold [27]. The balance can be disrupted
to by one or several of the degradation pathways which were described in the previous
section. Therefore, formulating monoclonal antibodies as therapeutic agents has the
purpose of controlling degradation and instability in order to allow for an adequate shelf
life for commercialisation. The most adequate formulation is done by choosing formu-
lation excipients (also denoted as additives) and conditions. However, it is known that
conditions and excipients chosen for a specific antibody to be formulated might not be
appropriate for another molecule due to small structural differences in each protein. A
successful formulation is defined as providing stability of the antibody as well as keep-
ing its activity and reducing potentiality of immunogenicity. Ideally excipients should
remain inert, be well tolerated and should not interfere with antibody’s structure and
activity, but contribute to protein stability [1, 2, 44].
In recent years, several reviews have been published regarding therapeutic protein
formulations (generally applied to antibodies) [1,2,27], types available [1,3], and regard-
ing excipients commonly used and their effect in protein stabilisation [44].
Liquid formulations are easily administrated and typically less expensive to produce
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compared to lyophilised drug products. However, A successful liquid formulation needs
to consider several aspects: protein concentration; effect of pH; buffering agents; effect
of formulation excipients including preservatives; effect of shearing / shaking; process
equipment used and product containers [1, 2].
Some antibodies cannot be formulated in liquid state, hence the necessity of turning
to lyophilised formulations. Critical issues of formulating in this solid state are to be
considered, such as the state that the protein is more stable at, the effect of formulation
excipients, effect of pH and buffering agents, protein concentration and moisture con-
tent [1,27]. Lyophilising a protein formulation not only focuses on maintaining stability,
it also means focusing in appropriate tonicity. However, during lyophilisation, isotonicity
can be difficult to achieve since both the protein and the formulation excipients can be
highly concentrated [5].
A widely applied method of increasing plasma half-life of proteins is to increase its
size by conjugating a poly(ethylene glycol) (PEG) molecule to the protein. This tech-
nique has been applied to antibody fragments that showed less half-life than when the
molecule contained its Fc portion. Conjugation of PEG is usually performed by attach-
ing site-specifically a PEG to an engineered antibody showing a PEG-reactive residue.
Site-specificity is important to reduce interference on losses in binding activity when
PEGylation occurs [1, 27].
Controlled release systems have been applied for proteins. The use of biodegrad-
able polymers, such as poly (lactic-glycolic) acid (PLGA), can offer controlled release of
antibodies [1, 3].
1.5 Formulating Solutions of High Protein Concentration
Typically, the amount of therapeutic protein tends to become relatively large per dose
(> 1 mg/kg), to attain the therapeutic effect [1]. A higher dose can mean that a large
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volume has to be infused, but due to out patient administration requirements, other
routes of administration are needed, such as subcutaneous route. Hence, it is necessary
to formulate therapeutic antibodies in high concentrations (> 50 mg/mL) with reduced
volume (< 1.5 mL) [8].
Formulating at high protein concentration has shown to present many challenges.
Not only it can affect protein stability, but it poses challenges to manufacture as well as
the administration of the protein drug by injection. Subcutaneous syringes are equipped
with 26 or 27 gauge needles (or of even higher gauges) which, if the preparation is too
viscous, may restrict administration. This represents the most challenging factor for for-
mulation at high protein concentration. Not only viscosity is related to painful delivery
but also means that it takes longer to deliver the requested amount, even if in a pre-filled
syringe. Therefore, it is very important to adjust and carefully study how to formulate
in order to prevent or control the product’s viscosity towards a good performance, not
only keeping in mind stability, but also manufacturing and delivery issues [1, 5, 8].
Achieving high concentration largely depends on the solubility of each therapeutical
potein. For practical purposes, protein solubility can be described as the maximum
amount of protein in co-solution with excipients, where the solution does not precipitate
nor generate a sediment [5]. Therefore, low protein solubility refers to in vitro situations,
which involves proteins that are expressed, purified and folded at room temperature, but
cannot be concentrated sufficiently for pharmaceutical or industrial applications [45].
Knowing what is the highest protein concentration achievable is still an empirical task
due to the protein’s conformational change, adsorption to surfaces and specific excipi-
ents, and more importantly, its capability to self-associate [5].
Factors such as ionic strength, salt form, pH, temperature and excipients, can con-
dition protein solubility [5, 45]. Protein solubility can also depend on how hydrated
proteins are by certain salts, amino acids or sugars, depending on these excipients’ in-
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teraction with the macromolecule [46, 47]
1.5.1 Factors leading to high viscosity at high protein concentration
From the study of flow and hydrodynamics in colloidal suspension rheology, it is known
that a material’s viscosity is a physical property which is sensitive to the material’s char-
acteristics and to the properties from its surrounding environment [48, 49]. Therefore,
in protein solutions, it is assumed that its specific properties such as shape, size and
charge, are important to consider when studying its flow behaviour [50].
Aggregation is expected to be the primary degradation pathway in highly concen-
trated protein formulations, since it depends in protein solubility and is influenced by
various interactions including protein-protein, protein-water, protein-ion and ion-water
interactions [5, 9, 45]. As previously described, aggregate formation depends on the size
of aggregates as well as the numerous mechanisms of association, which can occur sim-
ultaneously within the same product [38].
As described earlier, one form of protein aggregation is reversible self-association,
of either native monomer or non-native (partially unfolded) monomers. Reversible self-
association has been poorly studied, since the reversible aggregates may not be present
after a dilution is performed, thus being a limitation of analytical methodologies com-
monly used for aggregate detection. Moreover, when the rate of self-dissociation is low,
this condition may impact formulation and possibly affect the protein’s activity and
pharmacokinetics [51]. At high protein concentration, the equilibrium could be shifted
towards a greater amount of aggregates due to macromolecular crowding effects [5].
Whilst aggregation is due to formation of intermediate states leading to reversible
association or aggregation, protein-protein interactions are predicted to be the major
precursors of high viscosity at high concentrations [9, 52].
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Macromolecular crowding, as defined by Zhou et al., are the effects attributed to
excluded volume on the energetics and transport properties of macromolecules within
a solution of high concentration of macromolecules [53]. The author also refers mac-
romolecular confinement to be related to the effects attributed to excluded volume on
the free energy and reactivity of a macromolecule with fixed boundary, i.e. small com-
partments such as cytoskeletal structures, with an interior dimension only slightly larger
than the dimension of the largest macromolecule. Both macromolecular crowding and
confinement influence the equilibria and kinetics of macromolecule association [5,53]. As
the protein concentration increases, the fraction of total volume occupied by the pro-
tein increases resulting in the effective volume available to the protein decreasing. This
leads to an apparent higher protein concentration that favours self-association. This
association is thought to be one of the common macromolecular reactions to crowding
and confinement to increase the available volume, as well as formation of irreversible
aggregates. These solutions represent a non-ideal solution behaviour of increasing ther-
modynamic association which may be shelf-life limiting, particularly when the aggregates
become irreversible [5, 53–55].
Apart from these thermodynamically driven reactions, non specific protein-protein
interactions occurring in solution also play a part in highly concentrated macromolecular
solutions. The effects of protein-protein interactions have been explained by a model
in which macromolecules in solution, such as proteins, are comparable to effective hard
spheres, whose apparent size reflects not only steric effect but also short-ranged attrac-
tions or repulsions [53, 56]. However, this theory does not explain fully what occurs in
solutions containing high concentration of multiple solute species [56].
Non specific protein-protein interactions are mainly contributed by hydrogen bond-
ing, steric (excluded volume - i.e. volume of solution unavailable for another incoming
molecule), electrostatic, van der Waals and hydrophobic interactions. Of these, elec-
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trostatic and hydrophobic interactions are the major forces conducting protein-protein
interactions in a dilute solution. When a protein solution is highly concentrated, this
is changed [9]. The strength of the overall forces present between protein interactions
is expressed as a potential (W ). This potential measures the force between two protein
molecules averaged over all possible orientations and configurations of the solute and
solvent molecules. The intermolecular centre-centre distance is represented by (r). The
following equation represents the potential between two interacting proteins (W 22):
W22(r) =Whs(r) +Wcharge(r) +Wdisp(r) +Wosm(r) +Wassoc(r) +Wdip(r) (1.1)
In this equation, W hs is the hard sphere (excluded volume) potential, W charge refers
to charge-charge interactions, W disp is the attractive potential referred to van der Waals
forces, W osm accounts for osmotic effect of added salt, W assoc is related to the self-
association interaction of proteins, and W dip represents the interactions due to perman-
ent and induced dipole moment of interacting molecules [9, 57].
Forces that are inherently repulsive are charge-charge interactions and excluded
volume, resulting in a positive second virial coefficient. Excluded volume interactions
arise due to the inability of the centre of the molecule to penetrate the surface of an-
other molecule, hence becoming a repulsive force [50]. In high protein concentration, due
to smaller centre-centre distance, attractive and excluded volume forces are largely re-
sponsible by protein-protein interactions. Although all the interactions mentioned above
have their role in a protein solution, it is still difficult to predict solution behaviour in
all highly concentrated protein solutions, since it depends strongly on the involved pro-
tein [9].
It has been discussed in literature that strong protein-protein interactions may ex-
plain deviations from ideal behaviour of protein solutions, detected in different proper-
ties, such as osmotic pressure, density, rheology, sedimentation, among others [9]. Thus,
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studying and identifying non specific protein-protein interactions is important to protein
stability when the solution is modified under different conditions.
Factors influencing viscosity in protein solutions also include the molecule’s intrinsic
viscosity and hydrodynamics [9]. Intrinsic viscosity is dependent of the protein’s hydro-
dynamic behaviour in solution and represents the effective molecular volume when at
(i.e. close to) infinite dilution [48]. The electroviscous effect is discussed to be a overall
sum of three effects that influence a protein’s intrinsic viscosity: (i) a diffuse double layer
of the macromolecule; (ii) repulsion caused by double layers of two macromolecules; and
(iii) intermolecular repulsions that affect the shape of the molecule. Thus, this effect is
dependent on pH and ionic strength [50,58].
1.5.2 Brief review of revelant studies concerning therapeutic protein
solution rheology
Rheology is the study of the flow or deformation of materials [48, 59]. It has been
applied to the study of globular protein solutions, mainly due to the interest of food
science [60–62] and biologically relevant fluids (e.g. blood and synovial fluid) [63, 64].
In this section we summarise recent developments in the study of the flow properties of
therapeutic protein solutions.
Reversible self-association in therapeutic monoclonal antibodies and its relationship
with solution viscosity has been studied [6,51,65]. The work of Liu et al., demonstrated
that the viscosity of one of the study’s mAbs was highly dependent on its concentration,
pH and ionic strength of the buffer used. This study found that reversible self-association
was the cause behind the solution’s high viscosity, where at high ionic strengths a de-
crease of solution viscosity was observed, thus related to a disruption of electrostatic
charge interactions [6]. This study also demonstrated the effects of arginine to reduce
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the viscosity of a highly concentrated mAb solution [6]. Arginine is an amino acid com-
monly used in protein formulations due to its studied interactions with protein, which
have also been reported to generally improve a mAb’s solubility and stability. The
mechanisms involved in arginine-protein interactions appear to be of various nature,
that include preferential hydration of the protein molecule [44].
The work by Kanai et al. studied the effect of different ions of the Hofmeister series
(from kosmotropes to chaotropes: SO2−4 , Cl
−, Br−, I−, and SCN−) with solution rhe-
ology of the same monoclonal antibodies used in the previously described study [51,66].
It has been shown that the Hofmeister phenomenon has implications in direct interac-
tions between the ions and macromolecules, which cannot be fully explained by changes
in bulk water structure caused by these ions [66]. Kanai et al. showed that chao-
tropic agents (which destroy bulk water structure), such as urea and guanidine HCl,
reduced solution viscosity more than kosmotropic agents (which contribute to bulk wa-
ter structure). The authors also compared between full length mAb with its fragments,
to understand which domain would be implicated in reversible self-association [51].
Studies have also attempted at relating opalescence at high protein concentration
with high viscosity and degree of aggregation [67, 68]. The degree of opalescence in a
solution is related to the light absorbed or scattered on account of submicroscopic op-
tical density inhomogeneities of opalescent / turbid suspensions or solutions [69]. These
authors were able to demonstrate the relationship between ionic strength on the effective
charge of mAbs and its effects on viscosity and opalescence [50, 67].
It has been demonstrated how the non-ideality of rheological behaviour of high pro-
tein concentration is influenced by protein-protein interactions as well as fundamental
properties of the therapeutic molecules, such as their charge [50, 52, 70–73]. With high
surface charge and low ionic strength, this overall effect is expected to govern protein
solution behaviour [50]. Specific highly attractive interactions present in therapeutic
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proteins have been evidenced to influence the studied proteins’ charge-dependent in-
teractions, suggesting that it can explain the pH dependency of the measured high
viscosities, relating this to electroviscous effects [70, 71].
Regarding rheometry and viscometry in most literature studying rheology of thera-
peutic protein solutions, the type of instrumentation typically chosen is cone-and-plate1
rheometers [6, 9, 50, 51, 74]. Glass capillary or falling ball viscometers have also been
used [74,75].
However, as antibody products are still relatively expensive to produce, contributing
to the difficulty of accessing large quantities of material, there has been development
of instrumentation and techniques capable of measuring viscosities from materials at
sample volumes in the order of µL, constrasting to the volume of up to 1 mL when using
a cone-and-plate rheometer.
The system devised by Kalonia and colleagues, is based in a piezoelectric quartz
crystal, which is sensitive to the mechanical properties of the liquid placed on top of it.
By monitoring the quartz crystal’s electrical properties, it is possible to take measure-
ments at high frequencies (10 000 Hz), imparting such high stresses to the sample and
extracting its viscosity. An announced advantage of this system is the possibility of using
microlitre volumes (10-20 µL) [50,76,77]. Another example of an instrument using relat-
ively low quantities of sample is the microfluidics microviscometer/rheometer-on-a-chip
which has also been proven to be useful for protein solution rheology measurements [78].
Due to its construction and the operating principle2, this instrument typically allows
only measurements at high flow rates (that translate into shear stresses) [79]. This can
be an advantage, since it can allow exploring the viscosities of antibody formulations at
high flow rates similar to those achieved during syringe injection [8].
1The theoretical background to rheology and relevant instrumentation is described in Chapter 2.
2Detailed information regarding the microviscometer/rheometer-on-a-chip can be found in Chapter
2.
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An indirect measurement of protein solution viscosity using dynamic light scatter-
ing has been reported [80–82]. In this case, polystyrene particles of known diameter are
mixed with protein solutions and the particles’ apparent hydrodynamic size is measured.
Based on this instrument’s operating principle, this apparent size can then be converted
to viscosity. It has been regarded as a technique with potential advantages due to small
sample volume used and fast measurements. However, in this context, protein solutions
are assumed to have the same flow properties throughout the concentrations studied,
and problems may arise in terms of protein-particle interactions [82].
More details regarding recent developments in protein solution rheology studies are
addressed in the introduction to Chapter 4.
1.6 Characterisation of protein formulations
There are several techniques used in current research laboratories to characterise protein
formulations. There are many reviews in literature regarding this matter, referring to
advantages and disadvantages of each technique, its operating principle and [1,44,83]. A
key concept from the literature concerning the techniques used for protein formulation
characterisation, is that it is important to combine information from several techniques
with different measuring principles, known as orthogonal characterisation [10].
Several of these techniques were used throughout the work presented in this thesis
and their theoretical background is described in Chapter 2 (Materials and Methods).
Differential scanning calorimetry (DSC) is useful for determination of glass trans-
ition temperatures and phase transitions of the solid-state lyophile or dried matrix at
high protein concentration. Its use in liquid protein formulation (micro-DSC) has been
related to the determination of melting temperature of a protein when under different
formulation settings, thus determining which excipients contribute best to an increase
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of the protein’s melting temperature.
The use of vibrational spectroscopy is also important and practical to use in this
type of formulation since it is possible to analyse directly the sample without the need
for diluting or pre-analysis preparation. Fourier-Transform Infrared (FTIR) and Raman
are vibrational spectroscopy techniques that can give information on the protein’s sec-
ondary, which gives information on denaturation of the protein. Applications of FTIR
have been also on helping determining the protein’s melting temperature, for the same
purposes as those used with DSC [84].
Other techniques useful for determination of protein conformation are ultraviolet
absorption (UV), fluorescence, and near-UV (tertiary structure) and far-UV (secondary
structure) circular dichroism [5,84].
As previously mentioned, protein aggregation is important to monitor, several tech-
niques can be used for this monitorisation [10]. Separation techniques for the character-
isation of protein monomers and their aggregates include size exclusion chromatography
and protein electrophoresis using sodium dodecyl sulfate polyacrylamide gels. Tech-
niques such as dynamic and static light scattering, optical microscopy, light obscuration
and micro-flow imaging and visual inspection, are typically used for the detection and
size characterisation of protein aggregates or particulates.
Since protein aggregation can generate multiple oligomeric species of different size
range or due to different aggregation behaviour (reversibility), there have been recent
discussions in the terminology of such categories [85]. In attempt of harmonising such
terminology within the field, Nahri et al. have proposed classification of protein ag-
gregates by five different categories: size, reversibility, secondary or tertiary structure,
covalent modification and morphology (Table 1.1). Throughout this thesis, aggregate
denomination was related to its size characterisation, thus following the ’size category’
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proposed. In addition, aggregate terminology can also be addressed as soluble and insol-
uble. This has to do with the mechanism of aggregate growth, where a soluble oligomer
is molecularly soluble and grows with addition of one monomer at a time; whilst insol-
uble aggregates refer to rapidly growing oligomers that eventually precipitate or lead to
phase separation [28].
Table 1.1: Protein aggregate terminology proposed categories (adapted from [85]).
A major problem with analysis and characterisation of highly concentrated protein
formulations is that most of the analytical techniques require dilution prior analysis [5].
Diluting to lower concentration may have an impact on the result of the assay since there
will be a change in solvent concentration and content, possibly affecting the protein’s
state that may differ from the original conditions [5]. To address the issues of reduced
sample volume availability and to shorten analysis and measurement times, it has be-
come increasingly important to develop techniques in a high throughput methodology.
An example of this is the conversion of conventional protein characterisation techniques




In this chapter a description of materials and methods will be made. Information on the
proteins studied throughout the work can be found in the Materials section. A general
explanation of protocols used for buffer exchange using desalting columns and dialysis
cassettes, as well as sample concentration are also described. An account is made for
the purification, dialysis and concentration of the monoclonal antibody studied. Specific
sample preparation details will be addressed in its respective experimental chapter.
A summary of the theory related to rheology and its instrumentation is made, since
this was the principal technique used between all experimental chapters. Specific rhe-
ological protocol details will be addressed in each of the experimental chapters.
Other techniques such as UV-visible spectroscopy, light scattering, size exclusion
chromatography, tensiometry, density, micro-differential scanning calorimetry, protein
electrophoretic methods, circular dichroism, flow imaging microscopy for sub-visible
particle counting and visual inspection, are also described here since these will be referred
to in more than one experimental chapter. Each experimental chapter will include spe-
cific method details. Polymer synthesis and related characterisation methods, the pro-
tein solubility assay and determination of critical micellar concentration via fluorescence




2.1.1.1 Recombinant human albumin
Recombinant Human Albumin was kindly donated by Novozymes Biopharma UK, Ltd.
(Nottingham, UK) in the form of Recombumin R© Prime (batches used: 1104 and 1101).
The protein comes as a liquid formulation of concentration 200 mg/mL, stored at 2-8
◦C. The formulation buffer is composed of NaCl 145 mM, sodium octanoate 32 mM and
polysorbate-80 15 mg/L, at pH 7.0 ± 0.3.
2.1.1.2 Beta-lactoglobulin
The protein beta-lactoglobulin was obtained from Sigma-Aldrich (product L3908, batches
097K7012 and 080M7312V) as the mixture of bovine variants A and B, in a lyophilised
powder containing sodium chloride.
2.1.1.3 Monoclonal antibody, Immunoglobulin
The humanised monoclonal antibody studied was provided by MedImmune, LLC. (Gaith-
ersburg, Maryland, USA). It is an IgG1 of 145.461 kDa. The protein was supplied in
a lyophilised formulated format containing other additives, including a surfactant. The
formulation additives were removed by purifying the reconstituted material, as per de-
scription in section 2.2.3 of this chapter.
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2.1.2 Sample and buffer preparation details
2.1.2.1 Preparation of Buffers
All prepared buffers had a 2-month expiry date and were kept at 5 ◦. Ultrapure water
was obtained from a water cleaning resin system from NANOpure Diamond (Barnstead,
USA) with water quality of >18.0 mΩ-cm, and 0.22 µm filtered (PVDF membrane,
EMD Millipore, USA). All buffers were filtered using 0.22 µm vacuum-driven filter units
(Nalgene, USA), unless when 0.1 µm pore-size filtering was necessary (using syringe-
filters PDVF Millex-VV from EMD Millipore, USA).
(a) rAlbumin
For rAlbumin samples, the formulation buffer was composed of NaCl (145 mM), Polysorbate-
80 (145 mM) and sodium octanoate (32 mM) in ultrapure water (pH = 7.0 ± 0.3 at
room temperature). Polysorbate-80 was obtained from Fluka and of grade meeting the
standards from the European Pharmacopoeia. All other reagents were obtained from
Sigma-Aldrich, UK and were of analytical grade. Another buffer was prepared contain-
ing only NaCl (145 mM) in ultrapure water, maintaining the pH at 7.0.
(b) β-Lactoglobulin and mAb
All reagents were purchased from J.T. Baker Chemicals (Pennsylvania, USA) and were of
analytical grade. A histidine buffer was prepared containing L-Histidine and L-Histidine
monohydrochloride at 10 mM in ultrapure water (pH = 6.0 ± 0.2 at room temperature).
For circular dichroism analysis of mAb samples, a 10 mM sodium phosphate buffer pH
6.5 was prepared using monosodium phosphate monohydrate and dibasic sodium phos-
phate heptahydrate in ultrapure water.
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Buffer characterisation
The pH of buffers and samples was measured using a pH meter (model PHM220, Ra-
diometer Analytical, SAS, France) with combined Ag/ AgCl pH electrode, calibrated
with appropriate pH buffers traceable to NIST (all pH related components, including
pH calibrating buffers obtained from Radiometer Analytical SAS, France.
The buffers’ osmotic strength was measured for comparison when different samples
were dialysed into their respective buffers. A freezing-point osmometer Osmomat O30-D
(Gonotec GmbH, Germany) was used, zeroed with ultrapure water and calibrated with
a 300 mOsmol/kg NaCl aqueous solution (Gonotec GmBH, Germany). In this method,
the osmolality of a sample is measured by comparing the freezing point of pure water
with the freezing point of a sample which, if containing osmotically active compounds,
will depress water’s freezing point. For example, water has a freezing point of 0 ◦C
whereas an aqueous solution of NaCl at 1 Osmol/kg has a freezing point of -1.858 ◦C [13].
2.2 Methods
2.2.1 Buffer exchange desalting columns and sample concentration
For buffer exchange of mAb samples, disposable buffer exchange/ desalting columns were
used (PD-10 GE Healthcare, USA). These Sephadex G-25 matrix packed columns were
used via the centrifugation method, as per the manufacturer’s instructions, to avoid
sample dilution as much as possible. The columns were equilibrated with equilibration
buffer (that the samples would be exchanged to) prior to sample elution. Sample loading
was typically 2.5 mL. To guarantee an effective buffer exchange the same procedure was
repeated on freshly-equilibrated PD-10 columns.
Centrifugal concentrators were used since it was needed to concentrate protein samples
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to achieve a higher concentration than the starting material. The centrifugal concentrat-
ors were chosen accordingly to the protein’s size, as the membrane cut-off size should
always be at least 10 times smaller than the size of protein monomer. For rAlbumin
samples, the concentrators used were Vivaspin 20 5 kDa molecular weight cut-off size
of PES (polyethersulfone) membrane (Sartorius Stedim, Ltd., UK). For mAb samples
the centrifugal concentrators used were Amicon Ultra 30 kDa molecular weight cut-off
size of regenerated cellulose membrane (EMD Millipore, USA). For sample concentra-
tion the procedure was followed by the manufacturer’s recommendations and adapting
to the laboratory centrifuges available at the time: either a swing-bucket rotor (Heraeus
Mega Fuge 11R, Thermo Fisher Scientific, USA); or a fixed 45-angle rotor (Hermle Z400,
Labortechnik GmbH, Germany). On all occasions, the centrifugal concentrators were
rinsed before used. After centrifugation, all samples were collected, mixed and checked
for their concentration.
2.2.2 β-Lactoglobulin sample dialysis
For β-lactoglobulin samples, as the protein was obtained as a lyophilised powder, sample
preparation consisted of dissolving in a 10 mM His-His.HCl buffer (pH 6.0) with aid of a
oscillatory shaker at mild shaking conditions (∼ 70 rpm) until all sample was dissolved.
After complete dissolution, sample dialysis was done using a 3.5 kDa membrane cut-off
dialysis cassette (Slide-a-lyzer, Pierce Lab, Thermo Fisher Scientific, USA). Dialysis in
the appropriate buffer, in a volumetric ratio of 200 times more than sample volume,
was performed and repeated at least 3 times. After the dialysis, the sample was either
kept as an unfiltered stock or it was filtered using specific syringe-filters according to
the experiment requirements. After this procedure, the β-lactoglobulin samples were
checked for protein concentration, pH and osmolality.
33
2.2.3 Purification, dialysis and concentration of the IgG1 mAb
For complete removal of additives present in the original lyophilised formulation of the
mAb purification of the reconstituted material was performed with affinity chromato-
graphy. This technique separates proteins based on a reversible interaction between a
protein and a ligand attached to the chromatographic matrix when the elution conditions
are set up to enhance this interaction. In the case of immunoglobulins G, purification
can be made with high affinity of protein A and protein G for the Fc region of the IgG-
type of antibodies. Protein A and protein G are bacterial proteins (from Staphylococcus
aureus and Streptococcus sp. bacteria, respectively) which can be covalently attached to
the inert matrix and have relative binding strengths according to the different immuno-
globulins, making these ligands a useful media for antibody purification [86, 87]. In the
case of the IgG1 studied in this work, the media used was an agarose matrix with an
alkali-stabilised recombinant protein A.
A typical affinity chromatography method for protein purification involves the fol-
lowing steps (Figure 2.1) :
1. column equilibration with buffer that provides conditions for protein-ligand bind-
ing;
2. injection of the sample, where target protein(s) will bind reversibly and specifically
to the ligand while the unbound material will be eluted out of the column;
3. a recovery step where by changing the conditions to allow elution of the bound
protein(s) (e.g. change in pH, change in ionic strength or competitive binding);



































Figure 2.1: Scheme showing the general steps for affinity chromatography. Affinity chromato-
graphy was used to recover the mAb from a formulated product containing a surfactant. The
ligand that specifically bound to the IgG1 was a recombinant protein A, which is effectively and
widely used for purification of IgGs. (Image adapted from reference [87].)
mAb Purification protocol details
The chromatographic system used was an A¨KTA purifier 10, with a pH detector and
UV spectrophotometer detector (measuring absorbance at 280 nm). The column used
was a HiScale column (ID 2.6 mm x 40 cm) with MabSelect SuRe resin (with a capacity
of ∼ 30 mg of mAb/ 1 mL of resin). All components were obtained from GE Healthcare,
USA.
The following buffers were prepared/ used:
1. Dulbecco’s PBS 1x at pH 7.2 (from Sigma-Aldrich, USA) - equilibrating and elution
buffer for non-bound components;
2. 50 mM sodium hydroxide (NaOH) + 1 M sodium chloride (NaCl) - sanitising
buffer;
3. 50 mM glycine + 30 mM NaCl pH 3.5 - elution buffer for bound material;
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4. 1 M Tris pH 9.0 - titration buffer;
5. 10 mM His-His.HCl pH 6.0 - sample’s target buffer;
6. Water/ ethanol 80/20 %v/v - column storage buffer.
After loading the column with the resin, the run began with a sanitising elution with
buffer 2. Column equilibration with PBS followed this sanitising step until the pH of the
column eluant reached pH 7.2. After this was achieved, the reconstituted mAb sample
was loaded and the elution with PBS continued until at least 10 column volumes. To
elute the mAb, 50 mM glycine and 30 mM NaCl pH 3.5 buffer was used. Collection
of the material was monitored with the change in pH and absorption at 280 nm. After
all the product was eluted and collected, it was immediately titrated with 1 M Tris pH
9.0 buffer to pH 6.0. After titration, the material was filtered using a 0.22 µm pore
size membrane vacuum-driven filter unit (Nalgene, USA). Meanwhile, the column was
sanitised again with buffer 2 and re-equilibrated with PBS. These steps were repeated
until all mAb material was purified. If the column was not to be used again, it was
stored in water/ethanol 80/20 %v/v after running at least 5 column volumes and kept
in this buffer at 2-8 ◦C.. Flow rate in all steps was 10 ml/min.
For this study the mAb was purified using the protocol above on two different oc-
casions. It was the subsequent concentration step that differed between batches. The
concentration methods were chosen differently depending on the amount of protein ma-
terial that needed to be concentrated. Therefore, from this point forward, the material
that was concentrated using the stirred cell method is referred to as mAb batch 1 (mAb
b1), and the material that was concentrated using tangential flow filtration is referred
to as mAb batch 2 (mAb b2).
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Diafiltration and concentration steps
(a) Stirred ultrafiltration cell (mAb batch 1)
An Amicon Stirred cell system (EMD Millipore, USA) was used for batch 1 of the
purified mAb as the total volume collected was ∼ 400 mL. This method provides di-
afiltration and concentration of the material by use of a magnetic stirring bar which
keeps the fluid movement during operation thereby reducing the build-up of concen-
trated material on the membrane. An auxiliary reservoir containing the desired sample
buffer is coupled to the stirred cell system which will keep the stirred fluid volume and
concentration constant as the filtrate volume is replaced by the new buffer. This is a
substitution for membrane dialysis (such as that described in section 2.2.2). After dia-
lysis, the material was then concentrated on the same device by direct application of
gas pressure. The solutes above the membrane molecular weight cut-off (Ultracel PL
regenerated cellulose membrane, 30 kDa molecular weight cut-off, EMD Millipore, USA)
are retained in the cell, while water and solutes below the cut-off flow into the filtrate.
This batch was concentrated to ∼88 mg/mL.
(b) Tangential flow filtration (mAb batch 2)
Tangential flow filtration (TFF) is a pressure-driven ultrafiltration/concentration
method that uses membranes to separate proteins in a liquid solution on the basis of
size/ molecular weight. TFF differs from the method described above (stirred cell)
in the way that the fluid flows while it is being filtered. In the stirred cell, the fluid
containing its solutes is pushed against the membrane by applying gas pressure. In TFF,
the solute-containing fluid is flowing tangentially along the surface of the membrane.
Hence, TFF is designed so that the retained molecules do not build up at the surface of
the membrane [88]. This process also allows combination with diafiltration, where the
concentration of protein is maintained but a buffer exchange occurs while the filtrate is
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removed.
A Pellicon 2 mini cassette was used for diafiltration and TFF of this batch, the
polyethersulfone void free membrane was of 30 kDa molecular weight cut-off, surface
area 0.1 m2 with coarse screened feed channels (EMD Millipore, USA). The system
was composed of membrane, membrane holder, peristaltic pump, reservoirs, tubes and
manometers to measure the pressure applied to the membrane.
After concentrating most of the material to ∼100 mg/mL, another batch of material
was collected (∼17 mg/mL) by flushing out the remaining mAb left in the TFF system
with sample buffer (10 mM His-His.HCl, pH 6.0). Thus, mAb batch 2 was divided in
two sub-batches 2a and 2b, corresponding to the concentrated and dilute materials.
Independent of the diafiltration/ concentration method used, all mAb batches were
checked for concentration, pH, osmometry, aggregation level by HPSEC. Additionally,
all batches were checked for presence of the non-ionic surfactant that was an additive
in the original mAb lyophilised formulation (this procedure was performed at and
by MedImmune staff, in Gaithersburg, MD, USA). The three batches were collected
in Nalgene (ThermoScientific, USA) PET (polyethylene terephthalate) bottles of
appropriate volume, filtered with 0.2 µm pore-size membrane filters before storage and
kept at 2-5 ◦C conditions until used for experiments.
2.2.4 Rheology
2.2.4.1 Basic definitions
Rheology is the study of deformation of solids and the flow of fluids. This branch of
physics allows the study and characterisation of materials when under shear. Thus,
materials can be characterised between extremes between being ideal viscous fluids, e.g.
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a low-viscosity mineral oil, or purely elastic solids, e.g. a piece of steel. In between
there are materials that combine both viscous and elastic components, being therefore
denominated viscoelastic materials (e.g. toothpaste or shower gel). However, to determ-
ine these characteristics, it is important to understand that the rheological behaviour
of materials is dependent on the shear applied (e.g. low-shear or high-shear), the way
the sample is loaded (e.g. force applied), temperature and time, as well as many other
parameters (e.g. pH, concentration, presence and size of particles, etc.) [48, 49]
For easy understanding of the fundamental rheological parameters, a two-plates
model is used. In this case, the sample is between two plates and it is sheared in
the gap (h). The upper plate is set in motion by a shearing force (F ) on the shearing
area (A), while the lower plate remains fixed, with a resulting velocity (v) (Figure 2.2).
In this simple case, two assumptions are made: the sample does not slip nor slide out of
its shearing gap; the conditions are for laminar flow (i.e. flow in layers) [59, 89,90].





with the force (F, in [N]) and the shearing area (A, in [m2]), the S.I. unit for shear stress





with velocity (v, in [m/s]) and the distance (h, in [m]), the S.I. unit for shear rate is
[1/s or s−1]. For many processes, a shear rate can be calculated or estimated to have







Figure 2.2: Schematic of the velocity of a fluid using the two-plates model for shear rheology.
The top plate (boundary) moves due to an applied force (F ), causing the fluid to shear, while
the bottom plate remains stationary.





where viscosity (η) has S.I. units of [Pa.s]. Physically, viscosity represents the resistence
to flow that all materials will inherently show, since upon shear the molecules consti-
tuting the material will move in relation to each other, thus contributing to an internal
friction forces [49,89]. Although not a S.I. unit, the [P] (Poise) is still sometimes a unit





with the density ρ [kg/m3], where the S.I. unit for ν is [mm2/s] [49, 89, 90].
2.2.4.2 Flow curves and viscosity functions
Newton’s Law describes the flow behaviour of a purely viscous material:
τ = ηγ˙ (2.5)
The flow behaviour can be represented using flow curves and viscosity curves. A flow
curve represents the dependence of shear stress τ on shear rate γ˙, while a viscosity curve
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represents the dependence of shear viscosity η on shear rate.
Typically, in order to characterise the test material, if possible, flow and viscosity
curves are perfomed since the results can give an idea whether the material is ideal-
viscous or if appears to have signs of elasticity. In figure 2.3(a) (and corresponding
flow curve in figure 2.3(b)), the most common possible sample profiles are represented
for different flow behaviours: ideal-viscous, with constant viscosity along the applied
shear rates; shear-thinning, when there is a decrease of viscosity with shear rate; and
shear-thickening, when the viscosity increases with shear rate. The practical tests that
can yield these type of curves are denominated rotational tests. Rotational tests can
be performed with presets controlling the rotational speed (n, in [min−1] ), thus col-
lecting torque (M , in [mN.m]) as response of the sample; or by controlling the shear
stress, where the opposite occurs. These parameters (speed and torque) are the raw
parameters measured by a rheometer, and via the instrumental software are converted
automatically into shear rate, shear stress and shear viscosity. Examples of materials
with shear-thinning properties are polymer dispersions and polymer melts [49, 90]. The
case of shear-thinning materials represents the circumstance where the internal friction
forces are shear-load dependent. The ratio at which this happens can vary, thus it is
often to refer to ”apparent shear viscosity” where the viscosity at each shear rate rep-
resents that point only. Shear-thinning is often related to the structure of molecules and
the way these are originally entangled and disentangle as shear is applied, as an explana-
tion of how the intermolecular forces yield less flow resistance with the increase of shear
load. This is commonly interpreted with samples such as polymer solutions [49, 89].
In the case of colloidal dispersions, for example, the explanation is given in relation
to the intermolecular forces that can become weaker and weaker as the shear-load in-
creases [48, 49,90].
Examples of shear-thickening materials are those dispersions with very high concen-
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tration of solids or gel-like particles, such as ceramic suspensions or starch dispersions.
The term ”apparent shear viscosity” is also applied in this case. For shear-thickening
materials, which are less common in industry, the rationale to account for the increase
of viscosity with the increase of shear load is related to increased interaction between






















Figure 2.3: Examples of general of viscosity curves (a) and flow curves (b) for materials showing:
A - idealviscous (Newtonian flow), B - shear-thinning, and C - shear-thickening behaviour, and
D - yield behaviour with a yield point. Note that the axes are represented in linear scales.
However, it should be noted that shear-thickening effects can also appear during
experimental conditions due to flow instabilities and turbulance. These have to do
with hydrodynamic flow and the appearance of centrifugal or inertial forces due to the
mass of the fluid [49]. These can be particularly important for low-viscosity liquids.
Therefore there is one important dimensionless number that is critical to determine
if the experimental conditions are due to create hydrodynamic flow instabilities. The
Reynolds number (Re) represents the ratio between the force due to mass inertia of the








with vm as the mean velocity of the fluid, and L as the characteristic length of the
geometry used in the measurement [48]. Re numbers are thus used to characterise
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flow conditions. In the case of a couette (cup-and-bob) geometry, if Re < 1000, the
conditions are of laminar flow; 1000 < Re < 2000, correspond to a transition range; and
if Re > 2000, the conditions are of turbulent flow [48,49]. This turbulence can occur in
low-viscosity fluids particularly when using couette geometries where the cup is rotating
and the bob stationary, and is related to the dimension of the annular shearing gap in
this type of geometry [49,59].
There are materials can show yield type of behaviour (see general curve D, in Figure
2.3). Materials that yield only start flowing when the external applied force is larger
than the internal forces that are resistant to flow. Typically, below the material’s yield
point, it shows an elastic behaviour, a solid-like behaviour where the material flows to
a small degree. Yield stress (also called yield point) can be determined by controlled
shear rate experiments, where shear stress is measured in function of the shear rate.
Curve-fitting can be performed choosing one of the different models that account for
yield behaviour (e.g. Bingham, Casson or Herschel/Bulkley), where the yield point is
extrapolated to when γ˙ = 0 [48,49]
Time dependency of a material’s response is important to its rheological charac-
terisation. To monitor the shear behaviour of a sample in function of time, all the
other applied parameters (shear stress or shear rate, temperature) should remain
constant. Different behaviours can occur with time, such as thixotropy and rheopectic
behaviours. A material that shows thixotropy typically has its shear viscosity reduced
when shearing occurs. After this, and if left at rest, the same material can increase
its viscosity, showing a degree of ’memory’, regenerating the possible interactions that
were present before it was sheared. A thixotropic material thus undergoes a reversible
deformation process. When the opposite occurs, irreversibility of deformation, of the
test sample is considered ’non-thixotropic’. Another time-dependent behaviour is
rheopexy. In rheopetic fluids, when there is an increase of shear viscosity, structural
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strengthening can occur as result, which when followed by complete rest shows complete
decomposition of the structure [49, 89].
2.2.4.3 Oscillatory shear rheology
Oscillatory rheology concerns the detailed measurement of the material’s relative con-
tributions of its viscous and elastic properties. If a test material is again imagined in
between two-plates (Figure 2.4(a)), during an oscillatory test the moving top plate will
oscillate back and forth with a specific frequency and amplitude. The bottom plate
remains stationary and it is where the resulting force is measured. It is assumed that
homogeneous deformation occurs in the sample across the shear gap. When a strain (or
stress) is applied on the top plate at different frequency and amplitude, these will be the
parameters that define the timescales to which the material will respond to. Thus, when
a sinusoidal strain is applied to a material, the deformation function can be expressed
as:
γ(t) = γo sinωt (2.7)
where γ is strain, γo is the shear strain amplitude (in [%]) and ω is the angular frequency
(in [rad/s]).
The linear response of the material can be given by:
τ(t) = τo sin(ωt+ δ) (2.8)
where τ is the stress, and δ is the phase shift (in [◦] between applied strain and
measured stress (see figure 2.4(b)). Typically, linear responses are obtained if small
amplitudes are used of the applied strain. If larger stresses and/or amplitudes are used,
the measurement will tend to yield non-linear responses of the materials [48, 90]. In












Figure 2.4: (a) Two-plates model to represent oscillatory shear with the top plate oscillating
sideways due to the applied force (F ). The bottom plate remains stationary and the deflection
angle (ϕ) in the shear gap (h) is shown to represent the shearing of the material. (b) Shear strain
function (γ(t)) is represented with the resulting shear stress function (τ(t)). In this case, both
functions have the same frequency, but between the applied strain and the resulting stress there
is a phase shift angle (δ).
For an idealviscous fluid, Newton’s law applies:
τ(t) = η∗γ˙(t) (2.9)
where η∗ is complex viscosity, τ and γ˙ are sine functions in order of time. For these type
of samples the phase shift angle between strain and stress is δ = 90◦ [49, 89, 90].
For idealelastic materials, Hooke’s law applies:
τ(t) = G∗γ˙(t) (2.10)
where G∗ is the complex shear modulus, with τ and γ˙ being time-dependent in sine
functions. The phase shift angle for purely elastic samples will be δ = 0◦.
For viscoelastic samples, the phase shift will have an angle value between 0◦ < δ <
90◦. The rheological behaviour of these samples comprises both viscous and elastic
deformations, which can be characterised and quantified with the use of complex math-
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ematics by calculating the loss modulus (relative to the viscous portion) and the storage
modulus (relative to the elastic portion) [49, 89, 90]. The loss modulus, G′′, measures
the deformation energy used by the sample during and after shear. The energy loss
occurs while there is loss of the material’s structure, i.e. when the sample flows while
its molecules or particle components are moving in relation to each other, thus showing





The storage modulus, G′, measures the deformation energy stored by the sample during
shear. After shearing, the sample can recover partially or completely to compensate
the previous structure deformation, thus showing a reversible deformation behaviour.






From equation 2.8, and based on the material properties G′ and G′′, this function
can be written as:
τ = G′(ω) sinωt+G′′(ω) cosωt (2.13)
The relation between G′, G′′ and G∗ is that |G∗| =
√
(G′)2 + (G′′)2. The damping
factor, tan δ = G′′/G′, is the ratio between the viscous and elastic portion of a sample,
and for viscoelastic samples, it will have a value between 0 < tan δ <∞.
A simple model that describes the behaviour of viscoelastic materials is the Maxwell
model that relates the response of the material based on its characteristic relaxation





Large values of λ in practice mean that the material has elastic behaviour, while lower
values of λ represent a viscous behaviour. In this equation, η0 represents zero-shear
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viscosity, which is the viscosity at the limiting value of complex viscosity (η∗) at infinitely
low angular frequencies (limω→0 η
∗(ω)) [49, 89, 90].
Therefore, in the case of the Maxwell model for viscoelastic fluids, G′ and G′′ can be








In oscillatory shear rheology it is common to perform an amplitude test to determ-
ine the linear viscoelastic range (LVE) of a material. In this type of test the angular
frequency (ω) is kept constant while the amplitude of the applied strain is varied. Monit-
orisation of G′ and G′′, as well as δ and η∗ (or tan δ), in function of the strain. Typically,
if the applied strain is too large the sample’s structure or network (held by either chem-
ical or physical interactions) can be irreversibly affected. From that point onwards, it is
common to observe decrease of both loss and elastic moduli. The strain values before this
occurs are due to a stable structure where reversible deformation occurs nondestruct-
ively, hence denominating this range of linear viscoelastic range (usually performed at
small amplitudes) [90].
The linear viscoelastic range is defined by the proportionality of the applied strain
and measured parameters. If analysing the material’s behaviour well within its LVE
range, it is common to relate the resulting G′ and G′′ to characterise the sample. There-
fore, if G′ > G′′, the elastic behaviour dominates over the viscous portion, indicating a
solid-like behaviour; if G′′ > G′, the viscous behaviour is dominating the elastic charac-
teristics of the sample, indicating a liquid-like character. Another situation could be if
G′ = G′′, in which case the material has balanced characteristics of both elasticity and
viscosity [89].
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From the discussion above, it is clear that for an unknown sample it is desirable
to determine the LVE range and critical strain, and it is important to keep in mind
that these parameters are valid only for the angular frequency tested. Following the
amplitude sweep, is usual to test sample’s rheological behaviour at variable frequencies,
keeping the amplitude at a constant value. In a oscillatory frequency sweep the informa-
tion collected on the sample’s rheological behaviour (G′ and G′′), studied in the LVE, is
time-dependent. The sample’s behaviour can be interpreted in terms of its response to
the applied strain at long times (low frequencies) compared to its response to the same
strain at short times (high frequencies).
Knowing the amplitude and angular frequency that can relate to practical use of
the specific test sample, varying the temperature, pressure or analysing its behaviour
along time, are common experiments that can yield further information on the sample’s
rheology [49].
2.2.5 Rheometry and instrumentation
The rheological characterisation can be challenging due to the importance of choosing
the most suitable hardware to correctly characterise the sample. In this section, the
focus is on explaining how a conventional (rotational/ oscillation) rheometer works,
what were the different geometries used for all rheology experiments and an explanation
of how these measure the viscosity, as well as describing other instrumentation, such
as viscometers, used to acquire viscosity values at different conditions than those
measured with the rheometer. The equipment and techniques described in this section
were those proven to be the more convenient and available at the time to use for an
appropriate rheological measurement of protein solutions. It is worth noting that there
are more measurement equipment and for a complete revision of the different equipment
and techniques available, particularly for traditional techniques and instrumentation,
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references such as [91] and [59] are compreehensive sources for this information.
2.2.5.1 Rheometer
The rheometer is an advanced instrument that allows the user to characterise the rhe-
ological properties of samples through various rheological tests, such as stress or shear
rate controlled tests, creep and relaxation tests, including various types oscillatory tests.
Conventional rheometers have a single-head where the motor and transducer are in
the same system on the side which connects to the measuring geometry. This single-head
can be controlled in two modes: 1) controlled shear rate (CSR) , where the deflection
angles and rotational speeds are controlled by the motor, with the resulting torques be-
ing detected; or 2) controlled shear rate (CSS) , where the torques are set by the motor
and the deflection angles or rotational speeds are detected by the position sensor.
A bearing is needed in a rheometer to allow that its movable part can rotate around
a fixed axis. Bearings can be of different types (e.g. air, mechanical, or magnetic) and
their use in rheometer instrumentation are to reduce the internal friction effects and
inertia effects to the minimum, so that the total torque (Mtotal) measured is due to the
rheological response of the test sample only. In an air bearing, the rotating parts float on
an air ’bed’ created by the continuous supply of compressed air into a gap between the
rotor and the stationary component. This is to reduce direct mechanical contact between
moving and fixed parts, and to reduce potential increase of internal frictions [49].
The rheometers used throughout this work were an Anton-Paar (Graz, Austria)
Modular Compact Rheometer (MCR) 301, MCR 302 and MCR 501; as well as a TA
Instruments (New Castle, Delaware, United States of America) AR-G2 model.
49
2.2.5.2 Bulk measurements
Bulk rheology measurements can be performed with different type of geometries. In
this case, since protein solutions are generally considered low viscosity samples, the
choice of geometries is largely due to this fact. Besides low viscosity, the other limiting
factor can be availability of sample volume. For these reasons, this section will only
focus on the measuring geometries that were used specifically for the studies presented
in this thesis.
1. Cone-and-plate
A cone-and-plate geometry is composed by a lower fixed flat circular plate and a
top moving shallow cone which has a truncation (Figure 2.5)T˙he dimensions of
the geometry are given by its radius (R) and its angle (α). Truncation of the
cone avoids any friction between cone and the bottom plate, and allows a fixed
gap setting for analysis (as opposed with plate-plate geometry, where different gap
settings may be chosen). With a cone-and-plate, the measurement of shear stress
depends of torque (M) and its radius (R), where Css is the measuring system’s





Therefore an increased sensitivity can be achieved if the cone’s radius is larger
[48, 49].














where the maximum velocity and gap are reached at the edge of the cone, and
for cones with small angle (e.g. < 3◦) tanα is approximately equal to α. In these
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cases, and from this equation, the shear rate will be independent of cone angle
and radius, therefore, it will remain constant throughout the sample [48].
The advantages of the cone-and-plate geometry are: it shows constant shear rate
throughout the conical gap (in contrast to the varying shear rates conditions in
a parallel plate geometry); the sample volume can be very small; cleaning and
filling the gap is relatively easy. Disadvantages are: the limitation of particle
size regarding the fixed measurement gap; as the sample contains an air/water
interface at the cone’s edge, evaporation can be a problem [49].
Cone-and-plate geometries used throughout this study were stainless steel CP50-1
(R = 50 mm and cone angle = 1◦) and CP40-0.3 (R = 40 mm and cone angle
= 0.3◦), both from Anton-Paar. Sample volume for CP50-1 was 675 µL and
for CP40-0.3 was 150 µL. This geometry was always used with an evaporation




Figure 2.5: Schematics of the cone-and-plate measuring system. L represents the geometry’s
diameter, α is the cone angle and h is the cone’s fixed gap related to its truncation.
2. Double-gap concentric cylinder
The double-gap concentric cylinder geometry is a modified concentric cylinder that
allows measurement of low viscosity samples due to its increased shear area which
is in contact with the sample. An inner cylinder is in the centre of the cup which
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results in an annular gap (see figure 2.6). To achieve uniform shearing (rate)
conditions in the inner and outer gap, the length of the immersed part of the
rotating bob is L ≥ 3R3 and the ratio between radii is δcc = R4/R3 = R2/R1 ≤
1.15 [49]. The major advantage of this geometry is the capability of achieving lower
torques. However, sample volume is much larger than that used for cone-and-plate
and it can be more difficult to clean [49].
The double-gap geometry used in this work was a stainless steel DG26.7 (Anton-
Paar, Graz, Austria). Sample volume when using this measuring system was 3.8
mL. The relevant dimensions of the DG26.7 were: L = 40 mm; R1 = 11.914 mm;






Figure 2.6: Schematics of the double-gap concentric cylinder measuring system. L represents
the length of the geometry immersed in the sample, R1 to R4 are the different radii that define
the annular gap where the sample is loaded.
2.2.5.3 Interfacial shear rheology with the double wall-ring geometry
Interfacial rheology studies the fluid dynamics of films or layers that are formed on the
interfaces of liquids by measuring their response to a dilatational deformation or a shear
deformation. Interfacial rheology describes the relationship between the deformation of
the surface, the stresses applied on and in it, and the resulting flows in the sub-phases.
There are many techniques that can be used to describe the rheology of an interface,
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some being indirect by measuring via imaging and other being direct methods, meas-
uring directly the surface [92]. Examples of direct interfacial rheology measurement
techniques are with the double wall-ring, a bicone geometry, oscillating needles and tor-
sion pendulum technique [92,93].
In interfacial shear rheology, where the measurements are typically performed with
a constant surface area, the flows are generated by moving solid geometries within the
interface or by applying varying surface pressures [93]. It is therefore important that the
resulting flow can be decoupled only for the interfacial layer rather than having contribu-
tions due to the sub-phases. For this, the design of the geometry is very important where
the measurement of interfacial viscosity can be maximised. A dimensionless parameter,








where ηs is the interfacial shear viscosity, η is the bulk shear viscosity and L and LB are
characteristic length scales for the shear flow in the interface and bulk, respectively. Ps
is the contact perimeter between the interface and the geometry, AB is the contact area
between the geometry and the bulk, V is velocity, and lG is the characteristic length
scale of the geometry. If Bo ≫ 1, the surface shear viscosity dominates over bulk. This
can be increased with use of a geometry that has a larger contact area or that minimises
the characteristic length scale [93,94]. This is the case of the double wall-ring, since the
dimensions of the ring yield a lG = 0.7 mm, leading to higher Boussinesq numbers when
compared to the bicone [94].
The double wall-ring (DWR) (Figure 2.7) is a geometry composed by a trough and a
ring that is positioned at the gas/liquid or liquid/liquid interface and which is connected
to the rheometer (in this case, a AR-G2, TA Instruments, USA). The sample holder,
made of Teflon material, was placed on the bottom peltier plate of the rheometer. The
ring was square-shaped (cross-section), made of platinum/iridium so that it could be
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flamed to remove organic contaminants. The walls of the ring had a step to prevent
meniscus effects at the inner and outer sides of the trough. According to the developers
of this fairly recent geometry, the DWR presents a ration As to Ps, respectively, interfa-
cial contact area and perimeter, is about 48 times smaller when compared to a bi-cone
geometry with a similar radius that of the ring, which results in a high Boussinesq num-
ber for a given surface viscosity [94]. Sample volume for these experiments was of ∼18
mL of fresh sample. After sample loading, the ring was lowered and positioned on the
freshly formed air/water interface.
According to Vandebril et al., it is sometimes necessary to correct the experimental
data for the case that deviations between this data and theoretical values occurs. Cor-
rection of data is performed by computing corrected values via an algorithm developed
by the authors [94]. However, the authors also demonstrated that corrections are only
necessary when surface viscosities reach values below 10−5 Pa.s.m. In all the cases of
our measurements, our data points were above this limit.


Figure 2.7: Schematic of double wall-ring (DWR) measuring system for interfacial shear rheo-
metry (adapted from reference [94]). The ring has a square-shaped cross-section, with width
of 1 mm and is made out of Pt/Ir. The radii R1 to R6 are represented to show the different
dimensions of the fixture, the height H from the interface to the bottom of the channel measures
10 mm.
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2.2.5.4 Rheometer calibration check
Calibration tests with ideal viscous (Newtonian) fluids such as deionised water or other
solvents of similar viscosity (at 20 or 25 ◦C) were run to test if the instruments showed
the minimal torque according to expected (typically 0.1 µmN.m or better, depending on
the instrument).
The calibration checks, which were run for all geometries used, also served as dia-
gnostic that thel instruments were measuring the correct viscosities for the standard oils.
An error of 2 % was allowed for each of the standard oils being measured. The meas-
urements were done both at 20 and 25 ◦C. The standard oils were bought from Paragon
Scientific Ltd. (Wirral, UK) and Cannon Instruments (State College, Pennsylvania,
USA) in a range of viscosity that would cover the low viscosities of the test samples.
These general purpose viscosity reference oils were blends of hydrocarbonate oils. Viscos-
ities for all these general purpose standard oils were based on the value for the viscosity
of water (1.0016 mPa.s at 20 ◦C; defined by NIST).
2.2.5.5 Sample preparation for rheological analysis and other measurement
details
For all rheological experiments performed, the experimental settings had to comprise
of devices that would allow a constant temperature during analysis. For this reason,
the lower fixed plate or cup were connected to a peltier unit. As the moving fixtures
(cone or cylinder) were not connected to a peltier device, if possible, the measurement
temperature was maintained by use of a peltier hood.
An evaporation blocking system was used with the cone-and-plate to prevent
evaporation of sample. This system is comprised of a inner metal ring inside the peltier
hood that would sit in a solvent trap around the lower plate. Plastic vapour locks were
used to sit on top of the solvent trap present on top of the peltier hood.
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It was important to reduce the appearance of air bubbles in the samples and during
loading to avoid artifacts in the measurements. Regarding loading, this would be
resolved by fine tuning the speed used to lower the upper fixture. Generally, depending
on how concentrated the samples were, a low vacuum was used to induce bursting of
air bubbles. It was important to do this procedure for short times (<10 s) to prevent
sample evaporation.
Further protocol details for the rheological tests can be found in the methods section
of each of the experimental chapters.
2.2.6 Viscometers
The terms viscometer and rheometer are not well defined, however it is suggested that
a viscometer can be a simple device that can only measure flow and viscosity of fluids,
with some devices built to allow controlled shear rate rotational tests [49].
2.2.6.1 Falling ball viscometer
An example of a viscometer is the falling ball viscometer where a steel ball is sinking
due to gravity through the liquid which is filled in the glass capillary of define inner
diameter [49,59]. These viscometers track the time that a ball takes to move downwards
through the test fluid over a defined distance between two level marks. The viscosity
is then determined from this, based on the calibration of the system using viscosity
standards of known viscosity. By using different angles at which the glass capillary is
set, different velocities can be achieved by the falling ball, and thus different shear rates
can be experienced by the fluid. Testing with a falling (or rolling) ball viscometer is a
single-point viscosity test. During a test period, where the ball rolls at a particular angle,
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the shear rates are changing within a certain range depending on the uncontrolled motion
of the ball, on the distance of the ball to the capillary’s wall, and on its velocity. Only
ideal-viscous samples should be measured without error with this instrumentation as the
shear rate conditions are not constant [49,59]. From these measurements, the kinematic
viscosity is usually reported. As mentioned in section 2.2.4.1, by knowing the density
of the analysed samples, the kinematic viscosity can be converted to shear viscosity.
Throughout this work, viscosity values obtained from the falling ball viscometer are
reported in [Pa.s], since density measurements of the samples were performed (see section
2.2.11).
Some advantages of this instrumentation are its ease of use and that the measurement
is free of evaporation or any air/water interface. Micro falling-ball viscometers allow the
use of low sample volumes (∼ 1 mL) and in the case of protein solution analyses, the
inner interface can be silanised to prevent protein deposition and interaction with the
solid glass interface [49].
An automated micro falling-ball viscometer (AMVn) from Anton-Paar (Graz, Austria)
was used. The capillary used had an inner diameter of 1.6 mm and a steel ball of diameter
1.5 mm. With this instrument the motion of the ball was detected via induction using
magnetic sensors. For a simple measurement, the inclination angle was set at 70◦ (and
-70◦). This instrument allowed temperature control via an attached peltier unit.
Calibration of the capillary to be used with the test samples was performed by
running DI water and a viscosity standard oil at measurement angle matching that for
the sample measurement.
2.2.6.2 mVROC - microviscometer/rheometer-on-a-chip
Another type of viscometer used was the microviscometer/ rheometer-on-a-chip (mV-
ROC), by Rheosense, Inc. (San Ramon, California, USA). The mVROC is a microfluidics
57
slit rheometer where the microfluidics chip is composed of a microchannel (rectangular
slit) made of borosilicate glass mounted on a gold-coated silicon base. Viscosity is meas-
ured as a function of pressure drop as the fluid flows in the microchannel (width = 3.02
mm; depth depends on the chip used). As the fluid flows through the slit, pressure
is measured through three sensors located at increasing distances from the inlet [79]
(Figure 2.8). The pressure drop (∆P) which drives the flow (Q) streamwise through a
distance (L), is related to the wall shear stress (τw) by the following expression [79]:
wd.∆P = 2L(w + d)τw (2.20)
The nominal wall shear rate (γ˙w) associated to laminar flow of a Newtonian fluid is






Figure 2.8: Schematics of the Rheosense slit microviscometer/rheometer-on-a-chip (mVROC).
L is a length of 6.5 mm representing the distance where all pressure measurements are done
streamwise. ∆P represents the measured differential pressure; Q represents the flow and the
arrow is pointing in its direction; w and d represent the width and the depth of the channel,
respectively.
In a typical experiment, the flow rate, Q is varied using a syringe pump and Hamilton
gastight glass syringes (Reno, Nevada, USA). The mVROC device outputs the pressure
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drop as a function of flow rate, which is used to calculate the nominal or apparent
viscosity via η(γ˙) = τw/γ˙w [79]. For incompressible 2-D ows of liquids with a rate-
dependent viscosity, the calculation of γ˙w is more complex since the velocity prole is
no longer parabolic. The true shear rate (γ˙w,true) and true shear viscosities (η(γ˙w,true))















The chips used in this work were A05 and D05, with a channel depth of 50 µm each,
with different maximum pressure capability of 10 kPa and 1000 kPa, respectively [95].
2.2.7 Quantification of protein concentration by UV-visible spectro-
scopy
Ultra-violet (UV) spectroscopy is a method to analyse quantitatively the concentration
of a protein solution. The peptide bond has an absorption maximum at λ=205 nm, but
it is the absorbance of the aromatic rings of the amino acids tryptophan and tyrosine
that show its maxima between 275 nm < λ < 280 nm, also contributed by the disulfide
bonds although in less quantity [86, 96].
According to Lambert-Beer’s Law, that states that molar absorptivity (also known
as molar extinction coefficient)(ε) is constant and absorbance (A) is proportional to
concentration (c) for a given substance dissolved in a solute and measured at a specific
wavelength (λ):
Aλ = εcl = εc (2.24)
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with absorbance having arbitrary units, concentration in molar (M), when l is the
pathway in cm (usually 1 cm), and ε in L.mol−1cm−1 [86]. The molar extinction
coefficient (εmolar) converts into percent extinction coefficient (A
1%
1cm) by εmolar×10 =
ε%×MWprot. The proportions of the aminoacids tryptophan and tyrosine vary between
different proteins, thus for individual proteins its extinction coefficient will vary. Extinc-
tion coefficients can be calculated theoretically by knowing the numbers of Trp, Tyr and
disulfide bonds and then calculating by linearly combining the individual contributions
of these amino acid residues, knowing their respective extinction coefficients [97]. The
extinction coefficients for these residues depends on their microenvironment. In most
globular proteins, most of these cromophores are buried in hydrophobic patches in the
interior of these proteins. [97, 98].
For rHA solutions, the percent extinction coefficient, A1%1cm, of 5.8 was used [99].
For β-lactoglobulin solutions,A1%1cm = 9.6 [100]. For the mAb solutions, A
1%
1cm was 1.45,
calculated theoretically and provided by MedImmune.
2.2.7.1 UV-Vis spectrophotometer
An Agilent 8453 UV-Vis spectrophotometer was used (model G1103, Agilent Technolo-
gies, Germany). A quartz cuvette with 1 cm path length (Hellma, Germany) was used
for measurements. Cleaning of the cuvette was done with an aqueous solution of 2%
v/v Hellmanex (Hellma, Germany), and thoroughly rinsed with acetone and deionised
water.
The spectrophotometer had a range of 190 to 1100 nm, collecting spectra with a
resolution of 2 nm or better. This spectrophotometer had a UV light source, deuterium
lamp, as well as a visible light source from a tungsten-halogen lamp. It used on single
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beam mode, where the buffer solution was used as blank before measuring the absorb-
ance of diluted protein solutions.
For all protein solutions at higher concentration than 50 mg/mL, a double dilution
scheme was followed to allow a measurement of sample diluted to 0.5 mg/mL. Protein
samples diluted to this concentration would typically guarantee an absorbance value
at the mid-range of linearity for the Lambert-Beer function. Each second dilution was
produced in triplicate so that the absorbance measurement (and posterior concentration
calculation) was reported as an average of 3 measurements. Dilution factors were cal-
culated and used for determination of concentration. Dilutions were chosen so that the
dilution factors would not exceed 1000. An error of up to 10 % was accepted for these
measuremets.
Besides the absorbance measurement at 280 nm, absorbances at 310 and 340 nm were
also monitored. Protein concentrations were reported with its concentration corrected
for absorbance at 310 nm, related to possible interference of aggregates absorption. Thus,





where DF is the dilution factor.
2.2.7.2 NanoDrop - microquantitation spectrophotometer
When samples were not in sufficient volume to use for conventional UV-
spectrophotometry measurements, the NanoDrop 2000 spectrophotometer was used
(Thermo Scientific, UK). This microquantitation spectrophotometer uses samples of
2.5 µL to measure UV-Vis absorbance. The sample was held in place by its surface
tension between two optical fibers on a pedestal that could optimise the pathlength ac-
cording to the sample concentration, thus allowing measurement of UV -Vis absorbance
for highly concentrated protein samples. The instrument used a Xenon pulse lamp, with
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a wavelength range between 190-840 nm, and a linear CCD array detector analysed the
light with a spectral resolution below 2 nm. The pathlength could be fixed to 1 mm, as
well as it could automatically vary for high concentration samples [101].
2.2.8 Light Scattering techniques
When a solution with molecules is illuminated by light, depending on the optical para-
meters of the instrumentation, part of this light will be scattered by the molecules. This
scattered light can be analysed regarding its intensity or its fluctuations. Scattered light
measured in terms of its time-averaged intensity is called static light scattering. Whereas
when it is measured in terms of the fluctuation of intensity with time, it is called dynamic
light scattering. With the former, the parameters that can be derived are the weight-
average molecular weight of the molecules present in solution, as well as their radius of
gyration and self virial coefficient. DLS allows to characterise the molecule’s translation
diffusion coefficient and obtain a hydrodynamic radius (or diameter) [102,103].
2.2.8.1 Particle sizing using dynamic light scattering
Dynamic light scattering (DLS) is a technique for measuring the size of particles within
the sub micron region. DLS measurements are based on Brownian motion, the random
movement of particles in solution due to displacement of solvent molecules, and relates
to the size of the particles. An estimated measure of the hydrodynamic diameter (HD)
of the analysed particles is based on the measurement of the translational diffusion





where kB is Boltzmann’s constant, T is temperature and η is the solvent viscosity. HD
measured by DLS refers to the diameter of a sphere that has the same diffusion coefficient
as the sample particle. Besides temperature and viscosity, the diffusion speed can also
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be influenced by ionic strength of the medium [104]. From equation 2.26, the larger
the diameter of the particle, the lower its diffusion speed will be. The DLS instrument
thus measures the diffusion and relates to the size of the particles by illuminating these
with a laser and analysing the intensity fluctuations of the scattered light. The diffusion
coefficient is measured from the time correlation function:
g(τ) = 1 +B exp[−2Dq2τ ] (2.27)
where τ is the time (in µs), B is the signal amplitude of the correlation function. q , the










where n is the refractive index of the solvent, λ0 is the wavelength of the laser, and θ
is the scattering angle. The instrument uses a digital correlator to produce correlation
functions which relate to the particle size in the suspension tested by the rate of
decay of the correlation function - smaller particles show a rate of decay faster than
larger particles. The software then calculates statistically (through algorithms) the size
distribution of the test sample. The typical size distribution graph is a distribution of
size classes on the x-axis, while the y-axis shows the relative intensity of scattered light
(intensity distribution). This distribution can then be converted to volume distribution
and number distribution [105,106].
Sizing measurements were performed using the Zetasizer NanoZs dynamic light scatter-
ing instrument by Malvern Instruments (Malvern, UK). Samples were illuminated by
a 633 nm laser and light scattering was detected at 173◦ by an avalanche photodiode.
DLS results were managed and analysed using Malvern’s Zetasizer software version 7.01.
The quartz cuvette was for low sample volume (12 µL), and it was extensively cleaned
with detergent (2% v/v Hellmanex), thoroughly rinsed with DI water and acetone of
HPLC grade (Fisher, UK). An air duster was used to prevent any dust contamination
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that could originate artifacts during readings. Protein samples were measured at 1
mg/mL diluted in sample buffer, to reduce non-linearity effects on measurements by
increased viscosity of solvent with higher concentrations. Detailed protocols for these
measurements will be referred in each of the experimental chapters methods subsection
on DLS.
2.2.8.2 Static light scattering theory
The equation that relates the intensity of scattered light with the properties of the




2P 2(θ) + ... (2.29)
where Rθ is the excess Rayleigh ratio, c is the concentration of the macromolecule in solu-
tion (g/mL), M is the molecular weight, A22 is the self (or second) virial coefficient, K
∗
is the optical constant, and P (θ) is the particle scattering function. The excess Rayleigh
ratio (Rθ) is the normalised scattering intensity for a specific scattering angle, relating
the intensity of light, measured as voltage by photodiodes, to the scattering intensity














This constant is therefore a function of n0 the refractive index of the solution, λ0 the
incident light wavelength, NA Avogadro’s number, and of dn/dc the refractive index
increment specific for the scattering macromolecules.
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With infinitesimal dilutions (c → 0) and scattering angle tending to zero (θ → 0◦),




which determines the value of molecular weight for the macromolecule in solution. Since
in practice, static light scattering measurements are made of finite dilutions and scatter-
ing angles, an extrapolation to zero needs to be made with one or both limiting conditions
in order to calculate the molecular weight. Therefore, for polydisperse solutions this
molecular weight will be apparent, since higher concentrations may yield non-ideality in
solution, where non-specific interactions may occur between protein species causing the
molecular weight to differ from the actual molecular weight. It will also be a weight-
averaged molecular weight, since it accounts for the presence of more than one species
in solution [102,103].
The particle scattering function P (θ) refers to the change of scattered light intensity
with the angle of detection. It is typically a decline of scattered light with increasing
angle and it is due to intramolecular interference of light scattered by different points of
the same particle [102]. For protein species with a maximum dimension < λ0/20 there
is small angular dependence, thus behaving as isotropic light scatterers. In contrast,
for much larger sizes, protein species will scatter light differently from different points
of its structure, thus creating an angular dependence. It is from the particle scattering













where λ is the wavelength of incident light in a given solven, R2 is the mean square
radius of the macromolecule, and q is the scattering vector. According to equation 2.33,
for small angles, plotting P (θ) against sin2(θ/2) will yield straight lines with slopes pro-
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portional to R2. This means that the slope of the angular variation of scattered light
intensity, when extrapolated to angle zero, gives the root mean square radius of the mac-
romolecule (R). The radius can thus be determined without knowing the concentration
and dn/dc of the scattering particles. For the case of proteins, R can be used to model
protein conformation and understand better its triaxial structure [103].







2 + ... (2.34)
Equations 2.29 and 2.34 represent formalisms, i.e. different ways of processing the
experimental data and are denominated Debye and Zimm formalisms, respectively.
Performing measurements at multiple angles allows extrapolation of the ratio
K∗c/Rθ to zero angle (sin
2(θ/2), which with an extrapolation to zero concentration
forms the basis of the Zimm plot (Figure 2.9(a)). In this case, both concentration and
scattering angle dependence is taken in account. A Zimm plot is an analysis method
to extrapolate weight-average molecular weight, the second virial coefficient and the
radius of the macromolecule, based on the Zimm formalism.
A simpler way of processing the data is by plotting K∗c/Rθ versus concentration (c)
neglecting the scattering angle dependency, thus generating a Debye plot (figure 2.9(b)).
This can be the case for protein monomers when dimensions can be < λ0/20. From
this, by extrapolating to zero concentration, the (apparent) weight-averaged molecular
weight can be estimated from the interception at y-axis, and the self virial coefficient
can be estimated from the slope of the linear regression [102]. Note that processing
experimental data via a Debye plot can be performed by either using the Zimm or the
Debye formalisms and the same applies when processing data via a Zimm plot.
The parameter from equation 2.29, A2 the self virial coefficient, is related to the
thermodynamic aspect of the solution. The equation 2.29 has further terms for cross
(third) and higher virial coefficients that can be ignored for dilute concentrations. When
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plotting Rθ/K
∗c against concentration (c), the function becomes linear at the low
concentration region, with its slope directly proportional to the self virial coefficient.
The deviation from linearity occurs at higher concentrations, hence when working at
these conditions non-linearity terms need to be considered [102,103,107].
A2 can be useful in protein formulation since it helps characterise non-specific
intermolecular interactions. The buffer conditions (e.g. ionic strength, pH) can change
the virial coefficients, thus giving information on the effect of the buffer constituents
on the interactions. The virial coefficients do not give a specific form of interaction,
only the net average interaction. A positive value indicates a net repulsion, while a
negative value indicates a net attraction. It is also possible to calculate cross virial
coefficients which represent the non-specific interactions between different species in
solution [107,108].
Experimental details
1. Self virial coefficients
To determine the self virial coefficient for both the β-lactoglobulin (12.7 mg/mL)
and the mAb (5 mg/mL) in their buffers (10 mM His-His.HCl, pH 6.0), a compos-
ition gradient multi-angle light scattering (CG-MALS) Calypso I instrument from
Wyatt Technology Corp. was used. This system allowed samples to mix through
a series of feed syringe pumps that were controlled by the software. Therefore,
a protein stock solution would be continuously diluted with buffer in the number
of step dilutions required, in a continuous process. The mix was then fed into a
multi-angle light scattering system (DAWN-HELEOS II, λ0=658 nm, 18 angles,
fused-silica flow cell) and an OptilabREX differential refractometer (light source
































Figure 2.9: (a) Example of a Zimm plot, where K∗c/Rθ is plotted for four different concentra-
tions (c in mg/mL) and for various scattering angles (θ) (Zimm formalism; k is an arbitrary offset
factor). The molecular weight is calculated by common intercept of the extrapolation of each
concentration curve to zero angle (θ=0◦) and the extrapolation to c=0 mg/mL intercept. The
slopes can give the radius of the molecule (R) and the self virial coefficient values (A2). (Image
based on reference [103].) (b) Example of a Debye plot, where K∗c/Rθ is plotted in function
of concentration, using scattering data from only one angle (θ) (Zimm formalism). In this case,
molecular weight can be calculated from the intercept at y-axis and the slope can give the self
virial coefficient value.
nia, USA). All protein samples and buffers were filtered prior to analysis, using
0.1 µm pore-size Millex-VV PVDF syringe filters. Measurements were taken at
25 ◦C. The system was extensively cleaned with a detergent aqueous solution of
5% v/v Contrad 70, followed by a thorough flush with ultrapure water. Cleaning
solutions were filtered with 0.22 µm pore size Millex-GV PVDF membrane syringe
filters (EMD Millipore, USA). All buffers and solutions were previously degassed
to avoid presence of air bubbles.
2. Size-exclusion chromatography with static light scattering
Multi-angle light scattering was used for the determination of molecular weight
and radius of mAb monomer and aggregated species. The MALS detector was a
DAWN HELEOS II (λ0=658 nm, 18 angles, fused-silica flow cell), connected to an
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Agilent Technologies 1200 series liquid chromatography system (Agilent Technolo-
gies, Germany). Details of this experiment are described in section 2.2.9.3.
2.2.9 High performance size exclusion chromatography
Size exclusion chromatography (SEC) is a liquid chromatography technique, also known
as gel permeation chromatography (GPC) or known as gel filtration chromatography.
SEC will be referred to in this work as the general term that describes the method of
separation of molecules by molecular weight distribution via a chromatographic method.
This method was used in its high performance liquid chromatography format, for quant-
itative analysis purposes only and not for fractionation of materials. The use of high
performance size exclusion chromatography (HPSEC) allowed the analysis of synthetic
polymers and/or biomacromolecules in an appropriate mobile phase in less than 30
minutes.
SEC separates on the basis of molecular hydrodynamic volume or size, and not by an
enthalpic interaction with stationary phase, such as ionic exchange or adsorption parti-
tion chromatography. The sample is dissolved in its solvent and injected into a column
packed with porous particles of an average pore size and particle size. The mobile phase
can be the same as the sample’s solvent. After injection, the molecules elute through
the column and those which are too large to penetrate the pores of the stationary phase
will elute out first, in the column’s void volume. If smaller sized molecules are present,
these will penetrate the pores respectively to its pore size. The smallest material will
freely diffuse into and out of the pores, thus taking longer to elute from the column.
In summary, the high molecular weight material will elute first from a SEC column,
followed by low molecular weight species (Figure 2.10) [102,109].
This basic principle of separation is generally accepted as the major separation mech-
anism and is termed steric exclusion. However, there are other mechanisms that can play
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an important role, such as restricted diffusion and separation by flow. Restricted diffu-
sion refers to the depth of permeation of each molecule being governed by its diffusion
coefficient, which is indirectly related to the molecule’s size. In this case, the elution
volume (time that each molecule takes to elute out of the column) should depend on
the method’s flow rate. The concept of separation by flow is related to narrow capillary
flow that can be considered to be the case of the exclusion volume around the particles
contained in a SEC column. The larger molecules occur closer to the centre of capillary
flow and thus flow faster than the smaller molecules, which are statistically situated close
to the wall (stationary particles) where the flow is slower. Therefore, there is separation
due to hydrodynamic size and exclusion volume [102].
Figure 2.10: Basic schematics of how a size exclusion chromatography method works. After
sample is injected, the separation is based on the molecular size of the solution’s components.
The larger molecular weight species will flow out first and the smaller molecular weight species
will be eluted later.
In pratical SEC experiments, one can often encounter evidence of sample - stationary
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phase interaction by the appearance of peak tailling or changes in elution times. This
is related to various types of interactions between sample and column packing and/
or long-term use of the column. It is possible to minimise this by selecting suitable
column packing, as well as suitable mobile phase, temperature, possible use of additives
to the mobile phase or sample solvent. Peak broadening can also be another problem
in SEC experiments affecting the determination of molar mass distribution. Therefore,
it is necessary to tightly control the column’s efficiency throughout its lifetime. SEC
results, as with all other liquid chromatography techniques, will be highly sensitive to
variables such as temperature, flow rate, and sample concentration. The latter is the
most dependable of the user and therefore it is crucial to keep this parameter in mind
for sample comparability [102,109].
2.2.9.1 Calibration and detectors for HPSEC
As HPSEC is a relative and not an absolute molecular weight determining technique,
the column needs to be calibrated appropriately with standards of known molecular
weight. The most simple way of running a SEC system is the conventional SEC
method where only a concentration detector is connected on-line with the column.
The concentration detector can be a UV detector or refractive index, RI, detector.
Calibration is then performed and established, allowing the analysis of samples and
determination of their molecular weight in relation to the elution volume. To achieve
the most accurate calibration it is necessary to use a series of well-characterised narrow
standards as chemically similar as possible in composition to that of the sample to be
analysed. However, it is often the case that this is unavailable, therefore the alternative
is to use broad standards or a universal calibration [102].
Another method for HPSEC calibration can be the universal calibration method,
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where chemically different standards can be compared to the samples’ chemistry. The
use of universal calibration is related to the assumption that the hydrodynamic volumes
of all species eluting at the same elution volume are identical and that the product
[η]M represents a universal calibration parameter [102]. In this type of calibration, the
intrinsic viscosity can be measured by use of a viscometer on-line with the SEC column
and the concentration detector (e.g. RI).
Another alternative is triple detection and its calibration. The detectors used for
this type of calibration are: a concentration detector (UV or RI), a viscometer (for
measurement of intrinsic viscosity) and a light scattering detector. This type of detec-
tion has the advantage of providing with weight-average molecular weight, molecular
size (within the system’s resolution), and intrinsic viscosity, along with information on
the molecular structure and aggregation - in the case of polymer samples.
In triple detection, the system can be calibrated by running only a single narrow
standard to verify the instrument constants of the detectors and allow to correct for
inter-detector shifts and inter-detector preak broadening effects [110].
Column calibration should occur at identical conditions as those chosen for sample
characterisation (same solvent, temperature, and flow rate). A good calibration usually
comprises that the standard selection covers the entire molar mass range of the samples
to be analysed.
2.2.9.2 HPSEC for the determination of level of protein aggregation
To relatively quantify the level of protein aggregation, the HPLC system used was from
Agilent Technologies 1200 series (Germany) with the following components: degasser,
binary pump with a 100 µL injection loop, an autosampler, thermostatted sample tray
(usually at 5 ◦C, unless noted otherwise), a thermostatted (at room temperature) column
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holder and a UV detector. The software used for this system was Chemstation for LC
systems, by Agilent Technologies.
A Tosoh Biosciences, LLC (USA), model TSK gel G3000SWxl column was used (7.8
mm (ID) x 30 cm (L)), composed of silica gel particles with mean particle size of 5 µm
and pore size of 250A˙. A guard column (silica particles of 7 µm, 6 mm (ID) x 4 cm (L))
was also used with the analytical column.
Throughout this work for all protein sample HPSEC analysis, the mobile phase was an
aqueous buffer of 0.1 M sodium sulfate (NaSO4) and 0.1 M dibasic sodium phosphate
anhydrous (Na2HPO4), titrated to pH 6.8 with 6N HCl. This buffer was filtered with
0.22 µm pore size vacuum-driven filter units (PES membrane, EMD Millipore, USA).
All protein samples were diluted to 10 mg/mL, injection volume was of 25 µL. Run
time was 20 minutes at a flow rate of 1 ml/min. Each sample was injected at least three
times, unless stated otherwise. Formulation buffers respective to the protein samples
were also injected.
As this chromatography system allowed variable injection volumes, it was possible
to change both protein sample concentration and injection volume, keeping constant the
sample loading, to check for changes in aggregation level of protein species.
For this method the column was not calibrated for molecular weight analysis, the
chosen standards were used for system suitability. Bio-Rad gel filtration protein stand-
ards (Bio-rad Laboratories, Inc., USA) were prepared according to the manufacturer’s
instructions and an aliquot was injected (25 µL) once after every 20 injections of un-
known protein samples. Bio-Rad protein standards are composed of a mixture of five
molecular weight markers ranging from 1.35 to 670 kDa. The mixture includes vitamin
B12, myoglobulin, ovalbumin, bovine gamma-globulin and thyroglobulin. An example for
the Bio-Rad protein standards chromatogram is in Figure 2.11. The system suitability
criteria were as follows:
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• resolution of peak 4: ≥ 2.00;
• peak symmetry for peaks 4 and 5: > 0.65 and < 1.20.
All samples (including buffers and Bio-Rad protein standards) were filtered through
0.45 µm centrifugal filters (Ultrafree-MC PVDF, EMD Millipore, USA). The obtained
chromatograms followed integration and peak symmetry and resolution were calculated
via the method analysis used on the software.
Figure 2.11: Typical chromatogram obtained with high performance size-exclusion chroma-
tography systems described in section 2.2.9.2 for the Bio-rad gel filtration standards. Peaks
correspond to the following proteins present in the standards mixture: 1) thyroglobulin (670
kDa); 2) bovine gamma-globulin (158 kDa); 3) ovalbumin (44 kDa); 4) myoglobulin (17 kDa);
and 5) vitamin B (1.35 kDa). Inset table refers to chromatography data obtained to assess
system suitability.
2.2.9.3 HPSEC protein analysis with multiple detectors
Two systems were used depending on the information needed: molecular weight, size
and intrinsic viscosity; or only molecular weight and size of protein species.
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1. Calculation of molecular weight and intrinsic viscosity of protein
monomer and its associative species for rAlbumin solutions
The system used for this experiment was a Polymer Labs GPC 50 (Agilent
Technologies, USA) gel permeation chromatography unit that comprises an
autosampler, a fixed volume injection loop (20 µL), thermostatted column holder,
and the following detectors: a 90◦ light scattering detector, a refractive index
detector, and a differential pressure viscometer.
The column and guard column used in this experiment were the same as for
the previous section. Protein samples were diluted to 15 mg/mL. For system
suitability, Bio-Rad protein standards were injected after every 20 injections of
unknown samples. Each sample was injected three times, with buffers injected
at least once. Elution time was kept to 20 minutes, flow rate of 1 ml/min. The
mobile phase was the same as for the conventional HPSEC set-up described
previously.
Calibration of this system was according the triple detection method described
earlier, following the software’s algorithm for calibration. The standard used were
solutions of Polyethylene oxide in PBS. dn/dc used was 0.185 mL/g.
2. Calculation of molecular weight of monomer and its associative species
for mAb solutions
For this experiment the system used an Agilent Technologies system as described in
section 2.2.9.2 with a change in the detectors used. For concentration, an Optilab
REX RI detector was used and an on-line DAWN-HELEOS II multi-angle light
scattering detector was added. Details on both these detectors can be found in sec-
tion 2.2.8.2. The following method details were kept constant as stated in section
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2.2.9.2: HPSEC analytical column and guard column (Tosoh Biosciences), mo-
bile phase, run time, flow rate, number of injections per sample, injection volume
(25 µL), column temperature and system suitability checks with Bio-Rad protein
standards.
Calibration of this experimental setup was made using a BSA standard at 2 mg/mL
in phosphate buffer and sodium azide 0.2 % (dn/dc of 0.185 mL/g), obtained from
Pierce Labs (Thermo Scientific, UK). Analysis and integration of the chromato-
grams was performed using Astra 6 software (Wyatt, Santa Barbara, California,
USA).
2.2.9.4 HPSEC for synthetic polymers
The system used was a Polymer Labs GPC 50 (Agilent Technologies, USA) gel
permeation chromatography unit that was constituted by an autosampler, a degasser, a
fixed volume injection loop, and thermostatted column holder. The following detectors
were used: 90◦ light scattering detector, a refractive index detector, and a differential
pressure viscometer.
Two Polymer Labs PLgel mixed-D columns were used (porous polystyrene and
divinylbenzene matrix, 5 µm mean particle size, ID 7.8 mm x 30 cm) with a correspond-
ing guard column (5 µm mean particle size, ID 7.8 mm x 50 mm) (Agilent Technologies,
USA). For all the polymers analysed, the sample dissolving solvent and the mobile phase
were chloroform / triethylamine (CHCl3/TEA) 95/5 % v/v. Sample concentration was
typically 3 mg/mL, except for intrinsic viscosity measurement where several dilutions
were injected. Injection volume was of 100 µL. All samples were injected three times,
with a runtime of 30 min, flow rate at 1 ml/min and column temperature at room
temperature.
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1. Determination of molecular weight and intrinsic viscosity of polymers
Calibration of the system for this purpose was performed according to the triple de-
tection method where a narrow standard was a polystyrene polymer (2-5 mg/mL).
Linear polyethylglycols (PEGs) were also analysed for validation and for compar-
ison purposes.
2. Determination of molecular weight of polymers
The same system was calibrated using the conventional method where only the RI
detector was used for concentration detection. A mixture of narrow polystyrene
standards were used for calibration (EasiVials polysterene PS-M 2mL, Agilent
Technologies, Germany).
2.2.10 Tensiometry
Tensiometry is a measurement of surface tension at an interface, e.g. liquid - vapour.
Surface tension can be defined as a force resisting change and acting in right angles to
a line of unit length in the surface of a liquid [111].
This technique was used to measure the surface tension of β-lactoglobulin samples
(see Chapter 4), and polymer solutions (see Chapter 6). Tensiometry was measured
using a Kru¨ss K100 tensiometer using a curved Wilhelmy plate with 40.2 mm wetted
length (dimensions: 19.9 mm width, 0.2 mm thickness, 10 mm height). Experiments
were performed at room temperature (∼ 25 ◦) for at least 2 hours, and were performed
with freshly prepared samples. Sample volume was 1.2 mL and contained in a steel
vessel during measurements. Ultrapure water fitered with 0.22 µm pore-size syringe
filters (Millex-GV PVDF, EMD Millipore, USA) was measured to prior any sample
measurement, and after the plate was thoroughly cleaned. Cleaning the plate was done
with ultrapure water and then burning until incandescent to eliminate any contamin-
77
ants. Sample buffer’s surface tension was also measured for comparison. Surface tension
measurements were taken every second and values were reported when equilibrium was
attained as an average with standard deviation.
The plate was made of roughened platinum and optimally wetted so that the contact





surface tension should only be dependent of the force measurement, since the wetted
length is also fixed. Using a Wilhelmy plate had the advantages of not needing any
correction nor knowing the densities of the analysed liquids.
2.2.11 Density measurement
Density measurements were performed in order to determine the density of all protein
samples that were used throughout this work for later calculation of viscosity using the
falling-ball viscometry data. In all cases, the measurement was kept the same. The
densitometer DMA 35N was used (Anton-Paar, Graz, Austria). This instrument meas-
ures density via the oscillating U-tube principle, which is a U-shaped borosilicate glass
tube that contains the sample and is electronically vibrated at a specific frequency. The
characteristic frequency will change depending on the density of the sample. As density
is temperature dependent, the temperature of the measurement needs to be determined
with accuracy via a temperature sensor which is part of the instrument [112].
The densitometer was cleaned extensively with DI water and absolute ethanol before
and in between all measurements. Before every measurement of sample, the instrument’s
calibration was checked by measuring the density of DI water at room temperature (typ-
ically 23 ◦C) and cross-checked with the reference table provided by the manufacturer.
For each sample, the density measurement was made at the same temperature that was
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chosen for the viscometry measurement (with the AmVn). For this purpose, the densito-
meter was kept in an incubator for the time needed until the adequate temperature was
reached. Measurements were conducted in triplicate, recording also the temperature.
All samples were at a concentration of 1 mg/mL.
2.2.12 micro-Differential scanning calorimetry
Calorimetry is a technique for measuring the thermal properties of materials to directly
measure the enthalpy associated to physico-chemical processes related to thermal changes
[113]. Generally, there are two types of differential scanning calorimeters: heat-flux
and power-compensated. In a heat-flux calorimeter, the sample and a reference are
enclosed within a furnace which is heated at a linear rate. The thermocouples measure






where qh is the heat flow, ∆T is the temperature difference between the sample and
reference, and R is the resistence of the thermoelectric disk that transfers heat to the
sample and the reference [113, 114]. A power-compensated calorimeter has the sample
and reference in separate furnaces heated separately. This technique measures the
difference in thermal power, in function of temperature or time, necessary to keep the
sample and reference at the same temperature [114].
Micro differential scanning calorimetry (µDSC) is a commonly used technique
used and applied to protein physical-chemical analysis. µDSC is typically used to
determine the transition temperature (Tm - also called melting temperature) and
obtain thermodynamic analysis of protein folding and unfolding. The µDSC measures
the excess heat capacity of a sample relative to a reference, which in this case is the
sample buffer, as a function of temperature. Several parameters can be measured,
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such as the transition temperature at a peak maximum, the difference in enthalpy
(∆Hm) which is calculated via area under the heat capacity curve (Cp), and the change
in heat capacity (∆Cp) for the transition between folded and denatured state of the
protein sample. These parameters are related to the free energy change, calculated by
the Gibbs-Helmholtz equation 2.37, from disruptions of the stabilized native protein















As the µDSC is sensitive enough, it can help identify the most stable protein mutant,
describe the unfolding process and its kinetics (e.g. if it is reversible or irreversible), and
determine the interaction of proteins with various molecules (e.g. DNA, ligands, ions).
In addition, the DSC technique is increasingly used for biopharmaceutical formulation
as it can help detect and quantify the potential stabilisation effects of additives, as the
addition of excipients/additives can alter the transition temperature of the protein.
Therefore, DSC is widely used as one of the techniques for formulation screening,
as pH, ionic strength and the additives can influence the thermodynamics of protein
unfolding [84,113].
For this study, DSC was used for the determination of the monoclonal antibody’s
melting temperatures, as this molecule was the only without any literature reference for
its transition temperatures. For an IgG1 monoclonal antibody, a µDSC scan can show
melting temperatures for the CH2, Fab and CH3 domains. Depending on the secondary
structure for the IgG1 and if the mAb is glycosylated or not, the melting temperature
for each of these domains may or may not be resolved as individual transitions. An
advantage of using µDSC to study antibodies is that the transitions corresponding to
these domains can be identified and compared in most cases. Besides this, by comparing
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mAb µDSC analysis with the use of different formulation buffers, one can detect changes
in peak shape or peak area hence evaluating the possible influence of buffer excipients on
the unfolding of the analysed domains. In the case of storage stability being influenced
by conformational stability, the higher the thermal transition temperature is, often
corresponds to higher stability (keeping the same buffer conditions as studied) [116,117].
2.2.12.1 µ-DSC experimental details
DSC measurements were carried out in the temperature range 25 - 100 ◦C by using
a microcalorimeter VP Capillary DSC (MicroCal Inc., Northampton, MA, USA). A
scan rate 95 ◦C/h was performed for the present study. DSC curves were analysed
with MicroCal LLC Auto sample Origin software. The data were corrected for the
calorimetric baseline (by subtracting water - water scan) and for the difference in heat
capacity between the initial and the final state by choosing a sigmoidal baseline. System
calibration was performed with injection and measurement of melting temperature for
a lysozyme solution at a concentration of 3 mg/mL in ultrapure water (Lysozyme and
ultrapure water obtained from Sigma-Aldrich, UK). All monoclonal antibody samples
were measured at 5 mg/mL. Samples ran three times, each with volume of 500 µL. The
standard lysozyme solution was injected before and at the end of the DSC run, with
ultrapure water as reference. In this study all protein samples were dissolved in the same
buffer (10 mM His-His.HCl, pH 6), therefore only one pair of reference buffer was needed.
2.2.13 Protein electrophoretic methods
Protein electrophoretic methods are techniques that allow separation and identification
of proteins with basis on applying an electric field and therefore promoting migration
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of the charged biomacromolecule. Separation can be made on basis of the protein’s size
(sodium dodecyl sulfate polyacrylamide gel electrophoresis - SDS-PAGE) or the protein’s
charge (isoelectric focusing) [86].
2.2.13.1 Microfluidic chip SDS-PAGE
SDS-PAGE protein electrophoresis is a technique widely used for separation of proteins
according to their size under denaturing conditions by using the anionic detergent SDS
(sodium dodecyl sulfate). It can also determine the relative molecular mass of the
proteins analysed. This technique can allow the detection of dissulfide bonds in protein
structure where samples are diluted in a reducing buffer containing a reducing agent,
either β-mercaptothiol or dithiothreitol (DTT). These agents reduce the accessible
reducible covalent dissulfide bonds responsible for associating species, or associating
domains within the protein monomer (as in the case of an IgG1 antibody). As a
comparison, samples are also ran in a non reducing buffer, where these dissulfide
bonds are not reduced. Therefore, in protein formulation, SDS-PAGE has the utility
of separating aggregate, monomeric and fragmented protein forms in the 10 - 250 kDa
range, identifying the covalent aggregates and fragments [86, 118].
A microfluidic chip protein electrophoresis system was used for rapid qualitative
protein electrophoretic analysis. This recent ’lab-on-a-chip’ technique follows the same
principles as SDS-PAGE for proteins with the advantage of allowing to run samples
at the microscale using a microfludics chip with microliter sample volumes, therefore
providing much faster results [119,120].
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Microfluidic SDS-PAGE experimental details
An Agilent 2100 Bioanalyzer system and its corresponding Protein 230 kit were used
(Agilent Technologies, Germany). All the kit components, including the microfluidics
chip, were proprietary to Agilent Technologies. The kit reagents were: gel matrix
solution, protein dye concentrate, a marker protein sample buffer solution (containing
both a high and low molecular weight fluorescent marker, also present in the protein
ladder, as well as SDS) and a protein molecular mass ladder solution.
The gel matrix and destain solutions were prepared following the manufacturer’s
protocol with only slight changes. To prepare a 1 M DTT solution (dithiothreitol;
reducing agent), the contents of one tube of ’No-weigh’ DTT (Pierce Labs, Thermo
Fisher Scientific, UK) were added to 50 µL of ultrapure water. A reducing sample
buffer was prepared by adding and vortexing 3.6 µL of 1 M DTT solution to a sample
buffer 60 µL aliquot. 1 M Non-reducing NEM (N-ethylmaleidemide, Fluka Biochemika,
UK) solution was prepared by weighing 12.5 mg of NEM into 100 µL of ultrapure
water. This sample was vortexed and left for 2 min at 80 ◦C for full dissolution. The
non-reducing sample buffer was prepared by adding 3.6 µL of 1 M NEM solution into
60 µL of sample buffer. Protein samples to be analysed were individually diluted to 4
mg/mL in phosphate buffered saline (PBS) (constituting individual protein sample stock
solutions). From each of these sample stock solutions, 5 µL were taken and added to 5
µL of either non-reducing or reducing sample buffers in small tubes. The protein ladder
was prepared by aliquoting (6 µL) separately into a new tube. The protein samples and
protein ladder were heated at 80 ◦C for 5 minutes (reduced samples and protein ladder)
and for 1 minute (non-reduced samples). After heating, all tubes were cooled down
by centrifuging at 13 000 rpm for 1 minute (Haereus Pico, Thermo Fisher Scientific,
UK). In new tubes, 84 µL of ultrapure water was added to 6 µL of each reduced and
non-reduced samples, and to the protein ladder. All protein samples, protein ladder,
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reducing and non-reducing sample buffers were freshly prepared, thoroughly mixed and
used only within 24 hours.
After priming the chip with gel-dye mix, each of the 4 wells were filled with more
gel-dye mix (12 µL each). The destain solution (12 µL), protein ladder (6 µL) and
protein samples (6 µL each) were then aliquoted to their corresponding well (Figure
2.12). Detection of protein was made by laser-induced fluorescence. After reading the
chip, the software used a method for automated integration for the peaks detected in
each sample well.
Figure 2.12: Microfluidics SDS-PAGE chip schematics. There are a total of 16 wells where
four are for the gel-dye mix, one is for destain solution, another for the protein ladder and the
remaining wells for samples (all assigned in the figure). Also highlighted are the separation
channel (A), the position for destaining (B) and the position where fluorescence is detected (C)
(figure is adapted from reference [121]).
In this technique, migration times are normalised since the sample buffer contains low
and high molecular weight markers as internal standards. A calibration curve is created
from all the molecular weight markers present in the protein ladder sample [121, 122].
System suitability criteria were followed, particularly concerning the protein ladder used,
to check that the chip had run and samples were integrated correctly. The following
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parameters were checked for system suitability [119]:
• six ladder peaks should be observed;
• the lower molecular weight marker (4.5 kDa) should fall between migration times
of 15 - 22 seconds;
• the mid-molecular weight marker (63 kDa) should fall between migration times of
27.23 - 28.31 seconds;
• the upper marker (240 kDa) should fall between migration times of 37 - 46 seconds.
2.2.13.2 Isoelectric Focusing
Capillary isoelectric focusing (cIEF) is an protein electrophoretic technique that
separates proteins based on the macromolecule’s charge according to the protein’s
isoelectric point (pI) . In this method a pH gradient is formed by a mix of ampholytes,
typically polyamino-polycarboxylic acids which can cover either a wide or a narrow
range of pH, according to the expected pI of the proteins being analysed/ separ-
ated [86, 123]. Capillary electrophoresis uses very narrow bore tubes, allowing faster
method preparation and run time. As IEF is sensitive to any molecular differences
that can cause a change in the protein’s net charge, ciEF can be used to check for
batch-to-batch differences [124,125]. Imaging capillary IEF was used to analyse each of
the mAb batches available.
IEF experimental details
An iCE280 IEF analyser (ProteinSimple Ltd., California, USA) was used, with a mi-
croinjector autosampler and a cIEF cartridge fluorocarbon-coated filled with electrolyte
solution. For imaging, the system has a CCD camera with a UV absorption detector.
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A light source of 280 nm, from a deuterium lamp, was focused onto the capillary. All
reagents and other system specific components were supplied by ProteinSimple, Ltd.. 4
mL glass vials were placed on the autosampler containing 0.5% methyl cellulose solution
(in two vials, respectively, buffer and balance vials), a rinse vial with ultrapure water
and an empty vial. After the instrument start-up procedure, to ensure that the capillary
system was running correctly, it was checked that the anolyte (80 mM phosphoric acid)
and catholyte solutions (19 M sodium hydroxide) were full in their respective tanks (no
leakages were to be observed).
All samples (from the batches: mAb b1, b2a and b2b) were diluted in ultrapure
water to stock concentrations that when added to sample buffers would yield a final
concentration of 0.25 mg/mL. For each sample a buffer was prepared containing 8 µL of
pH 8 - 10.5 Pharmalyte (GE Healthcare, USA), 70 µL of 1% w/w methylcellulose (Pro-
teinSimple, Canada), and 1 µL of each of the pI markers (8.18 and 9.77) (ProteinSimple,
Canada), and remaining volume of ultrapure water (Sigma-Aldrich, UK) to make up to
250 µL total sample volume. Samples were aliquoted (100 µL) to appropriate glass vials
and were analysed in duplicate.
A hemoglobin control was ran for system suitability. This sample was freshly pre-
pared using the ProteinSimple iCE280 suitability kit: 2.5 µL of a hemoglobin stock
solution provided was added to a buffer solution already containing a 8% v/v pH 3-
10 Pharmalyte, internal pI markers 4.22 and 9.46 in 0.35% v/v methyl cellulose. The
control was always included in a cIEF run, typically running twice before and twice at
the end of each group of samples to be analysed. An example of hemoglobin control is
showed in 2.13. Acceptance criteria for the hemoglobin sample were the following:
• absorbance data for each of the pI markers needed to be within ± 3 times the
standard deviation of the mean of absorbance;
• HbA1c shoulder should be observed;
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• Four major peaks of hemoglobin control must be present (HbA, HbF, HbS and
HbC);
• HbA peak pI should be between 6.85 - 7.45.
Focusing conditions for hemoglobin controls were as follows: pre-focusing period - 1 min
and 1500 V; main focus period - 4.50 min and 3000 V. Focusing conditions for mAb
samples were as follows: pre-focusing period - 1 min and 1500 V; main focus period
- 7 min and 3000 V. Both hemoglobin and mAb samples were further analysed using
the analysis software ChromPerfect iCE280. The pI was reported for the main peak
observed.
Figure 2.13: Typical chromatogram obtained with capillary isoelectric focusing electrophoresis
for the hemoglobin standard. Peaks are assigned and identified according to manufacturer’s
details for the product, containing normal hemoglobins A (and its shoulder HbA1c) and F, and
abnormal hemoglobins S and C. pI markers are also assigned.
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2.2.14 Circular Dichroism
Circular dichroism (CD) was used to check the mAb’s conformation after its purification
and concentration. CD is a technique that refers to the difference in absorption of two
circularly polarised components of polarised UV light, left and right. These components
of polarised light (of the same amplitude and frequency) will be absorbed by the
protein, an optically active - chiral - solute, in different ways according to its secondary
and tertiary structures. The CD measurements are reported in ellipticity which is the
angular difference in absorbance (in mdegs), between left and right circularly polarised
light, in function of the wavelengths screened. The secondary structures existing in a
protein (α-helices, β-sheets, turns and random coils) can be identified by screening in
the far UV region (180 to 260 nm). The tertiary structures are identified when screening
the near UV region (250 to 360 nm) [86].
As all batches of mAb were in a 10 mM His-His.HCl pH 6.0 buffer and L-histidine is
an amino-acid commonly present in proteins, thereby showing chirality and absorbing
UV light, aliquots of each batch were buffer exchanged to 10 mM sodium phosphate
pH 6.5. Samples were diluted to 1 mg/mL and measured for both far UV and near UV
using a Jasco J815 circular dichroism spectrometer (Jasco, UK). Near UV required a
10 mm pathlength quartz cuvette (sample volume ∼ 1 mL), while for far UV slides of
0.1 mm pathlength were used (all optical cuvettes from Starna, UK). Each sample was
ran in triplicate and each final spectrum was an accumulation of 3 scans. For near UV
the wavelength range was between 250 - 320 nm, whereas for far UV the wavelength
range was 180 - 260 nm. All scans were performed with a 1 nm step and a scan rate
of 20 nm/min. Scans were collected at 20 ◦C using of a peltier cell holder and a water
cooling system. Blank scans with buffer only were also collected for posterior blank
subtraction from sample scans. For both far UV and near UV data collections, data
were converted using the Jasco Spectra Analysis software, from ellipticity degrees to
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molar ellipticity by accounting for mAb molar concentration (∼ 6.3×10−6 M) and the
optical pathlength. Data was further converted into molar residue ellipticity by dividing
the molecular ellipticity by the total number of amino-acids present in the mAb. For far
UV, final data analysis was performed using CDPro software package which provided
secondary structure information in relative % for each type of structure.
2.2.15 Flow imaging microscopy for sub-visible particle counting
Flow imaging microscopy is a technique that is currently used in biopharmaceutical
industry for the quantification and characterisation of sub-visible proteinaceous particles
in protein formulation [126]. Various protein degradation pathways can generally lead
to aggregation and the formation of sub-visible (1 - 100 µm) and visible (> 100 µm)
particulates, depending on their size. These proteinaceous particulates represent a loss
of monomeric species, potentially containing numerous monomer units [127]. Flow
microscopy, along with light obscuration particle counting and membrane microscopy
methods, are used in the biopharmaceutical industry to characterise and quantify these
proteinaceous particulates to monitor the potential link between protein aggregation
and immunogenicity [128].
Flow microscopy operates by digital image analysis to count the suspended particles
in the flowing liquid. The sample is pumped by a peristaltic pump through a flow
cell (100 µm, 1.6 mm), while images are recorded. The images are analysed relative
to the variations in transmitted light intensity, resulting from particles present in the
fluid [39,129].
A micro-flow imaging microscope DPA4200 (Brightwell Technologies Inc, Canada) was
used to detect and count particles sized between 1 - 150 µm for mAb solutions and
for β-lacroglobulin solutions, both at different concentrations and conditions. On the
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sample inlet, a 10 mL glass syring was fixed with a luer lock and through it 20 mL of
ultra pure water and 10 mL of Decon 90 10% v/v were flushed (6.65 mL/min) into the
flow cell to ensure the system was clean. This cleaning procedure was repeated between
samples and higher volume of water or detergent would be used until the system was
acceptably clean. During this step, it was important to ensure no air bubbles were
present in the flow cell.
The buffer (10 mM His-His.HCl pH 6.0) was run in triplicate as a sample for
negative control. The buffer was filtered prior analysis (0.1 µm pore size syringe filters).
Details on the protein samples’ concentration will be described in the experimental
chapter’s methods section. The filtered buffer was typically sonicated for 20 minutes
prior analysis. All protein samples were gently mixed for homogeneity, with care to not
introduce air bubbles. All liquids were left to equilibrate at room temperature for at
least 30 min to release air bubbles. 1 mL of sample buffer was ran before every sample
for baseline purposes, followed by measurement of 1.1 mL protein sample at a flow rate
of 0.22 mL/min. A purge volume of approximately 250 µL was done for all samples.
Data analysis was made with MFI View application software package. A filter was
applied to ignore all particles with an aspect ratio of ≥0.85. The results were reported
as average cumulative particle numbers per mL or particle counts per size range from
1 - 150 µm. The particle size was reported as equivalent circular diameter (ECD).
The cleaning procedure was resumed after measurements with aid of the glass syringe.
Flow cell calibration was performed with polysterene beads of referenced size (10 µm
diameter).
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2.2.16 Visual inspection of protein solutions
Presence of visible translucent particles in the samples and determination of colour were
determined against a black and white panel under white fluorescent light. The samples
were visually analysed and compared against particle standards, opalescence standards,
colour standards, and their respective blanks. Prior to analysis, standards and samples
were left at room temperature for equilibration and the illumination lamp was left on
for at least 30 minutes. Analysis consisted on gently shaking the vials (standards and
samples) for 15 seconds and visually inspect immediately after shaking. To improve
probability of detection of particles, if needed, this procedure was repeated multiple
times. In any case of doubt, a (blinded) second opinion by another trained person was
asked for confirmation of analysis.
The particle standards were aqueous dilutions from stock containing 1 mg/mL
barium sulfate (BaSO4) and 0.1% w/w sodium azide (NaN3). Six dilutions were
prepared (0.001 mg/mL to 0.2 mg/mL) as well as a blank (ultrapure water vial). Three
degrees of classification for presence of particles were: free from particles, corresponding
to the blank vial; practically free of particles, corresponding to standards 1 - 5; and
containing particles, corresponding to standards 5 - 7.
The opalescence standards were formazin references standards and its dilutions
described in the European Pharmacopeia [130]. Eight standards were prepared of
increasing nephelometric turbidity units (NTU) ranging from 3 (standard 1) to 1000
(standard 1000) and related to a blank (ultrapure water vial). The classification of
samples according to their opalescence were divided in four categories: clear, when
comparable to standards 0 - 1 (0 - 3 NTU); slightly opalescent, when comparable to
standards 1 - 3 (3 - 18 NTU); opalescent, when comparable to standards 3 - 6 (18 - 120
NTU); and opaque, when comparable to standards 6 - 8 (120 - 1000 NTU).
The colour references solutions (according to the European Pharmacopeia, Fluka,
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Sigma-Aldrich, UK) were of three types: yellow, brown and brown-yellow. Classific-
ation of samples was made according to four categories, compared to the provided
blank solution, as follows: colourless, if comparable to standards 7 - 8; slightly
coloured, if comparable to standards 4 - 7; coloured (yellow, brown-yellow or brown) if
comparable to standards 2 - 4; and intensively coloured, if comparable to standards 1 - 2.
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Chapter 3
The effect of protein concentration on the viscosity of a
recombinant albumin solution formulation
3.1 Introduction
The viscosity of protein formulations is an important issue for the biopharmaceutical
industry due to its practical implications [5]. As discussed earlier in the main intro-
duction, biopharmaceutical liquid formulations are frequently created with high protein
concentration, due to the need for high mass delivery to overcome low potency, and
low volumes to allow patient self-administration in cost effective devices [5,8]. However,
when biomacromolecules reach high solution concentrations problems such as high vis-
cosity and poor flow properties, as well as stability issues, can arise.
Several theories from colloidal science have been used to understand observed in-
creases in solution viscosities with increases in macromolecular content. Some of these
models are based on approximations to hard spherical repulsive particles, and have
been applied to proteins with some success. However, it has been suggested that there
are more factors, such as shape [131], charge distribution [67, 71] or kinetics of associ-
ation [6,51,72] which need to be considered for successful prediction of protein solution
viscosity.
The present theoretical models tend to assure that any change in composition of
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protein species in solution is negligible. Parameters present in these models typically
account for only one species of a specific shape and size. In the colloidal suspension
literature, some authors have addressed the problem for binary mixtures of different
sized particles, to predict the impact of this on the solution viscosity [132–135]. In the
biopharmaceutical literature, recent reports have studied binary blends of proteins by
controlling the content of each protein in solution and understanding the effect of this on
the overall solution viscosity [136, 137]. Nevertheless, a real biopharmaceutical formu-
lation will depend on various factors such as pH, temperature, ionic strength, different
stabilising additives in solution, and it will most likely be a solution composed of the
monomeric biomacromolecule coexisting with self-associative species that may or may
not be of reversible nature.
From a practical point of view, while developing protein solution formulations, it is
important to understand what the most important factors are in the prediction of protein
solution viscosity. In the work presented here, a recombinant human albumin solution
formulated in a buffer containing salt and a surfactant was studied. Samples were pre-
pared ranging from 0.1 mg/mL to approximately 500 mg/mL, and were investigated for
their rheological characteristics using steady shear rheology with a torsional rheometer
and other viscometric measurements. A detailed biophysical characterisation of these
samples was performed to account for its level of aggregation, size and shape of protein
species. Using this information, a comprehensive analysis of the rheometric data was
performed by applying the most commonly used models that predict protein solution
viscosity. This included a most recent approach reported in the literature, which takes
in account the variation in solution composition [136,137]. Additional experiments were
also done to understand the impact of the formulation buffer and its components.
The main aim of this work was to understand if at higher concentrations of rAlbu-
min, there is a relationship between the level of aggregation and the solution viscosity
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observed. By investigating this possible relationship, we aim at better understanding
why the highly concentrated globular protein solutions (> 200 mg/mL) are often found
to deviate from theoretic models.
3.2 Materials and Methods
3.2.1 Materials
3.2.1.1 Protein sample
Recombinant human albumin (rAlbumin) was donated by Novozymes Biopharma UK,
Ltd. (Nottingham, UK) in the form of Recombumin R© Prime (batches used: 1104 and
1101). The product is a liquid formulation of concentration 200 mg/mL, stored at 2-8 ◦C.
This rAlbumin is expressed in Saccharomyces cerevisiae and is identical to human serum
albumin (HSA) [138]. HSA is the most abundant protein in the blood at a concentration
of ∼40 mg/mL. It is the major transport protein for unsterified fatty acids, having the
capacity of binding numerous metabolites, active pharmaceutical ingredients as well as
other organic molecules [139].
Figure 3.1: Ribbon model of the x-ray chrystal structure of HSA marking the three domains
I, II and II, labeled in red, green and blue, respectively. Generated using the UCSF Chimera
package [140] using X-ray coordinates 1AO6 (Protein Data Bank, taken from reference [139]).
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HSA has three repeating domains (I-III), each divided into two sub-domains [139]
(Figure 3.1). The protein has an average molecular weight of 66.5 kDa, is comprised of
585 amino acids, and its secondary structure has approximately 67% α-helix content
with the remainder is β-turns and extended polypeptide chains [141]. HSA has 17
disulfide bonds. In physiological conditions there is only one free cysteine residue (Cys
34) [131, 138, 139]. The protein’s isoelectric point has been reported to be between
4.7-5.7 depending if the protein is lipid-bound and on the buffer used [106, 141]. In
physiological pH (pH = 7.4), HSA has a negative net charge, calculated to be -19e [141].
HSA has been commonly used as stabiliser for biological materials and with the
availability of recombinant human albumin, the latter has been approved as a substitute
for HSA as a formulation excipient [138].
3.2.1.2 Sample preparation
All reagents were obtained from Sigma-Aldrich, UK and were of analytical grade.
The formulation buffer of Recombumin is composed of NaCl (145 mM), polysorbate-
80 (15 mg/L) and sodium octanoate (32 mM) in ultrapure water (pH = 7.0 ± 0.3 at
room temperature). Another buffer was prepared containing only NaCl (145 mM) in
ultrapure water (pH = 7.0 ± 0.3).
Centrifugal concentrators (Vivaspin 20 - 5 kDa molecular weight cut-off - with PES
(polyethersulfone) membrane (Sartorius Stedim, Ltd., UK) were used to concentrate
rAlbumin samples to a higher concentration than the starting material (200 mg/mL).
The procedure recommended by the manufacturer was followed, using a fixed 45◦ rotor
centrifuge (Hermle Z400, Labortechnik GmbH, Germany). After centrifugation, samples
were collected, mixed and checked for their concentration using UV-Vis spectroscopy.
The stock solution of rAlbumin, as well as all samples in their respective buffers, were
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kept stored at 2 - 8 ◦C.
3.2.2 Methods
3.2.2.1 Quantification of protein concentration by UV-Vis spectroscopy
For the determination of concentration of rAlbumin solutions, the percent extinction
coefficient (A1%1cm) used was 5.8 [99]. The concentrations reported were calculated as an
average of measurements of 3 separate dilutions prepared from each sample or, in the
case of the NanoDrop, 3 separate samples when no dilution was required. An error of
up to 10 % was accepted for these measurements.
All details related to this method are described in section 2.2.7 in Chapter 2.
3.2.2.2 Rheology
The rheometers used were Anton-Paar (Graz, Austria) modular compact rheometers
(MCR) , models 301 and 501. Cone-and-plate geometries used throughout this study
were stainless steel CP50-1 (diameter = 50 mm and cone angle = 1◦) and CP40-0.3
(diameter = 40 mm and cone angle = 0.3◦). To prevent evaporation of sample and to
maintain a constant temperature of 20 ◦C ± 0.1 ◦C throughout the measurements, an
evaporation blocking system equipped with a peltier unit was used.
Reducing the presence of air bubbles in the samples and during loading was important
to avoid artifacts during measurements. Depending on how highly concentrated the
samples were, a low vacuum was used to induce bursting of air bubbles. This procedure
was done for short periods of time (∼10 s) to prevent sample evaporation. Prior to
measurements, all samples were allowed to equilibrate to room temperature (∼ 23 ◦C)
for at least 40 minutes.
Rotational tests (flow curves and viscosity curves) were performed by controlling the
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shear rate typically from 0.01 to 1000 s−1, and measuring torque, shear viscosity and
shear stress. To increase data validity and sensitivity of the method, each shear-rate
step had a 60 second duration time during which the instrument was averaging over the
collected data. Typically, two shear-rate sweeps (ramping down and up) were performed
per sample, without waiting time between sweeps.
3.2.2.3 Falling-ball viscometer
For the calculation of intrinsic viscosity (in section 3.3.3) was determined using the bulk
viscosity of lower concentrations of rAlbumin (0.1 - 2 mg/mL), an automated micro
capillary viscometer (Anton-Paar, Graz, Austria). The capillary had an inner diameter
of 1.6 mm and contained a steel ball of 1.5 mm diameter. For a standard measurement,
the inclination angle was set at 70◦ (and -70◦). Temperature control at 20 ◦C ±0.1 ◦C
was ensured via a peltier unit attached to the instrument. The capillary was calibrated
by running DI water and a viscosity standard oil at the same angle used for the sample
measurement. Viscosity values were calculated from measured kinematic viscosities,
accounting with the density values obtained for the studied samples, as described in
section 2.2.11.
3.2.2.4 Micro-viscometer/rheometer on-a-chip (mVROC)
The microviscometer/ rheometer on-a-chip (mVROC), by Rheosense, Inc. (San
Ramon, California, USA) was used for measurement of bulk viscosity at high shear
rates. Samples analysed were rAlbumin solutions at 200 and 500 mg/mL. For these
measurements, the A05 and D05 chips were used and temperature was kept constant
at 20◦C ± 0.1◦C using a water circulation system (ThermoCube, SS cooling systems,
USA) (for additional information, see section 2.2.6.2 in Chapter 2).
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3.2.2.5 High performance size exclusion chromatography (HPSEC)
(a) Determination of level of protein aggregation
rAlbumin samples were analysed for their level of aggregation on HPSEC. Details
related to method and equipment are described in section 2.2.9.2 in Chapter 2.
(b) Analysis with multiple detectors for determination of molecular weight
and intrinsic viscosity of rAlbumin solutions
For the calculation of bulk molecular weight and intrinsic viscosity, the chromatography
system used was a Polymer Labs GPC 50 Plus (Agilent Technologies, USA) gel per-
meation unit. Calibration of the system was made with polyethylene oxide solutions in
PBS.
The method details chosen for these experiments were almost the same as in sec-
tion the previous section with minor differences; samples were diluted to 15 mg/mL
thus injecting 300 µg of total protein. System suitability was still performed with Bio-
rad protein standards and the same buffer was used as mobile phase. Each rAlbumin
sample was injected three times, with buffers injected at least once. dn/dc used for
protein analysis was 0.185 mL/g [142].
3.2.2.6 Dynamic light scattering (DLS)
Details related to this method are described in section 2.2.8.1 in Chapter 2.
Measurement settings for rAlbumin size readings were at a constant temperature of
20 ◦C, performing 15 runs of 10 seconds each. An equilibration time of at least 5 minutes
was set before the measurement started. For all protein samples, size measurements
were made in triplicate with fresh aliquots for each reading.
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3.2.2.7 Microfluidic chip sodium-dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE)
All details related to this method are described in section 2.2.13.1 in Chapter 2.
The samples that were analysed were rAlbumin at ∼200, 250, 300, 350, 400, 450 and
500 mg/mL.
3.3 Results and Discussion
3.3.1 The rheological analysis of formulated recombinant human albu-
min solutions
The rheological analysis of rAlbumin solutions in its original formulation buffer
(containing polysorbate-80 as a surfactant and salt) was done using a conventional
rheometer equipped with cone-and-plate geometries (CP50-1 and CP40-0.3). As the
commercially available solution is provided at 200 mg/mL of rAlbumin, it was the only
sample studied directly from the manufacturer’s vial. All other samples were prepared
by either diluting in formulation buffer or concentrating using centrifugal concentrators.
Figures 3.2(a) and 3.2(b) showed that rAlbumin solutions showed constant shear
viscosities for the increasing shear rates applied (0.01 to 1000 s−1). Figure 3.3 showed
a linear increase of shear stress with the increasing applied shear rates. For the higher
concentration materials (400 - 500 mg/mL) the shear viscosities were from ∼1 s−1 on-
wards, while showing slight non-linear increase of viscosities when < 1 s−1. However, in
general, throughout the range of concentrations of rAlbumin presented and the applied
shear rates, it was considered that these solutions exhibited a Newtonian-like behaviour.
This is a clear contrast to what has been observed in previous studies of the rheology
of globular proteins [60–62, 78] where an apparent yield-behaviour has been reported,
particularly at lower shear rates. The reason for this purely viscous Newtonian-like
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behaviour is likely due to the presence of polysorbate-80, a well known surfactant used
in biopharmaceutical formulations. Similar rheological behaviour has been reported for
globular protein solutions in a buffer also containing a polysorbate [74, 143].
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Figure 3.2: Experimental steady shear rheology of rAlbumin solutions. Viscosity values are
shown for ramping down (closed circles) and ramping up (lines) shear rates. (a) Samples from
0.1 to 100 mg/mL. (b) Samples from 10 to 500 mg/mL. All data collected with cone-plate 50
mm, 1◦, and cone-plate 40 mm, 0.3◦, at 20 ◦C.
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Figure 3.3: Flow curves for experimental steady shear rheology of rAlbumin solutions from 10
to 500 mg/mL. Shear stress values are shown only for ramping down shear rates. Data collected
with cone-plate 50 mm, 1◦, and cone-plate 40 mm, 0.3◦, at 20 ◦C.
Each sample was measured using two consecutive shear rate sweeps, ramping down
and up, after a 10 minute waiting time (Figures 3.2(a) and 3.2(b)). Hysteresis effects
were not observed, in agreement with the literature [60, 61, 78]. However, the sample
identified as ∼500 mg/mL seemed to show a different behaviour when sweeping up
the shear rates, compared to the result seen with ramping down (Figure 3.2(b)). This
was possibly due to an artifact caused by the presence of air bubbles. As this sample
presented the highest concentration and was the most viscous, loading it on the lower
plate of the rheometer was difficult and small air bubbles could have been introduced.
After the slight increase in viscosity at mid range of shear rates, this sample showed a
gradual decrease of viscosity to values similar to those seen before, particularly at the
higher shear rates. This is an artificial shear-thinning-like behaviour, most likely to
do with presence of air bubbles being squeezed out of the sample as it was sheared at
higher shear rates (> 100 s−1) [144].
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The instrument’s lower detection limit for valid torque measured, according to the
manufacturer, is 0.1 µN.m for steady shear experiments. Therefore, rAlbumin samples
of concentrations from 0.1 up to 50 mg/mL, with viscosities very close to 1×10−3
Pa.s, showed valid data only up to ∼6 s−1. Below this shear rate, torque values were
not considered as valid. To demonstrate this in a clear way, a comparison was made
with calibrant standard hydrocarbonate oils N1.0 and N14 (Cannon Instruments), with
reported viscosities at 20 ◦C of 0.93 mPa.s and 24 mPa.s, respectively (Figure 3.4). As
the rAlbumin samples increased in protein concentration, with a corresponding increase
in viscosity, the measured torque was increasingly higher than the lower detection limit,
therefore increasing the data validity towards lower shear rates (0.01 s−1).



























Figure 3.4: Torque values from experimental steady shear rheology of rHA solutions. Triangles
- torque values for rAlbumin samples. Lines are representative of torque values for calibration
standard oils, N1.0 (solid line, η = 0.93 mPa.s) and N14 (dashed line, η = 24 mPa.s). Data
collected with cone-plate 50 mm, 1◦ at 20 ◦C.
For comparison between the concentration of samples and the obtained shear viscos-
ities, the viscosity values at 1000 s−1 were taken from three separate readings per sample
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and are reported in Figure 3.5 as an average with the respective standard deviation. The
viscosity values reported here are those at high shear viscosity, η∞, and it is assumed
that it is correct to extrapolate a similar viscosity per sample at zero shear (η0), since
the viscosities of these samples were overall shear-rate independent [78].
Table 3.1 shows the measured concentrations of samples in comparison to the tar-
get concentrations. It was difficult to achieve targeted concentration values with higher
concentrations (≥ 300 mg/mL), due to the difficulty of accurately achieving such values
using centrifugal concentrators. This was mostly relevant with the sample targeted at
500 mg/mL, where its higher viscosity yielded difficulties in further concentrating the
sample.
From Figure 3.5, it can be clearly seen that for lower protein concentrations the
viscosity values were similar. An increase of viscosity with increasing of concentration
was clearly seen, in agreement to what has been reported throughout the literature with
regards to serum albumin solutions [71,78,145]. Most importantly, the exponential trend
observed from the data in Figure 3.5 is also reported for other globular proteins, such
as immunoglobulins [6, 51, 70,72].
From correlation of the data in Figure 3.5 and Table 3.1, it is clear that the larger
increase in viscosity occurred between concentrations ∼250 and ∼500 mg/mL. The ∼500
mg/mL sample reached a high shear rate viscosity of ∼10000 times larger than that of
water (1.0016 mPa.s at 20 ◦C, as defined by NIST). Although biopharmaceutical for-
mulations are not formulated at such high concentrations (> 400 mg/mL), particularly
for monoclonal antibodies formulations, the literature has discussed similar increases of
viscosity [70, 136, 137]. Therefore, analysing the viscosity increase with concentration
of rAlbumin solutions as a biopharmaceutical formulation model will help understand
what factors govern this exponential function.
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Figure 3.5: Viscosity of rAlbumin solutions ranging from 0.1 mg/mL to 500 mg/mL (target
concentrations). Viscosites are taken at high shear (γ˙ = 1000 s−1) and at 20 ◦C. Viscosity values
are represented as an average and standard deviation (error bars) of 3 separate measurements
for each sample. Concentrations are represented as average of 3 measurements and error bars
are standard deviation.
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Table 3.1: Measured concentrations and respective viscosities corresponding to target con-
centrations of rAlbumin samples. All values reported are an average of 3 measurements, with
corresponding standard deviations.
3.3.2 Characterisation of protein species present in recombinant hu-
man albumin solutions
Our aim was to correlate the observed increase in viscosities with the level of aggregation
present in the increasing concentrations of rAlbumin samples. Therefore, an identifica-
tion, relative quantification and size characterisation of the monomeric and oligomeric
species present in solution was done using HPSEC, DLS and microfluidics SDS-PAGE.
3.3.2.1 High-performance size exclusion chromatography (HPSEC)
High performance size exclusion chromatography (HPSEC) was used to determine
the level of protein aggregation as a function of concentration. Retention times for
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the protein species typically present were ∼ 7.9, 8.7 and 9.8 minutes, corresponding
to trimer, dimer and monomers, respectively (Figure 3.6). This method of analysis
produced good resolution between the different identified species and it was comparable
to literature values using a similar setup [146]. No higher molecular weight species
other than dimers and trimers were found in any of the solutions analysed. This reflects
the high purity of the recombinant albumin material due to its manufacturing process
generating only a small percentage of trimers and dimers [138]. In this case all samples
analysed were not thermally stressed. Therefore, the monomer showed the highest
relative percentage with a peak area of >90%. Comparing peak areas between the
samples (50 - 500 mg/mL), showed that the samples from 50 to 200 mg/mL have similar
peak areas for all protein species. Only when concentrations reached approximately 250
mg/mL and over, a trend could be detected on the increase of dimers and trimers with
a corresponding decrease of monomer. This trend was clearer for samples ∼ 350, 400,







Figure 3.6: Size exclusion chromatograms for a 200 mg/mL rAlbumin solution, diluted to 10
mg/mL and analysed on a) HPSEC for level of aggregation and b) HPSEC with triple detection
to determine bulk intrinsic viscosity and bulk molecular weight. In the chromatograms, the
letters correspond to: A - trimer; B - dimer and C - monomer.
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Figure 3.7: HPSEC conventional method for determining level of aggregation of rAlbumin solu-
tions showing relative peak areas in %. Data in squares and represents an average of 3 readings.
Error bars are standard deviation per sample for peak area % (y-axis) and for concentration
(x-axis). All samples were diluted to 10 mg/mL prior to analysis.
Size exclusion chromatography required sample dilution for analysis when concentra-
tions were >10 mg/mL. Dilution can be a limitation of the method since it can influence
the material’s content in relative percentage of each species, as it can be a factor for
some aggregates to disassociate, and therefore be considered reversible [147,148]. It was
important to understand if this was the case with rAlbumin solutions. By comparing
neat injections of 50 mg/mL and 10 mg/mL, it was observed that their respective peak
areas were different in less than 1 % (Figure 3.8). Such low difference suggested that
reversibility of trimers and dimers could be negligible. Moreover, this complies to the
irreversibility of associative species that has been reported in literature [149].
In addition, a stability study of four weeks was done for fresh dilutions of rAlbumin
(10 and 50 mg/mL) stored at 5 ◦C. The aim was to confirm that rAlbumin solutions
would not aggregate when stored at 2-8 ◦C. It was found that within four weeks, a
decrease of approximately 1 % of dimer occurred, corresponding to a similar increase
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of monomer. This change attained a plateau after the first two weeks (Figure 3.8). It
has been found that it is possible that dimerisation of albumin can also be due to self-
association, not involving the free cysteine [150]. Therefore, in the case here, it could be
possible that the low relative percentage of dimers may have formed by self-association
during manufacture, remaining constant while the stock kept at 200 mg/mL and only
dissociating after dilution along the time. When comparing injections of neat rAlbumin
solutions, varying the sample concentration and injection volumes would possibly force
faster dissociation, which would explain why there was not a difference in the relative
peak areas between low and high concentrations of rAlbumin.

























Figure 3.8: HPSEC conventional method comparing neat injections of 10 and 50 mg/mL
rAlbumin solutions along 4 weeks with storage at 5 ◦C. Average and standard deviation (error
bars represented) were reported from 3 separate readings. Line is for eye guidance only.
Triple-detection HPSEC was used to experimentally determine the intrinsic viscosity
for each of the protein species present in rAlbumin samples: monomer, dimer and trimer.
The information provided by triple detection HPSEC is advantageous as it typically
allows the measurement of molecular weight, radius of gyration and intrisic viscosity for
the individual species present in the samples and separated by the analytical column
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[102]. Here, the determination of intrinsic viscosity and MW of rAlbumin species was
relevant for subsequent analysis discussed in the following section (section 3.3.3).
The results presented are relative to the two peaks detected which were the monomer
and dimer, since the differential pressure viscometer could not detect the low percentage
of trimers present in solution (Figure 3.6). Analysis of peak areas per sample showed
the same trend of increasing rAlbumin dimers, similar to what was observed previously
for conventional HPSEC (Table 3.2).
Bulk intrinsic viscosity and bulk molecular weight values match well with the values
reported in literature for human serum and bovine serum albumin [146]. No variation
within these parameters with concentration was observed, which is a good indication of
validity for both the samples and the experimental set-up.
Table 3.2: HPSEC triple detection values of peak area, bulk MW and bulk intrinsic viscosity
(IV) for monomers and dimers detected in rAlbumin solutions. Average and standard deviations
are reported for 3 separate measurements per sample.
3.3.2.2 Dynamic light scattering
The hydrodynamic size analysis of rAlbumin solutions by DLS was performed for the
entire range of solutions 1 - 500 mg/mL after dilution to 1 mg/mL, when applicable.
All solutions were analysed without prior filtration to assess if there were aggregates
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present within the instrument’s detection limit (up to 1 µm hydrodynamic diameter).
In all cases, the samples did not show presence of other aggregates and only one broad
peak was observed for size distribution by intensity (Figure 3.9). The hydrodynamic size
distribution by volume also resulted in a broad peak, with its mean peak value skewed
towards lower sizes, similar to that of the monomer. This reflects the higher relative
contribution of monomer in comparison to the low contribution of dimers and trimers
present in solution. For all the analysed samples, the measured hydrodynamic radii from
the size distributions by intensity ranged between 3.8 - 4.5 nm corresponding to values
commonly reported in literature [106] for a unstressed pure albumin solution.
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Figure 3.9: Dynamic light scattering plots for 200 mg/mL rAlbumin solution diluted to 1
mg/mL. A) Size distributions by intensity (black line), and by volume (red line). B) Correl-
ation data versus the decay time (in [µs]) via the correlation function of measured intensity.
Measurements taken at 20 ◦C.
3.3.2.3 Microfluidics SDS PAGE
Analysis with microfluidics SDS PAGE system allowed for further characterisation
of rAlbumin solutions of higher concentrations. The samples chosen for comparison
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were from 200 mg/mL to 500 mg/mL, since all prepared rAlbumin samples with
concentration below 200 mg/mL would have been diluted from the same stock solution.
For all analysed samples and in both reducing and non-reducing conditions, the major
peak/ band detected at approximately 63 kDa was attributed to rAlbumin’s monomer,
in agreement to literature [138]. The purity of rAlbumin solutions via SDS PAGE
showed consistency with the level of aggregation measured via HPSEC as it did not
detect any protein fragments nor other protein species besides the expected dimerisation
of monomers (peak/band present in reducing and non-reducing conditions, between 95
and 150 kDa markers). The absent detection of trimers, which are expected to have a
molecular weight of approximately 200 kDa [138], could be due to their low quantity
also observed in the HPSEC results (Figure 3.7).
Dimerisation of human serum albumin or bovine serum albumin is mostly due
to formation of a covalent disulfide bridge between the free cysteine present in the
monomer [151]. It was expected that dimers in rAlbumin solutions would be reduced by
dithriothreitol (DTT) at reducing conditions, although it has been reported that HSA’s
oligomeric species can remain present even at similar reducing conditions [138]. It was
seen that the peak percentage correspondent for dimer, although present in both gels
(Table 3.3), exhibited lower values at reducing conditions compared to non-reducing
conditions. To further reduce remaining dimers present in reducing conditions, it would
be the case of further method optimisation by adding higher concentration of reducing
agent (DTT) or allowing for longer heating time.
The protocol followed for this method was originally optimised for monoclonal
antibody analysis. To allow for system suitability evalution, a stable and high purity (>
98 % by HPSEC) mAb (IgG1) sample was added as a control to each of the microchips
(reducing and non-reducing). The peak/band detected on the non-reducing gel could be
attributed to a mAb monomer of approximately 150 kDa. Upon reducing conditions the
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mAb sample yielded two peaks/bands at approximately 50 and 25 kDa, corresponding
respectively to the heavy and light chains present in a IgG1 [1, 12] (Figures 3.10(b) and
3.10(a)).
Table 3.3: Microfluidics protein electrophoresis results for non-reducing and reducing con-
ditions of rAlbumin samples, showing peaks for relative quantity of monomer and dimer and
corresponding molecular weight.
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Figure 3.10: Microfluidics protein electrophoresis gel image for rAlbumin solutions originally
at high concentration. (a) Gel in reducing conditions and (b) gel in non-reducing conditions.
For both gels : [rAlbumin] = 200 (lane 1), 250 (lane 2), 300 (lane 3), 350 (lane 4), 400 (lane
5), 450 (lane 6) and 500 mg/mL (lane 7); formulation buffer (lane 8) and monoclonal antibody
control (lane 9).
3.3.3 Effect of high protein concentration on solution viscosity
The effect of protein concentration on solution viscosity has been discussed by several
authors [71, 137, 145, 152–155]. At dilute concentrations, protein solution viscosity has
been studied and accounted for by predictions that account for the hydrodynamic
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behaviour of proteins in a fluid [145]. Other theories that account for inter-protein
interaction potential and excluded volume have been applied with relative success in
predicting the increase of viscosity with protein concentration [78, 156]. In general,
all these models assume that (globular) proteins are hard spherical or quasispherical
macromolecules, and to some extent, this has been shown to explain the increase of
viscosity with concentration and allow a comparison with the behaviour of colloidal
dispersions. So far, there has not been a theoretical model that is capable of predicting
the viscosity of protein solutions in a range from dilute to highly concentrated (≫200
mg/mL). The following section provides an account for the analysis according to the
most used theories in literature.
(a) Analysis using Hard (quasi) spherical models: Ross-Minton and Krieger-
Dougherty equations
From polymer and protein rheology, the intrinsic viscosity is defined in terms of concen-






where η is the solution’s viscosity and η0 is the viscosity of the solvent. Intrinsic viscosity
is a hydrodynamic parameter that can pinpoint the overall aspect ratio of a molecule in
dilute solution and represents the effective molecular volume at these conditions [75]. By
preparing various dilute solutions (0.1 - 2 mg/mL) and measuring its bulk viscosity in a
capillary viscometer, the reduced (ηred) (eq. 3.2) or inherent (ηinh) (eq. 3.3) viscosities
of these solutions can be plotted versus its concentrations and the intrinsic viscosity can
be found by extrapolation to zero concentration.
















cosity (ηsp) is defined by ηsp = 1− ηrel [75, 145].
The first approach to the data was to experimentally determine the intrinsic viscosity
of this protein from viscometric data obtained via a falling ball capillary. The results
(Figure 3.11) demonstrated that by extrapolating to zero concentration via both ηred
and ηinh, the intrinsic viscosity had a similar value between the two methods, [η]inh =
0.00678 mL/mg and [η]red = 0.00677 mL/mg. The intrisinc viscosity of human serum
albumin has been reported to be of 0.00473 ± 1.2×10−3 mL/mg, for similar solution
conditions (temperature at 20 ◦C, pH ∼ 7.0) [131]. Values of intrinsic viscosity for bovine
serum albumin, have been reported to be 0.0037 mL/mg [145] or similar values [75,157].
Our intrinsic viscosity values, although agreeable between both methods, were slightly
increased to the expected value (between 0.003 - 0.004 mL/mg). Also, it did not corres-
pond to values measured via triple detection HPSEC (Table 3.2).
These experiments are sensitive to errors in sample preparation, where pippetting
errors can affect both sample preparation and an accurate concentration calculation,
compromising the viscosity measurements. Although various dilutions were prepared,
only four data points were selected to fit the data, thus reducing the accuracy in com-
puting the intrinsic viscosity of rAlbumin.
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Figure 3.11: Inherent and reduced viscosities of dilute samples of rAlbumin. The bulk viscos-
ities (circles) of these samples were measured with a capillary viscometer (AMVn, Anton Paar)
at 20 ◦C. Bulk viscosity of the formulation buffer was 1.0487 ± 0.0013 mPa.s. Samples were
measured in triplicate. Linear fit for reduced viscosity (blue line): r2=0.9461, [η]red = 0.00678 ±
1.83×10−3; linear fit for inherent viscosity (red line): r2=0.9473, [η]red = 0.00677 ± 1.83×10
−3.
The obtained intrinsic viscosity value, as well as values from literature [131, 145],
were used to fit the rheometry data (Figure 3.12) using the one of the hard (quasi)-
spherical models relating protein viscosity and concentration. This model was the mod-










where relative viscosity is an exponential function of concentration (c in [mg/mL]),
intrinsic viscosity ([η], in [mg/mL]), a crowding effect factor (κ, dimensionless) and
Simha’s shape factor [145] (ν, dimensionless). As the crowding effect is a consequence
of the excluded volume when the protein concentration increases, the model predicts
solution viscosity not only accounting for the protein’s shape but also its excluded
volume.
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Data was fitted with constraint to intrinsic viscosity but not the κ/ν factor (Figure
3.12). The computed values for κ/ν respective to the fixed intrinsic viscosities chosen
from literature were: κ/ν = 0.42, using [η]Tanford; and κ/ν = 0.31, using [η]Monkos.
These values were in agreement with the literature values reported for other globular
proteins, such as IgG (κ/ν = 0.37 to 0.49) and hemoglobin (κ/ν = 0.40) [51, 70, 153].
The calculated κ/ν value (0.18) obtained using the experimentally determined intrinsic
viscosity is far from the reported values in literature, thus suggesting no significance.





















 [η]=0.00472 mL/mg (Monkos)
 [η]=0.0037 mL/mg (Tanford)
 [η]=0.00677 mL/mg (from η
red)
 Experimental data
Figure 3.12: Experimental cone-and-plate rheometry data (squares) fitted to Ross-Minton’s
equation (eq. 3.4). Relative viscosity was obtained by dividing each of the samples high shear
viscosity (η1000s−1) by the averaged buffer viscosity 1.038 ± 0.013 mPa.s. Fits were calculated by
fixing [η] and leaving the parameter κ/ν free and are as follows: Blue line, [η] = 0.00472 mL/mg
(from [131]), κ/ν = 0.31 ± 6.6×10−4, r2 = 0.95; red line, [η] = 0.0037 mL/mg (from [145]), κ/ν
= 0.42 ± 6.9×10−4, r2 = 0.94 ; green line, [η] = 0.00677 mL/mg (from ηred), κ/ν = 0.18 ±
5.6×10−4, r2 = 0.96.
The Ross Minton model was also fitted to the data allowing free parameters. The
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best fit computed was using experimental data up to ∼ 350 mg/mL (Figure 3.13).
Both the [η] (0.0042 mL/mg) and κ/ν (0.45) values were in agreement to the values
reported in literature [75, 131, 145]. Also, this fitted intrinsic viscosity was similar to
the intrinsic viscosity value calculated with triple detection HPSEC for the monomer
peak of rAlbumin (Table 3.2). However, the Ross-Minton model did not predict solution
viscosity for the highest concentrations (≥ 350 mg/mL) which indicates that there are
other factors to consider to predict all of our experimental data.























Figure 3.13: Experimental cone-and-plate rheometry data (squares) fitted to Ross-Minton’s
equation (eq. 3.4), using free parameters. Relative viscosity was obtained by dividing each of
the samples high shear viscosity (η(1000s−1)) by the buffer’s viscosity 1.038 ± 0.013 mPa.s. Fit
was calculated leaving both [η] and κ/ν free: [η] = 0.00421 ± 1.5×10−4 mL/mg; κ/ν = 0.45 ±
0.024; r2 = 0.999 and χ2 = 0.40. Experimental data used for this fit was only up to 350 mg/mL.
From colloidal rheology, the Krieger-Dougherty model (eq. 3.5) was also applied to












As the Krieger-Dougherty equation is originally applied to infinite dilutions of
hard spherical particles, the intrinsic viscosity ([η]) in eq. 3.5) was fixed to 2.5, and is
dimensionless since it is defined in function of volume fraction (φ), with a maximum
packing fraction (φmax) of 0.64 in the case of random close packing of spheres at low
deformations [48, 156]. Still assuming the spherical shape, this maximum packing
fraction has been discussed to be around 0.71 [156] when the particles are exposed
to higher shear rates. In both cases, fixing intrinsic viscosity to 2.5 and φmax could
only predict the data up to 100 mg/mL, which is in agreement with the literature [78]
(Figure 3.14).
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Figure 3.14: Experimental cone-and-plate rheometry data (squares) plotted against expected
data (lines) from Krieger-Dougherty’s equation (eq. 3.5) with fixed parameters. Relative vis-
cosity was calculated by dividing each sample’s η(1000s−1) by the buffer’s viscosity (η0= 1.038 ±
0.013 mPa.s). For both lines, [η] was fixed to 2.5, but different φmax were used: 0.64 (red line);
0.71 (orange line).
Conversion of weight/volume concentration to volume fraction was calculated via
the polymer chemistry equation for volume fraction (φ = NAV cMW ), taking into account
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the hydrated molecular weight of the protein - MWh (eq. 3.6). The hydrated protein
molecular weight was calculated fromMWh =MWp(1+δ), whereMWp is the molecular












where c is the concentration in mg/mL, NA is Avogadro’s number, V is the protein’s
hydrodynamic volume (113.4 nm3), and ρ is the density of water at 20 ◦C (998.2×103
mg/mL) and δ = 0.379 [131].
The data was also fitted to equation 3.5 with free parameters, allowing a prediction
of viscosity applied to non-spherical particles (Figure 3.15). The parameters which were
best fits using data up to 350 mg/mL, where [η] = 6.94 ± 0.14 and φmax = 0.298 ±
0.002 (with r2 = 0.9996 and χ2 = 0.26). In this case, the fitted intrinsic viscosity showed
a higher value than that corresponding to spheres, indicating that particle aspect ratio
had increased and the φmax decreased respectively. These values suggest good physical
significance since their product is still within their usual range 1.4 < [η]φmax < 4 [90].
The fitted intrinsic viscosity value of ∼6.9 also agreed with the reported aspect ratio of
albumin, known to be a prolate ellipsoid [106, 131, 145]. These parameters, along with
the observations previously made from the Ross-Minton model, point to a difficulty in
prediction towards concentrations > 350 mg/mL (see Figures 3.13 and 3.15).
123









 Experimental data  
 Krieger-Dougherty model 













Figure 3.15: Experimental cone-and-plate rheometry data (blue diamonds) fitted to Krieger-
Dougherty’s equation using free parameters (eq. 3.5). Relative viscosity was calculated by
dividing each of the sample’s viscosity (η(1000s−1)) by the buffer’s viscosity (1.038 ± 0.013 mPa.s).
Fitting parameters were [η] = 6.9 ± 0.14, φmax = 0.30 ± 0.0025, with r
2 = 0.999 and χ2 = 0.26.
Experimental data used for this fit was up to 350 mg/mL.
(b) Analysis using Hard-spherical model considering interparticle interac-
tion: Batchelor’s equation
A more complex model, Russel’s revision of Batchelor’s equation [156], was also applied
to the experimental data (Equation 3.7). This model predicts the increase of viscosity
of hard spherical particles while taking into account the interparticle interaction based




= 1 + 2.5φ+ sφ2 +O(φ3) (3.7)
In equation 3.7, the coefficient s of the quadratic term is defined by,









being dependent of the effective interparticle distance, deff , and the radius of
particle, a. In its turn, deff is dependent on both the hydrodynamic contributions of
the particle as well as the interaction potential, relevant to the dispersion conditions.
Batchelor showed that for a concentrated dispersion of hard spherical repulsive particles,
the value of s is equal to 6.2, where deff = 2a [156]. Sharma et al. showed that the
data of BSA concentrated solutions up to 250 mg/mL could be fit with this model (with
data up to ≈ 250 mg/mL) using a value s = 10. The authors suggested that this value
would correspond to an interaction potential corresponding to a deff = 2.5a, reflecting
BSA’s repulsive net negative charge in a saline buffer.
Applying this model to the data could not anticipate the viscosity at concentrations
higher than ∼ 150 mg/mL (φ = 0.11), even when fixing s = 10 (Figure 3.16). The
discrepancies between our data and that of Sharma et al. could be due to the source
of raw viscosity data, since the authors used a mVROC. Our data, although collected
using a torsional rheometer with cone-and-plate, were of rAlbumin solutions in a buffer
containing a surfactant. There is no likely relation to measurement artifacts influencing
our results (see discussion further ahead in this chapter for more details). The solutions
studied by Sharma et al. were of the bovine version of albumin, a slightly different
protein. Moreover, this model fixes the intrinsic viscosity at 2.5 for hard spheres,
while it has been previously discussed that rAlbumin (and BSA) are not spherical but
prolates. Thus, the model may well not be the most appropriate to fit this data albeit
being the only model presented so far that includes surface charge as determinant to
the viscosity of globular protein solutions. It was not possible to fit this model to the
data when leaving the parameter s free.
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Figure 3.16: Experimental cone-and-plate rheometry data (squares) plotted against expected
data (lines) from Russel’s equation (eq. 3.7) using fixed parameters. Relative viscosity was
calculated by dividing each of the sample’s viscosity (η(1000s−1)) by the buffer’s viscosity (1.038
± 0.013 mPa.s). For both lines, [η] was fixed to 2.5, but s was: 6.2 (blue line); 10 (green line).
(c) Analysis using the generalised Ross-Minton and generalised Krieger-
Dougherty equations
Recently, Galush et al.(2012) presented a study on the viscosity of mixed protein solu-
tions, using mixtures of different monoclonal antibodies (mAbs) and of one mAb with
BSA. Their conclusions derived from measuring the viscosity of both the individual pro-
tein solutions and blends. They proposed that the viscosity of protein blends could be
predicted by an additive function of the viscosity of each individual protein multiplied
by its respective known weight fraction (eq. 3.9).
ln η(wtot, f2) = (1− f2) ln η1(wtot) + f2 ln η2(wtot) (3.9)
where η1 and η2 are the viscosities of pure protein 1 and 2, respectively, f1 and f2
are the weight fractions corresponding to the protein 1 and 2 present in the blend and
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wtot is the total weight/volume concentration of the protein mixture.
Minton [137] has recently contributed with the generalisation of equation 3.4 and
equation 3.5 and application to predicting the viscosity of globular protein solutions
containing only one protein, but with relatively well-known fractions of its monomeric
and higher order associative species. The generalised models of Ross-Minton (eq. 3.10)


















Note that the Krieger-Dougherty equation has been modified to allow the use of
weight/volume concentrations (wtot, in [mg/mL]), rather than volume fractions. Both
equations 3.10 and 3.11 are now represented as functions of wtot, [η]w and w
∗. The
parameter [η]w is weight-averaged intrinsic viscosity (in [mg/mL]), described in equation
3.12. The parameter w∗ represents an estimated protein concentration above which the





By fitting these two generalised models to the experimental rheology data, it
was found that the best fits would be achieved if the concentration range would not
include either the last three (generalised Krieger-Dougherty eq.) or two data points
(generalised Ross-Minton eq.) (Figures 3.17(a) and 3.17(b) respectively). The fitted
weight-averaged intrinsic viscosity and w∗ values suggest conformity between both
generalised models. Again, it is noted that using these generalised models it is still not
possible to predict the higher concentrations above ∼ 350 mg/mL. When fitting the
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experimental data, using all the data points available, the fitted parameters usually
presented poor statistical correlations (r2 < 0.9, χ2 >> 1) as well as higher values for
[η]w with no physical significance.
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Figure 3.17: (a) Experimental data fitted to the generalised Krieger-Dougherty equation (eq.
3.11). Fitting parameters were [η]w = 0.00517 ± 1.1×10
−4 mL/mg, w∗ = 399 ± 3.4 mg/mL,
with r2 = 0.999 and χ2 = 0.26. Data used for this fit was up to 350 mg/mL. (b) Experimental
data fitted to the generalised Ross-Minton equation (eq. 3.10). Fitting parameters were [η]w =
0.00479 ± 4.0×10−5 mL/mg, w∗ = 569 ± 2.2 mg/mL, with r2 = 1.0 and χ2 = 0.91. Data used
for this fit was up to 400 mg/mL. For both plots, relative viscosity was calculated by dividing
the sample’s η(1000s−1) by the buffer’s viscosity (1.038 ± 0.013 mPa.s).
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In the study by Galush et al.(2012), the protein mixtures were always prepared
to a known total weight/volume concentration and known weight fractions of each
of the proteins in the mixture. In our case, the presented HPSEC results (Figure
3.7) showed that the monomer, dimer and trimer composition was changing with
sample concentration. Therefore, a weight-averaged intrinsic viscosity was calculated
per sample, instead of being assumed to remain constant (Table 3.4), using the data
obtained by triple detection HPSEC (Table 3.2). The weight-averaged intrinsic viscosity
values were only slightly affected.
Table 3.4: Table with calculated [η]w for rAlbumin solutions based on the experimental HPSEC
triple detection data. [η]1 and [η]2 correspond to the average experimental intrinsic viscosity for
monomer and dimer, respectively. f1 and f2 correspond to the fraction of relative peak area for
monomer and dimer, respectively.
Using the calculated weight-averaged intrinsic viscosity, and assuming different w∗
values based on the fitted parameters obtained above, the viscosities were computed for
the studied concentrations (Figures 3.18(a) and 3.18(b)) for both generalised models.
When choosing w∗ of higher values (derived from fits using all data points), the
viscosities were typically underestimated. On the other hand, using w∗ values that
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were derived from the best fits, 568 mg/mL for the generalised Ross-Minton model, or
399 mg/mL for the generalised Krieger-Doughery model, the viscosities could not be
correctly predicted for the higher concentrations: >400 mg/mL and > 350 mg/mL,
respectively.
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Figure 3.18: (a) Experimental data (circles) plotted against the calculated viscosities (stars)
based on the generalised Ross Minton equation (eq. 3.10). Data in stars calculated when fixing
the w∗ to 530 mg/mL (red), 816 mg/mL (blue) and 568 mg/mL (green). Fitted w∗ values used
were from best fits to eq. 3.10. (b) Experimental data (circles) plotted against the calculated
viscosities (stars) based on the generalised Krieger-Dougherty equation (eq. 3.11). Data in stars
calculated when fixing the w∗ to 1298 mg/mL (dark cyan), 399 mg/mL (purple), 576 mg/mL
(orange), and 445 mg/mL (light green). Fitted w∗ values used are from best fits to eq. 3.11.
For both plots, expected viscosities were calculating using [η]w calculated in Table 3.4. Lines are
represented for guidance to the eye.
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In summary, the analysis suggested that concentrations above ∼ 350 mg/mL have
a solution viscosity that depends on factors other than those taken into account by the
models explored here. Most likely, at this concentration range, the protein solution can
be behaving in a different way to that observed in the less concentrated solutions. As
these models have been developed based on their application to low concentrations of
particle suspensions, where each particle would be far apart from another enough to not
influence each particle’s flow [145]. Therefore, it is not surprising that the equations so
far always apply well to lower concentrations of albumin.
Although the models presented here are based on hard quasi-spherical repulsive
particles and their excluded volume, the predicted data typically suggest that a max-
imum packing fraction of rAlbumin (based on the best fits) will always be lower than the
highest concentrations achieved experimentally (∼ 450 and 500 mg/mL). In addition,
viscosity prediction according to pure hard-sphere particle models clearly underestim-
ates the viscosity values for concentrations higher than ∼ 100 - 150 mg/mL.
One possible suggestion to explain such deviation from predictions at high concen-
trations, is that the maximum packing concentration could be dependent on solution
composition (e.g. the relative quantity of monomers, and oligomeric species such as
dimers and trimers). It is known that suspensions composed of binary sized spherical
particles yield a maximum packing fraction approximately larger than the random close
packing for a homogenous suspension [132–135]. However, the protein has a different
shape which has been shown to also influence the maximum packing fraction. It has
been predicted that for globular protein solutions up to approximately 250 mg/mL with
the protein having a 5:1 aspect ratio, the increase of jamming limit would not be sig-
nificant [137]. Analysis so far has always assumed that associative species remain with
the same globular quasispherical shape, which is clearly not the case.
Apart from shape, it is possible that rAlbumin would likely resemble a nearly hard
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sphere, as its homologous HSA has been reported to exhibit a drop in intrinsic viscosity
with temperature increase, thus a sign of less rigidity [131]. Moreover, as the protein
is further concentrated, less rigidity could be an added factor to account for the slow
increase of viscosity compared to hard sphere model predictions. This could be due
to repulsive nature of inter-particle interactions, which is a phenomenon that has been
observed for sterically stabilised colloids [48].
The deviation to models seen at higher concentrations (≥ 350 mg/mL) could be
related to a glass transition similar to what occurs with colloidal hard spheres. In this
case, accounting for repulsive excluded volume, suspensions are expected to approach
a glass transition at volume fractions φ ≈ 0.58 before approaching the random close
packing fraction (φ = 0.64) [48]. When the concentration approaches a glassy state,
the particle is caged by the presence of neighbouring particles thus slowing down its
flow and leading to increased viscosities. In the case of rAlbumin, an analogous glass
transition behaviour could be taking place at the concentrations between ∼ 400 to ∼ 500
mg/mL based on similar results seen with highly concentrated solutions of BSA [160].
This would suggest that these concentrations are approaching the jamming limit but
does not explain why viscosities cannot be predicted in conventional models. Finally,
it is precisely the range between 350 mg/mL and 500 mg/mL samples that showed an
increase in relative quantity of dimers (with a respective decrease of monomers). So it
does suggest that the change of composition and the increase of viscosity with increase
of concentration are somehow connected.
3.3.4 Surface tension effects on rheology measurements and other con-
trol experiments
To ensure that the rheological measurements were taken as accurately as possible and
were free of artifacts related to both the method or preparation of samples and the
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rheometer’s characteristics, a series of additional experiments were carried out.
The influence of surface tension at the air/water interface of protein solutions in
surfactant-free buffers has been shown to present apparent high-viscosities at low shear
rates. The use of conventional rheometer with cone-and-plate was suggested as not
being the most appropriate instrumentation for this type of samples precisely as it isn’t
an air/water interface-free technique [78].
The microfluidics slit rheometer (mVROC) was used to compare to the rheometry
results. rAlbumin solutions at 200 mg/mL (from the original formulation) and 500
mg/mL were analysed with the mVROC in separate microchips adequate to the sample’s
viscosities (A05 chip for 200 mg/mL and D05 chip for 500 mg/mL). Both samples
showed Newtonian-like behaviour, with the calculated shear viscosities remaining
constant as the the true shear rates were applied (Figure 3.19).
When superimposing the cone-and-plate (CP) rheometer data with mVROC data,
the sample at 200 mg/mL showed no difference in its viscosity values. As an example,
at shear rate γ˙ ≈ 1000 s−1, the average viscosities measured with each instrument were
ηCP ≈ 3.5 mPa.s and ηmV ROC ≈ 3.4 mPa.s (Figure 3.19). This clearly showed that the
CP rheometer data were most likely free of air/water interfacial artifacts.
The sample at 500 mg/mL showed a difference of approximately one decade
between CP and mVROC data (Figure 3.19). Although subsequent repeats had similar
values and rheological characteristics, it was not possible to further explain the sharp
difference. An explanation based on surface tension effects on CP rheometer data might
be ruled out since this data showed constant viscosities along the shear rates applied
up to relatively low shear rates (γ˙ ≈ 0.01 s−1), whereas a surface tension induced
apparent yield-behaviour would be expected. To our knowledge, there are no other
reports in literature analysing globular protein solutions at this level of concentration
using a mVROC. It could be possible that such high concentrations of protein solutions
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are problematic samples for this system due to, for example, a higher propensity of
adhesion to the construction materials.
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Figure 3.19: mVROC data for 200 (blue) and 500 (green) mg/mL of rAlbumin in comparison
to the cone-and-plate rheology data. mVROC data: crossed circles - ramping up shear rates,
dashed lines - ramping down shear rates; CP rheology data: closed circles - ramping up shear
rates; lines - ramping down shear rates.
In another experiment samples were prepared by diluting in a aqueous NaCl 145
mM surfactant-free solution. Dilutions at 5, 10, 50 and 100 mg/mL were analysed on
the CP rheometer as well as their level of aggregation was assessed by HPSEC and DLS.
Results from HPSEC and DLS analyses were similar to those of formulated rAlbumin.
A few differences were identified with the CP rheometer data. Samples at 5, 10 and 50
mg/mL in NaCl 145 mM showed an increase of viscosities towards low shear rates; only
the sample at 100 mg/mL of rAlbumin in NaCl 145 mM presented constant viscosities
throughout a similar shear rate range (Figure 3.20). Samples at 5 and 10 mg/mL
showed a slightly increased high shear viscosity (η∞ at γ˙ = 1000 s
−1), when compared
to the data collected from formulated samples.
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These two differences are possibly related to the lower concentration of polysorbate-
80 present in samples 5 and 10 mg/mL, and to some extent, 50 mg/mL. Polysorbate-80
is present in the formulation to prevent the macromolecule reaching the air/water and
solid/water interface [138]. As polysorbate was also diluted during sample preparation
below a critical concentration, it allowed the protein to form films at the air/water
interface present with the CP geometry. Such surface tension effects are proposed to
influence torque measurements at low shear rates, creating an apparent yield-behaviour
translated in a pronounced increase of the viscosity function’s slope [78, 143]. Other
authors also observed similar differences when adding surfactants to globular protein
solutions [8, 74]. By measuring the viscosity of protein samples prepared in surfactant-
containing buffer, true values of viscosity and shear stress are being measured and is
similar to a measurement performed with an air/water interface-free instrumentation,
such as the mVROC.
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Figure 3.20: Viscosity curves for rAlbumin solutions diluted in 145 mM NaCl buffer, in com-
parison to the formulated material at the same concentrations: 5, 10, 50 and 100 mg/mL. Half
circles - rAlbumin in 145 mM NaCl only; full circles - rAlbumin in formulation buffer.
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To demonstrate that using centrifugal concentrators would not affect the rheological
behaviour nor increase the level of aggregation, an aliquot of the original rAlbumin
solution at 200 mg/mL was diluted in formulation buffer to 50 mg/mL and then
concentrated back to 200 mg/mL. The centrifugal concentrators used would allow
smaller molecules to pass through, such as water, salts and polysorbate-80. The
comparison of the rheological behaviour between this control sample and the original
formulation showed that both had superimposable profiles (Figure 3.21). This sample
at ∼ 200 mg/mL showed similar results to the original 200 mg/mL sample via HPSEC
and DLS.
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Figure 3.21: Comparison of the viscosity curve between 200 mg/mL control sample prepared
via centrifugal concentration (crossed circles) and the originally formulated 200 mg/mL sample
(full circles). Respective lines correspond to ramping up shear rates, while the circles correspond
to ramping down data.
The possibility remains that polysorbate-80 was concentrated along with rAlbumin
for those samples between 250 and 500 mg/mL. In order to fully address this issue, it
would be necessary to directly quantify the presence of this surfactant in the protein
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solutions, which could not be done at the time of this study. To address the analysis
made here, the simplest case was considered, where the polysorbate would have diffused
through the concentrator’s membrane during centrifugation.
3.4 Conclusions
In this work a range of rAlbumin solutions, in a formulated buffer containing salt and a
surfactant, were analysed for their rheological behaviour with the aim to understand the
effects of high concentration on the solution viscosity. Rheological measurements showed
that the solutions (0.1 - ∼500 mg/mL) behaved as purely viscous fluids in the range of
the applied shear rates. It was observed that as the protein concentration increased in
solution, the samples presented an increase of viscosity.
Characterisation regarding the level of aggregation and species size was also made.
By HPSEC, all samples showed the same species were present in solution; monomers,
dimers and trimers of rAlbumin. The relative quantity of each species was fairly similar
between 0.1 - 200 mg/mL but as concentration increased to ∼500 mg/mL, the relat-
ive quantity of dimers and trimers increased along with a corresponding decrease of
monomer. By DLS and SDS-PAGE (microfluidics) analysis, the solutions showed no
other signs of impurities such as other higher order aggregates or protein fragments.
Throughout this study several experiments proved that concentrating the rAlbumin
≥200 mg/mL did not seem to have any other effect besides the increase of solution
viscosity and the change in relative composition of protein species. HPSEC was also
used with aid of triple detectors for the determination of the intrinsic viscosity and bulk
molecular weight. These results showed consistency throughout the concentrations stud-
ied, which was a sign of method and sample validity. Rheological analysis of rAlbumin
diluted in a surfactant-free buffer suggested that presence of polysorbate-80 in the for-
mulation buffer contributed for artifact-free measurements in rheometry, in light of what
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has been discussed in recent literature.
A comprehensive theoretical analysis of the rheological experimental data was per-
formed using different models that are currently assumed to be the most appropriate
to predict protein solution viscosity. These models are considered for hard spherical
or quasispherical particle suspensions and when plotted against the experimental data,
fixing the fitting parameters to the known shape and crowding conditions of spherical
particles, they could only predict the viscosity of rAlbumin up to ∼100 mg/mL. By
leaving these parameters free, the Ross-Minton and Krieger-Dougherty equations were
demonstrated to predict the solution viscosity well, up to 350 mg/mL, when excluding
concentrations >350 mg/mL. When applying an equation that accounted for the pro-
tein interdistance and thus, the effect of interaction potential upon viscosity (the Russel
equation), it couldn’t be applied to concentrations ≥ 150 mg/mL.
Generalised versions of the Ross-Minton and Krieger-Dougherty equations were also
studied and our best results showed that the former could successfully fit when using
experimental data up to ∼400 mg/mL of rAlbumin. These generalised models, although
still based on just two factors (shape or aspect/ratio and particle packing), introduce the
concept of a weight-averaged intrinsic viscosity. Our study showed that this approach
was the best to address the variation of protein species composition in solution. The fact
that our analysis produced better fits using these altered equations, further highlights
the importance of considering this variation in composition within a protein solution,
thus justifying its complete characterisation of oligomeric species. It is important to note
here that, so far no other analysis typically accounts for this variation within a sample
of one protein only - Galush et al.(2012) analysed binary mixtures of different mAbs and
a mAb and BSA. Moreover, while assuming there is no variation in protein species com-
position, the same theoretical models assume that the jamming limit remains unaltered
with changing composition. We still suggest that other factors related to highly con-
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centrated solutions may need to be considered, particularly since those concentrations
not fitted were the most concentrated (>400 mg/mL), where crowding effects should be
more accentuated.
In conclusion, our rAlbumin example explored here may well be a situation close to
what happens to reality in biopharmaceutical formulation science. Although a rather
complicated system, it highlights that the variation of protein species composition




The effect of insoluble protein aggregates on the rheology
of beta-lactoglobulin solutions
4.1 Introduction
The rheology of protein solutions have frequently been addressed in the literature
with regards to the flow properties of biological fluids, such as blood [64] and synovial
fluid [63], as well as food materials, including milk [161]. In recent years, due to
the rapid development of biopharmaceutical industry, attention has also turned to
therapeutically proteins such as monoclonal antibodies.
Although many of these studies have focused on different aims, it is easily noticed
that measurements performed with a conventional torsional rheometer show a flow
behaviour often addressed as being ’solid-like’ or ’shear thinning’ [61, 62]. The obser-
vations constantly point to this flow regime, commonly seen at lower shear stresses,
where viscosity seems to decrease as stress increases. This has been observed for
BSA, β-LG, ovalbumin and other globular proteins at concentrations ranging from
0.03 - 10 % (w/w) [60]. It has been discussed that this solid-like behaviour is due
to strong long-range repulsive interactions between globular protein monomers in
solution [60–62,162].
Recently, the work of Sharma et al.(2011) has suggested that the observed solid-
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like characteristics are typical of a material showing yield-behaviour. In colloidal
suspensions, viscosity is known to depend on the solids content of the suspension,
as well as interparticle interactions. These interactions confer specific behaviours to
the fluids depending on the force that must be overcome to create a deformation,
i.e. to flow. Following this logic, authors have suggested the existence of long-range
interactions that could generate a colloidal crystalline-like structure within a globular
protein solution [60–62, 162]. However, no evidence of such structures has yet been
demonstrated [63]. Sharma et al.(2011), proposed that protein-protein interactions
are responsible for this yield-behaviour. This suggestion was based on the fact that
most conventional bulk rheology measurements are performed with measuring systems
where a small air-water interface is present. Since macromolecules such as proteins are
known to be surface active [35, 163], it is proposed that inter-protein interactions are
responsible for a protein film that forms at the air-water interface which leads to the
observed yield-stress behaviour [78].
Yield-behaviour is commonly characterised in materials that only flow once a critical
stress is overcome [48, 49]. In colloids, yield stress is explained by the interactions
between the suspended material, which contribute to a strengthened network, and
can thus be related to interaction potential [90]. The work by Sharma et al.(2011)
is important since it was the first attempt at deriving a quantitative model of bulk
rheology including the influence of the air-water interface. However, other authors
have reported this viscoelastic behaviour to air-water interfacial effects when studying
biological solutions [164] and food materials [165]. Moreover, the rheology of globular
proteins in the presence of surfactant molecules (polysorbates) is Newtonian-like,
with no signs of yield-stress [74, 143]. This suggests that the presence of a surfactant
competes with the protein at the air-water interface enough to diminish the solid-like
behaviour observed in surfactant-free protein solutions [74, 166].
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The study presented here focuses on the rheology of β-lactoglobulin (β-LG) solutions
in surfactant-free aqueous buffer at pH 6.0. β-LG is a globular protein present in
milk whey and has been studied for its surface activity, flexible structure and ability
to foam and form stiff films at the air-water interface [163, 167, 168]. A conventional
torsional rheometer was used to characterise these solutions with cone-and-plate (CP)
and double-gap (DG) couette measuring systems, both of which exhibit a surface area
exposed to air. Interfacial shear rheology, using the double-wall ring (DWR) was also
performed. In addition, air-water interface-free measurements were obtained with a
microfluidics rheometer and the falling ball viscometer. Tensiometry data was collected
to compare with time-dependent bulk shear rheology measurements in an attempt to
understand the influence of the interfacial protein film and its effects on the solution
rheology. Further analysis was subsequently performed to quantify the bulk and
interfacial contributions on the observed solution rheology.
One of the aims of our work was to use β-LG as a model protein to identify the
origins of yield-behaviour often observed in protein solution rheology. Therefore we
hoped to contribute to a better understanding of excipient-free protein solution rheology
by demonstrating that this behaviour, and its causes, are inherent to such materials
in similar conditions. Our work also included a characterisation of protein species
present in the β-LG solutions, in terms of insoluble and soluble protein aggregates [85].
Generally, in protein solution rheology it is common to notice a lack of this type of
biophyiscal characterisation. However, as already outlined, the viscosities of protein
solutions are expected to depend not only on inter-particle interactions but the physical
characteristics of the components present in the fluid. Therefore, our other aim in
this work was to understand if by including an extendend particle characterisation, it
would be possible to relate the presence of insoluble particles to the observed yield-like
behaviour.
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4.2 Materials and Methods
4.2.1 Materials
4.2.1.1 Protein sample
β-LG was obtained from Sigma-Aldrich (product L3908, batches 097K7012 and
080M7312V) as a mixture of bovine variants A and B, in a lyophilised powder contain-
ing approximately 10% w/w of sodium chloride.
This protein is found in large quantity in the whey fraction of the milk of ruminants
(1.8 - 5 g/L) but not in human milk. It is a globular protein with molecular weight 18.4
kDa, with 162 amino acids and one free cystein (Cys121). There are more variants of
β-LG but variants A and B are the most common, of which differ by two amino acids.
The structure of β-LG is an eight-stranded, flattened β-barrel and flanking three-turn
α-helix with a ninth β-strand flanking the first strand (Figure 4.1). This protein has
been reported for having a pI at 5.2 [169]. It has a tendency to self-associate depending
on the pH and ionic strength of the buffer. Below pH 3 and above pH 9, β-LG is usually
present mainly as a monomer. Whereas between pH 5.2 and 9, monomers and dimers
coexist in equilibrium, with the dimers being more predominant. The dimer is stabilised
by hydrogen bonds between the surface of the AB loop and the ninth β-strand present
in each monomer, and by tight packing of the residues in the interface [169–172].
β-lactoglobulin undergoes changes of physical, chemical and spectroscopic properties
over the neutral pH range (6 - 8), which is related to the opening of the β-barrel (also
denominated calyx ). At basic pH, the calyx has an ”open” conformation providing
access of ligands to the hydrophobic cavity at its center. At acidic pH, there is structural
rearrangement to ”close” the calyx. This might help explain the physiologic relevance
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of this protein as having a possible role as a transporter of small hydrophobic ligands
protecting these from acidic pH present in the stomach [171,173].
(a) (b)
Figure 4.1: Structure of the β-lactoglobulin dimer from the X-ray coordinates, 1BEB (from the
RCSB Protein Data Bank, cited in [170]), showing a side view (a) and a top view (b). Letters
A-I are labels to the nine β-strands, coloured in blue. Figures were generated using the UCSF
Chimera package [140].
4.2.1.2 Sample preparation
Sample preparation for β-LG is described in section 2.2.2 in Chapter 2. For the work
presented in this chapter, a fresh batch of dialysed β-LG solution in 10 mM His-His.HCl
pH 6.0 was prepared at a stock concentration of ∼86 mg/mL. β-LG samples were checked
for protein concentration, pH and osmolality. Osmotic strength was measured using a
freezing-point osmometer (Osmomat O30-D, Gonotec GmbH, Germany), zeroed with
ultrapure water and calibrated with a 300 mOsmol/kg NaCl aqueous solution (Gonotec
GmBH, Germany). Samples were also checked for osmolality before and after dialysis.
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4.2.2 Methods
4.2.2.1 Quantification of protein concentration by UV spectroscopy
All details related to this method are described in section 2.2.7 in Chapter 2.
The percent extinction coefficient (A1%1cm) used was 9.6 [100]. The concentrations
reported were calculated as an average of 3 measurements of separate dilutions prepared
from each sample or, in the case of the NanoDrop, 3 separate aliquots when no dilution
was required. An error of up to 10 % was accepted for these measurements.
4.2.2.2 Bulk Rheology
The rheometers used were Anton-Paar (Graz, Austria) modular compact rheometers
(MCR) 301 and MCR 501 models. A CP geometry stainless steel CP50-1 (diameter =
50 mm and cone angle = 1◦) was used, purchased from Anton-Paar. To prevent evap-
oration of sample and to keep constant temperature of 25◦C ± 0.1◦C throughout the
measurements, an evaporation blocking system equipped with a peltier unit was used
with the CP50-1. A double gap concentric cylinder (DG26.7) stainless steel geometry
with an inner diameter of 26.7 mm was also used. In this case, the lower outer cylinder
was embedded in the peltier unit that kept the temperature at 25◦C ± 0.1◦C. Sample
volume for this geometry was of 3.8 mL sample, while for the CP50-1 it was of 650 µL.
Both measuring systems and rheometers were calibrated with hydrocarbonate standard
oils (N1.0 and N14) from Cannon Instruments (USA) using the same method for data
collection. Prior to measurements, all samples were allowed to equilibrate to room tem-
perature (∼ 23◦C) for at least 40 minutes. Samples that were analysed after filtration
were filtered immediately before the start of a measurement.
Rotational tests (flow curves and viscosity curves), on the MCR 301 and 501 rheo-
meters using both geometries, were performed by controlling the shear rate from 0.01
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to 1000 s−1. Each shear rate step had a 60 second duration time during which the
instrument was averaging over the collected data. For standard flow behaviour sample
characterisation, two shear rate sweeps (ramping down and up) were performed per
sample, without waiting time between sweeps. This set of two sweeps was measured
at least twice, per sample concentration. When testing for hysterisis, the same sample
would be repeatedly sheared after a first set of sweeps, testing the effect of waiting time
(0 minutes or 5 minutes) between ramping.
Steady shear time sweeps were performed with the CP. The method consisted of load-
ing a freshly prepared sample and as soon as the measuring gap position was reached,
the sample was sheared at constant shear rate of γ˙ = 1000 s−1 for 10 minutes. The shear
rate was then reduced to γ˙ = 0.01 s−1 for 60 minutes, followed by a period of rest (γ˙ =
0 s−1) for 10 minutes, and finally subjected to a γ˙ = 0.01 s−1 for 20 minutes.
4.2.2.3 Interfacial shear rheology with the double wall-ring geometry
For interfacial shear rheology measurements a double wall-ring (DWR) geometry was
used. The DWR is composed of a trough and a ring that is positioned at the air/liquid
and connected to the rheometer - in this case, an AR-G2 rheometer (TA Instruments,
USA). The sample holder was placed on the bottom peltier plate of the rheometer. The
ring had a square-shaped cross-section and was made of platinum/iridium. The sample
volume for these experiments was ∼18 mL. After loading, the ring was lowered and
positioned on the freshly formed air-water interface. Measurements were conducted at
25◦C. Samples were filtered prior the measurement, and analysed immediately, unless
otherwise stated.
With the DWR, flow and viscosity curves were obtained by controlling the shear rate
from 0.01 - 100 s−1, ramping down and up, collecting data every 45 seconds. Oscillatory
tests started with amplitude sweeps in order to determine the linear viscoelastic range of
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the studied sample. These sweeps were run separately at different but constant angular
frequencies: 0.1, 0.5, 1, 5, 10, 50 and 100 rad/s. Frequency sweeps were then performed
with a new sample where the range of studied angular frequencies was between 0.1 to
100 rad/s. Throughout the angular frequency sweep, constant strains used were of 2,
1.7 and 1.5 % for the frequency steps of 0.01 - 0.5 rad/s, 0.5 - 5 rad/s, and 5 - 50 rad/s,
respectively.
Time sweeps with the DWR were performed for oscillatory shear at a constant strain
of γ = 1% and constant angular frequency of ω = 5 rad/s, for 90 minutes. All interfacial
shear rheology tests were started immediately after a fresh sample was loaded and as
soon as the ring was set at the air-liquid interface.
4.2.2.4 Falling-ball viscometer
An automated micro capillary viscometer (Anton-Paar, Graz, Austria) was used as a
complimentary technique to determine bulk viscosity. The capillary had an inner dia-
meter of 1.6 mm and contained a steel ball of 1.5 mm diameter. For a standard meas-
urement, the inclination angle was set at 70◦ (and -70◦). Temperature control at 25◦C
± 0.1◦C was ensured via a peltier unit attached to the instrument. The capillary was
calibrated by running DI water and a viscosity standard oil at the same angle used for
the sample measurement. β-LG samples analysed with this technique were filtered (0.1
µm pore size) prior to these measurements. Viscosity values presented were computed
using the measured density of the analysed samples (for details of density measurement
procedure, see section 2.2.11 in Chapter 2).
4.2.2.5 Micro-viscometer/rheometer on-a-chip
The microviscometer/ rheometer on-a-chip (mVROC), by Rheosense, Inc. (San Ramon,
California, USA) was also used to measure the bulk viscosity of filtered (0.1 µm pore size)
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β-LG solutions only. For these measurements, the A05 chip was used and temperature
was kept constant at 25◦C ± 0.1◦C using a water circulation system (ThermoCube, SS
cooling systems, USA) (for additional information, see section 2.2.6.2 in Chapter 2).
4.2.2.6 High performance size exclusion chromatography for the determin-
ation of level of protein aggregation
All the details related to this method are described in section 2.2.9.2 in Chapter 2.
4.2.2.7 Dynamic light scattering
All details related to this method are described in section 2.2.8.1 in Chapter 2.
β-LG samples were measured at 1 mg/mL diluted from samples that at their original
concentration were either unfiltered or filtered (0.1 µm pore size). The measurement
settings for size readings were at a constant temperature of 25◦C ± 0.1◦C, performing a
total of 20 runs of 5 seconds duration each. Prior to the measurement, all samples had
an equilibration time of 5 minutes at the same temperature. Size measurements were
made in triplicate with fresh aliquots for each reading.
Time-dependence size measurements were performed using 1 mg/mL β-LG solution
filtered (0.1 µm pore-size) directly into the clean quartz cuvette. The measurement
duration was the same as for size characterisation, but repeated up to 40 consecutive
times with no delay between each measurement.
4.2.2.8 Microfluidic chip sodium-dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE)
All details related to this method are described in section 2.2.13.1 in Chapter 2.
A gel was run to compare dilutions of unfiltered and filtered β-LG solutions
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(originally at ∼68 mg/mL) .
4.2.2.9 Composition-gradient multi-angle light scattering (CG-MALS) for
the determination of protein self-virial coefficient
For the CGMALS experiment see details on section 2.2.8.2 of Chapter 2. The analysed
β-LG solution was a 12.7 mg/mL, doubly filtered with 0.1 µm pore-size syringe filters.
The sample was in 10 mM His-His.HCl pH 6.0 buffer and the successive dilutions were
analysed with the filtered sample buffer (0.1 µm). Data analysis was performed using
Calypso software (Wyatt Corporation Technologies, Santa Barbara, California, USA).
4.2.2.10 Tensiometry
All the details referring to this technique are described in section 2.2.10 in Chapter 2.
A freshly prepared filtered sample (0.1 µm pore size) of β-LG solution ∼68 mg/mL
in buffer was analysed.
4.2.2.11 Flow imaging microscopy for sub-visible particle counting
All details related to this method are described in section 2.2.15 in Chapter 2.
β-LG samples were either filtered (0.1 µm) or measured without prior filtration. β-
LG samples at 0.1, 10 and 35 mg/mL were measured without prior dilution. Since the
β-LG ∼68 mg/mL unfiltered solution showed visible particles and opalescence, it was
diluted to 10 mg/mL to prevent clogging of the flow cell. A dilution to 10 mg/mL of
the filtered β-LG 68 mg/mL solution was also analysed. All samples were measured at
least once, except for the diluted sample for β-LG 68 mg/mL which was measured three
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times (unfiltered and filtered samples).
4.2.2.12 Visual inspection of protein solutions
All details related to this method are described in section 2.2.16 in Chapter 2.
β-LG samples analysed for visual inspection were ∼0.1, 10, 35 and 68 mg/mL,
before and after filtration.
4.3 Results and Discussion
4.3.1 Bulk and interfacial shear rheology of β-LG solutions
β-LG solutions with concentrations of approximately 68, 35, 10 and 0.1 mg/mL were
prepared after dialysis and its rheology was characterised using CP and DG geometries
(Figures 4.2(a) and 4.2(b)). Samples exhibited a strong viscoelastic behaviour, showing
decreased shear viscosity as the shear rates were increased. Analysis of the shear
viscosity dependence on applied shear stresses, revealed a very sharp decrease of
viscosity at the lower shear stresses (Figure 4.3). The same observations could be drawn
for measurements from both type of geometry.
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Figure 4.2: Viscosity and flow curves of β-LG solutions using (a) CP and (b) DG geometries.
Circles represent the viscosity values, while the squares represent the shear stress values. Samples
were 0.1, 10, 35 and 68 mg/mL, all unfiltered solutions, measured at 25 ◦C.
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Figure 4.3: Viscosity curves versus shear stress for CP (larger graph) and DG rheology (inset
graph) of β-LG. Samples were 0.1, 10, 35 and 68 mg/mL, all unfiltered solutions, measured at
25 ◦C.
At low shear rates all samples showed a common linear slope of -1 representing
the decrease of viscosity. The results also pointed to a non-monotonic dependence of
viscosity with concentration at the lower shear rates (γ˙ < 10 s−1), whereas this depend-
ence could be observed at higher shear rates (e.g. γ˙ = 1000 s−1). Similar observations
can be identified in the literature with regards to globular protein solution rheology,
including that of β-LG solutions in similar excipient-free buffers [60–62]. The observed
behaviour at low shear rates has been often classified as shear-thinning. However, it
has been recently suggested that it is actually an apparent yield stress behaviour [78].
Analysis of Figures 4.2 and 4.3, with shear stress pointing towards a finite value at
the lower shear rates, and the sharp drop of viscosity at these low deformations, are
evidence of yield stress, i.e. where little flow is detected up to a point where external
forces overcome internal forces from which the material will deform [49]. Many authors
who referred to this behaviour as shear-thinning, suggested that it was related to the
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possible existence of colloidal crystals at low deformations, a consequence of long-range
electrostatic interactions [60–62]. Nevertheless, such globular proteins solutions did
not reveal the existence of any crystalline-like network [63]. However, shear-thinning
behaviour is typically characterised with stress increasing non proportionally to the
shear rate, often resulting in a linear plot in a log-log representation, which is different
to what was seen in our results at lower shear rates [48,49] (Figure 4.3). Shear-thinning
is a typical behaviour of a fluid, since by definition a shear-thinning fluid cannot be in
equilibrium if at rest [48].
For the highest concentration used, β-LG ∼68 mg/mL, steady state as well as
oscillatory interfacial shear rheology was studied. The use of the double wall ring as
an interfacial shear rheology geometry is one of the most adequate methods to measure
the surface viscosity due to its ratio of contact surface area to wetted perimeter [94].
A flow and viscosity curve characterisation of the air-water interface for β-LG at 68
mg/mL showed a linear decrease of viscosity with the applied shear rates (0.01 to 100
s−1) and a slope of -1 (Figure 4.4).
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Figure 4.4: Interfacial shear rheology flow and viscosity curves for β-LG at 68 mg/mL (filtered
0.1 µm). The experiment was run immediately after the interface was formed. There was no
waiting time between sweeps.
Further interfacial shear rheology characterisation included oscillatory studies, with
strain and frequency sweeps (Figures 4.5(a) and 4.5(b)). For both strain and frequency
sweeps the material always showed storage moduli (elastic portion) of higher values than
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Figure 4.5: Interfacial shear oscillatory rheology for β-LG 68 mg/mL filtered (0.1 µm). (a)
Strain sweeps at constant ω = 100; 50; 10; 50; 5; and 1 rad/s. (b) Frequency sweep was run
from 0.01 to 50 rad/s, with constant strains at 2, 1.7 and 1.5 % from low to higher frequencies.
For this test, the sample had an interface age of approximately 1.5 hour.
The strain sweeps with different constant angular frequencies of a range between 0.1
to 100 rad/s showed that the sample could still respond within the linear viscoelastic
range throughout the chosen angular frequency range. It was only for a strain sweep
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with ω = 50 rad/s that a drop in G′′s occurred at strain from 0.1 onwards, even
though G′s remained constant. This was a signature of how strongly elastic this protein
solution’s interface was, at the conditions studied.
For the interfacial shear frequency sweep (Figure 4.5(b)), G′s was always larger
than G′′s at all applied ω, showing a narrow difference of values at ω = 0.01 rad/s but
increasing G′s as ω increased, a sign of increased surface stiffness. This stiffness was
accompanied with the damping factor tans δ <1, suggesting a solid-like state. This
indicated that the phase angle δ, i.e. the shift between applied strain and the resulting
deformation, was approaching 0◦. All of these observations were signs characteristic of
viscoelastic behaviour, which in this case reflected in a protein solution with a surface
of increasingly stiff (elastic) characteristics. These observations were in agreement
with literature for interfacial shear rheology of β-LG films in similar experimental
conditions [167]. It was also noted that our frequency sweep did not show signs of
cross-over between G′s and G
′′
s at lower frequencies, possibly indicating the fast transport
of this protein to the air-water interface.
The linear increase observed for G′s from ω = 0.3 rad/s onwards was related to fluid
inertial effects inherent to the DWR geometry [94,174] and accounted for by evaluation
of the Reynolds number (Re) and consideration of the DWR’s characteristic geometry
length (1 mm).
Drawing together the viscosity curves of interfacial and bulk shear rheology (Figure
4.6) it is clear that similar flow behaviour can be identified independent of the geometry
used. Assuming that yield behaviour better explained these results, the simple Bingham
model for yield-stress of viscoelastic fluids (Equation 4.1) was fitted to these data.
τ = τBY + ηBY γ˙ (4.1)
This model is commonly used to find the yield point value (τBY ) by extrapolating
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the function τ(γ˙) to the zero shear rate value (γ˙ = 0 s−1), where ηBY represents the
function’s coefficient. Plotting the calculated viscosities (Figure 4.6), based on the
obtained fitting parameters (all with r2 >0.97), these fitted data (lines in the graph)
correlated well with the experimental data, highlighting that the underpinning factors
leading to the yield behaviour seen on bulk rheology (CP and DG) could indeed relate
to what causes the same behaviour at the interface of β-LG solutions. In addition, the
observations so far noted for this protein have been similarly made for bovine serum
albumin (BSA) solutions in PBS [78].
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Figure 4.6: Flow and viscosity curves comparing bulk viscosity obtained by CP (red circles)
and DG (green circles) with surface viscosity (blue circles) of a filtered 68 mg/mL β-LG solution.
The lines represent respective fitting of data to the Bingham equation for yield stress (equation
4.1).
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4.3.1.1 Air-water interfacial effects on conventional bulk rheology of β-LG
solutions in excipient-free buffers
In many studies, excipient-free protein solution rheology has been measured using
conventional (shear or stress-controlled) rheometers with geometries such as the CP.
Sharma et al. (2011) combined analysis (bulk and interfacial rheology) of BSA in PBS
lead to their suggestion that the apparent yield behaviour observed resulted from a
protein film formed at the air-water interface. Indeed, β-LG is known to adsorb and
form a film at the air-water interface [175] and its rheology at the interface has been
extensively studied [167, 176–178]. Thus, our interpretation of bulk rheology results
take on the suggestion that an apparent solid-like behaviour is inherently present in CP
and DG bulk shear rheology of surfactant-free globular protein solutions. However, it
is important to better understand which underpinning factors influence this behaviour
and how do these interplay in protein solution rheology of surfactant-free samples.
Therefore, the combination of rheological time sweep measurements and surface tension
measurements were performed to seek if any correlations could be drawn.
A steady state time sweep rheological measurement of a β-LG ∼68 mg/mL (filtered
solution with 0.1 µm pore-sized syringe filter) was performed on a CP to characterise
the effect of time with continuous shearing (Figure 4.7(a)). The viscosity increased
until it reached a maximum at a time point of approximately 1940 seconds (from the
start of the second step). Viscosity then remained constant, and a rest period did not
seem to affect the sample, since the viscosity values remained similar. The time point
at which viscosity attained a steady state on the CP experiment, did not match the
timescale measured from the tensiometry experiment shown in Figure 4.7(b). The latter
experiment showed that surface tension reached an equilibrium (52.4 ± 0.37 mN/m)
just after ∼1000 s. Filtered (0.22 µm) pure water and filtered (0.1 µm) sample buffer
were measured as controls and had surface tension values of 72.9 ± 0.14 mN/m and
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73.0 ± 0.34 mN/m.





















































Figure 4.7: (a) Steady state time sweep with CP rheology and (b) a tensiometry curve for the
β-LG 68 mg/mL filtered (0.1 µm) in 10 mM His-His.HCl pH 6.0. Stages for the time sweep (a)
were: constant shear rate at 1000 s−1 for 10 min (a); γ˙ = 0.01 s−1 for 60 min (b); rest period
(c); γ˙ = 0.01 s−1 for 20 min (d).
While the surface tension measurement was performed without shearing the air-
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water interface, the CP rheological time sweep kept the sample volume with aid of an
evaporation blocking system, to resemble the conditions of the tensiometry experiment.
In the case of constant shearing, after the shear rate was dropped to 0.01 s−1, the
protein not likely formed the film at the air-water interface since the shear rate should
be low enough to allow protein transport to the surface. The differences in methodology,
inherent to the instrumentation, could explain why the timescales do not match between
the different measurements. Nevertheless, the combination of these time-dependent
experiments could represent, to different extents, the kinetics of protein transfer from
bulk sub-phase to the air-water interface. Analogous time sweep experiments of BSA
solutions and synovial fluid using bulk and interfacial shear rheology yielded similar
results [63, 78].This suggests that the observed time and surface dependency is likely
inherent to general surface activity properties of proteins.
In addition to timesweep results, consecutive rotational tests with the same sample
(β-LG at ∼68 mg/mL filtered) were performed with CP and DG (Figure 4.8). With
both geometries, no hysterisis was observed when ramping down and up with no
waiting time. However, between runs, resting for at least 5 minutes seemed to produce
slightly lower viscosity values at the lower shear rates (<10 s−1) while still presenting
an apparent yield behaviour. This difference was clearer with the CP data than with
the DG data. Interpretation of these results would require further tests to understand
if the main reasons leading to the observed hysterisis relies solely upon surface activity.
Although all the CP measurements were performed at a controlled environment with an
evaporation blocking system, evaporation could still be possible, thus becoming another
variable to consider as an influence to the changes observed at low stresses.
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Figure 4.8: Viscosity curves of consecutive runs for βLG ∼68 mg/mL comparison using CP and
double gap. Circles (full or hollow) correspond to ramping down the shear rates, while lines (full
or dashed) correspond to ramping up. CP data is represented in dark red, and DG is represented
in blue. Time between runs was 5 minutes. Measurements taken at 25 ◦C.
These time-dependent results support the hypothesis that air-water interfacial
effects need to be accounted for when measuring this type of fluid on a CP and DG
geometries, since these are not free of an air-water surface area. Therefore, when using
such geometries care needs to be taken to avoid unreliable readings for excipient-free
protein solutions, particularly at the lower shear rates.
4.3.1.2 Air-water interface-free bulk rheological measurements of β-LG
solutions and extrapolation of surface viscosity from CP and DG
rheology
Having established that the air-water interface may influence the conventional bulk
measurements, a comparison to air-water interface-free bulk measurements was needed
as a control. Therefore, measurements at the higher shear rates (γ˙ > 1000 s−1) using
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a mVROC were performed (Figure 4.9 and Figure A.3 in Appendix A). The flow
behaviour observed with the mVROC showed constant viscosities along the shear rates,
suggesting that the samples had a Newtonian-like flow, comparable to a purely viscous
liquid. Superimposition of mVROC data with CP and DG data at high shear (γ˙ >10
s−1) showed that the DG data matched better with the mVROC viscosity values. This
has been observed by Sharma et al. (2011) with BSA solutions.
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Figure 4.9: Rheology profiles of β-lactoglobulin samples comparing CP and DG data of un-
filtered samples, with mVROC data (filtered samples). mVROC data are the crosses, CP data
are the full circles and DG data are the hollow circles. Data shown only for higher shear rates
of CP data. Measurements with mVROC were taken using the A05 chip. All data was taken at
25 ◦C.
A falling ball viscometer was also used for comparison, since the shearing rates
applied by the falling ball to the fluid produce much lower shear rates than those
imposed by the mVROC [49]. The viscosity values measured per solution were similar
to those measured at γ˙ = 1000 s−1 with both the CP and the DG (Table 4.1).
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Table 4.1: Comparison between the viscosity values of β-LG filtered (0.1 µm) samples obtained
using the CP and DG geometries, and the mVROC and falling ball viscometers. The results
shown are mean and standard deviation of three separate measurements from each instrument.
Both AMVn and mVROC results demonstrated that applying high shear rates (γ˙
= 1000 s−1) using a CP or DG would be approximate to a bulk viscosity measurement
performed with an air-water interface-free viscometer or rheometer. Although mVROC
data did not allow measurements at the lower shear rates, it can be suggested that
extrapolation to zero-shear viscosity (η0(γ˙ → 0)) would yield values similar to those
measured at the higher shear rates. As seen from previously discussed results (e.g.
Figure 4.6), the same extrapolation to zero-shear rate cannot be made with CP and DG
data without accounting for the yield-like behaviour [78].
The suggestion that bulk viscosities measured with CP and DG are not true bulk
viscosities implies that it is important to understand how the interface can influence
the measurements. A rheometer fitted with a CP or a DG geometry will measure the
torque as response of all the fluid in contact with the moving geometries, i.e. the cone
and the bob, respectively. Therefore, if a surface active molecule forms a film at the
air-water interface, the torque response will depend of the film’s response to shear as
well as the bulk’s deformation. Calculating the surface area exposed to the air-water
interface present in a CP and a DG system, we conclude that these areas are roughly
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similar (73 mm2 and 71 mm2 for the CP50-1 and DG26.7, respectively). This could
explain why the viscosities with CP are only just above to those obtained with the DG.
The Boussinesq number (Bo) is a dimensionless parameter that allows the calculation








Bo depends on ls, which is the geometry’s characteristic length scale, where ls ≈
Ab/Pi. ls depends on the geometry’s dimensions, since Ab is the contact area between
the geometry and the bulk sub-phase and Pi is the perimeter of wetted geometry in
contact with the interface. From Equation 4.2, Bo ≫1 when the interfacial stresses
contribute more to the flow than the bulk stresses, while the contrary happens when
Bo ≪1. A geometry with a maximised wetted perimeter also contributes to high Bo
values. This is the case of the DWR where ls = 0.7 mm allows it to have higher sens-
itivity for interfacial measurements [94, 179]. The ls for CP and DG were calculated
considering the geometry’s dimensions and are ls(CP ) ≈ 12.5 mm and ls(DG) ≈ 40.5
mm, respectively (details are shown in Appendix A).
Figure 4.10 represents the calculated Bo for these three geometries using the meas-
ured interfacial shear viscosities and assuming η∞ = ηb from mVROC data.
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Figure 4.10: Boussinesq parameter dependent of shear rate calculated for DWR, CP and DG
geometries using respective steady state shear rheology data, interface and bulk, from a filtered
∼68 mg/mL β-LG solution.
These results showed that BoDWR ≫ BoCP > BoDG at the shear rates studied, and
that Bo ≫1 for these geometries, particularly at the lower shear rates (γ˙ <10 s−1). It
showed that the bulk stresses started matching the interfacial stresses on the DG and
the CP only when γ˙ >16 s−1 and >63 s−1, respectively. This also coincided to when
viscosity values of the ∼68 mg/mL sample reached constant values (cf. Figure 4.6). Our
results were similar to those observed for BSA solutions from ref. [78], although in that
study a CP of smaller dimensions (40 mm diameter) and a DG with a ls of 59.5 mm were
used. These differences in geometry were reflected in the Bo values, their DG provided
lower Bo values at lower shear rates, thus measuring viscosities free from interfacial
effects from slightly lower shear rates [78]. The opposite was reflected with the CP of
their choice, which explained why our mVROC data superimpose better to our CP50-1
viscosity data at the higher shear rates (> 100 s−1) (cf. Figure 4.9).
Following the proposal of Sharma et al. (2011), it was possible to quantify the
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connection between these interfacial contributions and the torsional rheometry bulk
measurement. The authors proposed the Equations 4.3 and 4.4, from which is possible
to estimate bulk viscosities for a DG and CP from interfacial shear and a interface-free
bulk measurements (e.g. mVROC, where ηb ≈ η∞ ≈ η0(γ˙ → 0)). Assumptions have to
be taken in account, such as the thickness of the surface active component is assumed
to be smaller compared to the bulk geometry’s effective characteristic length lG. In
addition, these derivations were made assuming that the measured torque (M(γ˙)) has
contributions from the bulk sub-phase shear stress (τb = ηb γ˙) and the surface shear
stress (τs = ηs γ˙). Finally, these contributions are calculated for the simple case where




≈ ηb + l
−1
G ηs(γ˙)














The effective characteristic length scales for each geometry, lG, were also derived from
the torque expressions and calculated to be lG(DG)= L and lG(CP ) = R/3, for the DG
and CP, respectively [78]. Note that both equations (4.3 and 4.4) can be generalised to
the same format (since ηs(γ˙) = τs/γ˙).
Conversely, it was possible to estimate the surface viscosities extracted from the
bulk measurements with CP and DG, based in a general equation derived similarly and
assuming the same scenarios (Equation 4.5).
ηs(γ˙) ≈ lG (η(γ˙)− η∞) (4.5)
All results related to the extrapolation of surface viscosity from the bulk measure-
ments and estimation of CP and DG data from surface measurement were based on
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filtered (0.1 µm) β-LG ∼68 mg/mL (Figures 4.11(a) and 4.11(b)).
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(a) Estimation of bulk viscosities from CP and DG experimental data
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(b) Estimation of surface viscosity from CP and DG experimental data
Figure 4.11: (a) Bulk viscosity for CP and DG rheology estimated from interfacial rheology
measurements. Measured data from CP and DG are shown for comparison. (b) Estimation of
surface viscosity from CP and DG rheology. Measured data from DWR is plotted for comparison.
All experimental data was obtained at 25 ◦C.
Estimation of bulk viscosity from the interfacial data (Figure 4.11(a)) resulted
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in slightly underestimated values, particularly for the DG geometry. However, the
estimated values for surface viscosity (Figure 4.11(b) seem to closely agree with the
measured ηs using the DWR, especially for the CP data. The discrepancies here found
may be due to the assumed scenario avoiding a coupling between sheared surface
and sub-phase, i.e. the interfacial contributions from a CP or DG most likely come
from a length larger than the film thickness, thus including a small proportion of bulk
sub-phase [78]. Beyond these discrepancies, these latter calculations, in addition to the
Boussinesq calculations, helped understand how the CP measurements were subject to
higher influence of air-water interface, compared to the DG.
Since our results generally compare well to literature [78], even though when ob-
tained from solutions of a different protein and using slightly different bulk geometries,
they show that the air-water interface influence is inherent to CP and DG rheology of
globular protein solutions. This also reinforces the importance of a better understand-
ing of what happened at the lower shear rates of flow and viscosity curves of such samples.
4.3.2 Studying the influence of protein aggregates in bulk rheology of
β-LG solutions
If protein solution viscosity is expected to be a function of volume fraction of the
solutes present, it would be expected that all particles in a protein solution would
also contribute to its viscosity proportionally to its concentration. Thus, it was
hypothesised that the presence of insoluble aggregates could be a reason why the
non-monotonic dependence appeared particularly at low shear rates. For this study,
a comparison of rheological behaviour was made between unfiltered and filtered (0.1
µm) solutions, as well as an aggregate characterisation of the particles present in the
samples. A further characterisation of the protein was made to understand its level
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of aggregation and self-associative tendency at the solution conditions used in this study.
β-LG is known to be self-associative with the level of self-association dependent on
the solution pH. At pH 6.0 β-LG was expected to be present mostly as a dimer, since pH
6.0 is higher than it’s reported pI (5.2) and the dimers can associate further at between
pH 5 - 8 [169]. In our case, a measurement with CG-MALS allowed characterisation
of the associative state that β-LG was in the sample buffer at pH 6.0 (Figure 4.12).
The MW was estimated to be 33.4 ± 0.14 kDa, which is close to the expected β-LG
dimer MW of ∼36 kDa. The calculated self-virial coeffcient was -1.46×10−4± 4.9×10−6
mol.mL/g2. The negative value reflected the overall attractive self-interactions that
can explain the self-associative characteristics of this protein at low ionic strength
and close to physiologic pH [169]. CG-MALS data therefore showed that this pro-
tein was present mostly as a dimer at the solution conditions used throughout this study.
Figure 4.12: Static light scattering data (R/K∗) versus concentration of β-LG starting at a
stock concentration of 12.7 mg/mL and diluted with 10 mM His-His.HCl pH 6.0 buffer. The red
squares represent the data and the line is for guidance only.
An analysis with HPSEC showed no difference in the number of peaks (species)
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detected and respective elution times, between the unfiltered and the filtered samples
(see Figure A.1 in Appendix A for an example of a chromatogram). Filtration of β-LG
solutions did not affect the peak areas, as these remained essentially the same as seen
with the unfiltered samples (Figure 4.13).
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Figure 4.13: HPSEC chromatography data of β-LG species present in unfiltered and filtered
solutions.
On microfluidics SDS-PAGE analysis, both unfiltered and filtered β-LG samples
showed one band on both reducing and non-reducing conditions, identified to have a
molecular weight of approximately 19 and 16 kDa, respectively (Figure 4.14). Consid-
ering the self-associative tendency of this protein, and due to successive dilutions used
in this technique, all dimer dissociated into monomer. It was not possible to resolve
the two variants A and B from this analysis. The purity of the material was confirmed,
since no other MW band of a potential protein contaminant was identified [100, 169].
Although the MW obtained from this analysis were slightly lower than expected for the
β-LG monomer, similar results were obtained in literature [121].
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Figure 4.14: A microfluidics protein electrophoresis gel image for reduced and non-reduced
conditions of β-LG samples. All samples diluted to 4 mg/mL with PBS. Lanes are: protein
ladder, 1 - reduced β-LG unfiltered sample, 2 - reduced β-LG filtered 0.1 µm sample, 3 - reduced
standard mAb sample (control), 4 - non-reduced β-LG unfiltered sample, 5 - non-reduced β-LG
filtered 0.1 µm, 6 - non-reduced standard mAb sample (control).
After dialysis of several batches of β-LG stock, typically of∼80 mg/mL, these samples
were always found to have visible particles. A qualitative characterisation of the prepared
unfiltered samples was made via visual inspection (Table 4.2) regarding visible particles,
opalescence and colour. After filtration into a clean vial, all samples were free of visible
particles, showed no colour and were non opalescent (Figure 4.15).
The undialysed and dialysed β-LG stocks solutions were assessed on its osmolality
with a calibrated freezing-point osmometer. A typical β-LG undialysed batch had an
average of 55 ± 0.001 mOsmol/kg, whereas the dialysed batch would be 21 ± 0.002
mOsmol/kg which was similar to the value found for the filtered sample buffer (15
± 0.001 mOsmol/kg). All batches of β-LG showed a similar osmolality value. pH
measurements also showed that the samples retained their pH to 6.0.
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Figure 4.15: Image of β-LG solutions (∼68 mg/mL) before (right) and after (left) filtration
using a 0.1 µm pore-sized syringe filter.
Table 4.2: Visual inspection classification for β-LG unfiltered samples. The material was
assessed based on its colour, opalescence and visible particles content against a black and white
screen with aid of a white light. Values or codes in parenthesis correspond to the standard to
which the sample was similar.
Unfiltered samples were measured on the rheometer using both the CP and the
DG geometries, as shown on Figures 4.2(a) and 4.2(b) in section 4.3.1. These samples
exhibited a non-monotonic concentration dependence at the low shear rates (< 10 s−1).
It was expected that filtration would yield lower viscosities, reduce the influence to the
flow of larger insoluble particles (visible and sub-visible) and thus restore a monotonic
concentration dependence at the lower shear rates. The results suggest that this was the
case for the CP data, but not with the DG data (Figures 4.16(a) and 4.16(b)). Filtration
could change slightly the concentration of material, where some monomer/dimers of
β-LG could be adsorbed to the filter while the larger protein aggregates were filtered
out. However, the difference between unfiltered and filtered solution concentrations
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was lower than the accepted instrumental error for determination of concentration (10
%), except in the case of β-LG at 0.1 mg/mL (Table 4.3), while still being close to
this error percentage. This slight drop in concentration can explain these differences
between the viscosities at the higher shear rate (1000 s1). Nevertheless, the larger
differences between unfiltered and filtered samples were detected within the lower
shear rates γ˙ <10 s−1, particularly and consistently with the CP data. One possible
reason for disagreement with the DG data might be due the difficulty of loading the
sample onto the cylinder gap, especially immediately after filtration where it is possible
to inadvertently introduce micro-air bubbles that can further influence this measurement.
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Figure 4.16: (a) CP data and (b) DG data of viscosity curves for samples of β-LG of different
concentrations, comparing between the unfiltered and filtered (0.1 µm) solutions. Larger plots
show the data at the lower shear rates (<100 s−1) and the inset graphs show the data at the
higher shear rates > 100 s−1. All measurements taken at 25 ◦C.
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Table 4.3: Measured concentrations via UV-Vis spectroscopy, of β-LG before and after filtra-
tion. Results are showed as an average and standard deviation of three separate measurements.
1 - ∆concentration was calculated from
[Unfilt.]−[Filt.]
[Unfilt.] × 100.
A comparison between the mVROC data superimposed with the CP and DG data of
equally filtered samples, highlighted the similarity at the higher shear rates of viscosity
values between the DG data and mVROC, with a slightly larger difference between CP
and mVROC data (Figure 4.17).
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Figure 4.17: Rheology profiles of β-LG samples comparing mVROC, CP and DG data. Protein
samples were all previously filtered with 0.1 µm pore-size syringe filters. Measurements were all
taken at 25 ◦C.
It was necessary to identify what type of aggregates (soluble or insoluble) would
influence this protein’s solution rheology. The DLS correlation function data showed
two steps, reflecting the existence of two different-sized populations (Figure 4.18). After
filtration, slightly faster diffusion times were noted for the second population, while the
first population remained unaltered (see Table A.1 in Appendix A). Size distribution
by intensity (Figure 4.18, see inset graph) showed that apart from a main peak with a
mean hydrodynamic diameter (HD) of ∼6 nm, these solutions presented a second peak
with a Dh > 100 nm. According to literature, the typical hydrodynamic diameter of
β-LG dimers in physiological pH conditions is around 5.2 - 5.8 nm [100, 180] assuming
a thin hydration layer. Our DLS data was similar, taking in account differences in pH
and ionic strength referred in literature, but also confirmed with the data obtained by
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CG-MALS.








β-LG unfiltered solution 
β-LG filtered solution
 fit β-LG unfiltered




































Hydrodynamic diameter size [nm]
Figure 4.18: Size distribution by intensity of β-LG 68 mg/mL before and after filtration.
Large graph corresponds to the normalised correlation function data versus decay times (hollow
circles), as well as the fit to an exponential decay curve (dashed lines) for the before and after
filtration β-LG 68 mg/mL samples. For both fits, the good-fitting parameter of r2 was larger
than 0.99. The inset graph shows the size distribution by intensity of the same samples shown
on the correlation data.
It was expected that after filtering the solutions, the second population would
have lower hydrodynamic size (HD) or disappear altogether. However, filtration could
generate new protein aggregates [127]. Other authors have also found that β-LG
has an ability of forming aggregates (of diameter between 100 - 800 nm) quickly
after being filtered, even when filtered directly to the DLS clean cuvette which was
also our case [169]. This particular spontaneous clustering (or aggregation) of β-LG,
particularly of variant A, has been addressed regarding the protein’s specific surface
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charge distribution [180,181].
A time-sweep DLS measurement was done for a 1 mg/mL β-LG sample freshly
filtered into the cuvette to investigate if this was the case, or if the equipment could
detect the time point where the β-LG protein soluble aggregates would appear. Results
showed that as soon as the sample was filtered and measured, it demonstrated a second
peak with a mean HD of between 200 - 500 nm, which fluctuated towards 1000 or higher
nm with time (Figure 4.19). Although the populations with HD > 1000 nm should not
be considered due to the instrument’s limit of detection [110], this was a sign that the
monomers/ dimers could be clustering into aggregates of higher diameters shortly after
filtration, in agreement to literature [169].



















































Figure 4.19: DLS time sweep of filtered 1 mg/mL β-lactoglobulin solution. The hydrodynamic
diameter size by intensity for monomer/dimer ( blue circles) and for aggregates (green circles).
The lines correspond to their relative peak areas, also by intensity (monomer/dimer - blue;
soluble aggregates - green).
A comparison with DLS and HPSEC analysis was also made between unsheared
samples (’before rheology’) and after being sheared (’after rheology’). DLS data is shown
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in Appendix A (see Figures A.6(a) and A.6(b), and Table A.1). On HPSEC there was
no difference detected on the chromatographic profiles and relative peak areas between
before/after rheology on both unfiltered and filtered samples. With the ’after rheology’
samples, there was a tendency towards larger aggregates detected by DLS. This could
be have been an effect of shearing and the presence air-water interface on CP and DG
measuring systems. Moreover, the possibility of shearing conditions and the adsorption
to stainless-steel surfaces, such as those from CP and DG geometries, could contribute to
the observed increase of soluble aggregates [29, 30]. Nevertheless, further investigations
would be needed to determine the exact origin of these aggregates, taking in account
the specific physical-chemical properties of β-LG.
To allow for a quantitative measurement and characterisation of sub-visible particles
with a circular diameter (ECD) between 1 - 150 µm, all samples were analysed with
micro-flow imaging. Filtration considerably reduced the number of sub-visible particles
detected by micro-flow imaging (Figures 4.20(a) and 4.20(b)).
It would be assumed that after filtration, the material would be free from sub-visible
particles, since the pore-size was of 0.1 µm. However, literature has shown that
proteinaceous particles can remain even after filtration [127], where particles which have
an axis length < 0.1 µm can still go through the membrane’s pores. It can also be the
case of filtered-induced protein aggregation [127]. As a control, 0.1 µm filtered sample
buffer was measured in triplicate and repeatedly presented less than 10 particles per mL
(see Table A.2 and Figures A.7 and A.8 in Appendix A). Therefore, when working with
the MFI one has to consider the cleanliness of the environment, tubes or vials used, and
be aware that there will be a residual number of sub-visible particles still present even
after sample filtration.
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Figure 4.20: MFI sub-visible frequency histograms of (a) unfiltered and (b) filtered (0.1 µm)
β-LG samples. Samples at ∼68 mg/mL were diluted to 10 mg/mL to avoid clogging of the flow
cell with visible particles present. The diluted 68 mg/mL unfiltered and filtered β-LG samples
were measured in triplicate. Other concentrations (∼0.1, ∼10 and ∼35 mg/mL) were measured
with no further dilution and only once.
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From MFI characterisation one concludes that these insoluble sub-visible protein-
aceous particles were not only of different shapes, sizes and opacity (see Figures A.7 and
A.8 in Appendix A), but also when under shear these aggregates were suspended in the
sample. Therefore, to explain the differences seen between the rheology of unfiltered
and filtered β-LG samples, especially with the CP data, it could be possible that these
insoluble particles were contributing to increased viscosities at the shear rates applied.
To estimate impact of this, the use of a rheological dimensionless parameter, the dressed









Pe∗, also known as reduced stress, measures whether the applied stress (in this
case, shear stress τ) is large or small relative to the characteristic stress arising from
Brownian motion (since kB is Boltzmann’s constant and T the fluid’s temperature).
Thus, equation 4.6 is dependent of the particle size, where a corresponds to the particle’s
characteristic length scale. Equation 4.6 is a ratio between the rate of advection imposed
to the flow and the rate of the particle’s relaxation by Brownian motion [48]. When
Pe∗ ≫1, the shear stress effects overcome the particle’s Brownian motion, whereas if
Pe∗ ≪1, the opposite occurs [48].
The calculations of Pe∗(γ˙) shown in Figures 4.21(a) and 4.21(b) represent the
simplified situation where Pe∗(γ˙) was in order of each of the sizes assumed to be
present in a ∼68 mg/mL β-LG solution. In this case, it is considered only for the
case of a monodispersed suspension composed of those separate sizes only. Besides
polydispersity being a problem in calculating true Pe´clet numbers, the interparticle
interactions also play an important role in colloidal suspensions, therefore interfering in
the hydrodynamics of the suspension [48]. Finally, it was also assumed that the applied
shear stresses were not disturbing the sizes of the protein soluble and insoluble species.
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Figure 4.21: Comparison of Pe´clet number dependent on shear rate using different size data
between unfiltered and filtered ∼68 mg/mL β-LG sample. (a) Calculations using DG shear
rheology data. (b) Calculations using CP shear rheology data.
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Nevertheless, these simplified calculations of Pe∗(γ˙) highlighted that the larger
the sizes of proteinaceous particles in a protein sample, the higher their influence the
shear rheology particularly at low shear rates. For the CP and DG, only the Pe∗(MFI
ECD data) >1. This meant that the stresses imposed to the fluid influenced the way
these larger particles flowed, while the soluble aggregates and dimers flowed due to
their Brownian motion. For both geometries the Pe∗unfiltered < Pe
∗
filtered from the MFI
data, when we should expect the opposite and as it is seen from the aggregate data.
This discrepancy can be explained by the constant presence of large (ECD > 10 µm)
sub-visible particles in the filtered samples, therefore skewing the mean ECD used for
Pe∗ calculations (Table A.2 in Appendix A).
4.4 Conclusions
In this chapter a detailed evaluation of the rheology of excipient-free β-LG solutions was
made, where this protein served as a model for globular proteins. By collecting data from
different types of rheometric instrumentation and comparing these, it was possible to
identify that these solutions had a complex flow behaviour dependent on the shear rates
applied. At low shear rates the flow properties of these samples seemed to be similar to
solid-like flow, with a corresponding yield behaviour observed. Further analysis and close
agreement of the data to a simple yield-stress Bingham model, supported our findings.
At the higher shear rates, achieved with both the conventional torsional rheometers (CP
and DG geometries) and a microfluidic rheometer (mVROC), these solutions produced
a Newtonian-like flow, i.e. characteristic of a purely viscous fluid.
The origin of this yield-behaviour was also studied and suggested to be related to
the surface activity of the protein and its time dependent formation of a protein film
at the air-water interface. Comparison between interfacial rheology, tensiometry and
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time-dependent bulk measurements with CP, although not reflecting matched timescales
between measurements, further highlighted the importance of the presence of the air-
water interface in the rheology of excipient-free protein solutions. Complementary data
obtained from mVROC and AMVn provided evidence that when lacking this influence,
protein solutions seem to show low viscosities and with constant values (e.g. mVROC).
Further analysis of this apparent change in regime between low and high shear showed
that it was dependent, in an simple additive way, on contributions from surface effects
and bulk sub-phase to the measured torque. Although our calculations included a few
simplistic assumptions, these highlighted the fundamental hypothesis that a protein
film at the air-water interface present in CP or DG experiments will be detected and
translated in high viscosities at low shear rates.
Our detailed results add to recent findings in the literature [78] to the extent that
this hypothesis was applied to another globular protein model. This brings emphasis
to the broad application of this knowledge to protein solution rheology, in particular by
applying to the study of therapeutically relevant proteins such as monoclonal antibodies.
We also hypothesised that the rheological properties depended on the soluble and
insoluble protein species present in these samples. Even though filtration could have
limitations, it was shown that the presence of sub-visible proteinaceous particles had an
impact on the sample rheology, particularly at the lower shear rates. Small differences
in rheology were detected, between the unfiltered and filtered samples, but this could be
due to the small proportion of sub-visible particles (and visible, although not quantified)
on the sample’s total solids content. These findings highlight that the contents and size
of protein species within a protein solution are key factors to understand in order to
correctly and realistically evaluate its rheology.
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Chapter 5
The rheology of a monoclonal antibody solution: a case
study on the effect of aggregation of a model monoclonal
IgG1 on its solution rheology
5.1 Introduction
It is known that protein solutions will inherently contain different associative species
that are formed with time, solution conditions, temperature, and/or dependent on other
physical-chemical factors [28]. For the perspective of biopharmaceutical formulations,
determination of stability is therefore an important part of development to ensure that
the right conditions are chosen to prevent any loss of protein monomer, which in the
case of antibodies, is the pharmacologically active substance [1, 44].
The generation of protein associative species can be lead by several pathways from
which a protein monomer can degrade [28, 43]. The consequence of these pathways
can ultimately lead to proteinaceous aggregates that vary in its size, morphology,
reversibility properties, secondary and/or tertiary structure, and if cross-linked by
covalent bonds [85]. In the protein formulation, it is important to understand the
mechanisms that may lead to protein aggregation, in order to inhibit these as much as
possible. Characterisation of proteinaceous associative species and their quantification
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is therefore necessary to account for the stability and safety of the formulated drug
product [10].
For colloidal suspensions, it is known that viscosity is a physical parameter con-
nected to the suspension’s content, to the particle morphology and the inter-particle
interactions present [48]. This has been discussed in literature [182], and was discussed
in the previous chapters of this thesis (Chapters 3 and 4) as a concept that should
be addressed when understanding the rheology of protein solutions. Moreover, the
importance of influence of the air-water interface in conventional rheology measurements
of protein solutions was highlighted in Chapter 4 [74, 78, 143]. Therefore, the work in
this chapter focused on extending these concepts to mAb solution rheology.
The mAb used for the studies presented in this thesis was a humanised IgG1,
provided as a lyophilised product containing stabilising additives. It was necessary to
remove these excipients to generate the excipient-free mAb solution needed for this
study. The first section of this chapter accounts for the physico-chemical comparisons
of the different batches obtained after this removal procedure. This mAb has been
characterised in literature, for its engineered ADCC enhancement via three mutations
which were introduced to its CH2 domain [183].
The general aim of this work was to understand if and how protein aggregation
influenced the solution viscosity of this mAb. Thermal stressing over defined periods
was the chosen method to promote the protein aggregation process. The solutions
were characterised using several biophysical techniques to help understand the level
of aggregation, the size, morphology, and quantity of the aggregates. In addition, by
extending this case to the complexity of monoclonal antibody aggregation, we aimed to
understand the effects of aggregation on the yield-like behaviour typically observed in
excipient-free protein solutions. The ultimate aim of this chapter was, in light of the
discusssions concerning the effect of concentration on the viscosity of protein solutions
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(Chapter 3), if it was possible to relate the volume fractions of protein aggregates, as
well as their size and shape to the solution’ viscosities. An achievement in that regard,
could help the development of future biopharmaceutical formulations in predicting
mAb solution viscosity based on the physico-chemical characterisation of the protein
aggregates generated during stability test.
5.2 Materials and Methods
5.2.1 Materials
5.2.1.1 Protein sample
The humanised monoclonal antibody studied was provided by MedImmune, LLC.
(Gaithersburg, Maryland, USA). It is an IgG1 of 145.461 kDa. The protein was
supplied in a lyophilised formulation containing other additives, including a surfactant.
The formulation additives were removed by purifying the reconstituted material, as
described in section 2.2.3 of Chapter 2.
5.2.1.2 Sample preparation
After purification, diafiltration and concentration steps were performed to collect the
mAb solutions (section 2.2.3 in Chapter 2). Three batches were obtained depending on
the processing step and concentration: batch 1, 2a and 2b.
Independent of the diafiltration/ concentration method used, all mAb batches were
checked for concentration, pH, osmolality, and their aggregation level by HPSEC.
Additionally, all batches were checked for presence of the non-ionic surfactant which
was an additive in the original lyophilised formulation (this procedure was performed
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at and by MedImmune, Gaithersburg, MD, USA).
mAb solutions were prepared in a histidine buffer containing L-Histidine and
L-Histidine monohydrochloride at 10 mM in ultrapure water, with a pH of 6.0 ± 0.2
at room temperature. L-Histidine salts were obtained from J.T. Baker Chemicals
(Pennsylvania, USA) and were of analytical grade.
For circular dichroism analysis, a 10 mM sodium phosphate buffer pH 6.5 was
prepared using monosodium phosphate monohydrate and dibasic sodium phosphate
heptahydrate in ultrapure, both purchased from J.T. Baker Chemicals and of analytical
grade. Ultrapure water was obtained from a water cleaning resin system from NAN-
Opure Diamond, Barnstead, USA, with water quality of 18.0 mΩ-cm, and 0.22 µm
filtered (EMD Millipore, USA). All buffers were filtered using 0.22 µm vacuum-driven
filter units (Nalgene, USA), unless when 0.1 µm pore-size filtering was necessary (using
PDVF syringe-filters Millex-VV from EMD Millipore, USA).
Filtration of mAb samples, using syringe filters, was done under a vertical laminar-
flow fumehood to avoid any contamination by dust particles (LabCaire fumehood VLF6
Clean Air, PuriCore, Inc., USA).
Thermal stress aggregation study
After filtration of batches 2a (∼100 mg/mL) and 2b (∼17 mg/mL), the samples were
left at 40 ◦C and 5 ◦C (control) for 6 weeks. Aliquots of the samples were analysed
at 2 week intervals. The samples were typically taken out of the incubator and left at
room temperature to equilibrate (∼30 minutes), since most of the experiments required
readings at room temperature.
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Dilution and temperature study of reversible aggregates
The sample used was stored at 40 ◦C for 7 weeks. Dilutions of 10 and 50 mg/mL of
this sample were analysed on DLS and on HPSEC (with a sample tray temperature)
either at 25 ◦C or 5◦C. Injection concentration was kept 10 and 50 mg/mL, therefore
the injection volume was changed according to keep constant the protein load in the
chromatography column. For the HPSEC experiment at 5 ◦C, injections were made
over a period of time of 7 days, whereas the experiment at 25 ◦C took a total of 21
hours. The DLS experiments lasted 25 hours.
For the rheology and HPSEC parallel studies of the effect of reversible aggregates,
a mAb sample of 100 mg/mL left at 40 ◦C for 2 weeks was used. After the first
measurement, for rheology and HPSEC, the original sample was stored at 5 ◦C. Fresh
aliquots were measured on HPSEC as well as on the double-gap rheometer 24 hours later.
5.2.2 Methods
5.2.2.1 Quantification of protein concentration by UV spectroscopy
A calculated percent extinction coefficient (A1%1cm) of 1.45 was used for mAb solutions.
The concentrations reported were calculated as an average of measurements of 3 separate
dilutions prepared from each sample. An error of up to 10 % was accepted for this
measurement. All details related to this method are described in section 2.2.7 in Chapter
2.
5.2.2.2 Freezing-point osmometry
The osmotic strength of buffers and samples was measured. A freezing-point osmometer
Osmomat O30-D (Gonotec GmbH, Germany) was used, zeroed with ultrapure water and
calibrated with a 300 mOsmol/kg NaCl aqueous solution (Gonotec GmBH, Germany).
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5.2.2.3 Differential scanning calorimetry
All details related to this method are described in section 2.2.12.1 in Chapter 2.
5.2.2.4 Isoelectric Focusing
All details related to this method are described in section 2.2.13.2 in Chapter 2.
5.2.2.5 Circular Dichroism
All details related to this method are described in section 2.2.14 in Chapter 2. The
far-UV data collected was processed and fitted using the CONTINLL, SELCON3 and
CDSSTR algorithms available on with the CDPRO software. The protein base reference
used for these computations was reference set SP43. The data shown in this work is
obtained from using the CDSSTR algorithm, since it was the best fit, having the lowest
root mean squared (RMS) values compared to the other fits.
5.2.2.6 Bulk Rheology
The rheometer used was Anton-Paar (Graz, Austria) MCR 301 model. A cone-and-plate
geometry was a stainless steel CP50-1 (diameter = 50 mm and cone angle = 1 ◦; Anton-
Paar). To prevent evaporation of sample and to keep constant temperature of 25◦C ±
0.1◦C throughout the measurements, an evaporation blocking system equipped with a
peltier unit was used. A double gap concentric cylinder geometry (DG26.7) was also
used. The rheometer was calibrated with hydrocarbonate standard oils (N1.0 and N14)
from Cannon Instruments (USA) using the same method for data collection. Prior to
measurements, all samples were allowed to equilibrate to room temperature (∼ 23◦C)
for at least 30 minutes.
The reconstituted mAb formulation was analysed on the TA AR-G2 rheometer (TA
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Instruments, USA), using a CP40-1 (40 mm diameter, 1 ◦ cone angle; TA Instruments).
This measurement was performed at 25 ◦C.
Rotational tests (flow curves and viscosity curves) were performed by controlling the
shear rate typically from 0.01 to 1000 s−1. Each shear-rate step had a 60 second duration
time during which the instrument was averaging over the collected data. For the TA
AR-G2 rheometer, the shear-rate step had a 45 second duration time. Typically, two
shear-rate sweeps (ramping down and up) were performed per sample, without waiting
time between sweeps.
5.2.2.7 Micro-viscometer/rheometer on-a-chip
The microviscometer/ rheometer on-a-chip (mVROC), by Rheosense, Inc. (San Ramon,
California, USA) was also used to measure the bulk viscosity of filtered (0.1 µm pore size)
mAb solutions only. For these measurements, the A05 chip was used and temperature
was kept constant at 25◦C ± 0.1◦C using a water circulation system (ThermoCube, SS
cooling systems, USA) (for additional information, see section 2.2.6.2 in Chapter 2).
5.2.2.8 High performance size exclusion chromatography for determination
of level of protein aggregation
All the details related to this method are described in section 2.2.9.2 in Chapter 2.
5.2.2.9 Static light scattering - HPSEC-MALS and CGMALS
For the HPSEC-MALS experiments, the system was an Agilent Technologies chroma-
tography system as that described in section 2.2.9.2 of Chapter 2, adding an Optilab
REX refractive index detector and an on-line DAWN-HELEOS II multi-angle light
scattering detector. Details on both these detectors can be found in section 2.2.8.2 in
Chapter 2. The method details were kept constant as stated for the HPSEC method.
Calibration of this experimental setup was made using a BSA standard at 2 mg/mL
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in phophate buffer and sodium azide 0.2 %, obtained from Pierce Labs (Thermo
Scientific, UK). Analysis and integration of the chromatograms was performed using
Astra 6 software (Wyatt Corporation Technologies, Santa Barbara, California, USA).
The dn/dc (refractive increment) used for this experiment was set at 0.185 mL/g [142].
The mAb samples analysed were: a non-stressed 100 mg/mL samples (stored at 5
◦C); a 17 mg/mL sample stored at 40 ◦C for 2 weeks; and two 100 mg/mL samples
stressed at 40 ◦C for T= 2 and T= 6 weeks, respectively. All the 100 mg/mL mAb
samples were injected at 10 mg/mL dilutions and the 17 mg/mL samples were injected
neat.
For the CGMALS experiment see details on section 2.2.8.2 of Chapter 2. The
analysed mAb solution was a 5 mg/mL dilution from batch 2a, doubly filtered with 0.1
µm pore-size syringe filters. The sample was in 10 mM His-His.HCl pH 6.0 buffer and
the successive dilutions were analysed with the filtered sample buffer (0.1 µm pore size).
Data analysis was performed using Calypso software (Wyatt Corporation Technologies,
Santa Barbara, California, USA).
5.2.2.10 Dynamic light scattering (DLS)
All details related to this method are described in section 2.2.8.1 in Chapter 2. mAb
samples were measured at 1 mg/mL to reduce non-linearity effects on measurements due
to increased viscosity of the samples at higher concentrations. Measurement settings
for size readings were at a constant temperature of 25◦C ± 0.1◦C, performing 20 runs
of 20 seconds duration each. Sample equilibration for 5 minutes was done at the same
temperature. Size measurements were made in triplicate with fresh aliquots for each
reading.
For time sweeps, the samples were also measured at 1 mg/mL and set up for
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continuous readings for 24 hours. The number of runs were 20, with 20 seconds duration
each. The temperature was either at 5 ◦C or 25 ◦C. With the sample measurement at 5
◦C, a nitrogen gas flow was run through the sample compartiment at sufficient pressure
to prevent condensation on the cuvette’s sides.
5.2.2.11 Microfluidic chip sodium-dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE)
All details related to this method are described in section 2.2.13.1 in Chapter 2. A gel
was run to compare the dilutions of the three batches of excipient-free mAb solutions
(batch 1, 2a and 2b). Another µ-SDS-PAGE experiment was performed to check the
purity of thermally-stressed mAb samples. A comparison was made between samples
at the last time point of the study with those at T=0. For the 100 mg/mL mAb
samples, this experiment was performed after the study had finished, due to lack of
timing before completion of the study. Therefore, about 250 µL of the samples at T=0
and T= 6 weeks were frozen at -80 ◦C and then thawed for the preparation of the gel
electrophoresis test. Concerning the 17 mg/mL mAb samples, the comparison made
was between the last time point (T=6 weeks) at 5 and 40 ◦C and the frozen sample at
T= 0 at 5 ◦C (Figure 5.14(b)).
5.2.2.12 Flow imaging microscopy for sub-visible particle counting
All details related to this method are described in section 2.2.15 in Chapter 2. The mAb
samples chosen for MFI analysis were, for both ∼100 and ∼17 mg/mL, unfiltered and
filtered (0.1 µm) solutions. During the thermal stress study, aliquots from these two
dilutions were measured at each time point (T= 0, 2, 4 and 6 weeks). Aliquots from
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stressed samples at 40 ◦C and 5 ◦C were measured. The samples (100 and 17 mg/mL)
at T= 0 corresponded to the initially filtered material. After the first filtration, no
other filtration step was performed before measuring the solutions at the remaining time
points.
5.2.2.13 Visual inspection of protein solutions
All details related to this method are described in section 2.2.16 in Chapter 2. Unfiltered
and filtered (0.1 µm) samples of ∼100 and ∼17 mg/mL mAb solutions were visually
inspected regarding their colour, opalescence and visible particle content.
5.3 Results and Discussion
5.3.1 Excipient removal and mAb characterisation
In order to explore the effects of aggregation on viscosity, this study utilised an
excipient-free solution. To guarantee that none of the additives remained in solution,
affinity chromatography followed by diafiltration/ concentration steps were employed.
mAb batch 1 was obtained using a stirred-cell diafiltration-concentration method,
while mAb batch 2 was obtained via a tangential flow filtration (TFF) method. Batch
2 was divided into 2a and 2b, and the solutions were kept separate, since batch 2b
corresponded to the washings of the TFF membrane. All mAb batches were diafiltered
in 10 mM His-His.HCl pH 6.0 buffer. These were characterised to confirm that, despite
the different diafiltration-concentration methods used, the protein remained the same
in its physical-chemical characteristics.
mAb Batch 1 had a total volume of ∼35 mL at a concentration of ∼88 mg/mL.
Batch 2a had a total volume of ∼180 mL at ∼100 mg/mL, while batch 2b had a total
volume of ∼140 mL at ∼17 mg/mL. After extracting the excipients, the mAb solutions
were checked for osmolality. The excipients were clearly removed from the original
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solution, since the purified mAb solutions presented an osmolality of ∼26 mOsmol/kg,
comparable to the buffer (15 ± 2 mOsmol/kg) and much lower than the value measured
for the formulation (896 ± 19 mOsmol/kg). The consistency of these solutions’ pH was
also checked and it remained to pH 6.0 at room temperature. Additionally the batches
were checked for the non-ionic surfactant additive present in the original formulation.
The gas chromatography method demonstrated that this additive was not detectable
in the excipient-free material. The batches were submitted to circular dichroism,
micro-differential scanning calorimetry, capillary isoelectric focusing, HPSEC, and
microfluidics SDS-PAGE. Flow and viscosity plots of each batch were obtained using a
cone-and-plate geometry and compared to the formulated material.
Since the diafiltration/concentration methods are a processing step common in mAb
solution preparations, it has been discussed in literature its role in influencing the pro-
tein’s structure and level of insoluble and soluble aggregates due to the high fluid shear
rates involved [5]. As an initial characterisation, the circular dichroism technique was
used to confirm the secondary and tertiary structures of the mAb remained unaltered.
Figure 5.1 summarises the obtained circular dichroism scans made at far and near UV
wavelengths. Figure 5.1(a) includes a table that shows the relative content of secondary
structures present in this mAb. Between batches, no evident change was observed in the
secondary structure, although the spectra were not super-imposable. The goodness of
fit values of the CDSSTR algorithm fit to the experimental data represent these subtle
differences between spectra at far UV wavelengths, though producing similar relative
percentages of each secondary structure present in this macromolecule. The negative
peak at ∼217 nm and a positive peak at ∼203 nm, as well as the resulting relative
percentages high percentage (total ∼70 %) in β-sheet and low percentage of α-helix
showed agreement with the expected results for a IgG1 mAb [184, 185]. For the near
UV wavelengths (Figure 5.1(b)), there was no major difference between the spectra
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collected showing that the tertiary structure remained similar across the batches. The
near UV spectra showed peak values slightly shifted to lower wavelengths, compared
to literature [184–186]. A positive peak at ∼285 nm (related to tryptophan residues),
followed by a negative band with a range between 270-250 nm, were still observed and
considered to be typical to IgG near UV dichroisms. In summary, there was no evident
difference found between the batches collected and, although this CD analysis had to
be made at a different non-chiral buffer than in which the mAb was originally diluted,
the macromolecule seemed to retain its structure.
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(a) Far UV spectra
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 batch 2b
(b) Near UV spectra
Figure 5.1: Circular dichroism spectra for the three batches of excipient-free mAb in a 10 mM
phosphate buffer pH 6.5: a) Far UV from 180 - 260 nm, including a table showing the relative
percentages of each secondary structure present in the studied monoclonal antibody (results
obtained from CDSSTR algorithm fitting and showing the calculated RMSD (root mean square
deviation) as a measure of accuracy of the fit; b) Near UV spectra from 250 - 320 nm
CD data suggested that the mAb would be structurally similar throughout the
solutions, however for an additional check and related to future studies (see following
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section in this chapter), a calorimetry scan was obtained. Figure 5.2 shows that there
were no evident differences in the identified melting temperatures (positive peaks in
the spectra) between the different batches. Three peaks were found, corresponding to
the melting temperatures of specific domains of the mAb. Throughout the solutions,
these melting temperatures presented consistency in their values and were as follows:
Tm1 ∼48.5
◦C; Tm2 ∼72.4
◦C; and Tm3 ∼83.7
◦C. Correspondence of these peaks to
the mAb’s domains was as follows: Tm1 was attributed to the CH2 domain; Tm2 to
the F(ab’)2 domain; and the Tm3 to the CH3 domain [183]. This mAb was originally
studied for its engineered 3-point mutation in the Fc region, more specifically in the
CH2 domain. It was found that this change was sufficient to produce an additional
melting temperature at a lower value (∼48.5 ◦C), than the commonly main peak
typically around 72-73 ◦C, attributed to melting of both CH2 and F(ab)’2, found in
non-mutated IgG1 [183,187]. It is noted that µ-DSC is also a commonly used technique
for excipient screening, since the Tm values can shift due to the presence of several
additives at different content [44]. The agreement of our measured Tm values with
literature available about this mAb, studied in the same solution conditions as in our
case, were a guarantee that the different process steps to obtain an excipient-free mAb
solution were successful.
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Figure 5.2: Micro differential scanning calorimetry data for the three batches of excipient-free
mAb in 10 mM His-His.HCl pH 6.0 buffer. The melting temperatures were attributed to the
different mAb domains as follows: Tm1 = CH2 domain; Tm2 = F(ab’)2 domains; Tm3 = CH3
domain.
Capillary isoelectric focusing was performed to verify that the batches of mAb
were similar in their charge heterogeneity. cIEF is a commonly used technique to help
identify batch-to-batch consistency between the same macromolecule submitted to
several processing steps [123]. As with CD and µ-DSC, the cIEF results showed that
there were no evident differences between batches of this mAb (Figure 5.3). The cIEF
electropherogram of this mAb had a main peak of pI = 8.94. Two acidic isoforms were
detected, as well as one basic isoform. The acidic species are often related to sialylation
and deamidation reactions which generate acidic isoforms of the mAb, due to storage or
processing steps [125]. On the other hand, the basic isoforms can be due to a C-terminal
lysine at the heavy chain [124].
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Figure 5.3: Example of capillary isoelectric focusing electropherogram showing the isoforms for
batch 2b of the excipient-free mAb. All batch samples were analysed in a Pharmalyte composition
between pI 8 and 10.5, with the pI markers 8.18 and 9.77. Each sample was analysed in duplicate.
The summarised cIEF results for the three batches are shown in the table.
The mAb batches was checked for its level of aggregation by HPSEC. In general,
all batches had a monomer content of >98 % (with a retention time of ∼8.7-8.9 min),
a small presence of higher molecular weight species (HMWS, eluting at ∼7.4 min) and
a low percentage of lower molecular weight species (LMWS, eluting at 10.8-10.9 min)
(Table 5.1). For an example of a chromatogram of a non-stressed mAb sample, see
Figure B.1 in Appendix B. By comparing these batches, the only difference is with
batch 2a where there was a slightly lower content of monomer. As this material was
concentrated to the highest value of concentration (∼100 mg/mL) and that step was
performed with TFF, the slight increase in HMWS could be a result of the effect of
shear and high concentration [5]. In fact, during TFF it is common to concentrate to
higher values than intended, only to dilute it to the actual target concentration.
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Table 5.1: Table showing the relative peak area for the species detected by HPSEC analysis of
the three batches of mAb. Each batch was analysed in triplicate. Data is shown as average and
its standard deviation.
The microfluidics SDS-PAGE gel image shown in Figure 5.4 compared the mAb
present in these three solutions. Lanes 1 to 3 show these samples after exposure
to reducing-conditions. The two typical strong bands at ∼56 kDa and ∼25 kDa,
correspond to the expected heavy and light chains present in a IgG1, respectively [186].
These bands are in agreement with the those observed for the other mAb in lane 4, also
an IgG1, used here for control and system suitability purposes. Under non-reducing
conditions (lanes 5 - 7), the samples had a strong band at ∼145 kDa, in agreement with
the control sample. The high purity of these samples, with > 98 % relative presence of
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Figure 5.4: Microfluidics SDS-PAGE gel image of non-reduced and reduced samples of each of
the three batches of the excipient-free mAb. Legend to the lane number is as follows: 1) reduced
- batch 1; 2) reduced - batch 2a; 3) reduced - batch 2b; 4) reduced control mAb; 5) non-reduced -
batch 1; 6) non-reduced - batch 2a; 7) non-reduced - batch 2b; 8) non-reduced control mAb. The
control mAb was a different IgG1 from the mAb in our study, and was used for this technique’s
system suitability check.
The three batches of excipient-free mAb were compared to the formulated material in
terms of its rheological response. Figures 5.5(a) and 5.5(b) represent the viscosity curves
and the flow curves, respectively. In Figure 5.5(a), a striking difference between the for-
mulated mAb and the additive-free solutions was observed, where the former showed
a Newtonian-like behaviour, while the latter had a change of viscosity throughout the
applied shear rates. As with what was discussed in Chapter 4, the viscosity profiles of
the additive-free mAb samples had an apparent yield-like behaviour. In Figure 5.5(b),
the linear decrease of shear stress with shear rates, for formulated mAb solution, was a
marked difference in comparison to the almost shear-rate independent shear stress val-
ues at lower shear rates seen on the additive-free mAb solutions. Since the formulation
included a non-ionic surfactant, the data suggested that the yield behaviour seen on the
other mAb solutions was a result of the lack of competitive surface active molecules such
as the surfactant. This comparison has been observed in literature and similar results
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to ours were obtained [74, 143]. However, as the formulation contained other additives
apart from the non-ionic surfactant it is was not clear if the surfactant’s presence was
solely responsible for this Newtonian-like effect. On the other hand, this experiment em-
phasised that conducting the previous ’purification’ with affinity chromatography was
a successful method for eliminating the formulation additives from the original mAb
solution.
In detail, at the higher shear rates the additive-free material showed that its viscos-
ities were monotonically dependent of concentration (see inset of Figure 5.5(a)). The
formulated material had a slightly higher viscosity (∼5 mPa.s) compared to the ∼100
mg/mL solution. This could be due only to its concentration ∼120 mg/mL, or a com-
bination of that with the presence of additives in solution. At a lower shear rate (γ˙=
0.01 s−1, the batches of mAb demonstrated viscosities decreasing with the solution con-
centration (see inset of Figure 5.5(a)).
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Figure 5.5: Experimental rheology data showing a) viscosity and b) flow curves comparing the
three excipient-free mAb batches and the formulated mAb sample, all prior any filtration. Inset
graph in a) is the relative viscosity at low shear (η(0.01 s−1)) and at high shear (η(1000 s−1))
versus the concentrations of three batches of non-formulated mAb.
In summary, throughout this batch characterisation, the material was similar in its
phyiscal-chemical properties even though it suffered different post-processing steps. The
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additives present in the original mAb formulation were efficiently removed. Nevertheless,
for future studies discussed in this chapter and the following chapter, these batches were
not combined into one. Since batch 2a had the largest volume and highest concentration,
it was chosen for the studies regarding the effect of thermal stress on its solution rheology.
For this study, the comparison with a diluted mAb sample was made using batch 2b.
Batch 1 was used solely for the results presented and discussed in Chapter 6.
5.3.2 mAb solution rheology: a case study on the effect of aggregates
This section is focused on the effect of aggregation on the mAb’s solution rheology.
Since the mAb had a melting temperature of about ∼48 ◦C, it was expected that its
stability at this buffer conditions would be compromised by thermal stressing at 40
◦C. Thus, this was the chosen method to force protein aggregation. However, before
starting this study, large particles (of size > 0.1 µm diameter) were filtered out to reduce
a possible nucleation effect influencing the generation of further protein aggregation.
Therefore, the time point when filtration occurred was considered the initial time point
(T= 0) for the aggregation study that lasted for 6 weeks.
For the study of filtration and aggregation of the mAb solutions, the rheology was
measured with cone-and-plate and double-gap geometries, and characterisation of the
protein oligomers was performed by HPSEC, MFI, DLS, and µ-SDS-PAGE. Micro-
fluidics rheometry with mVROC was used to measure only the filtered mAb solutions.
The sample’s concentration was also monitored during the study. Also, a study was
done on the potential effect of CP and DG rheology on these samples, focusing on the
relative quantity and/or size of the aggregates before and after the rheology experiments.
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5.3.2.1 Effect of insoluble particles on the mAb solution rheology
The unfiltered ∼100 and ∼17 mg/mL mAb solutions were visually inspected before
filtration with 0.1 µm pore-size membrane syringe filters. The results are shown
in Table 5.2. Although the ∼100 mg/mL sample was practically free of particles,
these usually formed a dust-like spiral from the bottom of the vial after swirling
the sample for inspection. The 17 mg/mL sample did not show this. The sample
at 100 mg/mL presented higher degree of opalescence and colour than the diluted
mAb solution. This could be related to the concentration effect. After filtration both
samples showed to be free of particles, the colour was maintained respective to each
concentration, while the 100 mg/mL mAb solution showed slight opalescence (score: III).
Table 5.2: Visual inspection score for mAb unfiltered samples at 100 and 17 mg/mL. The
material was assessed based on its colour, opalescence and visible particles content against a
black and white screen with aid of a white light. Values or codes in parenthesis correspond to
the standard to which the sample was similar.
Since visual inspection is a qualitative analysis, a quantitative evaluation of filtration
efficiency was performed with micro-flow imaging. Figure 5.6 shows the comparison of
particle count frequency histograms along the equivalent circular diameters between
the unfiltered and filtered mAb samples. As expected from visual inspection analysis,
the ∼100 mg/mL sample showed higher particle count, mostly concentrated towards
smaller sizes. This was a feature also seen with the diluted mAb solution, however its
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total particle count was lower (2213 particles) compared to the higher concentration
(43987 particles) (see Table B.2 in Appendix B). Both filtered samples showed an
evident decrease of particle count per size class and in the analysed volume. Filtered
sample buffer was also measured, as a control sample. Sub-visible particles were present
in the filtered buffer although to a much reduced level compared to the filtered mAb
solutions (Table B.2 in Appendix B). As discussed in the previous chapter, although
MFI allowed a quantitative analysis of sub-visible size range proteinaceous particles (1 -
100 µm), it still drew uncertainties regarding the effectiveness of filtration since filtered
solutions always presented some sub-visible particles.
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Figure 5.6: MFI sub-visible protein aggregates frequency histograms comparing between un-
filtered and filtered 100 mg/mL mAb solutions (large graph) and 17 mg/mL mAb solutions (inset
graph).
For HPSEC data, no change was observed between unfiltered and filtered mAb
solutions (Table 5.3). Since the HPSEC technique allows the detection of soluble
aggregates only up to a certain MW size (∼600 kDa, in this case), and the unfiltered
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solutions had over 98 % relative amount of mAb monomer, it was expected that
filtration would not affect the sample’s HPSEC profiles.
Table 5.3: Table with the relative peak area for the species detected by HPSEC analysis
comparing unfiltered and filtered 100 mg/mL and 17 mg/mL mAb solutions. Data is represented
as average and standard deviation of three measurements of each sample.
On the DLS analysis of the unfiltered mAb samples a main peak was identified by
intensity distribution with a mean HD of ∼11 nm (Figure 5.7). The values agreed
with the commonly reported hydrodynamic diameter corresponding to an equilibrium
between IgG1 monomer and dimer [104], where monomer content is much larger than
the dimer’s.
Only the unfiltered 100 mg/mL mAb sample showed two peaks by intensity distri-
bution. The relative amplitude of the second population with larger diameters (∼1000
nm) was lower (∼3 %). The likelihood that these particles were present in such low
number was evidenced by volume distribution showing only one peak (∼11 nm) (values
on Table 5.4 in section 5.3.2.2). After filtration, a slightly narrower monomer/dimer
peak was observed on the intensity distribution plot, corresponding to a slight difference
in the HD and relaxation times (Figure 5.7(a) and Table 5.4). For the 17 mg/mL mAb
unfiltered/ filtered samples, the slight change to a narrower main peak (at ∼11 nm)
after filtration could be representative of the loss of proteinaceous material to the filter’s
membrane (Figure 5.7(b) and Table 5.4).
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Figure 5.7: Comparison of DLS data for unfiltered and filtered samples (1 mg/mL dilutions)
from a) 100 and b) 17 mg/mL mAb solutions. For both a) and b): the large graph represents
the normalised correlation data (circles) and the lines are the fit to the exponential decay curve;
and the inset graph shows the same data presented as hydrodynamic diameter size distribution
by intensity.
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Evaluation of both MFI and DLS results suggested that the 100 mg/mL unfiltered
solution had a larger heterogeneity in particle size. However, analysis by HPSEC showed
that most of the soluble proteinaceous material was in the monomeric state. Moreover,
from the MFI analysis reports, for both filtered and unfiltered samples, the insoluble
particles had a volume fraction of <1 % of total sample volume.
The results discussed above, along with the previous chapter’s conclusions, helped to
understand that the rheology could still be affected by presence of these larger particles
related to their actual volume fraction in suspension (Figure 5.8). The DG rheology
data demonstrated a smaller difference in the viscosities between the unfiltered and
filtered samples, when compared to those differences in the CP rheology data. Other
similarities were found in these solutions to the results discussed for the β-LG data.
On both mAb concentrations, the unfiltered samples measured with CP had higher
viscosities throughout the applied shear rates, compared to the DG data. The mVROC
data of filtered mAb solutions, shown in Figures 5.8(a) and 5.8(b), demonstrated the
Newtonian-like behaviour at the higer shear rates (≥1000 s−1). The viscosities measured
with mVROC were almost superimposed with the filtered sample CP and DG data.
In addition, at all instances, the data obtained with CP and DG geometries always
demonstrated a yield-like behaviour at low shear rates such as also observed for β-LG
solutions. The rheological data was fitted to the Bingham equation for yield stress for
viscoelastic samples (Equation 5.1), resulting in good correlation to the experimental
data (all r2 > 0.97).
τ = τBY + ηBY γ˙ (5.1)
where τBY represents the yield point value. An example of how τBY is extra-
polated when plotting the τ(γ˙) to the zero shear rate value (γ˙ = 0 s−1), is shown
in Figure B.3, and the computed τBY values are shown in Table B.3, both in Appendix B.
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Figure 5.8: Rheology data for unfiltered and filtered a) 100 mg/mL and b) 17 mg/mL mAb
solutions, comparing results obtained from CP and DG geometries. The experimental data
was fitted to the Bingham equation (lines - full and dashed). On both plots, mVROC data is
represented for the filtered samples. All measurements were made at 25 ◦C.
The similarities in the rheological observations between the IgG and β-LG protein
studies, and comparison to literature [74, 78, 143, 182], suggests that in this case it
could also be assumed an air-water interface influence on the conventional rheology
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measurements. Moreover, these observations point towards the hypothesis that protein
species contribute to the rheology as a response of their own surface activity at the
air-water interface during these measurements.
After filtration, the CP data presented lower viscosities than the DG rheology data.
This was in disagreement to similar data obtained with β-LG filtered solutions. The
Bousssinesq parameter, accounting for the influence of surface effects compared to bulk
sub-phase contributions, was calculated to better understand this case (Figure 5.9).
With the mAb filtered samples, BoCP > BoDG. Since Bo was computed using the
data provided in Figure 5.8, and ηCP,filt. < ηDG,filt these results suggested that the
mAb CP data was influenced more by the bulk flow contributions than the DG data.
The reason why this was observed may well be related to the surface activity of the
macromolecular species present in solution. It could be possible that this mAb had
less air-water surface activity, compared to β-LG. Time restraints did not allow a ten-
siometry study to be performed for mAb solutions which would allow us to ascertain this.
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Figure 5.9: Boussinesq parameter (shear-rate dependent) calculated for CP (hollow diamonds)
and DG (full diamonds) rheology of filtered 100 (red) and 17 mg/mL (blue) solutions. The
inset graph shows the viscosity curves correpondent to the data used to calculate the Boussinesq
number (full circles - DG; hollow circles - CP).
The estimated surface viscosity was calculated using on the filtered mAb viscosities,
based on the same arguments in section 4.3.1.1 in Chapter 4. As seen in Figure
5.10, for both concentrations, CP and DG rheology data suggested that these samples’
estimated surface viscosity would be similar with the exception of the higher shear rates.
Unfortunately, it was not possible to perform any interfacial rheology measurements
using the DWR with these mAb solutions.
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Figure 5.10: Estimated surface viscosity from the measured CP and DG rheology for 100 and
17 mg/mL filtered (T= 0) mAb solutions. The calculations are made using the average ηbulk
obtained from measurements of these samples with mVROC.
5.3.2.2 Effect of thermal stress on the mAb solution rheology
After the previous assessment, the filtered mAb material at 100 and 17 mg/mL was left
at 40 ◦C for 6 weeks and its level of aggregation and rheology were characterised every
2 weeks.
Figures 5.11(a) and 5.11(b) represent the relative peak areas for monomer, total
high MW and low MW species from 100 and 17 mg/mL mAb samples at each time
point, respectively. Samples at the same concentration were stored at 5 ◦C and also
characterised on HPSEC for control purposes. Results from the 100 mg/mL mAb
samples showed a steep decrease of monomer through time, with a corresponding
increase of high MW species, while the low MW species remained the same (Figure
5.11(a)). Total monomer loss after 6 weeks for this sample was ∼40 %. Soluble
aggregates were observed for the 17 mg/mL sample, with a total monomer loss of
∼10 % after 6 weeks. It is important to remember that the 100 mg/mL samples were
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diluted to 10 mg/mL prior HPSEC analysis, while the 17 mg/mL samples were injected
neat. Therefore, it was expected that these relative peak areas from the analysis
of the dilution would be representative of the original sample. Peak area values are
summarised in Table B.1 in Appendix B.
Examples of chromatograms throughout the time points are shown in Figure B.1
in Appendix B. From the 2 weeks time point onwards, the chromatograms of the
100 mg/mL samples had four peaks corresponding to high MW samples. For clarity,
the level of aggregation relative to high MW species was chosen to be represented as
sum of the four peak areas. Chromatograms of the 17 mg/mL sample had two peaks
corresponding to the HMWS. At 6 weeks, for both concentrations of mAb, a shoulder
peak with retention time ∼9.3 min was detected. This shoulder peak was inconsistently
detected by the analysis software, therefore it was counted as part of the monomer peak
for comparison with the remaining time points.
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Figure 5.11: Relative peak percentage of monomer, fragment and total aggregates detected by
HPSEC for a) 100 mg/mL (injected at 10 mg/mL) and b) 17 mg/mL (injected neat) at 40 ◦C
and 5 ◦C during 6 weeks. Error bars are standard deviation of three measurements per sample.
Figure 5.12 shows the sub-visible particle count throughout time and for each of the
studied samples. An increase in the particle count between time points indicated that
besides the increase of soluble aggregates with temperature stress, a small percentage
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of sub-visible particles was generated. From the MFI reports, the volume fraction of
these particles although increasing, was still < 1% of total sample volume. It was
noted that, in comparison to the previously discussed unfiltered mAb samples, the
aggregated materials did not reach such high particle counts even at the end of this study.


























 mAb 100 mg/mL at 40 oC
 mAb 17 mg/mL at 40 oC
Figure 5.12: MFI sub-visible particle count comparing 100 and 17 mg/mL mAb samples at
different time points after aggregation at 40 ◦C.
The DLS analyses showed the increased aggregation of mAb along the study.
However, the peaks obtained by this technique did not allow any resolution by intensity
or volume distribution between the possible sizes of the aggregates. Figure 5.13(a)
shows results for the 1 mg/mL dilutions from 100 mg/mL mAb samples throughout
the time points. By intensity, the peak clearly shows a mean hydrodynamic diameter
size changing to higher values (> 20 nm). The detected peak was wider with time,
corresponding to the known increase of soluble aggregates’ volume fraction in the
samples. By volume distribution, the increased tailing of the peak towards higher
diameters confirmed the increase in soluble aggregate volume fraction. For ∼17 mg/mL
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samples very slight changes to the hydrodynamic sizes were noted (Figure 5.13(b)).
This corresponded well with the small changes in monomer loss/ increase of high MW
species observed with HPSEC. DLS confirmed that protein aggregation was occurring
with exposure at 40 ◦C, generating soluble aggregates of HD < 100 nm. However, in
correlation to the collected HPSEC data, DLS did not allow any resolution between this
IgG monomer and its oligomers sizes. Table 5.4 summarises the size differences for the
mAb samples measured by DLS. The DLS intensity distribution data was also fitted to
exponential decay functions in order to determine the relaxation times of the detected
size-populations. In general, these relaxation times increased, reflecting the presence
of soluble species of higher sizes. The lack of resolution between mAb monomer and
protein oligomers yielded one computed relaxation time.
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(b) 17 mg/mL mAb samples
Figure 5.13: Comparison of hydrodynamic diameter size by intensity and by volume distribu-
tion, for a) 100 and b) 17 mg/mL mAb samples stressed for 6 weeks at 40 ◦C. For both a) and
b), the large graph represents the size distribution by intensity and the inset graph corresponds
to the size distribution by volume.
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Table 5.4: Mean hydrodynamic size and relaxation times obtained by DLS for the 100 and 17
mg/mL mAb samples (unfiltered, filtered and aggregated at 40 ◦C). 1 - Data was obtained by
diluting samples to 1 mg/mL; 2 - the dilution from 100 mg/mL mAb unfiltered solution was the
only sample to present two peaks in size distribution by intensity; 3 - mean hydrodynamic size
by intensity distribution and standard deviation of three measurements; 4 - mean hydrodynamic
size by volume distribution and standard deviation of three measurements; 5 - relaxation time
obtained by fitting the correlation data with exponential decay equations, showing the standard
error from fit.
µ-SDS-PAGE was used for evaluation of sample degradation products. Figure
5.14(a) shows the gel corresponding to the non-reduced and reduced samples of 100
mg/mL mAb at T=0 , T= 6 weeks, at 5 and 40 ◦C, respectively, compared to the T=2.5
months samples at 5 and 40 ◦C (as controls). The controls in this experiment were
both the frozen samples at T=0 but also the aggregated mAb sample after 2.5 months
exposure to 40 ◦C. At non-reducing conditions, samples exposed to 40 ◦C showed extra
bands at lower MW than the main monomer band (∼150 kDa), typically at ∼143 kDa
and ∼137 kDa. This could correspond the lower MW species corresponding to the
shoulder-peak observed with HPSEC.
The 100 mg/mL mAb samples exposed to reducing conditions showed a consistent
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break-down between heavy (∼60 kDa) and light (∼27 kDa) chains (Figure 5.14(a)).
Extra bands were observed at ∼121 kDa and ∼93 kDa, which could correspond to
other reductions at different dissulfide bond locations in the original monomer, such
as producing a half-IgG or F(ab)’2 fragments [188]. Reduced samples at 5
◦C did not
show extra bands, supporting the conclusion that these bands are most likely products
of mAb degradation.
As seen previously via HPSEC and DLS results, the 17 mg/mL samples stored
at 40 ◦C suffered degradation to a lower extent to that observed with the higher
concentration. This was observed with µ-SDS-PAGE, where extra bands of lower MW
than monomer (non-reducing conditions) and higher MW than the heavy chain (at
reducing conditions), were detected. This indicated the mAb had similar degradation
products and degradation mechanisms independent of concentration.
Those samples exposed at 40 ◦C showed bands with lower relative intensity com-
pared to the non-aggregated mAb samples. This was another indication of the loss of
monomer throughout the time exposure at 40 ◦C. In summary, µ-SDS-PAGE analysis
provided further information regarding mAb degradation products. It addition, these
observations added evidence to the heterogeneity of protein species present in solution
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(b) 17 mg/mL mAb samples
Figure 5.14: Microfluidics SDS-PAGE gel images for a) 100 mg/mL and b) 17 mg/mL mAb
samples, comparing stressed samples at 40 ◦C with those at 5 ◦C at different time points. For
a), dilutions from 100 mg/mL mAb solutions, lanes are: 1) non-reduced - 40 ◦C, T= 6 weeks; 2)
non-reduced - 5 ◦C, T= 0; 3) non-reduced - 40 ◦C, T= 2.5 months; 4) non-reduced - 5 ◦C, T=
2.5 months; 5) reduced - 40 ◦C, T= 6 weeks; 6) reduced - 5 ◦C, T= 0; 7) reduced - 40 ◦C, T=
2.5 months; 8) reduced - 5 ◦C, T= 2.5 months. For b), dilutions from 17 mg/mL mAb solutions,
lanes are: 1) non-reduced - 40 ◦C, T = 6 weeks; 2) non-reduced - 5 ◦C, T= 0; 3) non-reduced -
5 ◦C, T= 6 weeks; 4) reduced - 40 ◦C, T= 6 weeks; 5) reduced - 5 ◦C, T= 0; 6) reduced - 5 ◦C,
T= 6 weeks.
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So far, one can conclude that this is a very complex model in terms of its components.
It has also been demonstrated that there could be an increase of insoluble particles
as result of this thermodynamic stress. As the materials change in its composition of
monomer, dimers and other oligomers, soluble or insoluble, and even mAb fragments,
it would be expected that the viscosity of this mAb’s aggregated material would be
affected.
The measurements on double-gap and cone-and-plate geometries demonstrated that,
in general, the viscosities were increasing with exposure time at 40 ◦C (Figure 5.15).
This trend was more visible with the 100 mg/mL mAb samples than with the samples
at 17 mg/mL and particularly looking at the high shear viscosities (γ˙ = 1000 s−1)
(Figure 5.16(a)). However, at lower shear rates, for time points such as the CP data of
100 mg/mL at T= 6 weeks, the viscosities were lower than the material had showed at
previous time points. Superimposition of the CP and DG viscosities showed that, at
the higher shear rates, the CP data was generally slightly higher than the viscosities
measured by DG rheology (Figure B.2 in Appendix B).
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(a) 100 mg/mL mAb samples













































(b) 17 mg/mL mAb samples
Figure 5.15: Rheology data obtained for both cone-and-plate and double-gap geometries of a)
100 mg/mL and b) 17 mg/mL mAb solutions left for 6 weeks at 40 ◦C and analysed at room
temperature (25 ◦C).
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The rheological profiles of these protein solutions, even though of altered contents,
did not change its flow behaviour. The data showed no hysteresis between sweeping up
and down the shear rates. The profiles remained with yield-behaviour characteristics,
and the experimental data was fitted with the Bingham model (Equation 5.1) to find
if the yield points would follow a similar trend as the high-shear viscosities (Figure
5.16(b)). Yield points and r2 values from corresponding fits are represented in Table
B.3 in Appendix B.
Figure 5.16(b) showed that throughout the time points, yield values for each sample
were not consistently increasing. It was inconclusive if the increase of aggregation had
an impact on the yield behaviour of these samples. The hypothesis would be that the
proteinaceous aggregates generated would potentially contribute to this yield-behaviour
as it is known that the increase of solid content in dispersions that demonstrate
yield-like behaviour originate higher yield points [48]. If the contents would be solely
involved in contributions to the air-water interface protein films hypothetically present
in these geometries would be another point to investigate. Presumably, part of the
monomers here present could be in a partially unfolded state, where hydrophobic areas
of the protein would be exposed and therefore more air-water surface active [189].
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 17 mg/mL CP
 17 mg/mL DG
(b)
Figure 5.16: a) High shear viscosity (η = 1000 s−1) of mAb samples stressed at 40 ◦C for 6
weeks (from CP and DG data). Data points are average of three readings at 1000 s−1. Error
bars represent the standard deviation. b) Yield point values of the same mAb solutions stressed
at 40 ◦C for 6 weeks. Yield points were obtained by fitting the Bingham model to the CP and
DG rheology experimental data. Error bars correspond to the standard error given by the linear
regression.
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On a detailed note, the CP rheology data suffered irreproducibility within repeating
samples, such as what is demonstrated in Figure 5.17. At times, a Newtonian-like
behaviour was observed, whereas a new loading from the same sample would have a
yield-like behaviour at low shear rates. Double-gap rheology presented reproducibility
across mAb samples at all the time points/ conditions of sample. It could be possible
that the same events observed here were related to those described with reference to the
rheology of unfiltered and filtered mAb solutions. In light of our hypothesis discussed
so far, and what recent literature has proposed [74, 78], the Newtonian-like behaviour
observed in protein solutions would be related to a lack of protein-film formation at
the air-water interface present in these measurements. However, since both measuring
systems used here were shown to have a similar air-water interface surface area (73
mm2 and 71 mm2 for the CP50-1 and DG26.7, respectively), it was interesting to
observe that the DG did not show inconsistencies similar to those from the CP geometry.
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Figure 5.17: Comparison between waiting times before measurements of a 100 mg/mL mAb
sample thermally stressed at 40 ◦C after 2 weeks, with CP and DG geometries. Circles - data
ramping down shear rates; lines - data sweeping up shear rates. On CP rheology, run 1 and run
2 were obtained from the same sample, while run 3 and run 4 were another aliquot, both from
100 mg/mL T= 2 weeks at 40 ◦C sample. Run 1 and 2 for DG rheology data were performed
on the same loaded sample. All measurements performed at 25 ◦C.
5.3.2.3 Analysis of level of aggregation of recovered mAb solutions after
cone-and-plate and double-gap rheology
The CP and DG geometries are made of stainless steel, which is a material that has
been shown to cause aggregation of mAbs, suggested to be via an oxidation mediated
degradation pathway [30]. Therefore, there was an interest in understanding if this
surface in conjugation to shearing, would evidence any signs of change in aggregation
pattern.
Aliquots of mAb samples ran on the cone-and-plate and double-gap geometries were
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recovered and analysed for its level of aggregation by DLS and HPSEC. Table 5.5 shows
a summary of the concentrations measured for all the samples analysed throughout
this study. There was a slight increase within the material that was stored for 6 weeks
at 40 ◦C. This variation in concentration was within the 10 % error allowed for the
UV-vis spectroscopy method. Despite this, a larger difference was identified between
mAb samples after the CP rheology experiments and the same samples before that
experiment. Although the technique used the evaporation blocking system, evaporation
seemed to be inevitable, probably due to the lower sample volume (675 µL) when
compared to the double-gap (3.8 mL).
Table 5.5: Table summarising the concentrations of mAb for its different batches, and in
different conditions (when applicable): before and after filtration with 0.1 µm pore-size syringe
filter, before and after the rheology experiments, and along the time at 40 ◦C.
On HPSEC analysis, comparing before/after rheology sample from 17 mg/mL
mAb samples did not show any differences (Figure 5.18(b)). Results derived from
the 100 mg/mL mAb samples showed differences at 4 weeks and 6 weeks data with
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contradicting tendencies. The apparent lack of any consistent deviation of ’after CP’
or ’after DG’ data from ’before rheology’ data suggests that these differences could
be minor. Therefore, no change of aggregate content could be conclusively related to
be due to rheological experiments only. In all of these samples, the low MW species
presented superimposed data suggesting that these were not changed (not shown in the
figures, to improve graphical clarity).
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(a) 100 mg/mL mAb samples


























(b) 17 mg/mL mAb samples
Figure 5.18: Comparison of level of aggregation by HPSEC between the same samples before
and after the rheology experiments. a) corresponds to data from 100 mg/mL mAb samples, and
b) corresponds to data from 17 mg/mL mAb samples, all stressed at 40 ◦C for 6 weeks. Low
MW species not represented since all data points were superimposed for both concentrations.
For the DLS analysis of these samples, similar observations were made (Figure
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5.19). In general, for the 17 mg/mL samples no change between ’after’ and ’before’
hydrodynamic diameter sizes (by volume distribution) was observed. The 100 mg/mL
sample set showed slight variation on the data although no evident trend was found.


































Figure 5.19: Hydrodynamic diameter by volume distribution comparison between before and
after rheology for dilutions of 100 and 17 mg/mL mAb samples stressed at 40 ◦C for 6 weeks.
Based on these observations, even though the ’after rheology’ samples generally
had increased concentrations when compared to the ’before rheology’ solutions, the
evaporation of sample and use of these geometries did not seem to influence the mAb’s
level of aggregation. However, HPSEC and DLS were the only techniques used here,
leaving unanswered questions regarding if changes to the mAb’s tertiary or secondary
structure occurred.
The importance of investigating the effect of shearing on the studied mAbs, during
these rheological experiments, became clear when it was detected that thermally
stressed mAb samples that had undergone rheology showed a slight change of colour
between yellow and brown. This was found for the 100 mg/mL solutions stressed at
40 ◦C at T= 2 weeks and T= 4 weeks, for CP and DG rheology. After analysis, these
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recovered samples were restored to the incubator at 40 ◦C . The change of colour
was noticed 2 months after the study had started. HPSEC analysis revealed that the
coloured samples had an extra low MW species peak compared to the control sample
(100 mg/mL mAb at 40 ◦C for T= 2 months, not undergone the rheology experiment).
Due to a lack of time further investigations were not pursued. This could have been
result of further chemical degradation due to the degraded mAb being in contact with
stainless steel leading to protein oxidation [30]. In addition, it was noted that the
control sample did not show any change of colour. Moreover, non-thermally stressed
mAb samples that had been previously analysed on the rheometer, recovered and stored
at 5 ◦C, did not have any colour change.
5.3.3 Soluble reversible aggregates: biophysical characterisation and
effect on the viscosity of the mAb solution
It was important to understand if the analysis of the diluted aggregated mAb samples
would be a good representation of the original content of soluble aggregates. It is known
that reversible self-association can occur with proteins and due to various reasons, such
as changes in pH or ionic strength [6, 51].
The IgG1 studied here was characterised by CG-MALS to measure its self-virial coef-
ficient and determine if the monomer would show reversible self-associative properties in
10 mM His-His.HCl pH 6.0. The mAb was found to have an estimated A2 = 3.97×10
−4±
5×10−6 mol.mL/g2 and a MW = 150.02 ± 0.6 kDa. The MW estimate was close to
the actual predicted MW. The positive self-virial coefficient value suggested that there
would be mainly repulsive interactions between the monomers in the studied conditions.
This information suggested that the mAb monomer would not be expected to show signs






Figure 5.20: Static light scattering data (R/K∗) versus concentration of mAb solution starting
at a stock concentration of ∼5 mg/mL and diluted with 10 mM His-His.HCl pH 6.0 buffer. The
red squares represent the light scattering data and the line is for guidance only.
The question remained whether the relative quantification of the level of aggregation
by size-exclusion would be representative of the total soluble aggregates after stressing
at 40 ◦C. Therefore, a dilution and temperature study were performed. Dilutions of 10
and 50 mg/mL from a 100 mg/mL mAb sample at 40 ◦C were analysed on HPSEC,
keeping the auto-sampler tray temperature either at 25 ◦C or 5◦C. The results are
shown in the two following sets of Figures 5.21 and 5.22.
Figure 5.21 shows the first analysis of 10 and 50 mg/mL dilutions at a constant
temperature of 5 ◦C, which is the typical auto-sampler tray temperature of the HPLC
system used throughout our work. A difference of 3 to 4 % was observed for the
peak areas for total high MW species and monomer between the 10 and 50 mg/mL
dilutions. There was no change in the low MW species relative content. Between
the first measurement and the last, there was a ’gain’ in monomer peak area of ∼9
and ∼7 % for 10 and 50 mg/mL dilutions, respectively (Figure 5.21(a)). Figure
5.21(b) shows the different relative peak areas versus time, discriminated by each
of the identified high MW species peaks. It was observed that only the peak area
corresponding to the retention time at ∼7.5 min remained almost constant. Peaks with
retention times at ∼6.6 and ∼7.0 min evidenced a descending trend on their relative area.
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Figure 5.21: Level of aggregation along a 5 day period of 10 and 50 mg/mL dilutions from
100 mg/mL mAb sample that was at 40 ◦C for 7 weeks. a) corresponds to the global level of
aggregation, where total HMWS is represented. b) shows the detailed peak areas correspondent
to the eluted HMWS only. Graph a) and b) represent the HPSEC study performed leaving the
analysed dilutions at 5 ◦C (HPSEC tray temperature).
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A similar experiment was performed, with the auto-sampler tray at 25 ◦C (Figure
5.22). Since the previous experiment showed a large decrease in total aggregate species
during the first 50 hours, this experiment had a total time of 21 hours. At 25 ◦C, the
monomer increase was not as sharp, with a difference of ∼4 and ∼3 % for 10 and 50
mg/mL dilutions, respectively. The difference in peak area between the dilutions at
each time point remained at 3 - 4 ∼ (Figure 5.22(a)). Within each of the detected
high MW species peaks, the peak area corresponding to the retention time at ∼7.4 min
remained constant (Figure 5.22(b)).
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Figure 5.22: Level of aggregation along a 24 hour period of 10 and 50 mg/mL dilutions from
100 mg/mL mAb sample that was at 40 ◦C for 7 weeks. a) corresponds to the global level of
aggregation, where total HMWS is represented. b) shows the detailed peak areas correspondent
to the eluted HMWS only. Graph a) and b) represent the HPSEC study performed leaving the
analysed dilutions at 25 ◦C (HPSEC tray temperature).
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A quick analysis with DLS was performed measuring HD sizes at 5 and 25
◦C for
24 hours (Figure 5.23). By diluting to 1 mg/mL, the potential ’break-up’ of aggregates
is most likely higher than when diluting to 10 mg/mL, leaving less larger sized species
in solution.
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Figure 5.23: Time sweep of measured hydrodynamic size of 1 mg/mL dilution from 100 mg/mL
mAb sample stressed at 40 ◦C for 2.5 months. The full circles represent the diameter size by
intensity distribution and the open circles are correspondent to the hydrdynamic size by volume.
The data is also comparing the difference in size along time when performing the measurement
at 5 ◦C (blue) and 25 ◦C (red).
In summary, it was demonstrated that once this mAb presented soluble aggregates, a
part of these species could dissociate into monomer. This suggested that this percentage
of aggregates were most likely formed by non-covalent bonds, thus suggesting their
reversible nature. It was observed that dilution and low temperature (5 ◦C), promoted
this aggregate dissociation to monomer. These findings were most evident with the
sample at 100 mg/mL, whereas the sample at 17 mg/mL also studied for its rheology
did not show such a significant change on its aggregate relative content, while still
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demonstrating signs of the same phenomenon (Figure B.5(b) in Appendix B).
The impact of these observations reflect on the quantitative and qualitatitive
analysis of the thermally stressed mAb samples studied so far. In this mAb’s specific
case, it could impact its rheology measurements. Attempting at quantitatively relating
the level of aggregation of these samples to their viscosity at 100 mg/mL would not
be accurate, since HPSEC was typically conducted with 10 mg/mL dilutions and the
samples left at the auto-sampler at 5 ◦C until analysed.
5.3.3.1 Evaluation of the effect of soluble aggregate reversibility on rheolo-
gical measurements
A rheology experiment alongside HPSEC analysis was performed with a 100 mg/mL
mAb solution stressed at 40 ◦C for 2 weeks, to understand the implications of these
findings in the viscosity measurements of this IgG1 in this buffer. After the first
measurement, the original sample was stored at 5 ◦C. Fresh aliquots were measured
on HPSEC as well as on the double-gap rheometer 24 hours later, for comparison. A
slight drop in viscosities across the shear rate range was observed between the time
points, e.g. at 1000 s−1 the difference was ∼0.15 mPa.s (Figure 5.24). This difference
in viscosities was too small (<1 mPa.s) to be considered significant. This suggests that
the percentage of aggregates that dissociate to monomer, at this stage, would not likely
affect the rheological measurements of this mAb solution, not only in terms of its flow
(as it was not changed) but also in terms of the viscosity values.
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Figure 5.24: Double-gap rheology of a 100 mg/mL mAb sample stressed at 40 ◦C for 2 weeks
measured with a 24 hour interval. After the first rheological measurement (T= 0), the mAb
solution was stored for 24 hours at 5 ◦C and another aliquot was analysed on the DG geometry
when T= 24 hours. Measurement temperature was 25 ◦C.
With the HPSEC results, similar results were found to those previously described
in this section. A difference of about 3 % was seen between the 10 and 50 mg/mL
injections at each time point; and an increase of monomer/ decrease of total high MW
species of ∼3 and 2 % was found for the 10 and 50 mg/mL injections, respectively
(Figure 5.25). Such low percentage of reversible soluble aggregates could well explain

































Figure 5.25: Level of aggregation of a 40 ◦C stressed T=2 weeks 100 mg/mL mAb sample,
diluted and analysed at 10 and 50 mg/mL, measured with a 24 hour interval. This experiment
was performed at the same time the rheology experiment was conducted. The mAb solution was
stored for 24 hours at 5 ◦C and another aliquot was analysed on HPSEC when T= 24 hours.
HPSEC tray temperature was 5 ◦C.
5.3.3.2 HPSEC-MALS analysis of mAb solutions: calculation of the MW
Static light scattering analysis was performed to obtain information of MW of HMWS
and monomer peaks. Figure 5.26 represents examples of one injection per each of the
analysed samples. These plots correspond to the computed (fitted) molecular weight
for each of the peaks identified and analysed, versus the elution time. Note that the
lower molecular weight species (at 10.9 min, with the UV-detector) were not fitted.
This is because of their small size yielding that their relative signal in light scattering
data was poor and thus making its analysis difficult [102]. Therefore, the peaks that
were analysed were those with relevant light scattering signal (full line in the figure),
and corresponded to the monomer peak (∼8.9 min), and aggregates at ∼7.5 min, ∼6.9
min, ∼6.5 min and ∼6.1 min.
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Analysis of these samples was made by applying the Debye formalism to each
of the peaks detected. The degree of fitting of each of the peaks experimental data
was changed accordingly to achieve higher R2. Note that the fittings were done for a
particular elution volume slice and checked if adequate for the remaining slices. An
example of this analysis are Figures 5.27(a) and 5.27(b) which show the Debye plots -
light scattering data versus sin2(θ/2) - corresponding to a specific elution volume slice
of peak 1 and peak 2, respectively, from different samples. Included in these figures are


















































Figure 5.26: HPSEC-MALS experiments showing light scattering (full line), differential re-
fractive index data (dotted line), and calculated molecular weight (circles) for each detected
peak from mAb solutions at different time points during thermal stressing at 40 ◦C: A) un-
stressed mAb solution; B) 17 mg/mL mAb sample that was stressed for 6 weeks at 40 ◦C; C)
100 mg/mL mAb after 2 weeks at 40 ◦C; D) 100 mg/mL mAb solution after 6 weeks at 40 ◦C.
The 100 mg/mL mAb solutions here presented were diluted to 10 mg/mL, while the 17 mg/mL
mAb solution was injected neat.
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Figure 5.27: Debye plots for two of the analysed peaks of the mAbs samples, along with the
data respective to each of the analysed elution volume slices . a) Debye plot for 100 mg/mL
mAb sample at T= 0, 5 ◦C; b) Debye plot for 17 mg/mL mAb sample at T= 6 weeks, 40 ◦C.
Raleigh ratio experimental data are represented in full circles, and the fit corresponds to the line.
Data analysed using the Debye formalism.
From this analysis, the molecular weights were computed as a sum per peak for
each sample. Table 5.6 summarises these results showing the weight-averaged molecular
weight. The root mean square radius is not reported since these scatterers, including
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the higher MW oligomers, had a radius < 1/20*λ of the incident light used in the
instrument, thus disabling computation of the RMS radius for these macromolecules
Table 5.6: Molecular weight (weight-averaged) (Mw) for each peak identified from mAb samples
exposed to 40 ◦C, compared to storage at 5 ◦C. Each sample was analysed in triplicate. Molecular
weight reported is the average, and the standard error is from the 3 measurements.
From the data in Table 5.6, and knowing that the predicted MW of this mAb was
∼145.46 kDa, a correspondence of these calculated MW with the number of associated
monomers for each peak, was made. Peak 1 was attributed to the mAb monomer since
the calculated MW was within 5 % of the predicted monomer’s MW. A dimer, trimer,
tetramer and pentamer of this mAb would be expected to have the following molecular
mass: ∼290; ∼435; ∼580; and ∼725 kDa. Our data suggested that the only plausible
correlation to dimers and trimers, could be for peak 2 and peak 3, respectively. As
for peaks 4 and 5, the calculated MW indicated that these eluted volume fractions were
composed of mAb oligomers of higher order than pentamers. Even though the calculated
polydispersity for each of these peaks was ∼1, it is noted that for the highly aggregated
samples (100 mg/mL after T= 2 and T= 6 weeks), fitting of these peaks to the Debye
model required higher order fit degrees. This was a consequence of higher error in light
scattering data, due to the species of higher mass and possibly of irregular shape. Peak 3
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was better analysed from the 17 mg/mL mAb sample, since its chromatographic profile
showed better separating resolution.
Relating the MALS data to the detailed study of the reversible high MW species,
indicated that the nth-oligomers’ dissolution was mostly directly to monomer, without
including a gradual step dissociation into dimer. Therefore, it is likely that this IgG’s
dimers were not the ’reactive species’ for nth-oligomer formation.
Judging by the DLS data and the close MW values calculated for these aggregates,
it is expected that its aspect ratios would be very similar. This would likely yield a very
small difference between the aggregates’ intrinsic viscosities, explaining how although the
relatively high percentage present of these aggregates after 6 weeks at 40 ◦C, the increase
in viscosity at high shear remained a difference of ∼5-6 mPa.s for the 100 mg/mL mAb
sample.
5.4 Conclusions
In the first section it was shown that the mAb material purified and concentrated was
free of previously added excipients. It was also shown that the different processing steps
did not influence the physico-chemical properties of the mAb. All the batches were of
high monomer content (>98 %), revealing the material’s high purity.
A comparison between the flow and viscosity curves of these batches and the ori-
ginal formulation suggested that the original formulation additives had an effect on the
rheology of this mAb. Removing the excipients contributed to a yield-like behaviour at
low shear rates, regardless of the mAb concentration. The rheology data observed with
the excipient-free material had similar features to those previously observed with β-LG
solutions and discussed in literature [78, 182]. This indicated that similar factors were
underpinning this type of sample’s flow properties.
A comparison between unfiltered and filtered mAb solutions was made to understand
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the influence of visible and sub-visible particles in the flow behaviour. A drop in the
viscosities was detected, although more marked at the lower shear rates and particularly
with the CP geometry. Further characterisation suggested that, by filtering out most of
the insoluble visible and sub-visible particles, lead to this reduction of viscosities at the
lower shear rates.
The filtered material was then studied during thermal stress at 40 ◦C for 6 weeks.
Results obtained from HPSEC, µ-SDS-PAGE, DLS, and MFI provided information on
the type of aggregates formed, their relative quantification and size. DLS did not allow
a resolution in sizes between the IgG monomer and any possible oligomers, showing that
the mean HD sizes were increasing slightly. HPSEC results were advantageous for de-
termining the level of aggregation, although it demonstrated that the oligomers formed
were most likely of similar MW. µ-SDS-PAGE and HPSEC were particularly useful to
emphasize other products of degradation where possible fragmentation could have oc-
curred, although further analysis would be needed to clarify this.
In general, the thermally stressed material showed increased viscosities throughout
the time of exposure, while the increasing amount of oligomers dominated. The evident
differences were detected with samples at the highest mAb concentration (100 mg/mL).
The 40 ◦C stressed ∼17 mg/mL mAb solution also demonstrated loss of monomer, al-
though to much lower extent (∼10 %, after 6 weeks), when compared to the higher
concentration (∼40 %), the latter being an effect of high concentration. This increase of
aggregates did not seem to change whatsoever their flow behaviour at low shear rates,
remaining as a yield-like behaviour at that shear rate range (0.01 - 10 s−1). At the
highest shear rates, the difference in viscosities between time points was evident and did
follow a increasing trend. However, there was no evident increase of yield values with
time at stressing conditions. The increase of viscosity observed in these samples was
suggested to be mostly due to the increase in soluble aggregates. Even though there was
251
an increase in the sub-visible particle content, these were calculated to be <1 % of total
sample volume.
Tests on the level of aggregation comparing samples before and recovered from rhe-
ology experiments showed that, in our case, no obvious tendencies were detected. The
case of ’after rheology’ degraded mAb material had a change in colour towards brown
could not be conclusively attributed to the effect of shear stress and stainless steel on
these samples.
In addition, it was shown that a percentage of these aggregates were dissolving to
monomer after dilution (10 mg/mL) and at lower temperatures (5 ◦C). This phenomena
was as a drawback for the accurate quantification of soluble aggregates via HPSEC.
Implications of this aggregate-to-monomer reversibility in the accuracy of the viscosity
measurements performed during the study, were however likely to be negligible.
Finally, mAb samples were submitted to HPSEC-MALS analysis to calculate the
MW of the detectable protein species. Poor resolution between the high MW species did
not allow a accurate measurements for the highest MW oligomers, but it was possible to
compute that this IgG monomer tended to aggregate in dimers and trimers, and other
oligomers.
This mAb was a case study to demonstrate that protein degradation, by entailing a
complex interpretation and quantification of different protein species, makes the inter-
pretation of its solution rheology difficult. In this case, the non-static protein species
content, due to soluble aggregate reversibility, adds to this complexity. However, our
aim of studying the rheology of this mAb solutions using orthogonal characterisation
biophysical techniques, allowed an analysis at the molecular level to a detail that shed
light into variables commonly dismissed in study of protein solution rheology.
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Chapter 6
Exploring the impact of surface active macromolecular
excipients on the flow properties of protein solutions
6.1 Introduction
In the previous two chapters, the rheology of globular proteins was studied using β-LG
and mAb as model proteins in additive-free solutions. The discussion of factors likely
influencing the flow properties observed, particularly at the low shear rates, reflected
the concept that the macromolecules’ surface-activity was underpinning the materials’
rheology [78]. Moreover, our studies of formulated rAlbumin and mAb solutions
contributed to the argument, as without a surfactant additive, the rheology of this
protein solution also demonstrated a tendency towards a yield stress.
Therefore, to further this knowledge, for the work in the present chapter two studies
were envisioned. The first focussed on further understanding the rAlbumin solution rhe-
ology, exploring further the role of polysorbate-80 in the case of thermal stressing. The
second part of this chapter refers to the synthesis and study of amphiphilic brush-like
poly(ethylene glycol) methacrylate polymers as potential additives to biopharmaceutical
formulations as modifiers of rheology.
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6.1.1 The use of polysorbate-80 in biopharmaceutical formulations
Polysorbates are compounds frequently used in pharmaceutical, cosmetic and food
products for their properties as non-ionic amphiphilic surfactants [190]. A polysorbate
is a viscous liquid that is composed of fatty acid esters of poly(oxyethyelene) sorbitan,
where in the case of polysorbate 80 the fatty acid ester is octadecenoic ester (Figure
6.1) [191]. However, polysorbates are known to contain a variety of derivatives of













Figure 6.1: Structure of polysorbate-80, where w+x+y+z= 20, referring to the total number
of oxyethylene groups.
Specifically in biopharmaceutical formulations, the use of polysorbate (e.g. poly-
sorbate 20 and 80) has been due its capabilities in preventing protein aggregation
and potential interactions of the biomacromolecule with interfaces (solid and/or li-
quid) [33,193]. Since there are numerous processes that biopharmaceutical solutions are
subjected to where interface cannot be avoided, the use of polysorbates in monoclonal
antibody drug products is predominant [194].
The reason why these surfactants are very successful in biopharmaceutical formula-
tions lies in their low critical micelle concentrations [195], thus enabling the use of low
amounts of the compound. The mechanism of how polysorbates interact with proteins is
attributed to their capability to slowly competitively displace the adsorption of proteins
at interfaces [37, 163]. It has been found that this mechanism in protein-surfactant
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mixtures, denominated as orogenic displacement, occurs with an increase of surfactant
in solution resulting in a decrease of protein absorption, even if the molar ratios
between both are fixed [37]. This mechanism is suggested to be complex involving not
only interfacial adsorption, but also interactions between protein-surfactant. The free
surfactant molecules are suggested to interact hydrophobically with the hydrophobic
’patches’ of an absorbed protein at the interface, forming protein-surfactant complexes
which will lead to a less surface active protein. When higher surfactant concentrations
are present, free molecules will therefore gradually displace these hydrophilic protein-
surfactant complexes, thus displacing completely the protein from the hydrophobic
interface [34,163,196]. This theory has been verified through various techniques, such as
surface tension [163, 166, 189], interfacial dilatational and shear rheology [143, 176, 196],
and using atomic force microscopy [176, 177]. Recently, theoretical models have been
developed to describe this mechanism [163].
The use of polysorbates in biopharmaceutical industry, can however come with
the risk of adding degradation reactions to protein formulations. It has been shown
that these surfactants can induce protein aggregation if stored for long periods of
time at high temperature [32, 197]. Protein degradation by oxidation has also been
demonstrated to occur via peroxide contamination of the surfactant [198]. Recently,
assessment of polysorbate degradation under similar conditions to those imposed in
biopharmaceutical studies has revealed that an increased presence of peroxides leads to
an auto-oxidation degradation mechanism of the surfactant [189]. For these reasons, it
remains highly important that the addition of surfactants such as polysorbates needs
to be at as low concentration as possible, so to reduce its effects on the drug product
degradation [197].
In the context of the work presented here, the use of polysorbate 80 in the rAlbumin
formulation was investigated for its rheological effects, in conjugation with thermal
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stressing at 60 ◦C. The study involved characterisation of the solution’s rheology with
CP measuring system, and characterisation of level of protein aggregation, by DLS,
HPSEC and gel electrophoresis.
6.1.2 Exploring the effect of brush-like PEG methacrylate amphiphilic
polymers as excipients in protein formulations
Applications of synthetic polymers spans a large range of areas, from nanoelectronics,
cosmetics, healthcare, biomedical to biotechnology processes [199], particularly with the
advent of polymerisation processes allowing versatile synthesis of materials [200].
One particular class of polymeric materials that stands out in its applications in
biotechnology and biomedical purposes, are stimuli-responsive polymer brushes [201].
This type of polymer, of varying architecture and composition, can be prepared by
grafting polymers into a linear polymer chain (’backbone’) or grafted from a sur-
face [201]. Various types of stimuli-responsive molecular brushes have been developed,
with changes in their properties that are dependent on their surrounding environment,
such as temperature, pH, type of ion or magnetic field [201–203]. When present in
a specific stimuli-predominant environment this type of polymers typically undergoes
conformational changes such as collapse of the brushes’ linear chains into globules,
yielding reversible changes in solubility and a tendency to self-assemble into micelles or
vesicles [201,203,204].
The development of versatile polymerisation processes, such as controlled/living
radical polymerisation techniques (LRP), were key to advancing the synthesis and
application of such polymers [199, 201, 205]. These techniques include atom transfer
radical polymerisation (ATRP), reversible addition fragmentation chain transfer
(RAFT), and nitroxide-mediated radical polymerisation (NMRP), among other types
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of processes [205]. Since in this work we used the ATRP technique to synthesise
poly[poly(ethylene glycol) methyl ether methacrylate] homopolymers, an explanation of
its mechanism will follow.
Figure 6.2 summarises the mechanism of ATRP, which is a catalytic reaction that
uses a metal-ligand complex. The radicals (R·) are generated by reaction of the ATRP
initiator (R − X, an alkyl halide) with the transition metal complex (Myt /L, where
L is the ligand) at its lower oxidation state (y). This reaction yields the radical and
increases the transition metal’s oxidation state, coupling it to the halide (X−My+1t /L).
This is denominated the activation reaction (with rate constant kact). The generated
radicals R· can polymerise with the (macro)monomer, in a propagation reaction with
rate constant of kp. However, the transition metal complex can also transfer the halide
to the R· regenerating the original alkyl halide compound, which corresponds to a
deactivation reaction (kdeact originating a dormant polymer chain capped with the
halide. In parallel, the radicals can undergo other termination reactions (rate constant
kt), reacting with each other (R − R), or by disproportionation (generating R − H,
R−HC = CH2) [200,205].









Figure 6.2: Scheme for general ATRP reaction. Adaptaed from [205].
Polymerisation by ATRP is therefore a catalytic process where the persistent radical
effect self-regulates the reaction’s equilibrium between activation and deactivation by
transfering the atom between the growing chains and the transition metal catalyst.
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For this reason, the equilibrium is shifted towards the deactivation reaction producing
dormant polymerised chains [200,205].
In the case of poly[poly(ethylene glycol) methyl ether methacrylate] polymers,
ATRP gives a good control in polymerisation and molecule architecture, producing
polymers of narrow molecular weight distribution [205]. The reaction can be conducted
in organic solvents and high temperature [199], although it has also been performed
under aqueous and room temperature conditions [203,204].
In the case of the study presented here these polymer brushes were synthesised by
grafting through, i.e. by polymerising macromonomers (Figure 6.3). Other possible
ways of constructing brush-like polymers in general consist of coupling individual side
chains to a common backbone, and polymerising the side chains from a backbone
chain [199, 201]. In our case, the chosen method proves simple particularly since the
ether-capped poly(ethylene glycol) methacrylates used (PEGMA) were commercially
available, needing only the synthesis of the ATRP initiator. Provided a high purity
of the original macromonomer, the technique exemplified in the scheme of Figure 6.3

























Figure 6.3: General schematics of poly[poly(ethylene glycol) methyl ether methacrylate] brush
polymers. The PEGMA is the functional (methacrylate) macromonomer that was polymerised,
thus creating a homopolymer with a brush-type structure.
The choice for the synthesis and use of PEGMA brushes in their effect on protein
rheology laid also with their suggested biocompatibility [204], good solubility in aqueous
media [199, 201], amphiphilic properties [202, 204, 206], and capacity to micellise [199].
Other uses of PEGMA brushes have been on protein-resistant antifouling membranes or
films [204,207]. The latter reason has large potential in the biopharmaceutical industry
since, as mentioned above, they may be useful in preventing interaction with different
interfaces along the biopharmaceutical processing steps which can lead to protein de-
gradation [194]. Other authors have developed techniques to conjugate PEGMA brushes
to proteins, proving an alternative to linear PEG conjugation [208,209].
As a starting point, the work shown in this chapter focused only on the synthesis of
homopolymers of PEGMA, using ATRP as the polymerisation technique. The materials
recovered were then characterised by 1H-NMR and HPSEC with triple detection. The
polymers were assessed for their capability of micellisation and their molecular crowd-
inducing properties in the presence of proteins. These experiments were prepared in
order to help detect any possible limit in concentration of these materials when blending
with proteins. The chosen proteins were again β-LG and the mAb, the same proteins de-
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scribed in the previous chapters of this thesis. Once the protein-polymer mixtures were
prepared, measurements with cone-and-plate rheology and mVROC were performed, as
well as characterisation with HPSEC and DLS for the level of aggregation.
6.2 Materials and Methods
6.2.1 Materials
6.2.1.1 Protein samples
The monoclonal antibody studied was provided by MedImmune, LLC. (Gaithersburg,
Maryland, USA). It is an IgG1 of 145.461 kDa. The protein was supplied in a lyophilised
formulated format containing other additives, including a surfactant. The formulation
additives were removed by purifying the reconstituted material, as per description in
section 2.2.3 of Chapter 2.
The protein β-LG was obtained from Sigma-Aldrich (product L3908, batches
097K7012 and 080M7312V) as a mixture of bovine variants A and B, in a lyophilised
powder containing approximately 10% w/w of sodium chloride.
rAlbumin used in this work was kindly donated by Novozymes Biopharma UK Ltd.
(Nottingham, UK). The original sample was formulated at 200 mg/mL concentration.
For rAlbumin samples, the formulation buffer was composed of NaCl (145 mM),
Polysorbate-80 (15 mg/L) and sodium octanoate (32 mM) in ultrapure water (pH =
7.0 ± 0.3 at room temperature).
6.2.1.2 Reagents
All reagents used for the rAlbumin formulation buffer preparation were obtained from
Sigma-Aldrich and were of analytical grade. Polysorbate-80 used for the rAlbumin buffer
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and its determination of critical micellar concentration by fluorescence was obtained
from Fluka and of grade meeting the standards from the European Pharmacopoeia.
PEG 8000 for the protein solubility test was purchased from Alpha-Aesar.
All the chemicals used for polymer synthesis were purchased from Sigma-Aldrich
or Acros. All the solvents used for polymer synthesis, purification and analysis (size
exclusion chromatography and nuclear magnetic ressonance) were purchased from
Sigma-Aldrich or Fisher Scientific and were of HPLC grade, and used without further
purification.
The histidine buffer was prepared containing L-Histidine and L-Histidine mono-
hydrochloride at 10 mM in ultrapure water (pH = 6.0 ± 0.2 at room temperature).
Histidine salts were purchased from J.T. Baker Chemicals (Pennsylvania, USA) and
were of analytical grade.
All prepared buffers had a 2-month expiry date and were kept at 5 ◦C. Ultrapure
water was obtained from a water cleaning resin system from NANOpure Diamond
(Barnstead, USA) with water quality of >18.0 mΩ-cm, and 0.22 µm filtered (PVDF
membrane, EMD Millipore, USA). All buffers were filtered using 0.22 µm vacuum-driven
filter units (Nalgene, USA), unless when 0.1 µm pore-size filtering was necessary (using
PDVF syringe-filters Millex-VV from EMD Millipore, USA).
6.2.1.3 Sample preparation
(a) rAlbumin thermal stress study
For the thermal stress study of rAlbumin, samples at 200 mg/mL and at 20 mg/mL were
used. The 20 mg/mL sample was prepared by 1:10 dilution of original stock sample in
rAlbumin formulation buffer. Samples were stored in closed glass vials at 60 ◦C and
5 ◦C (control samples). Aliquots of thermally-stressed and non-stressed samples were
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analysed at the following time points: T= 0, T= 3 days, T= 7 days, T= 14 days, T=
28 days. If sample dilution was needed, these were prepared into formulation buffer.
(b) mAb and β-LG blends with polyPEGMAs
For the work described in this chapter, mAb batch 1 was used. This batch (∼89
mg/mL) was concentrated to ∼100 mg/mL using centrifugal concentrators Millipore
MW cut-off 30 kDA (Millipore EMD) by following the manufacturer’s protocol. The
final mAb sample was then filtered with 0.22 µm pore-size syringe filters.
Sample preparation for β-LG is described in section 2.2.2 in Chapter 2. For the work
presented in this chapter, a fresh batch of dialysed β-LG solution in 10 mM His-His.HCl
pH 6.0 was prepared at a stock concentration of ∼79 mg/mL after filtration (0.22 µm).
Any dilution of either mAb or β-LG samples was prepared in 10 mM His-His.HCl
pH 6.0 buffer.
Blends of β-LG and mAb samples were prepared individually with each of the
synthetic polyPEGMAs. All β-LG samples were at ∼68 mg/mL, while all mAb
samples were used at ∼100 mg/mL. Each of the polyPEGMAs were added to each
of the protein solutions at the following concentrations: 0.1, 1, 2.5 % w/v. A total
of 7 samples were prepared per protein solution: 3 with increasing concentrations of
polyPEGMA475 and 3 with increasing concentrations of polyPEGMA1100, and one
control protein sample without any added polymer. All samples were prepared in 10
mM His-His.HCl pH 6.0 buffer, into sterile glass vials with a rubberised cap. All sample
preparation and any filtration of mAb or β-LG solutions, using syringe filters, was done
under a vertical laminar-flow fumehood to avoid any contamination by dust particles
(LabCaire fumehood VLF6 Clean Air, PuriCore, Inc., USA). After preparation, to
ensure full mixing of the materials, all samples were subjected to a gentle oscillatory
shake (∼50 rpm) for at least 5 hours. The materials were then left for 24 hour at
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5 ◦C to before being analysed. All samples were checked for the pH at room temperature.
6.2.2 Methods
6.2.2.1 Protocol for ATRP pPEGMA synthesis
(1) Synthesis of ATRP initiator
The ATRP initiator 2-bromo-2-methylpropionic benzyl ester (3) was synthesised in the
following conditions and used for synthesis of both pPEGMAs studied in this work.
The commercially available phenylmethanol ((2), 50 g, 0.462 mol) was dissolved in
dicloromethane (DCM ∼ 200 mL) in a 1 L round-bottom flask with a magnetic stirrer
bar under argon gas. Triethylamine (97 mL, 0.694 mol) was added with a syringe, and
the flask was put over ice (0-5 ◦C). Attached to the flask was a closed glass ampoule
that was filled with 2-bromoisobutyrylbromide (1) (86 mL, 0.692 mol) which was slowly
added dropwise to the solution in the flask, over a 1 hour period. After this addition,
the reaction was left overnight at room temperature remaining under argon. The
precipitate formed (triethylammonium bromide) was removed by filtration twice and
discarded. All filtrate was collected and the solvent removed by rotary evaporation. The
product was then put through a basic alumina column with DCM, consecutively until
the extracted fraction was a yellow coloured liquid. This fraction was collected, the
DCM evaporated, and the product was dried over phosphorus pentoxide in a vacuum
desiccator.
The initiator (2-bromo-2-methylpropionic benzyl ester) (3) was characterised by
1H-NMR to ensure its purity.
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(2) Synthesis by ATRP and purification of polyPEGMA-475 and
polyPEGMA-1100
Prior to the synthesis of polyPEGMA homopolymers, each of the commercially
available monomers PEGMA-475 and PEGMA-1100 were separately dissolved in DCM
and passed through a neutral alumina column to remove the inhibitor present in
solution. The monomers were collected and the recovered after evaporation of solvent.
Then the respective monomer (PEGMA-475 or PEGMA-1100), along with PMDETA
(N,N,N’,N”,N”-pentamethyldiethylenetriamine) and 2-bromo-2-methylpropionic benzyl
ester were added to a two-neck round-bottom flask with a magnetic stirrer and dissolved
with toluene (see Table 6.1 for the reagents’ quantities used per reaction). The flask was
sealed with rubber septums and degassed with argon for at least 20 minutes. Cu(I)Br
was added under argon atmosphere, the mixture was continually stirred and put at 60
◦C under continuous argon bubbling. The polymerisation was stopped after 1 hour
by removing the flask from the heat, cooling it on ice and immediately exposing its
contents to air.
The unreacted PEGMA monomer was precipitated in petroleum ether, recovering
the supernatant. The solvents were then evaporated, and the resulting product was
dissolved in DCM and passed through an alumina column at least three times to
remove the copper catalyst. The excess DCM was removed by evaporation. The
polymer was further dissolved in purified water (∼500 mL) and Na2S was added to
react with any remaining copper (II). This reaction was left stirring overnight at room
temperature. The precipitate was filtered out (0.22 µm pore-size nylon membrane,
Millipore) by vacuum-driven filtration. The aqueous polymer solution was dialysed in
purified water (1000 Da cut-off membrane, Spectra/Por-6). The final dialysed solution
was freeze-dried.
The polyPEGMA-475 and polyPEGMA-1100 resulting polymers were further dried
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under vacuum for several days, and kept at 2-5 ◦C, under argon atmosphere when not
in use. The polymers were characterised by 1H-NMR and HPSEC.
Table 6.1: Quantities of the reagents used for the synthesis of polyPEGMA-475 and
polyPEGMA-1100.
6.2.2.2 Quantification of protein concentration by UV spectroscopy
The calculated percent extinction coefficient (A1%1cm) was of 1.45 for mAb solutions. For
β-LG A1%1cm= 9.6 [100], and for rAlbumin A
1%
1cm = 5.8 [99]. The protein and polyPEGMA
blends, as well as the controls (polyPEGMA in buffer) were also analysed on Nanodrop
without diluting to obtain a UV-Vis scan from 200 - 800 nm. All details related to this
method are described in section 2.2.7 in Chapter 2.
6.2.2.3 Bulk Rheology
The rheometer used was an Anton-Paar (Graz, Austria) modular compact rheometers
(MCR) 301. For the rheology measurements of rAlbumin solutions, a cone-and-plate
CP50-1 (diameter = 50 mm and cone angle = 1 ◦) was used. For the analysis of
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polymer-protein blends a cone-and-plate CP40-0.3 was used (diameter = 40 mm, cone
angle = 0.3 ◦). To prevent evaporation of sample and to keep constant temperature of
25◦C ± 0.1◦C, an evaporation blocking system equipped with a peltier unit was used.
Prior to measurements, all samples were allowed to equilibrate to room temperature (∼
23◦C) for at least 30 minutes.
Rotational tests (flow curves and viscosity curves) were performed by controlling the
shear rate typically from 0.01 to 1000 s−1, and measuring torque, shear viscosity and
shear stress. To increase data validity and sensitivity of the method, each shear-rate
step had a 60 second duration time during which the instrument was averaging over the
collected data. Typically, two shear-rate sweeps (ramping down and up) were performed
per sample, without waiting time between sweeps.
6.2.2.4 Micro-viscometer/rheometer on-a-chip
The microviscometer/ rheometer on-a-chip (mVROC), by Rheosense, Inc. (San Ramon,
California, USA) was used for measurement of bulk viscosity at high shear rates. All
samples analysed with the mVROC were filtered with 0.1 µm pore-size syringe filters
(Millex-VV Millipore filters). For these measurements, the A05 chip was used and
temperature was kept constant at 25◦C ± 0.1◦C using a water circulation system
(ThermoCube, SS cooling systems, USA) (for additional information, see section 2.2.6.2
in Chapter 2).
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6.2.2.5 High performance size exclusion chromatography for determination
of level of protein aggregation
rAlbumin samples were analysed for their level of aggregation on HPSEC. β-LG
and mAb solutions only as well as the blends of these proteins with the synthetic
polyPEGMAs were also analysed for their level of aggregation. Details related to
method and equipment are described in section 2.2.9.2 in Chapter 2.
6.2.2.6 HPSEC for synthetic polymers
During and immediately after synthesis, aliquots of polyPEGMA homopolymers were
characterised using a chloroform/ TEA 95/5 % v/v HPSEC (or GPC) system to check
solely for their molar masses and purity. For this purpose, the system was calibrated
for conventional calibration with a mixture of narrow MW polystyrene standards
commercially available (EasiVial PS-M, Agilent Technologies, UK).
The synthesised polyPEGMAs and PEG 8000 were analysed for MW and intrinsic
viscosity on a chloroform/ TEA 95/5 % v/v gel-permeation chromatography system
calibrated for triple detection (refractive index, 90 ◦ light scattering detector, and
differential pressure). A narrow polystyrene was used as standard for detector response
and inter-detector delay. Polyethylene glycol standards from Polymer Labs (Agilent,
UK) were also analysed for comparison. All PEG/PEO samples were injected only once
at concentrations 3-5 mg/mL, while the polyPEGMAs were injected at ∼2.5 mg/mL
and in triplicate. The refractive index increment used for analysis of all PEG or PEO
polymers was dn/dc = 0.053 mL/g, while for the polyPEGMA analysis dn/dc = 0.057
mL/g.
All equipment and method details for both HPSEC/GPC systems are described in
section 2.2.9.4 in Chapter 2.
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6.2.2.7 1H-Nuclear magnetic resonance
1H-Nuclear Magnetic Resonance (1H-NMR) spectra were recorded on a Bru¨ker 400 MHz
spectrometer (Bru¨ker, Germany). Chemical shifts are reported in ppm (δ units) downeld
from internal tetramethylsilane standard. Polymer samples were dissolved (1:3 parts) in
CDCl3.
6.2.2.8 Dynamic light scattering
Details related to this method are described in section 2.2.8.1 in Chapter 2. Meas-
urement settings for rAlbumin size readings were at a constant temperature of 25 ◦C,
performing 15 runs of 10 seconds each. For the β-LG, a total of 10 runs of 10 seconds
each were performed. For mAb solution size measurements, 20 runs of 20 seconds each
were collected. For β-LG and for IgG samples, measurements were performed at 25 ◦C.
Analysis of polyPEGMA and protein blends were measured at the same conditions as
those chosen for each protein, respectively. The polyPEGMA solutions (in buffer) were
analysed at their original concentration (1, 10 and 25 mg/mL), while the protein and
polyPEGMA mixtures were measured at a protein concentration of ∼1 mg/mL. An
equilibration time of at least 5 minutes was set before the measurement started. For all
protein samples, size measurements were made in triplicate with fresh aliquots for each
reading.
6.2.2.9 Microfluidic chip sodium-dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE)
Details related to this method are described in section 2.2.13.1 in Chapter 2. rAlbumin
samples used for this experiment were: 200 and 20 mg/mL at 5 ◦C T= 4 weeks; and
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200 and 20 mg/mL at 60 ◦C at T= 4 weeks.
6.2.2.10 Tensiometry
All the detailes referring to this technique are described in section 2.2.10 in Chapter
2. A freshly prepared filtered solution (0.1 µm pore-size syringe filters, Millex-VV,
EMDMillipore, USA) of polyPEGMA-475 in buffer at 1 mg/mL was analysed.
6.2.2.11 Detection of critical micellar concentration by fluorescence spec-
troscopy
Polysorbate-80 (PS-80) and polyPEGMA solutions were prepared in 10 mM His-
His.HCl pH 6.0 buffer, by dissolving the materials in purified water to prepare stock
concentrations (100 µM for PS-80, and 5 mg/mL for polyPEGMAs) and diluting with
water to achieve all concentrations for the experiment.
A stock solution of pyrene (Sigma-Aldrich) in acetone was prepared at a concentra-
tion of 0.05 mg/mL. Aliquots of 24 µL from the pyrene stock solution were transferred
to capped clean glass vials, and left to evaporate the acetone. After solvent evaporation,
surfactant and polymer dilutions were individually added to each of the vials yielding a
final concentration of 6×10−7 M of pyrene (each vial containing 10 mL of solution). This
procedure was done in triplicate for each dilution per studied compound. The samples
were shaken well and then incubated at 25 ◦C overnight away from light in a water
bath with a gentle oscillatory shake (∼70 rpm). After this, the samples were measured
on a Varian Cary Eclipse fluorescence spectrophotometer with an excitation wavelength
of 342 nm. The emission spectra was collected at a scan rate of 10 nm/s, emission slit
of 2.5 nm, from 350 to 400 nm. The pyrene fluorescence peaks between 373-374 nm
269
(peak I) and 383-385 nm (peak III) were obtained and its ratio (IpeakI/ IpeakIII) was
calculated per sample.
6.2.2.12 Protein solubility assay using polymers
Polymer solutions were prepared at 40% w/w in separate acidic and basic buffer
components. In this study, the sample buffer was 10 mM His-His.HCl pH 6.0. The basic
polymer solution was titrated with the acidic polymer solution while being thoroughly
stirred. Protein samples were prepared in 10 mg/mL stock solutions in the same buffer.
In a 96-well plate (UV-Vis clear plates, Greiner Bio-One, Ltd., UK) the buffer was
loaded, followed by the protein sample and then the polymer solution, mixing well.
Each protein-polymer blend was prepared in triplicate. The microplate was covered and
left in an incubator at 25◦C overnight. After this time, the microplate was centrifuged
(Heraeus Megafuge 11R, Thermo Fisher Scientific, UK) at the temperature of the assay
at 338 g for up to 2 hours at a time, until a precipitation or distinct phase-separation
was observed. Subsequently, 70 µL of supernatant from each well were transferred to
a new UV-Vis clear 96-well plate. These solutions were then measured for absorbance
at 280 nm on a UV-Vis plate reader (FluoStar Optima, BMG Labtech, Germany).
A UV-visible scan was obtained from these solutions, including for the polyPEGMA
solutions only, without any protein added (considered as control solutions). The
absorbance at 280 nm data was converted to calculate the concentration of protein
present in each well. The logarithm of protein concentrations were plotted versus
% w/w of polymer present in solution. The slope of the graph was reported as the
apparent solubility for the studied protein in the tested buffer containing the selected
polymer. The reported solubility values for the proteins tests were used for relative
comparison only, therefore being denominated as ’apparent’ solubility.
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This method was used with the commercially available polymer polyethylene
glycol (PEG) with molecular weight of 8 kDa (Alfa Aesar, UK) as well as the poly-
poly(ethylene glycol)methyl ether methacrylates (polyPEGMAs) prepared in this work.
The % w/w of polymer used had to be changed between the different proteins and when
using different polymers.
6.3 Results and Discussion
6.3.1 Part I - The effect of thermal stressing of rAlbumin solutions on
its solution rheology
Vials of rAlbumin at two concentrations (200 and 20 mg/mL) were left at 60 ◦C for
28 days to thermally stress the protein into forming higher order aggregates. From
literature, the melting temperatures of human serum albumin have been reported
to be a two-state transition with Tm1 of ∼56
◦C and Tm2 of ∼63
◦C, due to the
sequential unfolding of the protein’s domains [27, 210, 211]. Since rAlbumin solutions
were biopharmaceutical preparations formulated to withstand stresses and prevent
protein agregation, the chosen temperature to thermally stress this protein had to be
approximate to the monomer’s ’melting’ temperature.
From the evaluation by HPSEC, those samples at 200 mg/mL showed clear signs of
loss of monomer, with increasing presence of dimers, trimers and evidence of higher MW
species. Figure 6.4 shows a drop in monomer peak area of ∼7 %, with the corresponding
increase of higher MW species distributed between dimer, trimer and other oligomers,
but no evidence of lower MW species. At the last time point, it was noticed an increase
of monomer, contradicting the previously seen tendency of monomer loss. This sudden
increase in monomer content, was most likely related to a large fraction of proteinaceous
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material that was retained on the 0.45 µm pore-size membrane centrifuge filters, since
it was noticed that it took longer time to fully centrifuge the samples from this time
point. Therefore, with much of the protein aggregates retained at the filter’s membrane,
it reduced the quantity of soluble protein aggregates present in solution which most
certainly did not correspond to the material’s true level of aggregation.
























Figure 6.4: Level of aggregation of 200 mg/mL rAlbumin sample after 4 weeks at 60 ◦C for 4
weeks. Results shown are average values of analysis in triplicate, with error bars corresponding
to the standard deviation of these measurements.
Examples of HPSEC chromatograms are shown on Figure 6.5, for both dilutions
of 200 and 20 mg/mL of rAlbumin. The 20 mg/mL sample at T=0 weeks evidenced
the typical rAlbumin chromatogram with monomer, dimer and trimer peaks, but for
the remaining time points, the trimer peak was not observed. The assessment of this
sample’s aggregation level by HPSEC suggested that the aggregation was occurring at
a lower rate than that experienced by the higher concentration.
Control samples, at the same concentrations, were also analysed by HPSEC and
showed a very slight decrease of monomer with corresponding increase in dimer content,
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generally showing that the samples were stable at this concentration (detailed data is
shown in Tables C.1(a) and C.1(b), in Appendix C).

























Figure 6.5: Example of HPSEC chromatograms from rAlbumin samples at 200 and 20 mg/mL
exposed to 60 ◦C for 4 weeks. A comparison between chromatograms shown for the 200 and 20
mg/mL at 5 ◦C, T= 0 weeks (control) is shown against samples at the same concentration but
after study completion (at 60 ◦C, T= 4 weeks). All samples subjected to HPSEC analysis were
diluted to ∼10 mg/mL and filtered with 0.45 µm centrifuge-filters.
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The data observed after DLS analysis of these same samples at the chosen times
points for the HPSEC study, demonstrated further evidence of protein aggregation
occurring with time exposure at 60 ◦C. Those dilutions obtained from 200 mg/mL
sample showed larger difference compared to the samples analysed from 20 mg/mL of
rAlbumin.
With the 200 mg/mL samples, an increase in protein aggregate species were observed
by the presence of the second peak which had increasingly higher peak area with time.
Comparatively, the analyses from 20 mg/mL of rAlbumin also showed peaks at higher
mean hydrodynamic diameter but at lower intensities. By volume distribution, these
samples evidenced less influence of these larger scatterering species, since the only peak
detected did not seem to trend to much higher hydrodynamic diameters. However, the
changes observed on intensity plot for samples diluted from 200 mg/mL rAlbumin, had
a marked deviation to higher HD of the peak detected by volume distribution. Detailed
data are shown in Table C.2 in Appendix C.
All samples were analysed after preparing fresh dilutions at 1 mg/mL, without any
further filtration. However, the rHA sample originally at 200 mg/mL after 4 weeks
at 60 ◦C had to be filtered using 0.45 µm centrifugal concentrators to remove large
proteineaceous particles to record feasible DLS measurements.
These results, confirmed the tendency seen with the HPSEC results. Both of these
experiments showed that, with time, the protein aggregates formed at 200 mg/mL of
rAlbumin monomer were demonstrating higher sizes towards 1 µm of diameter and
were becoming insoluble.
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Figure 6.6: DLS data of rAlbumin samples thermally stressed for 28 days at 60 ◦C, showing
hydrodynamic diameter of detected peaks by intensity (large graph) and volume (inset graph)
distributions. (a) Samples diluted from 200 mg/mL rAlbumin. (b) Samples diluted from 20
mg/mL.
µ-SDS-PAGE analysis comparing dilutions from each concentration of rAlbumin
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after 4 weeks at 60 and 5 ◦C was performed. The comparison with samples at 5 ◦C
served as control, where samples where not expected to show any signs of aggregation
(as demonstrated by HPSEC). As discussed previously in Chapter 3, the correspondence
to albumin monomer was attributed to the band at ∼53-54 kDa. A slight band at ∼110
kDa observed with the non-reduced 200 mg/mL T= 28 days at 60 ◦C corresponded
to the increase of dimerisation of rAlbumin after thermal stressing. The remaining
analysed non-reduced samples also demonstrated a peak/ band at this MW, having a
peak area of ∼3 %, compared to the ∼10 % observed for the fully aggregated sample.
At reducing conditions the band at ∼60 kDa was present in all samples with peak areas
of >96 %, indicating an almost full reduction of the dimers detected in non-reducing
conditions.
Although the 200 mg/mL sample presented higher aggregation levels and contained
species of higher oligomeric association than trimers (in HPSEC and DLS), both these
nor trimers were not detected with µ-SDS-PAGE. Species of higher MW than 240 kDa
would not be detected with this system, and the trimers were most likely present at
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Figure 6.7: Gel image for rAlbumin samples after storage at 60 ◦C for 28 days. At non reducing
conditions, lanes: 1) 200 mg/mL dilution, at 60 ◦C, T= 28 days; 2) 20 mg/mL dilution, at 60
◦C, T= 28 days; 3) 200 mg/mL dilution, at 5 ◦C, T= 28 days; 4) 20 mg/mL dilution, at 5 ◦C,
T= 28 days; 5) non-reduced control mAb sample. At reducing conditions, lanes: 6) 200 mg/mL
dilution, at 60 ◦C, T= 28 days; 7) 20 mg/mL dilution, at 60 ◦C, T= 28 days; 8) 200 mg/mL
dilution, at 5 ◦C, T= 28 days; 9) 20 mg/mL dilution, at 5 ◦C, T= 28 days; 10) reduced control
mAb solution. The mAb sample was used for system suitability purposes.
Up to 28 days the samples had a constant visual appearance where those solutions
with 200 mg/mL of rAlbumin had a light yellow colour, whereas the 20 mg/mL solution
presented no colour, and both typically did not show any signs of opalescence nor
visible insoluble particles. However, after the fourth week at 60 ◦C, the samples at 200
mg/mL had a gel-like viscous residue formed at the bottom of its vials. These samples
were opalescent but did not have any visible particulates or fibers.
The rheology profiles of these samples at each of the time points are shown in
Figures 6.8(a) and 6.8(b). At the initial time point, before submitting the samples
to high temperatures, the solutions at both concentrations showed a Newtonian-like
behaviour, with constant shear viscosities along the applied shear rates. This had been
observed previously for the formulated rAlbumin solutions addressed in Chapter 3.
However, the rheological behaviour of those samples at 200 mg/mL exposed to 60 ◦C
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changed with time. After 3 and 7 days, the samples exhibited increased viscosities at
low shear rates, resembling an apparent yield-stress behaviour. The material exposed
to 60 ◦C after 14 days showed signs of transition in its profile. At 28 days, the sample
clearly had signs of shear thinning, that of a gel-like fluid (slope <-1).
Apart from these changes in behaviour, particularly at low shear rates, the samples
seemed to show constant viscosities at the higher shear rates (> 100 s−1), with exception
of the sample at T= 28 days.
Those samples at 20 ◦C did not show signs of change in their rheological profiles
nor a significant variation of their shear viscosities. This correlated well with the data
shown for HPSEC, DLS and µ-SDS-PAGE, where it was proven that the degree of
rAlbumin aggregation was much lower when compared to the solutions at 200 mg/mL
also at 60 ◦C. Particularly from the DLS data, it was seen that the 20 mg/mL samples
had an increasingly higher level of aggregation but of low relative volume fraction in
the solutions. Therefore, the small amount of protein aggregates present did not affect
these samples’ rheological behaviour, at least at a level detectable by CP rheology and
at these conditions.
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Figure 6.8: Cone-and-plate rheology data for rAlbumin samples along the time exposed to 60
◦C, up to 28 days. (a) 200 mg/mL rAlbumin samples. (b) 20 mg/mL rAlbumin samples.
Following from the discussions and conclusions of the previous chapters in this
thesis, and from literature evidencing the effect of PS-80 in the rheology of globular
protein solutions [74, 143], the results shown here point to the fact that this non-ionic
surfactant was responsible for the Newtonian-like behaviour observed for the rAlbumin
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samples at the initial time point. In the case presented here and based on the literature,
we assumed that the PS-80, being a surface active molecule, would out-compete the
albumin species to the air-water interface present when using the cone-and-plate. In
our data, after protein aggregation was induced by increased temperature, the fact that
the rheological profile showed a change to an apparent yield stress behaviour could
be an indication that the surfactant was not enough to prevent the protein species
from reaching the air-water interface. It remained uncertain whether this change was
caused from presence of protein aggregates or solely albumin species partially unfolded,
exhibiting higher areas of hydrophobic patches. Further studies should follow in order
to determine this effect.
The change in rheological behaviour, from the apparent yield stress behaviour to a
shear thinning behaviour was attributed to the higher levels of aggregation. Visually,
the samples exposed to 60 ◦C after 28 days did evidence signs of gelation. From the
literature, it is known that albumin can create gels after thermal stressing [61, 212].
These properties have been discussed to originate from the formation of aggregates,
which create an inter-particle network [210].
Also present in this formulation buffer was NaCl, at 145 mM, which could also
impact on the rheological results. Recalling results from Chapter 3 regarding the
dilution of rAlbumin solutions provided from the commercially available stock into
a 145 mM NaCl only buffer, showed that the apparent yield stress properties were
increasingly evident with higher dilution of these solutions. As the concentration of salt
was maintained in the studies in that chapter, the presence of PS-80 and protein were
gradually reduced as the dilutions progressed. It was clear that there was tendency
towards an apparent yield stress rheological profile at the lower shear rates in these
solutions, and it was suggested that it was this difference that mainly contributed to the
changes observed in rheology. The study shown in the present chapter aims to support
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this suggestion, by showing that after a 3 days at extreme thermal stress, the effect
of PS-80 on surface activity was no longer seen on the rheology of such rAlbumin samples.
6.3.2 Part II - Novel use of polyPEGMA brush-type polymers as ad-
ditives in protein solutions and their effect in rheology
In this section we describe the synthesis and use of polyPEGMA brush-type polymers
as additives in protein solutions. As mentioned earlier, the aim was to synthesise homo-
polymers poly[poly(ethylene glycol) methyl ether methacrylate]. Two compounds were
synthesised aiming for a 10 000 Da molecular weight each, using as macromonomers
the PEGMA-475 and PEGMA-1100, both commercially available PEG-methacrylates,
differing only in the chain length.
It was discussed earlier that brush-like polymers based on PEGMAs can be stimuli-
responsive, with temperature as an example of a stimulus [201, 213]. The PEG chain
length has been shown to impart solubility limitations when it comes to temperature re-
sponse in aqueous environment, i.e. beyond a lower critical solution temperature (LCST)
the materials tend to precipitate [201]. This is an important factor to consider for our
purposes, since biopharmaceutical formulations are typically tested for protein stability
at high temperature (40 ◦C) and for long periods of time. Therefore, it was important
to avoid phase transitions that could affect the protein’s native state even though it is a
reversible event [201]. The macromonomers chosen here are known to have a high LCST
in aqueous conditions, well above 40 ◦C. The LCST of these compounds tends to increase
with chain length, e.g. LCST of PEGMA-475, estimated to be ∼90 ◦C [199, 201]. In
the case of PEGMA-1100, as it comprises 22-23 units of PEG versus its methacrylate
backbone, it remains soluble in water even at temperatures ∼ 100 ◦C [213].
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6.3.2.1 Synthesis and characterisation of polyPEGMAs
The synthesis of the brush-type PEG based polymers was performed by controlled
ATRP. The initiator for this synthesis, 2-bromo-2-methylpropionic benzyl ester (3),
was synthesised as shown in Figure 6.9, by acylation of benzyl alcohol (2) with
2-bromo-2-methylpropionyl bromide (1) at freezing conditions, as per similar reactions
described in literature [214]. The yield obtained was ∼63 %. Compound 3 was further
purified and dried to ensure it was free of solvents and at high purity. Its 1H-NMR














Figure 6.9: Scheme for the synthesis of ATRP initiator. 1 - 2-bromo-2-methylpropionyl brom-
ide; 2 - benzyl alcohol; Et3N - triethylamine; reaction conditions were dichloromethane (CH2Cl2)
and ∼0 ◦C; 3 - 2-bromo-2-methlypropionic benzyl ester; Et3NHBr - triethylammonium bromide.
The homopolymers poly[poly(ethylene glycol) methyl ether methacrylate] (5a
and 5b) were synthesised in presence of Cu(I)Br catalyst and the ligand PMDETA
(N,N,N’,N’,N”-pentamethyldiethylenetriamine) from polymerisation of monomers
PEGMA-475 (4a) or PEGMA-1100 (4b) [203, 208, 214]. The products were isolated
and purified as described in the methods, yielding highly pure homopolymers cor-
responding to compounds 5a (yellow viscous liquid) and 5b (white powder). For
simplicity, the two poly[poly(ethylene glycol) methyl ether methacrylate] polymers
synthetised will be referred in this work as polyPEGMA-475 or pPEGMA-475, and






























Figure 6.10: Scheme for the synthesis of poly[poly(ethylene glycol) methyl ether methac-
rylate] by ATRP. 3 - 2-bromo-2-methlypropionic benzyl ester; 4a - PEGMA monomer 475
g/mol; 4a - PEGMA monomer 1100 g/mol; reaction conditions were PMDETA (N,N,N’,N’,N”-
pentamethyldiethylenetriamine), Cu(I)Br, in toluene at 60 ◦C; 5a - polyPEGMA-475; 5b -
polyPEGMA-1100.
Synthesis of these brush-like homopolymers was carried out up to one hour, yielding
∼90 % conversion of monomer to polymer. Monomer conversion was calculated via
1H-NMR analysis of aliquots during synthesis. This estimation was made by comparing
the integration of the vinyl protons present in the monomer (δ = 5.71 and 6.31 ppm,
corresponding to one proton each) to the overall integration of protons corresponding
to the ester protons of monomer (δ = 4.41 ppm) and polymer (δ = 4.27 ppm).
1H-NMR analysis of both polymers evidenced peaks characteristic to the PEG
pendant chains (brush) of the polymer, at δ = 3.37 ppm (methoxyl protons, g) and δ
∼ 3.64 ppm (methylene protons, f (Figure 6.11) [204]. Another signal corresponding to
protons present in the PEG brush were δ = 4.07 ppm (e), the ester protons. From the
methacrylate backbone, the group of peaks in the range ∼0.6 - 1.2 ppm were assigned
to the methyl protons (d), and the range ∼1.78 - 2.1 ppm to the methylene protons (c).
The remaining peaks at δ = 7.30 ppm and 5.05 ppm, correspond to the aromatic (a)
and the benzyl protons (b), present in the end group present in each homopolymer.
The degree of polymerisation could be estimated from the 1H-NMR analysis of these
polymers. This was estimated by fixing the integration of the aromatic protons (a, in
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Figure 6.11) to 5, and integrating either the ester protons (e) or methoxyl protons (g).
By dividing integrations of e or g by 2 or 3, respectively, it was estimated that for
the polyPEGMA was constituted by polymerisation of 8-9 monomer units, and that






































































Figure 6.11: NMR spectra for poly[poly(ethylene glycol) methyl ether methacrylate]-1100.
Sample was dissolved in CDCl3.
The target MW for these homopolymers was at 10 kDa. HPSEC analysis, with
triple detection, was performed to characterise these polyPEGMAs in terms of their
purity, weight and intrinsic viscosity. Table 6.2 compares the calculated peak MW
(Mp), number-averaged MW (Mn), weight-averaged MW (Mw), polydispersity index
(PDI = Mw/Mn), and calculated intrinsic viscosity for the polymers analysed. The
synthesised polyPEGMAs were analysed on the same HPSEC system along with linear
PEG or PEO of Mp ranging from 1970 Da to 43580 Da. These linear PEG polymers
were compared to the polyPEGs regarding the intrinsic viscosity and MW.
From triple detection HPSEC analysis, the calculated MW for the polyPEGMAs
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was revealed to be quite similar, with the polyPEGMA-475 having slightly lower Mn
(∼10709 Da) compared to the poly-PEGMA1100 (∼10973 Da). This corresponded
to the expected MW target. The polydispersity index was relatively low for both
polymers, indicating a narrow range of polymer sizes. Since the PEG/ PEOs chosen for
analyses were of high purity grade for standard purposes (except for PEG 8000), it was
expected that these materials would exhibit a PDI of ∼1.0.
Table 6.2: Data obtained from HPSEC calibrated for triple detection with PEG/ PEOs of
standard quality (range 1970 - 43580). Mp - peak MW; Mn - number-averaged MW; Mw -
weight-averaged MW; PDI - polydispersity index, corresponding to Mw/Mn. 1 - PEG 8000 of
analytical grade, was the linear PEG used for protein solubility studies; 2 - polyPEGMAs were
analysed in triplicate, where data is reported as average and standard deviation; 3 - [η] values
obtained from analytical specifications of the PEG/PEO standards; 4 - [η] values calculated from
this analysis.
The intrinsic viscosities measured for polyPEGMA-475 and polyPEGMA-1100 were
0.0682 ± 0.001 and 0.1096 ± 0.002, respectively. In comparison to the linear PEG/PEO,
the [η] measured showed a linear increase with MW. polyPEGMA-475, although having
a similar molar mass to polyPEGMA-1100, was the analysed polymer which yielded
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the lowest intrinsic viscosity. As this physical parameter is dependent on the shape
and aspect ratio of the molecule, and in this case, all polymers were measured in a
good solvent and at the same temperature (∼25 ◦C), the overall shape/aspect ratio was
expected to be the variable changing between polymer. Although both polyPEGMAs
had a Mn ∼10 kDa, which is larger than the first three analysed PEG standards, the
brush-like shape of the synthesised polymers clearly translated in a difference in intrinsic
viscosity. Between the polyPEGMAs, it was clear from its [η] value that the shorter
PEG chains of 475 Da (brushes), would probably yield a compact molecule, compared
to the longer chains of 1100 Da. Even though these calculations were performed in
chloroform, a good solvent for these analysed polymers, it is assumed that the materials
should have similar tendencies when dissolved in water, another good solvent for PEG
and PEGMA polymers [199].
The relatively low MW and the lower intrinsic viscosities of the polyPEGMAs
were two important properties sought after for this study. If using these amphiphilic
polymers as potential additives in protein formulations, minor viscosity increase due to
its addition would be critical.
6.3.2.2 Study of the required concentration of polyPEGMA for the protein-
polymer blends
The study of a concentration range of polyPEGMAs to use with the protein solutions was
an important issue to address. Macromolecules such as PEG based polymers are known
to influence the solubility of biomacromolecules, such as globular proteins, particularly
forcing protein precipitation due to polymer-protein interactions in crowding solution
conditions [215, 216]. From another perspective, since homopolymers polyPEGMAs are
known for its self-assembly properties at aqueous conditions [199, 204], our additional
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criteria in terms of concentration limits was to prevent micellisation of this material in a
protein solution. By keeping the polymer concentration lower than its potential critical
micellar concentration, the single chain brush polymers would be available in solution
for possible inter-particle interactions, or if solely acting as amphiphiles, to be free to
interact with any potential interfaces. Moreover, this is a common practice when adding
polysorbates in biopharmaceutical formulations. For these two reasons, a protein ’solu-
bility’ test was performed with the polyPEGMAs, as well as an indirect assessment of
their potential critical micellar concentrations.
The technique chosen to determine the critical micellar concentration (CMC) was
an indirect method utilising a hydrophobic molecule (pyrene), which should preferably
stay at the hydrophobic core of a micelle once it is formed in an aqueous solution [190].
The guest probe pyrene has been studied for this purpose since changes in its polar
enviroment can be easily measured through its fluorescence emission. The intensity of
its peaks change accordingly to the change in pyrene’s local environment, and the fluor-
escence intensity ratio between its first (λ ∼373 nm) and third peak (λ ∼383 nm) is
typically reported. The higher the ratio (measuring in fluorescence emission intensity)
the more polar the environment is. The hydrophobic cores of micelles should contribute
to high solubility of pyrene therefore allowing detection of micellisation [190].
For comparison purposes and to guarantee that the chosen technique details were
adequate, detection of polysorbate-80’s CMC was made (Figure 6.12). From the figure,
the data showed that at lower concentrations of polysorbate the intensity ratio of peaks
I and III was higher, whereas from polysorbate concentrations higher than 10 µM the
ratio was reduced. Polysorbate-80 reported CMC is ∼10 µM, with which our data is in
agreement [190]. The change in this ratio was visually detected in the fluorescence emis-
sion scans (λexcitation = 342 nm), where the third peak increased its emission intensity
(Figure 6.12 inset graph, arrow pointing at ∼383 nm).
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Figure 6.12: Determination of critical micellar concentration of polysorbate-80 by guest probe
pyrene emission fluorescence intensity. The large graph refers to the ratio between intensities of
peak I and III for pyrene, at λ ∼373 nm and ∼383 nm, respectively. The inset graph shows the
fluorescence emission scans from 360 to 400 nm. Arrows are pointing to the peaks I and III.
The polyPEGMA polymers were also subjected to this experiment, but yielded
completely different results. From Figure 6.13, it was concluded that these polymers did
not seem to micellise at these experimental conditions (water, at room temperature).
The intensity ratio measured, throughout the range of concentrations used (0.01 - 5
mg/mL), suggested that pyrene was always present in a polar environment. According
to literature, micellisation of similar polyPEGMA homopolymers should occur promptly
at aqueous environment and at room temperature [204]. However, the materials dis-
cussed in Hussain et al. (2008) although homopolymers composed of the same 475 and
1100 Da monomer units, and of similar MW, have a short chain poly(ethylene glycol)
end group, which could contribute differently to its self-assembly.
From tensiometry studies, it was possible to measure the surface tension
polyPEGMA-475 at 1 mg/mL, at the air-liquid interface. In a 1 mg/mL aqueous
solution, polyPEGMA-475 at 1 mg/mL had a surface tension of 56.6 ± 0.18 mN/m,
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having a similar surface tension at the same concentration in 10 mM His-His.HCl pH 6.0
buffer (55.6 ± 0.19 mN/m). Filtered (0.22 µm) pure water and filtered (0.1 µm) buffer
had surface tension values of 72.9 ± 0.14 mN/m and 73.0 ± 0.34 mN/m, respectively.
Since no significant change was observed in the polymer’s surface tension in water vs.
buffer, it was concluded that the polymer would not micellise at buffer conditions. The
fluorescence emission spectra for this experiment is shown in Figure C.5 in Appendix C.
Therefore, these polymers were proven to be surface active at the air-liquid interface,
but did not seem to micellise readily at room temperature in water. From this study a
limitation in concentration could not be derived.




























Figure 6.13: Determination of critical micellar concentration of polysorbate-80 by guest probe
pyrene emission fluorescence intensity. The graph refers to the ratio between intensities of peak
I and III for pyrene, at λ ∼373 nm and ∼383 nm, respectively, and compares data obtained for
polyPEGMA-475 and polyPEGMA-1100.
The mAb and β-LG apparent solubilities were studied by testing if the protein would
precipitate using a linear polymer (PEG 8000) and our synthetic polymers. In theory,
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as the polymer concentration increases, the protein should have lower free volume
and protein self-assembly should eventually lead to its own precipitation [215, 217]. A
micro-plate technique adapted from ref. [217] was chosen for this assessment. Solutions
were all in buffer conditions and the test was conducted at 25 ◦C, since these would be
the same conditions for the rheology experiments.
As with the pyrene probe studies, apparent solubility of mAb and β-LG solutions
were first prepared in presence of increasing concentrations (% w/w) of PEG 8000.
From literature, it has been shown that using PEG of MW up to 6000 can yield different
results, however from that MW onwards, the globular proteins seem to precipitate in
presence of the same PEG concentration, regardless of chain length [215, 216]. When
there a decrease of protein concentration, precipitation occurred and it is the slope
of the linearity in that decrease which is often reported as the protein’s ’apparent
solubility’ [215,217].
Figure 6.14(a) shows this assessment for β-LG solutions. Comparing the results
between the different polymers, it was observed that β-LG precipated at ∼8 % w/w
of PEG 8000, while its concentration only started decreasing from ∼10 % w/w of
polyPEGMA-1100 and from ∼13.2 % w/w of polyPEGMA-475. From Figure 6.14(b)
this comparison did not produce significant changes across the polymers used, where
these did not induce precipitation of the mAb.
The polymer concentrations identified to induce protein precipitation (or even just
opalescence) were determined as a maximum polymer quantity in solution that could
be used for further studies.
Although it is not reported that PEG and PEG-based materials should absorb at
280 nm, the solutions of polyPEGMA only were analysed for its UV-visible absorption
and any residual absorbance at this wavelength was subtracted (see Figure C.4 in
290


















































Figure 6.14: (a) β-LG and (b) mAb ’apparent solubility’ assessment in the presence of increased
concentrations (% w/w) of PEG 8000 and the synthesised polyPEGMAS (-475 and -1100). The




6.3.2.3 Characterisation of protein-polyPEGMA blends
β-LG and mAb solutions, at ∼68 and ∼100 mg/mL concentrations respectively, were
blended with three chosen concentrations of each polyPEGMA at: 1, 10 and 25 mg/mL.
Even though the [η] values of polyPEGMAs were demonstrated to be low in comparison
to a linear polymer, there would be no interest in increasing its concentration in these
blends to avoid the risk of increasing of overal sample viscosity.
The samples were prepared and characterised on basis of its size distribution by
DLS, its level of aggregation by HPSEC, and for its rheology.
The polymer in buffer solutions were analysed upon UV-visible spectrometry to
check for consistency in their preparation. Absorption maximum peaks at ∼230 and
∼258 nm were identified.























 pPEGMA-475 1 mg/mL
 pPEGMA-475 10 mg/mL
 pPEGMA-475 25 mg/mL
 pPEGMA-1100 1 mg/mL
 pPEGMA-1100 10 mg/mL
 pPEGMA-1100 25 mg/mL
~230 nm
~258 nm
Figure 6.15: UV-Vis spectrum for polyPEGMA solutions in buffer.
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In parallel to the DLS data measured from 1 mg/mL (to protein concentration)
of each sample, the mean HD were measured for each of the polymer only solutions
(Figure 6.16). From both Figures 6.16(a) and 6.16(b) the data suggested that be-
sides a main peak present in the intensity distribution, other populations of higher
HD were present at any of the concentrations studied. However, these larger sized
populations constituted a low relative percentage of total sample, as per observed
by volume distribution where the main peak had HD towards the lower sizes (∼4 - 5 nm).
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Figure 6.16: Hydrodynamic diameter size by intensity distribution (large graph) and volume
distribution (inset graph) of polyPEGMA solutions in buffer. (a) DLS data for polyPEGMA-475
solutions; (b) DLS data for polyPEGMA-1100 solutions. All measurements taken at 25 ◦C.
A comparison of our data to the literature showed that the HD at ∼4.48 - 5.24 nm
and ∼4.81 - 5.89 nm, for polyPEGMA-475 and polyPEGMA-1100, respectively, corres-
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ponded to the single chain sizes [204]. The larger sized scatterers detected by intensity
distribution, were most likely self-assembled micelles of the polyPEGMAs [204]. Their
heterogeneity and presence at low fraction in solution, would explain why it was not
consistently possibly to detect these material’s CMC by the guest probe technique.
Within each polyPEGMA’s DLS data, the increase in concentration seemed to pro-
duce a narrower main peak at volume distribution suggesting lower presence of larger
sized scatterers. Between the two polyPEGMAs, the hydrodynamic diameter size corres-
pondent to single chain was slightly within the same range size, possibly due to similar
MW even though the PEG-chain length was higher with polyPEGMA-1100.
The mAb-polymer blends presented consistent values for both intensity and volume
distributions, where only the peak attributed to the mAb monomer-dimer equilibrium
was detected at a HD ∼ 11 nm (by intensity distribution). By diluting the protein-
polymer samples, the detection by light scattering of single chain polymers or possible
self-associative polymer species was not possible. However, for the β-LG-polymer blends,
higher diameter-sized populations were detected, although the original β-LG sample
evidenced peaks at the similar size range. The results shown here were consistent to ob-
servations on DLS measurements of filtered (0.1 µm) β-LG samples discussed in chapter
4). These results also demonstrated that after filtration (0.22 µm) protein aggregates
were always detected. DLS data are reported in tables summarising the mean peaks
HD by intensity and volume distribution measured for the polyPEGMA buffers and
β-LG-polymer blends (Tables C.3 and C.4).
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Figure 6.17: Hydrodynamic diameter size by intensity distribution and volume distribution of
polyPEGMA and protien blends. (a) data for blends with polyPEGMA-475; (b) data for blends
with polyPEGMA-1100. All measurements performed at 25 ◦C.
As well as with DLS data, the HPSEC analysis of these protein-polymer blends
proved to show no differences between the blends and the protein only sample. The
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chromatograms of β-LG and mAb blends with polymers showed the same peaks and at
similar retention times. Examples of chromatograms for the studied blends are shown
in Figure C.3 in Appendix C. Tables 6.3(a) and 6.3(b) summarise this HPLC data,
where the relative mean peak areas (in %) showed consistency throughout the β-LG
and mAb samples, respectively.
Table 6.3: Tables summarising the HPSEC peak area relative percentage for (a) β-LG and (b)
mAb blends with polyPEGMAs.
(a)
(b)
The protein-polymer blends, as well as the polymers solutions in buffer, were
measured on a CP rheometer and on mVROC. The polyPEGMA solutions in 10 mM
His-His.HCl pH 6.0 buffer had a Newtonian-like behaviour throughout the range of
applied shear rates (Figure 6.18. The values measured with CP at shear rates ∼600-1000
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s−1 are close to the values measured with mVROC, with no significant change (see
Table C.5).
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Figure 6.18: Cone-and-plate and mVROC rheology data for buffer and polyPEGMA solutions
in buffer. Large graph - polyPEGMA-475 samples; inset graph - polyPEGMA-1100 samples.
The cone-and-plate (CP) experimental data are circles (sweep down) and respective lines (sweep
up). mVROC data are represented in crosses/pluses (average of triplicate measurements with
error bars as standard deviation. Measurements performed at 25 ◦C.
Rheology data for the β-LG-polyPEGMA blends showed that adding these poly-
mers to this protein solution (at ∼68 mg/mL), did not change the protein’s original
rheological profile (Figure 6.19(a)). At low shear rates, yield-like behaviour was still
dominant. With increased concentrations of added polyPEGMA-475, the viscosities at
low shear rates (0.01 - 1 s−1) had a slight decrease when compared to the protein only
solution. However, the data with polyPEGMA-1100 did not show the same tendency.
At higher shear rates (>100 s−1), the samples typically showed a tendency towards
constant viscosity. The viscosity values at high shear rates (∼600-1000 s−1) were very
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similar to the viscosities measured by mVROC, with the latter showing slightly lower
values (∼0.2-0.3 mPa.s difference).
299














 β-LG + pPEGMA-475 1 mg/mL
 β-LG + pPEGMA-475 10 mg/mL





















 β-LG + pPEGMA-1100 1 mg/mL
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 mAb + pPEGMA-475 1 mg/mL
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Figure 6.19: Cone-and-plate and mVROC rheology data for (a) β-LG and polyPEGMA blends,
and (b) mAb and polyPEGMA blends, both in 10 mM His-His.HCl pH 6.0 buffer. Large graphs
- polyPEGMA-475 samples; inset graphs - polyPEGMA-1100 samples. The cone-and-plate (CP)
experimental data are circles (sweep down shear rates). mVROC data are represented as crosses/
pluses (average of triplicate measurements with error bars as standard deviation. All measure-
ments were taken at 25 ◦C.
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For the mAb-polymer blends, a noticeable change in these sample’s rheological
profiles was observed (Figure 6.19(b)). Between the mAb sample (∼100 mg/mL) and
the mAb plus polyPEGMA at 1 mg/mL (both -475 and -1100), no major differences
were observed at low shear rates, where a yield-like behaviour was prominent. However,
for both polymers, the increase of its concentration to 25 mg/mL led to a change in the
flow properties towards a Newtonian-like behaviour. This was evident with addition
of polyPEGMA-475 at 25 mg/mL. The intermediate concentration of polyPEGMAs
at 10 mg/mL produced different results at low shear rates. Nevertheless, the values
of viscosities of the blends when the polyPEGMAs had their concentration increased,
showed a tendency to increased viscosities. This was valid for all blends with each of
the proteins.
In general, the rheology data showed that only when adding 25 mg/mL of poly-
PEGMAs, an effect could be observed on the rheology of the studied protein solutions.
Considering the data discussed in previous chapters, and in the previous Part I of the
present chapter related to the effects of polysorbate-80, we suggest that it is the surface
tension of the solution’s components what dominates the rheological response at the
lower shear rates. The differences observed between the flow properties of β-LG and
mAb to the presence of the amphiphilic polyPEGMAs may well be related to each of
these protein’s own surface-activity and its difference to the polymers surface tension
at the air-liquid interface. However, possible interactions between the proteins and
polymers could be considered, without involving the same thermodynamic mechanisms
involved in surfactant-protein competition at air-liquid interfaces. Although it has been
shown that brush-type copolymers of PEGMA have the tendency of repel interaction
with proteins [207], to our knowledge no studies towards protein and homopolymer
polyPEGMAs have not been made. Moreover, the PEG side-chain length could play an
important role, since it confers higher hydrophilicity to the polymer [213]. This would
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explain the difference in the behaviour noted between mAb + polyPEGMA-475 at 25
mg/mL and mAb + polyPEGMA-1100 at the same concentrations. Therefore, further
work would be needed towards understanding what possible underpinning interactions
could be involved between these chosen proteins and the polyPEGMAs synthesised
here.
The effects of using relatively low MW brush-polymers, yielding low intrinsic
viscosities compared to linear PEG polymers, were noted on the rheology since only at
the highest concentration of polyPEGMAs a change in the flow behaviour was observed
(difference ∼1 mPa.s). Protein samples (both β-LG and mAb) added with 1 mg/mL
of either polyPEGMA had virtually no increase in solution viscosities (when γ˙ ∼1000
s−1), with an addition of 10 mg/mL yielding a viscosity difference of < 0.5 mPa.s.
6.4 Conclusions
This chapter presented studies with its aims following from the investigations discussed
throughout this thesis. In the first part we aimed to further understand the role of PS-80
in protein solution rheology, by exploring the changes in flow behaviour along a time
period after thermal stressing. In the second part, synthetic brush-type PEG-based
polymers were used for their amphiphilic properties to explore their potential at
reducing the yield behaviour exhibited by globular protein solutions, at low shear rates.
By stressing formulated rAlbumin solutions at 60 ◦C, it was observed that after
14 days, the protein had aggregated highly, culminating in formation of a gel after
28 days at 60 ◦C. Since gelation of albumin solutions have been demonstrated to
happen at such temperature conditions but in faster rates [61,210], it can be concluded
that the additives present in this rAlbumin formulation were effective in delaying
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the protein’s degradation and aggregation, in agreement with literature [218]. In
terms of the rheological aspects, this gradual protein degradation was observed by a
change in flow properties which started as Newtonian-like fluids (non stressed samples),
showing increased yield-like behaviours (after 7 days at 60 ◦C), followed by signs of
shear-thinning.
To contribute to these findings, we recall the experiment in Chapter 3, where dilution
of a stock formulation was made with 145 mM NaCl buffer. At these conditions, while
the concentration of protein and polysorbate-80 were being diluted, its rheology showed
that a yield-like behaviour was emerging, coinciding with reports in literature [143].
Again, as with the mAb solutions studied in Chapter 5, it is assumed that the
aggregated material increases in its complexity throughout the time of the study, not
only in terms of protein species contents, but also possible degradation products of
the excipients involved could also influence the rheology data. As mentioned earlier,
and according to literature, it was expected that at 60 ◦C polysorbate-80 would
degrade by hydrolysis and oxidation, which could have effects on the rheology by
consequently reducing the capability of this surfactant to out-compete the protein at
the air-water interface [189]. Nevertheless, it is suggested that it was due to the level
of rAlbumin aggregation that should have mostly contributed to the change of phase of
this material, in agreement with other literature concerning human serum albumin [210].
Regarding the second part of this chapter, synthetic brush-type polyPEGMAs
(polyPEGMA-475 and polyPEGMA-1100) were used as additives in protein solutions
(β-LG and mAb, individually), with the aim of exploring their amphiphilic properties
and effects on shear rheology. The study did not involve any thermal aggregation,
instead it focused only on the use of these polymers in protein blends at room temper-
ature. Following from the first part of this chapter, using conventional rheometry with
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a cone-and-plate where an air-water interface is present, the rheology measurements
revealed to be an indirect way to evaluate the surface activity of these polymers in
comparison to polysorbate-80.
The polymers were studied for their capability of self-assembly, which was shown
by DLS that it possibly occurs at low concentrations (1 mg/mL), although through
indirect determination by fluorescence of pyrene as a guest probe, the CMC was not
identified. Based on HPSEC triple detection, measurement of these polymers’ intrinsic
viscosity yielded low [η] values when compared to linear PEGs of similar MW. For
protein ’apparent solubility’ studies, where it was expected that only excluded-volume
play a role, the polyPEGMAs caused each of the proteins to precipitate at higher
concentrations of polymer compared to PEG 8000. This corroborated with results
from [η] determination - lower aspect ratios would cause lower excluded volume effects.
Finally, the analysis by aqueous HPSEC for protein purity showed that the presence
of these materials did not alter the protein level of aggregation when compared to the
polymer-free samples.
Rheology experiments showed that the increase of polymer, particularly at 25
mg/mL, did result in a slight increase of overall solution viscosity at the higher shear
rates. At low shear rates, the three concentrations used of polyPEGMAs (1, 10 and
25 mg/mL), showed different results depending on the protein used in the mixture.
For β-LG solutions, the rheological profiles remained to be yield-like, throughout the
concentrations of added polyPEGMA. For mAb solutions, only the addition of 25
mg/mL of polyPEGMA-475 markedly changed the protein solution’s flow behaviour
from showing an apparent yield to constant viscosities throughout the applied shear
rates. The polyPEGMA1100 at 25 mg/mL showed a similar result, although did not
fully show a Newtonian-like behaviour.
We suggest that the reason for this could be with the different surface-activity of
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each of the proteins, where it is known that β-LG forms strong elastic films at the
air-water interface [167]. Therefore, although the polyPEGMAs are surface active
amphiphilic materials, their surface activity might not reach such low surface pressure
as those from these proteins, or even if compared to polysorbate-80.
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Chapter 7
Conclusions and future work
7.1 Conclusions
7.1.1 The effect of protein concentration on the viscosity of a recom-
binant albumin solution formulation
In this work, a range of rAlbumin solutions, in a formulated buffer containing salt and a
surfactant, were analysed for their rheological behaviour with the aim of understanding
the effects of high protein concentration on the solution viscosity. Rheological measure-
ments showed that the solutions (∼0.1 - 500 mg/mL) behaved as purely viscous fluids
in the range of the applied shear rates. It was observed an increase in viscosity as the
protein concentration was increased in solution.
Characterisation with regards the level of aggregation and species size proved that
concentrating the rAlbumin had the effects of increasing solution viscosity and the
change in relative composition of protein species.
The rAlbumin viscosity data was fitted using theoretical models known to predict
suspension viscosity, which have been applied to protein solution rheology. Based on
the shape or aspect ratio of particles and its packing fraction (or concentration), these
equations are applied to hard spherical or quasispherical particles [153,159], and account
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for interparticle distance [156]. However, these models did not predict successfully the
viscosities for the entire range of rAlbumin concentrations.
The most successful viscosity predictions, up to 400 mg/mL, were obtained when
using generalised versions of the original models [136, 137]. These revised equations
introduce the concept of a weight-averaged intrinsic viscosity, allowing for its applic-
ation to suspensions containing known concentrations of multiple particles of varying
shape. Our results further highlighted the importance of considering this variation
in composition within a protein solution, thus justifying its complete characterisation
of oligomeric species. To our knowledge, no other analysis typically accounts for this
variation within a sample containing one protein.
These recent generalised models assume that the jamming limit remains unaltered
with changing composition. However, since the highest concentrations (450 and 500
mg/mL) were not computed with these fits, it may well be that at such concentrations
this jamming limit may change. At such high concentrations, close to predicted
jamming limits, other crowding effects such as protein-protein interactions should be
also considered into these models. This possibly leaves space for these considerations to
be accounted for in future theoretical models to be developed.
The simple model of rAlbumin was studied as an example of a ’real-life’ biophar-
maceutical formulation at high concentrations and to explore successful predictions
of its solution viscosity. To be able to predict the effect of high concentrations (e.g.
400 mg/mL) of a monoclonal antibody based on species shape/ aspect ratio and its
contents, is an ultimate goal in this field. However, this does not exclude the possibility
of existing complex flow behaviours of protein solutions at high concentrations, or
additional physicochemical variables related to protein degradation. Nevertheless, the
application of these generalised models to biopharmaceutical formulation is important,
as the need for developing protein drugs at high concentrations has been a demanding
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parameter [5, 8]. Our results highlighted that the number of protein species, and its
variation in composition, are key factors for predicting the solution viscosity of protein
solutions.
7.1.2 The effect of insoluble protein aggregates on the rheology of beta-
lactoglobulin solutions
β-LG excipient-free solutions were characterised by bulk and interfacial shear rheology.
Solutions at various concentrations, characterised using conventional rheology instru-
mentation, evidenced an apparent yield stress behaviour at a low shear rate range (0.01
- 10 s−1), whilst showing constant viscosities throughout higher shear rates. Comparing
interfacial shear rheology, air-water interface-free bulk viscosity measurements, and
tensiometry results, it was demonstrated that the observed yield-like behaviour was
due to the formation of a protein viscoelastic film at the air-water interface, as present
in conventional rheometry. Further application of theoretical equations to our data,
concerning this yield-stress at lower shear rates, evidenced that our results were in
agreement with literature. In addition, the results highlighted the importance of taking
in account the presence of air-water interface in conventional rheology measurements
of excipient-free protein solutions. In this practical perspective, the results contributed
to a better understanding of rheological measurements of such samples, when using
conventional rheometry (e.g. cone-and-plate), being such a commonly used instrument-
ation to evaluate the rheology of biopharmaceutical liquid formulations.
Our detailed results add to recent findings [78] in the extent that this hypothesis
was applied to another globular protein model. This brings emphasis to the broad
application of this knowledge to protein solution rheology, in particular by applying to
the study of therapeutically relevant proteins such as monoclonal antibodies.
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Further studies considered the effect of insoluble β-LG aggregates on the solutions’
rheology, linking with their characterisation in size and quantification. The presence
of insoluble proteinaceous particles was suggested to have an impact on the solution’s
flow behaviour, particularly at the lower shear rates. These findings highlighted that
the content in protein species and their size characteristics of a protein solution are
key factors to understand correctly and realistically evaluate its rheology. Moreover,
the results emphasized the importance of understanding and interpreting better these
measurements of protein solutions, looking at the widest range of shear rates possible,
taking advantage of complementary rheometry instrumentation (e.g. mVROC besides
the conventional rheometer), to extract useful information obtained throughout this
range.
7.1.3 The rheology of a monoclonal antibody solution: a case study
on the effect of aggregation of a model monoclonal IgG1 on its
solution rheology
Since the monoclonal antibody was provided formulated, several steps were performed
not only to extract the excipients from this solution but to confirm similarity between
batches of this macromolecule’s excipient-free solutions. These were proved to have no
evident difference between them.
The rheological response of the excipient-free mAb solutions, was similar to the re-
sponse of β-LG samples: a yield-like behaviour at low shear rates was present, when
using cone-and-plate or double-gap geometries. These observations highlighted the com-
mon features regarding this characterisation, observed across globular protein solution
rheology, indicating that similar factors (e.g. macromolecule’s surface-activity) were un-
derpinning this type of sample’s flow properties.
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With the mAb solutions (not thermally stressed samples), the presence of insoluble
protein particles was suggested to have a pronounced effect on the solution’s flow be-
haviour at the lower shear rates, revealing a drop in viscosities. By thermally stressing
the mAb samples at 40 ◦C, throughout a period of 6 weeks, the materials showed higher
viscosities overall, but particularly was evident at the higher shear rates (∼600 - 1000
s−1). However, their flow behaviour remained similar - still observing yield-stress at
low shear rates (0.01 - 10 s−1). Although relationships between computed yield values
along sample time points were attempted, the hypothesis that the presence of generated
protein aggregates (soluble and insoluble) do contribute to this yield-like behaviour re-
mained unanswered. However, judging by quantifications made of the different types of
aggregates (by size/ soluble/ insoluble), it was suggested that for this mAb, the large
increase of soluble aggregates (detected by HPSEC and DLS) may have contributed the
most to the increase of protein viscosity. Further analysis of the mAb’s different species
formed during this study revealed that for this particular case, its aggregation behaviour,
i.e. aggregate reversibility, yielded implications in accurately quantifying these species.
The aim of studying mAb solution rheology under these extreme conditions, using
orthogonal characterisation biophysical techniques, allowed an analysis at the molecular
level to a detail that focused on variables commonly dismissed in the study of protein
solution rheology.
7.1.4 Exploring the impact of surface active macromolecular excipients
on the flow properties of protein solutions
Since it was observed, and supported by literature, that the yield-like behaviour at low
shear rates on CP or DG rheology were likely to be related to protein surface-activity,
it was then investigated the role of a non-ionic surfactant (polysorbate-80) commonly
used in protein formulation. Indeed, the role of PS-80 in suppressing yield behaviour in
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these measurements was observed in Chapter 3. In this chapter, however, formulated
rAlbumin samples were stressed at 60 ◦C. In comparison to the previously discussed
mAb study, thermally stressed rAlbumin samples evidenced a change of rheological
behaviour throughout the period of time - starting as Newtonian-like fluids (non
stressed samples), showing increased yield-like behaviours (after 7 days at 60 ◦C), and
followed by signs of shear-thinning at the end of the study. This was suggested to be
mostly related to the observed aggregation of albumin [212], and the loss of PS-80’s
competitive mechanisms at the air-water interface [189].
In another take of the findings reported so far, a study was also developed
to use synthethic poly[poly(ethylene glycol) methyl ether methacrylate] polymers
(polyPEGMA-475 and polyPEGMA-1100), with amphiphilic properties, to investigate
their potential effects in protein solution rheology, in a similar perspective as the
observed role of PS-80.
After polymer characterisation with 1H-NMR and HPSEC, studies for polymer
self-assembly and protein-polymer crowding effects were performed. The aim was to
establish concentration limits when adding the synthetic macromolecules to the chosen
protein solutions (β-LG and mAb). The physicochemical properties of the polymers,
measured directly (MW and intrinsic viscosity) or indirectly (e.g. CMC determination),
helped understanding the rheological results obtained for the studied protein-polymer
blends. The results suggested that a change in flow behaviour, from the typical
yield observed on excipient-free protein solutions, could only be suppressed towards
a Newtonian-like behaviour if higher concentrations of the polymers were used - this
was observed when mixing with a ∼100 mg/mL mAb solution. The almost unchanged
yield-behaviour observed with the ∼68 mg/mL β-LG blends highlighted the importance
of having sufficiently surface-active additives present in formulations to minimise the
yield-like behaviour, since this protein is known to rapidly form strong elastic films at
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the air-water interface [167].
Overall, this chapter’s results highlighted the importance of understanding the un-
derpinning molecular interactions governing protein solution rheology, by relating these
to commonly used excipients in protein formulations and their possible mechanisms of
action.
7.2 Future Work
Regarding the effect of concentration on the viscosity of protein solutions, it was
clear that current theoretical models are simplified to a point which its applicability
is no longer possible when concentrations reach higher values. Other factors at this
range (in the case of rAlbumin, >400 mg/mL) are suggested to be implicated in the
viscosities observed. These could involve protein-protein interactions, since the models
are ideally applied to hard spherical or other-shaped particles, assuming interparticle
repulsion [153, 159]. Further work should include investigations of the jamming limit
variations at high concentrations, which could also help develop applicable equations.
The study of mAb samples, in a way similar to ours, could also bring benefit partic-
ularly since mAb are typically relevant to biopharmaceutical formulations [5]. Direct
quantifications should be performed of PS-80 in the highly concentrated rAlbumin
solutions (> 200 mg/mL), to understand if there could be any potential effect on these
samples’ viscosity, species distribution and inter-particle interaction.
Overall, for the remaining chapters of this thesis, it was evident that surface-activity
of macromolecules (of bio or synthetic source) was an important parameter throughout
the presented discussions. Although tensiometry data was initially developed for
the β-LG samples, in parallel with interfacial shear rheology, further work would be
necessary to complement the data regarding the mAb and the surfactant/ polymer
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studies. In relation to β-LG and mAb data, one of the interests was to explore the effect
of protein aggregates present in solution could contribute to the air-water interface.
This would be most important regarding the mAb case-study and the effect of its
increasing protein aggregates during thermal stressing, on the samples’ interfacial
properties.
It is important to highlight that the results observed regarding the mAb study were
markedly related to this molecule’s specific properties [183]. Knowing that mAbs are
engineered for specific pharmacological targets this can yield individual particularities
concerning their properties [1, 219]. Thus, it is largely assumed that studies concerning
mAb samples are usually a case-to-case scenario. Based on the rationale presented
here, studying other mAbs could be of benefit to explore common underpinning factors
involving their aggregation behaviour and its effects on mAb solution rheology.
The results related to the role of PS-80 in biopharmaceutical formulations, in
a rheological perspective, could be basis to investigations concerning therapeutic
proteins formulated in other commonly used excipients. In the case of PS-80, due
to its mechanism of action in competing with proteins at the air-water interface,
this was indirectly observed via our data. Other excipients could also be of interest,
such as arginine, shown to markedly reduce the viscosity of high concentration mAb
solutions [6] and to be implicated on the protein’s surface-activity via preferential
hydration among other mechanisms of interactions [44]. Once more, it is emphasised
the importance of studying throughout the largest shear rate range possible, preferably
considering the lower shear rates (0.01 - 10 s−1) where the yield-like behaviour observed
for excipient-free protein solutions.
Suggested future work concerning the synthetic brush-like polyPEGMA homo-
polymers, would be mostly focused on polymer structure. For example, still using
PEG side-chains of low MW but taking into account the LCST of the monomer used,
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would enhance the hydrophobicity of the polymer, but possibly restricting to the use of
PEGMA-475 would be the best option. The initiator used could be changed towards
fine tuning the surface-activity of the single-chain brush polymers [204]. In terms of
polymer MW, keeping to low degrees of polymerisation, thus low MW (∼8 - 10 kDa)
would be ideal to maintain the low intrinsic viscosity values observed here. However,
the steric hindrance present in polyPEGMAs of low MW could be a problem [199].
Synthesis of PEG-brush copolymerised with other monomers containing different
moieties or creating copolymer of mixed length PEG side-chains, could be considered
to fine-tune the macromolecule’s hydrophilic - hydrophobic balance. Desirably, these
architectures should be designed to benefit of hydrophilicity, low MW, minimum steric
hinderance between side chains, low intrinsic viscosity, non-ionic surface-activity yield-




A.1 β-LG size exclusion chromatogram
Figure A.1 is an example of a size-exclusion chromatogram of a 10 mg/mL injection of
β-LG. The peak at ∼ 10.4 minutes represents the dimer of β-LG at a approximate 98-99
% peak area and the peak at ∼9.2 minutes represents dimer aggregates at a roughly 1
% peak area [220]. The peaks shown between 12.5 and 15 minutes are correspondent to
the His-His.HCl sample buffer.
Figure A.1: β-LG high performance size-exclusion chromatogram. Peaks at 10.4 minutes
and 9.2 minutes corresponded to β-LG species, respectively, dimers and aggregates. The peaks
between 12.5 and 15 minutes were related to the sample’s buffer.
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A.2 mVROC data
Figure A.2 shows the shear stress values from a ∼68 mg/mL β-LG filtered solution
versus the sensor’s distance on the microfluidics channel of the chip used (A05) on the
instrument. The linear decrease of shear stress along the microchannel was seen at all
the flow rates (Q) applied to the sample and were considered valid measurements since
it’s r2 = 1.0. This plot represents an example of the raw data that was measured for this
sample and all samples while using the mVROC. Figure A.3 shows the mVROC results
obtained from all β-LG filtered solutions, measured in triplicate.
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Figure A.2: Distance of the A05 chip’s sensors versus the shear stress of a β-LG 68 mg/mL
sample on the mVROC. Each line corresponded to a flow rate Q imposed to the sample in the
syringe. The decrease in stress has a linear correlation of r2 = 1.
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Figure A.3: Rheology profiles of β-lactoglobulin samples obtained from mVROC experiments.
Protein samples were all previously filtered with 0.1 µm pore-size syringe filteres. Each sample
was measured three times. Error bars represent standard deviation. Measurements taken using
the A05 chip.
A.3 Calculation of ls
In section 4.3.1.2, regarding the calculation of Boussinesq shear rate dependency for each





ls depends on the dimensions of the measuring system since it is a ratio between Ab,
the area of a geometry in contact with the bulk of the sample, and Pi, the perimeter
of wetted geometry in contact with the interface. In the case of the cone-and-plate, As
corresponded to the lateral surface area of the cone (Figure A.4(a)). This measuring
system had a truncation, which was accounted for in our calculations shown below. The
Pi of the CP corresponded to the perimeter of a circle. Consequently, the ls(CP ) was
319














The known dimensions of CP are the cone’s angle (θ, 1◦), the radius (R, 25 mm)
and the truncation gap (h2, 0.104 mm), therefore computing ls(CP ) ≈ 0.0125 mm.
In the case of the double-gap, the As was a sum of the two lateral faces of the moving
bob (hollow cylinder) and the area corresponding to the thickness of the hollow cylinder
(Figure A.4(b)). The Pi was the sum of two perimeters, corresponding to the outer and








The dimensions of the double-gap were its immersed length (L, 40 mm), and the
outer and inner radius of the bob (Ro and Ri, 13.334 mm and 12.333 mm, respecitvely).







Figure A.4: Schematic side-view of the (a) cone-and-plate and the (b) double-gap measuring
systems. Dimensions correspondent to the letters in the figures are given in the text.
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A.4 Additional DLS data
The following figures and table summarise the data obtained using dynamic light scat-
tering to characterise various samples. In the main text, Figure 4.18 summarised the
results for the β-LG 68 mg/mL. Here, the remaining results are shown. All samples
suggest that filtration yielded a population of protein aggregates of lower hydrodynamic
diameter compared to the unfiltered sample (Figure A.5 and Table A.1).
The β-LG sample at 68 mg/mL was also compared regarding its size characterisation
between before and after the cone-and-plate and double-gap rheology. Results seen on
Figures A.6(a) and A.6(b) correspond to the unfiltered and filtered ∼68 mg/mL only
and respectively. Table A.1 shows the results for the relaxation times corresponding to
each of the populations detected, obtained from fitting the 2-term exponential decay
equation, which followed the data’s tendency (Equation A.4). All the fits had a r2 >
0.99.




















β-LG 10 mg/mL Unf.
β-LG 10 mg/mL Filt.
β-LG 35 mg/mL Unf.
β-LG 35 mg/mL Filt.
 fit β-LG 10 mg/mL Unf.
 fit β-LG 10 mg/mL Filt.
 fit β-LG 35 mg/mL Unf.
 fit β-LG 35 mg/mL Filt.
Figure A.5: Normalised correlation data from DLS for 10 and 35 mg/mL β-LG samples (hollow
circles) comparing between unfiltered and filtered solutions, and its respective 2-term exponential
decay fits (lines).
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 β-LG Unfilt. before rheology
 β-LG Unfiltered, after CP
 β-LG Unfiltered, after DG
 fit (Unfilt.; after CP)
 fit (Unfilt.; after DG)
(a)
















 β-LG filt. before rheology
 β-LG filtered, after CP
 β-LG filtered, after DG
 fit (filt.; after CP)
 fit (filt.; after DG)
(b)
Figure A.6: Normalised correlation data from DLS for 68 mg/mL β-LG unfiltered and filtered
solutions diluted to 1 mg/mL comparing between before and after rheology with cone-and-plate
and double-gap. The shown data (hollow circles) were fitted to a 2-term exponential decay
equation (lines).
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Table A.1: Table summarising DLS results of β-LG samples. 1 - all samples were measured
after dilution to 1 mg/mL and were not obtained after rheological measurements; 2 - results for
68 mg/mL sample (unfiltered and filtered) obtained after cone-and-plate rheology, and diluted
to 1 mg/mL; 3 - results for 68 mg/mL sample (unfiltered and filtered) obtained after double-gap
rheology, and diluted to 1 mg/mL; 4 - mean hydrodynamic diameter size and standard mean
obtained by intensity results from the DTS software; 5 - relaxation times were obtained from
fitting the 2-term exponential decay equations to the normalised correlation data, and are here
reported as its value with standard error.
A.5 Additional MFI data
Table A.2 summarises the reported results of β-LG samples and sample buffer in particle
concentration (#/mL), particle count, equivalent circular diameter (in µm) mean size
with standard deviation, and the size range of the detected particles. The samples were
read as unfiltered solutions and after filtration with 0.1 µm pore-size syringe filters. The
buffer was also analysed after filtration.
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Table A.2: Table with the final reported results from micro-flow imaging analysis of unfiltered
and filtered (0.1 µm) β-LG samples at 0.1, 10, 35 and 68 mg/mL. The table also includes data
for three separate measurements of the sample buffer, also filtered with 0.1 µm syringe filters.
Samples at 0.1, 10 and 35 mg/mL (unfiltered and filtered) were only read once. The unfiltered
and filtered samples at 68 mg/mL were analysed in three separate runs. 1 - Particle concentration
values were approximated to units; 2 - ECD is ”equivalent circular diameter”.
The figures below are an example of one frame and a few examples of sub-visible
particles detected for a unfiltered and a filtered ∼68 mg/mL β-LG (diluted to 10 mg/mL)
(Figures A.7 and A.8, respectively). Included in the figures are also its respective particle
size properties. Circularity represents the ratio of the circumference of an equivalent area
circle over the measured perimeter. The intensity parameter of a particle is expressed
in illumination intensity levels that are related to the bit depth supported by the digital
camera on the instrument. Intensity is dependent of the difference in refractive index
between formulation buffer and the particle. The aspect ratio is the ratio between the
longitudinal and transversal axis of the particle [39, 127].
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Figure A.7: Images and sizing properties of examples of particles detected with MFI for un-












B.1 Additional data on HPSEC
Table B.1 summarises the values obtained from HPSEC analysis of the 100 and 17
mg/mL mAb samples stressed at 40 ◦C and, as a control, from samples stored at 5 ◦C.
Figure B.1 represents some examples for the chromatograms obtained from the 100
and 17 mg/mL mAb. Typically, a non stressed mAb sample would elute such as what
is represented in the first chromatogram of this figure. After 2 weeks storage at 40 ◦C,
the 100 mg/mL mAb sample showed four peaks of high MW species (chromatogram
B, in the figure). The difference between the sample after 2 weeks and 6 weeks not
only was the increase in peak area of the higher MW species (with respective drop for
the monomer), but a shoulder peak on the tail of the monomer peak. This shoulder
was not always detected by the software. An example of this shoulder peak is given on
chromatogram D, from the sample 17 mg/mL at 40 ◦C after 6 weeks. Here, the high
MW species were only detected as two small peaks.
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Table B.1: Relative peak percentage of monomer, fragment and total aggregates detected by
HPSEC for a) 100 and b) 17 mg/mL at 40 ◦C and 5 ◦C during 6 weeks. Each sample was











































Figure B.1: HPSEC chromatograms of mAb solutions at different time points during thermal
stressing at 40 ◦C:A) represents the typical chromatogram of unstressed mAb solution, showing a
monomer peak (B), the higher molecular weight species (HMWS) peak (C), and a lower molecular
weight species (LMWS); B) corresponds to the 100 mg/mL mAb sample that was stressed for
2 weeks at 40 ◦C, where peaks B and C remained similar to T=0 but more HMWS peaks (A)
were identified; C) 100 mg/mL mAb after 6 weeks at 40 ◦C showing higher peak area percentage
for all detected HMWS (A); D) a 17 mg/mL mAb solution after 6 weeks at 40 ◦C, where only
two peaks of HMWS were detected but another LMWS peak was identified. The 100 mg/mL
mAb solutions here presented were diluted to 10 mg/mL, while the 17 mg/mL mAb solution was
injected neat.
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B.2 Additional MFI data for the mAb samples
Table B.2 gives the particle concentration, particle count, ECD mean size and its
standard deviation and the range of detected sizes per mAb sample analysed with
the MFI. Note that control mAb samples at both concentrations stored at 5 ◦C were
measured at the same time points. Also included in the table are the data for three
separate measurements of the sample buffer (10 mM His-His.HCl at pH 6.0).
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Table B.2: Table with the final reported results from micro-flow imaging analysis of 100 and
17 mg/mL mAb solutions for: unfiltered and filtered material; as well as a comparison between
aggregated and non-aggregated material along a 6 week period time. The table also includes
data for three separate measurements of the sample buffer, also filtered with 0.1 µm syringe
filters. mAb samples were only read once. 1 - Particle concentration values were approximated
to units; 2 - ECD is ”equivalent circular diameter”.
B.3 Additional data on the mAb rheology
The figures below show the superimposed CP and DG rheology data of mAb samples
through the time points after storage at 40 ◦C for 6 weeks. The larger graphs are focused
at the lower shear rates up to 100 s−1, whereas the inset graphs show the viscosities of
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these samples at the higher shear rates (Figures B.2(a) and B.2(b)).
















































(a) 100 mg/mL mAb samples













































(b) 17 mg/mL mAb samples
Figure B.2: Superimposition of cone-and-plate and double-gap rheology data looking in detail
at low and high shear rates of a) 100 mg/mL and b) 17 mg/mL mAb solutions aggregated for
6 weeks at 40 ◦C and analysed at 25 ◦C.
Figure B.3 is an example for fitting the Bingham model for yield-stress to the
experimental flow data (shear stress versus shear rate). Here represented are the
cone-and-plate and double-gap data from 100 mg/mL mAb solution after storage at
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40 ◦C at T=0 and T= 6 week. The yield points correspond to the y-axis intercepts of
the fitted linear functions. The calculated yield points and r2 values to the respective
regressions are summarised in Table B.3.








T=0 data ; T=6 weeks data
CP data
DG data 
 fit to Bingham eq. (T=0; DG)
 fit to Bingham eq. (T=6 weeks; DG)
 fit to Bingham eq. (T=0; CP)















Figure B.3: Example of fitting to Bingham equation for yield stress, for flow curves comparing
T= 0 and T= 6 weeks time point samples of 100 mg/mL mAb solution after thermal stressing
at 40 ◦C. Data obtained using both CP and DG geometries, and measured at 25 ◦C.
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Table B.3: Yield stress values calculated from fitting the Bingham equation for yield stress to
the experimental flow curves of mAb samples at 100 and 17 mg/mL, unfiltered and filtered, and
after thermally stressing these samples at 40 ◦C for 6 weeks. The yield stress values are reported
with its standard error from the linear regression. The values in brackets represent the fitting’s
adjusted R-squared.
B.4 Additional data on DLS
The correlation data for the mAb samples at 100 mg/mL and 17 mg/mL (after dilution
to 1 mg/mL) analysed on DLS are shown on Figure B.4. The data was fitted with an
exponential decay function (of one term only) and the relaxation time values obtained
from these fits are shown in Table 5.4 in the main text. For all the fits to the correlation
data, the r2 > 0.97.
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Figure B.4: DLS correlation data for the 100 and 17 mg/mL mAb solutions, diluted to 1
mg/mL for analysis, after aggregation at 40 ◦C for 6 weeks. The large graph shows data related
to the samples diluted from 100 mg/mL mAb solution, and the inset graph corresponds to data
from 17 mg/mL mAb solution. For each time point, the correlation data (circles) was fitted with
an exponential decay curve (lines) to find the correspondent relaxation times.
The data shown on Tables B.4(a) and B.4(b) correspond to the mean hydrodynamic
size by intensity and by volume for the mAb samples recovered after CP and DG
rheology, respectively. This data is represented on Figure 5.19 in the main text.
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Table B.4: Mean hydrodynamic size obtained by DLS for the 100 and 17 mg/mL mAb samples
(aggregated at 40 ◦C) after a) cone-and-plate and b) double-gap rheology. 1 - Data was obtained
by diluting samples to 1 mg/mL; 2 - mean hydrodynamic size by intensity distribution and
standard deviation of three measurements; 3 - mean hydrodynamic size by volume distribution
and standard deviation of three measurements.
(a)
(b)
Figure B.5(a) represents the HPSEC data of 10 mg/mL dilutions from the 100
mg/mL mAb sample (40 ◦C, T= 2.5 months) that was collected in parallel to the DLS
time sweep study of the same stock sample (see Figure 5.23). This was related to the
study of reversible aggregates present in the thermally stressed mAb samples at 5 ◦C
and 25 ◦C conditions. Note that at this point in time (2.5 months), the total HMWS
was ∼60 %, while monomer peak area was ∼40 %. This data is also a reference for the
µ-m-SDS-PAGE experiment, which made use of an aliquot of this aggregated material
for one of its control samples.
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Figure B.5(b) summarises the data obtained for the neat injections of 17 mg/mL at
40 ◦C at T= 7 weeks. The red data points were obtained while leaving the samples on
the HPSEC auto-sampler tray at 5 ◦C; while the green data points correspond to the
25 ◦C conditions.
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Figure B.5: Time sweeps relating the level of aggregation of diluted mAb solutions and the
effect of temperature - experiment conducted in parallel to similar time sweep performed with
DLS (dilution of 100 mg/mL mAb solution only). a) Corresponds to dilutions made from 100
mg/mL mAb sample, thermally stressed after T= 2.5 months at 40 ◦C. b) Corresponds to 17




C.1 Part I - The effect of thermal stressing of rAlbumin
solutions on its solution rheology
The following tables summarise the relative peak areas for the detected protein
species of rAlbumin samples exposed to 60 ◦C throughout a 4 week study (Table
C.1(a) and C.1(b)). Samples at 200 and 20 mg/mL of rAlbumin were also left at
5 ◦C for control purposes. In the case of thermally stressed 200 mg/mL rAlbumin
samples, these evidenced a third peak corresponding to high molecular weight protein
species that increased in peak area with time. Presence of trimers or high MW spe-
cies were not detected for 20 mg/mL as early as at the 3rd day after the start of the study.
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Table C.1: Relative peak areas of protein species detected by HPSEC of rAlbumin samples
at 5 and 60 ◦C, during a time period of 28 days. (a) Refers to data for 200 mg/mL rAlbumin
solutions. (b) Refers to data for 20 mg/mL rAlbumin solutions. These samples were all diluted




DLS results for the analysis of rAlbumin at 60 ◦C for 28 days are shown on Table C.2.
The protein samples were analysed after dilution to ∼1 mg/mL and the data shown are
the mean hydrodynamic diameter sizes by intensity and volume. The relaxation times
were obtained by fitting the experimental correlation data to a one or two step decay
exponential function. All samples were analysed directly after dilution, without any
filtration, except for the 200 mg/mL T= 28 days sample, where a filtration (0.45 µm)
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was needed to allow a reading on the instrument.
Table C.2: DLS results for the rAlbumin samples stressed at 60 ◦C for 28 days. 1 - Data was
obtained by diluting samples to 1 mg/mL; 2 - mean hydrodynamic size by intensity distribution
and standard deviation of three measurements; 3 - mean hydrodynamic size by volume distribu-
tion and standard deviation of three measurements; 4 - relaxation times were obtained by fitting
an exponential decay curve (1 or 2 step) to the experimental data.
C.2 Part II - Novel use of polyPEGMA brush-type poly-
mers as additives in protein solutions and their effect
in rheology
Figures C.1 and C.2 refer to the 1H-NMR spectra of 2-bromo-2-methylpropionic benzyl
ester and poly[poly(ethylene glycol)methylether methacrylate]-475, respectively.
NMR characterisation of the synthesised initiator yielded three peaks at δ = 7.38
ppm (a), 5.22 ppm (b) and 1.96 ppm (c), corresponding respectively to the aromatic
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Figure C.1: NMR spectra for 2-bromo-2-methylpropionic benzyl ester. Sample was dissolved
in CDCl3.
The NMR spectra for polyPEGMA-475 (Figure C.2) has the same peaks at the
approximately the same chemical shifts as the NMR results found for polyPEGMA-
1100 (Figure 6.11). The difference between these spectra has to do with the integra-
tion for most of its peaks, corresponding to the less number of protons present in the
polyPEGMA-475 molecule. The peaks that remain with equal integration are for those
protons present in the end group at chemical shifts δ = 7.33 ppm and δ = 5.05 ppm,










































































Figure C.2: NMR spectra for poly[poly(ethylene glycol)methylether methacrylate]-475. Sample
was dissolved in CDCl3.
Figure C.3 shows the calculated molar mass after analysis of the polyPEGMAs on
HPSEC calibrated with triple detection. The polymers were injected in triplicate and
represented here is an example of one analysis per polymer.
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Figure C.3: Example of chromatograms for polyPEGMA analysis on HPSEC calibrated with
triple detection. (A) pPEGMA-475 (B) pPEGMA-1100. Black points represent the calculated
molar mass per peak; blue line refers to the refractive index signal (concentration); red line
corresponds to the light scattering (90 ◦) detector; and green line corresponds to the differential
pressure signal from the viscometer.
Figure C.4 represents the UV-visible absorbance spectra of the polyPEGMA solutions
(in % w/w) used for the protein solubility studies. Aliquots of these samples were
analysed to ensure the correct increase of polyPEGMA presence in each sample. These
were also measured for any possible absorbance at 280 nm, useful when determining the
protein concentration of the protein in the blends prepared for this experiment. The
arrows on the graph are pointing at the two maximum peaks of UV absorbance for
polyPEGMAs (at this buffer conditions): at ∼230 nm and ∼258 nm. The third arrow
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points at λ = 280 nm, where it can be observed that there was an increase of absorption
at this wavelength, with an increase of polymer concentration.
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Figure C.4: UV-Visible absorption spectra of polyPEGMA solutions in buffer, in the concentra-
tions used for the protein solubility test. The larger graph corresponds to data of polyPEGMA-
1100 dispersions, while the polyPEGMA-475 data is represented on the inset graph. The three
arrows are pointing to the following wavelengths: ∼230 nm, ∼258 nm and 280 nm.
The figures below represent the emission spectra for pyrene fluorescence a probe for
micellisation occurrence on polyPEGMA solutions (in the range of 0.01 to 5 mg/mL)
(Figures C.5(a) and C.5(b)). Although there was an increase of emission with the in-
crease of the polymer concentrations, on each of the cases, the increase in intensity of
peak III (λ ∼ 384 nm) was not observed.
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Figure C.5: Emission spectra for fluorescence of pyrene probe on the micellisation studies with
polyPEGMA solutions. a) polyPEGMA-475 solutions, and b) polyPEGMA-1100 solutions.
The tables below summarise the measured hydrodynamic diameter (HD) in nm
measured by intensity and volume distribution for the polyPEGMA solutions and the
β-LG samples (Tables C.3 and C.4). The polymer solutions in buffer (10 mM His-
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His.HCl pH 6.0) were analysed at their actual concentration, without further dilution.
The protein-polymer blends were diluted to 1 mg/mL (of protein concentration, at 280
nm), so to allow a comparison to the previous results of protein only DLS measurements
(discussed in the other chapters of this thesis).
Table C.3: Table with the hydrodynamic diameter sizes by intensity and volume distribution
of the polyPEGMA samples. 1 - polymer samples were measured at the stated concentrations;
2 - mean hydrodynamic size by intensity distribution and standard deviation of three meas-
urements; 3 - mean hydrodynamic size by volume distribution and standard deviation of three
measurements.
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Table C.4: Table with the hydrodynamic diameter sizes by intensity and volume distribution
of of β-LG and polyPEGMA blends. 1 - Data was obtained by diluting samples to 1 mg/mL;
2 - mean hydrodynamic size by intensity distribution and standard deviation of three meas-
urements; 3 - mean hydrodynamic size by volume distribution and standard deviation of three
measurements.
Figure C.6 shows examples of HPSEC chromatograms obtained from β-LG and mAb
blends with polyPEGMA at 25 mg/mL. The samples were all diluted to 10 mg/mL
(at protein concentration), prior HPSEC analysis. These chromatograms are examples
representative for all the blends analysed, since there was no difference between samples,
within the same protein type of sample.
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Figure C.6: HPSEC chromatograms for polyPEGMA and protein blends. A and B - ∼68
mg/mL of β-LG solution with 25 mg/mL polyPEGMA-475 or polyPEGMA-1100, respectively.
C and D - ∼100 mg/mL of mAb solution with 25 mg/mL of polyPEGMA-475 or polyPEGMA-
1100, respectively. Samples were analysed on HPSEC after dilution to 10 mg/mL of protein.
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The following tables C.5, C.6 and C.7 list the average values and standard deviation
of three readings of each sample from the cone-and-plate rheology experiments and the
mVROC experiments. For the CP rheology data, the represented viscosity values were
those at 1000 s−1 and for the mVROC experiments, those at 990-1000 s−1. As the
sample’s viscosities vary slightly, the calculated true shear rates applied on the mVROC
measurements varied correspondingly still being close to 990 - 1000 s−1.
Table C.5: High shear rate viscosities measured with cone-and-plate and mVROC for buffer
and polyPEGMA solutions.
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Table C.6: High shear rate viscosities measured with cone-and-plate and mVROC for β-LG
solution and its blends with polyPEGMAs. β-LG solution was at ∼68 mg/mL in all samples,
while the concentrations of polyPEGMA-475 and polyPEGMA-1100 were varying.
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Table C.7: High shear rate viscosities measured with cone-and-plate and mVROC for mAb
solution and its blends with polyPEGMAs. The mAb solution was at ∼100 mg/mL in all
samples, while the concentrations of polyPEGMA-475 and polyPEGMA-1100 were varying.
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